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Theileria parva is a tick-borne intracellular protozoan parasite which infects cattle 
and African buffalo in Eastern and Southern Africa. Cattle may be immunised 
against T. parva by the infection and treatment method (ITM), which involves 
inoculation with live sporozoites and simultaneous treatment with oxytetracycline. 
One such ITM vaccine is the Muguga Cocktail, which is composed of a mixture of 
three parasite stocks: Muguga, Serengeti-transformed and Kiambu 5. Although the 
vaccine has been used with success in the field in several areas in Eastern Africa, 
there is evidence that vaccination using cattle-derived parasites does not always 
provide adequate protection against buffalo-derived T. parva. A number of T. parva 
antigens recognised by CD8+ T cells from cattle immunised by ITM have been 
identified in previous studies. A proportion of these antigens show a high degree of 
sequence polymorphism and allelic diversity is believed to be much greater in 
buffalo-derived T. parva than in cattle-derived parasites. The present study focussed 
on the development and application of a deep sequencing technique for 
characterising genotypically heterogeneous T. parva DNA samples. A panel of genes 
encoding CD8+ T cell antigens was used as the basis of a multi-locus sequence 
typing system (MLST) built upon Roche 454 amplicon sequencing technology. This 
system was validated using parasite stocks of known composition and then utilised to 
investigate genetic and antigenic diversity in vaccine stabilates and samples derived 
from African buffalo. The MLST profile obtained for the Muguga Cocktail stocks 
was compared to those of African buffalo in two geographically separated sites and 
was also compared with micro/mini-satellite DNA profiles of Muguga Cocktail 
stocks. 
The three components of the T. parva Muguga Cocktail vaccine were found to have 
limited genotypic and antigenic diversity using both methods. The composition of 
vaccine batches produced in a single production run (ILRI0801-ILRI0804) was 
shown to be relatively consistent. In contrast, the composition of the component 
stocks was shown to alter following passage through cattle and ticks. The deep multi-
locus sequence profile and satellite DNA profile established in this study may be 
used as a reference for comparison with future vaccine batches. It is suggested that 
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formulation of a new cocktail vaccine containing three parasite clones selected on the 
basis of genotypic and antigenic divergence may well provide protection comparable 
to that obtained with the Muguga Cocktail. The components of such a vaccine could 
readily be distinguished and the composition of vaccine batches monitored, thus 
allowing improved quality control and greater consistency of the vaccine. 
Genetic and antigenic diversity was found to be very high in parasite populations 
from African buffalo from the Kruger National Park, South Africa and the Ol Pejeta 
conservancy, Kenya. The estimated average genetic ‘distance’ between any two 
alleles in the Kruger National Park and within the Ol Pejeta conservancy was very 
similar for all six genes investigated. Many of the identified alleles were ‘private’ to 
either the buffalo from Ol Pejeta or the Kruger National Park and many of these 
alleles were present in several individuals in one location. Principal co-ordinate 
analysis and phylogenetic investigation of several antigen-encoding loci indicated 
that extant buffalo parasite populations are geographically sub-structured although 
some of the underlying diversity may reflect ‘ancient’ polymorphism in an ancestral 
population. 
A subset of the CD8+ T cell antigens examined exhibited extensive antigenic 
polymorphism while others were highly conserved at the amino acid level. These 
conserved genes may represent good candidates for the development of next 
generation vaccines, as strain specificity may be overcome if protective CD8+ T cell 
responses could be generated against these conserved antigens. This would enable 
the use of sub-unit vaccines in areas where cattle co-graze with buffalo. 
Theileria sp (buffalo) was identified in cell lines isolated from cattle, indicating that 
this parasite can transform bovine lymphocytes and may therefore be implicated in 
pathology in cattle. Phylogenetic analysis of T. parva and T. sp (buffalo) clones using 
the 5S subunit ribosomal RNA gene, Tp6, Tp7 and Tp8 showed a clear distinction 
between the two parasite species. These genes could thus be considered as candidates 
for an improved diagnostic test for T. parva in South Africa.
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3BChapter 1: General introduction 
1.1 Theileria parva  
The tick-borne protozoan parasite Theileria parva causes disease in cattle in Eastern 
and Southern Africa. The disease is a major constraint on the development of the 
livestock industry in affected areas as it is associated with high mortality rates 
together with economic losses sustained through treatment and prevention measures 
(Minjauw and McLeod, 2003; Nambota et al., 1994). Both indigenous (Bos indicus) 
and exotic breeds (Bos taurus) are susceptible to infection with T. parva (Ndungu et 
al., 2005). However, the exotic taurine breeds, which are in demand for high 
production, are more susceptible to tick infestation and tend to develop more severe 
disease (Wambura et al., 1998) 
1.1.1 Life-cycle 
The main vector transmitting Theileria parva is Rhipicephalus appendiculatus, but a 
closely related species Rhipicephalus zambeziensis also plays an important role in 
transmission in Southern Africa. R. appendiculatus is a three-host tick and 
transmission of T. parva occurs transstadially from larvae to nymphs or from nymphs 
to adult. The transmission of T. parva from nymph to adults is quantitatively more 
important (Anonymous, 1981; Blouin et al., 1989; Jongejan et al., 2004; Lawrence et 
al., 1983; Potgieter et al., 1988). The tick vector infects cattle by inoculating 
sporozoites while taking a blood meal. The non-motile sporozoites are released 
several days after the tick commences feeding and rapidly enter lymphocytes by 
receptor-mediated endocytosis; this is believed to occur at the site of the tick bite 
(Fawcett et al., 1984; Fawcett et al., 1982b). The sporozoite surface coat is shed 
during the entry process, resulting in a more close apposition of the parasite and host 
cell membranes (Shaw, 2003). The Theileria parasites then rapidly escape into the 
cytoplasm of the host cell by dissolution of the surrounding host cell membranes 
(Shaw et al., 1991). T. parva infects lymphocytes of the T- and B-cell lineages, but 
infected T cells dominate in vivo and in in vitro cell lines (Baldwin et al., 1988). 
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Development of the sporozoites into the intracellular multinucleate schizont stage, 
which occurs over 3-4 days, results in activation and proliferation (transformation) of 
the infected cells. Division of the parasite is synchronised with division of the host 
cell, enabling the parasites to remain in an intracellular position while replicating 
(Shaw, 2003). The schizont-infected cells disseminate throughout the lymphoid 
system and other tissues, such as the lungs and intestine (Siefert, 1996). Rapid 
multiplication of parasitised cells is followed by extensive lymphocytolysis, affecting 
infected and uninfected cells, and profound leukopenia (Morrison et al., 1981). The 
most important clinical signs of T. parva infection are pyrexia, enlarged lymph nodes 
and pulmonary oedema, which develops rapidly, usually 1-2 days before death. 
Clinical signs associated with disease occur within two to four weeks of infection, 
with lung pathology being the primary cause of death (Siefert, 1996). 
After about ten days, a proportion of the multinucleated schizonts undergo a 
differentiation process called merogony, which coincides with reduced proliferation 
of the host cell, enlargement of the schizonts with increasing numbers of nuclei and 
eventually production of uni-nucleated merozoites through a budding process from 
the enlarged schizont (Shaw et al., 1992). The infected cells lyse releasing mature 
merozoites into the bloodstream where they enter erythrocytes to give rise to 
piroplasms (Shaw et al., 1995). The piroplasm stage of T. parva does not multiply.  
Animals that recover from infection can continue to carry small numbers of parasites 
(schizonts and piroplasms) for years (Kariuki et al., 1995; Odongo et al., 2010; Oura 
et al., 2007b; Oura et al., 2004b; Skilton et al., 2002). The piroplasms in these carrier 
animals, although often undetectable microscopically, are infective for feeding ticks 
(Shaw, 2003; Siefert, 1996). 
All parasite stages in cattle have a haploid genome. Diploid zygotes are formed in the 
tick gut through fusion of male and female gametes, which develop from ingested 
piroplasms (Gauer et al., 1995). Feeding ticks are likely to ingest a mixture of 
parasite genotypes, as mixed infections are common in cattle under field conditions 
(Muleya et al., 2012; Oura et al., 2005). This allows sexual recombination during 
development within the tick vector (Katzer et al., 2006) and can lead to the exchange 





gut epithelial cells of the tick and develop into motile kinetes, which enter the 
haemolymph and migrate to the tick’s salivary glands. The kinetes enter a specialised 
cell type (the E cell) within the salivary gland, in which each kinete transforms into a 
sporoblast and subsequent sporogony is initiated by the commencement of a tick feed 
(Fawcett et al., 1982a). Sporogony in the salivary gland, which involves several 
nuclear divisions, results in the production of thousands of sporozoites (Fawcett et 
al., 1982a; Shaw, 2003).  
 
Figure 1.1 Life-cycle of Theileria parva 
Sporozoites are inoculated into cattle by the tick host and invade monocytes of the 
T cell and B cell lineages. The parasites develop into schizonts within the cytoplasm 
of the host cell and induce clonal expansion of the host cell. Merozoites are produced 
during merogony, which upon release from the host cell invade erythrocytes. Ticks 
ingest erythrocytes containing piroplasms when feeding on an infected animal. 
Diploid zygotes are formed, which invade the ticks gut epithelial cells and develop 
into motile kinetes, which migrate to the tick’s salivary glands where sporogony 





1.1.2 Clinical signs and nomenclature 
 The classical presentation of the disease in cattle caused by Theileria parva has been 
named East Coast fever (ECF) and is characterised by anorexia, fever, enlarged 
lymph nodes containing large number of parasitised cells and breathing difficulties. 
High mortality rates have been observed in naïve cattle with death ensuing two to 
four weeks after infection. 
African buffalo can carry T. parva and may play a role in disease epidemiology in 
areas where buffalo are present. Cattle infected with buffalo-derived parasites 
develop severe disease rapidly, despite having relatively low levels of parasites in 
superficial lymph nodes and blood (Potgieter et al., 1988). In South Africa, disease in 
cattle caused by buffalo-derived T. parva was named Corridor disease, because of its 
occurrence in a corridor between two game reserves (Norval et al., 1992). 
Transmission of buffalo-derived parasites from cattle to cattle is limited, due to the 
low levels of the tick-infective piroplasm stage and the lack of long term carrier 
infections in cattle (Lawrence, 1979). 
While only the buffalo-associated form of disease occurs in South Africa, a milder, 
seasonal form of disease due to T. parva is seen in other regions of Southern Africa 
(e.g. Zimbabwe). This disease has been named January disease due to its seasonal 
occurrence after the cold dry season from January to March after which the rainy 
season commences. The milder nature of the disease and its seasonal occurrence has 
been proposed to be due to differences in the distribution of tick vectors and their 
ability to transmit Theileria (Norval et al., 1991b; Ochanda et al., 1988). In addition, 
ticks in Southern Africa can undergo diapause, a predetermined state of low activity 
and metabolism, which is dependent on changes in hours of daylight and other 
factors. This aspect of their biology, results in only a single generation of ticks per 
calendar year (Norval et al., 1991a; Young et al., 1994). 
The differences in transmission dynamics and clinical manifestation of theileriosis 
have led to a variety of nomenclatures being introduced to describe the parasites 
responsible (Lawrence, 1977, 1979). At the beginning of the twentieth century, three 
different disease presentations of theileriosis transmitted by Rhipicephalus 
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appendiculatus were recognised and the causative pathogens of East coast fever, 
corridor disease and January disease were named T. parva, T. lawrencei and T. bovis. 
However, after the occasional successful transmission of T. lawrencei from cattle to 
cattle, the morphological similarities between the parasites (Young and Purnell, 
1973) and the cross-reactivity of monoclonal antibodies raised against buffalo-
derived T. parva with cattle derived T. parva (Conrad et al., 1989), it was suggested 
that the three parasites should be considered sub-species of T. parva; hence parasites 
causing the classical cattle disease were named T. parva parva, those derived from 
buffalo T. parva lawrencei and those causing January disease T. parva bovis 
(Lawrence, 1979; Uilenberg, 1978). The subsequent finding that these sub-species 
could not be distinguished genetically based on DNA typing methods then led to the 
recommendation that all parasites be named T. parva and that further descriptive 
terms may be used: cattle-derived T. parva and buffalo-derived T. parva (Perry et al., 
1993). Cattle-derived T. parva includes the previously named T. parva parva and T. 
parva bovis (Anonymous, 1988; Norval et al., 1991a; Perry et al., 1993). 
1.1.3 Diagnosis  
Diagnosis in the field relies on clinical signs and, in some cases, is confirmed by 
microscopic detection of parasites in leukocytes (the schizont stage) or erythrocytes 
(the piroplasm stage) in Giemsa-stained smears of lymph node biopsies and/or blood 
(Minjauw et al., 2003; Siefert, 1996). However, when parasitaemia is low, it can be 
difficult to detect parasites and differentiation between the different haemoparasites 
by microscopy is challenging (Norval et al., 1992). Exposure to T. parva can also be 
assessed by measuring antibody responses. Initially an indirect immunofluorescent 
antibody test (IFAT) was employed using fixed smears of schizont-infected cells as 
antigen (Goddeeris et al., 1982).  More recently this has been replaced with an 
antibody enzyme-linked immunosorbent assay (ELISA) using a recombinant protein 
of the polymorphic immunodominant molecule (PIM), a schizont surface protein that 
induces strong antibody responses (Katende et al., 1998). In South Africa, a real-time 
PCR assay based on the 18S rRNA gene is used for the detection of T. parva in 
African buffalo and cattle (Sibeko et al., 2008). Other methods developed for 





p104 gene and a reverse line blot (RLB) assay based on amplification of the 18S 
rRNA gene using Theileria/Babesia specific primers and hybridisation with species-
specific oligonucleotide probes (Bishop et al., 2001; Odongo et al., 2010; Oura et al., 
2004a; Tait and Oura, 2004). 
1.1.4 Control of T. parva  
Tick control is an important aspect of the management of tick-borne diseases, 
including Theileria parva. However, frequent application of acaricide is required to 
prevent transmission of the parasite and this demands organisation and expense.  
Intensive use of acaricide favours the development of acaricide-resistance (Jongejan 
and Uilenberg, 2004). Furthermore, there are issues with acaricides in terms of 
residues in the environment and in livestock products and there is a direct risk to the 
animal handlers (Morrison and McKeever, 2006; Mugisha et al., 2005). In situations 
where acaricides are used frequently, the cattle may remain fully susceptible to tick-
borne diseases and disruption in the supply of acaricides can lead to devastating 
outbreaks of disease (Jongejan and Uilenberg, 2004).  The use of acaricides is 
therefore viewed as an unsustainable method for the control of T. parva and other 
tick-borne diseases. A more integrated form of control for ticks and tick-borne 
disease is advocated, which includes a more strategic use of acaricides in 
combination with vaccination against ticks and/or tick-borne pathogens (Jongejan et 
al., 2004; Morrison and McKeever, 2006). 
Affected animals can be treated successfully using theilericidal compounds such as 
parvaquone or buparvaquone, providing treatment is started in the early stages of 
clinical disease (Muraguri et al., 1999). In the later stages of the disease, several 
doses of drug may be required to cure the animal and recovery may be protracted. 
Although drugs can be effective, they are relatively expensive and may not always be 
available to poor smallholder farmers (Morrison and McKeever, 2006; Norval et al., 
1992). 
The policy of the South African government, where African buffalo are the source of 
infection, is focussed on prevention of cattle becoming infected with  Theileria parva 
rather than control (Anonymous, 2002). Game reserves and game ranches are fenced 
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to prevent cattle and buffalo grazing on the same land. Quarantine measures are 
firmly enforced and these are coupled with strict tick control of cattle in areas 
bordering the disease-endemic areas, particularly when outbreaks occur. Spread of T. 
parva from African buffalo to cattle is also prevented by prohibiting the translocation 
of T. parva-carrying buffalo into non-endemic areas (Anonymous, 2002; Sibeko et 
al., 2008). Despite these measures, occasional small outbreaks of disease due to T. 
parva infection are still recorded in cattle (Mbizeni et al., 2013; Thompson et al., 
2008; Yusufmia et al., 2010). 
Cattle may be immunised against ECF using the ‘infection and treatment’ method 
(ITM), which involves infection with live sporozoites in the form of cryopreserved 
stabilates and simultaneous treatment with long-acting tetracycline (Radley et al., 
1975b). Cattle immunised experimentally by this method are solidly immune against 
challenge with the same (homologous) parasite stock. However, immunity induced 
by one parasite stock does not always give full protection against challenge with 
other stocks (Hove et al., 1995; Radley et al., 1975a; Taracha et al., 1995a). To 
overcome this, the Muguga cocktail vaccine was developed in the 1970s and is 
composed of three T. parva stocks. These stocks were selected on the basis of 
experimental cross-immunity trials in cattle (Radley et al., 1975b). The Muguga 
cocktail has been used successfully to vaccinate cattle in the field (discussed further 
below). 
Other T. parva stocks have also been used in different local regions in sub-Saharan 
Africa where T. parva is prevalent. The Katete and Chitongo stocks, are used for 
immunisation in Malawi and Zambia (Geysen et al., 1999; Marcotty et al., 2002). 
The Marikebuni stock, isolated from the coastal region of Kenya,  has been used for 
immunisation in Kenya (Minami et al., 1983; Morzaria et al., 1987; Wanjohi et al., 
2001) and the Boleni stock has been used for vaccination in Zimbabwe (Hove et al., 





1.2 The Muguga cocktail  
1.2.1 Introduction 
The Muguga cocktail is the most widely used parasite preparation for vaccination by 
ITM.  The three T. parva stocks incorporated in the vaccine are Muguga, Serengeti-
transformed and Kiambu 5 (Radley et al., 1975b). The T. parva Muguga stock was 
isolated in the 1950s and was originally maintained at the East African Veterinary 
Research Organization (EAVRO) by acute passage through ticks and cattle before a 
stabilate was made in 1970. The Kiambu 5 stock was isolated in the early 1970s by 
tick pick-up from a cow with clinical East coast fever in the Kiambu district of 
Kenya (Radley et al., 1975a) The Serengeti-transformed stock was derived from an 
isolate from a buffalo in the Serengeti National Park, Tanzania by feeding ticks on an 
African buffalo that was captured from the Serengeti National Park as a calf in the 
early 1970s. This stock is said to be ‘transformed’ since following serial passage 
through cattle, the isolate produced infections characteristic of cattle-derived T. 
parva (Young and Purnell, 1973). 
The Muguga cocktail has been used in experimental and field trials with encouraging 
but variable results. Protection was observed against a range of cattle-derived T. 
parva stabilates from different geographical areas (Radley et al., 1975b). A 
substantial reduction of the number of deaths due to theileriosis was also seen under 
field conditions in Kenya and Tanzania. However, fatality was still observed in 
immunised animals in the different experiments; between 0.2% and 20% of the 
animals in immunised groups died compared to a death rate of between 20% and 
100% in groups of naïve animals (Radley, 1976). In other studies, breakthroughs 
were observed upon challenge with the Malawian T. parva Kasobo stock (Musisi et 
al., 1996) and the Zambian T. parva Katete stock (Geysen, 2000). Broad protection 
has been reported against field challenge under pastoral conditions in Tanzania 
where large numbers of animals have been immunised using the Muguga cocktail 
over the last two decades (Giulio et al., 2009; Martins et al., 2010; Morzaria and 
Williamson, 1999). However, the protection provided against challenge with buffalo-
derived T. parva parasites is in most cases disappointing (Lohre, 1978; Radley et al., 
1979). 
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Although the Muguga cocktail has been used with a degree of success in 
experimental and field conditions, large-scale uptake of the vaccine has been limited 
by complexities in production, standardisation of the vaccine production process and 
control of vaccine safety and consistency. Another major constraint to the delivery of 
vaccine stabilate is the requirement to maintain a liquid nitrogen cold chain for the 
transport of stabilates to the field. In some regions, there have also been concerns 
regarding the risk of introducing the vaccine strains into local tick populations should 
immunised animals become carriers (De Deken et al., 2007; Geysen, 2008; Geysen et 
al., 1999; Giulio et al., 2009; Kariuki et al., 1995; Oura et al., 2007a). The fear is that 
the introduced parasites would undergo sexual recombination with local strains, 
which could potentially create parasites with altered virulence or antigenicity 
(Morzaria and Williamson, 1999). Nevertheless, efforts have been made to 
commercially produce and distribute the Muguga cocktail and to promote its 
widespread use. 
1.2.2 Vaccine stabilate production – Muguga Cocktail 
The production process for the ITM vaccine (illustrated in Figure 1.2) is intricate and 
relies on passaging of the three component stocks through cattle and ticks. There are 
currently no guidelines for assaying the composition of the components and it is 
possible that stocks may vary at the genotypic level from generation to generation. 
This clearly has implications for vaccine consistency and quality control. It is 
important to appreciate the way in which the vaccine is manufactured. Immunising 
stabilates are derived from working seed stabilates that are in turn derived from 
master seed stabilates. In other words, a master seed parasite population will go on to 
complete the life-cycle twice before it forms an actual vaccine stabilate. Importantly, 
this method includes the potential for two rounds of sexual recombination in the tick. 
Unfortunately, the production of a live multi-component vaccine such as this is 
necessarily complex and the methodology used has been developed in order to 
minimise passage of the parasite stocks and to allow production of large quantities of 
vaccine stabilates. 
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Production of the stabilates is carried out as follows (OIE, 2008). Healthy cattle, 
serologically negative for tick-borne diseases, are infected by subcutaneous injection 
of the master seed stabilate. During the following parasitaemic phase, laboratory-
raised R. appendiculatus nymphs are applied to the ears of the cattle in ear bags. The 
engorged ticks are collected, allowed to moult and then fed on the ears of rabbits for 
four days to allow maturation of sporozoites in the tick salivary glands (Kimbita and 
Silayo, 1997; OIE, 2008). The replete ticks are removed from the rabbit ears after 
four days and the infection rate of dissected salivary glands is determined in a sample 
of the ticks; the remaining ticks are used to produce the working seed (OIE, 2008) 
stabilates. 
In order to produce a stabilate, batches of 1,000 infected ticks are washed under fast-
flowing tap water and the surface of the ticks disinfected by washing with 1% 
benzalkonium chloride or 70% alcohol and rinsed with distilled water. The ticks are 
then ground up and deposited in 7.5% glycerol minimum essential media 
supplemented with bovine serum albumin (MEM/BSA) and the resulting ground up 
tick stabilates (GUTS) are aliquoted and frozen. Stabilate may be stored in glass vials 
or plastic artificial insemination straws. Artificial insemination straws have the 
benefit that colour coding can be used to indicate the identity of the immunising 
stabilate. Stabilates are frozen in a deep freezer within a container that facilitates a 
slow rate of freezing. Once frozen, the stabilates are transferred to liquid nitrogen for 
permanent storage. The same procedure is used to produce the immunising stabilate 
from working seed stabilates. However, ticks infected with each of the three 
components are mixed before grinding, to provide batches with equivalent infectious 
units of each component stock (OIE, 2008; Speybroeck et al., 2008). Normally, the 
mixture would be formulated to contain approximately ten tick-equivalents per ml, 
but this can be adjusted if the salivary gland infection rate in a particular tick batch is 
either very high or very low (OIE, 2008). 
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Figure 1.2 Schematic representation of the production process of the Muguga cocktail 
Three groups of cattle are inoculated with a single component of the Muguga cocktail (Muguga, 
Serengeti or Kiambu 5; one component per group) and clean laboratory Rhipicephalus appendiculatus 
nymphs fed on the ears of these cattle. The resulting infected ticks are allowed to moult before being 
allowed to pre-feed on rabbits for four days in order to allow maturation of sporozoites. These ticks 
are then used to produce the working seed stabilates for each of the components in the form of 
cryopreserved ground up tick stabilate (GUTS). This process is then repeated using the working seed 
stabilates for each of the three component stocks. The resulting infected ticks, containing mature 
sporozoites, are pooled to provide batches for immunisation with equivalent infectious units of each of 
the components. 
The infectivity of the immunising stabilates is determined by inoculating groups of 
susceptible cattle with a series of stabilate dilutions in a standard volume of one ml. 
It is essential to titrate the effective dose, despite the number of infected acini/tick 
being known prior stabilate production. This is because an unknown proportion of 
infectivity is lost during the stabilate production process and through freezing and 
thawing. For the titration, the contents of two to four randomly selected aliquots are 
mixed and cattle are then inoculated with different dilutions of the stabilate to 
establish its infectivity and lethality. The aim of this procedure is to determine an 
immunising dose of stabilate that, in combination with the tetracycline, reproducibly 
infects all animals but results in a very mild or inapparent clinical reaction. All 
animals should develop a parasite-specific antibody response after immunisation and 
be immune to lethal homologous parasite challenge. Once a safe and effective 
immunising dose is established, it is adopted for vaccination in the field (OIE, 2008). 
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1.2.3 Challenges in the vaccine production process 
The production process is reliant on live animals and ticks and these potentially 
harbour pathogens that could contaminate the vaccine. By using laboratory-reared 
rabbits and ticks, this risk is greatly reduced. However, cattle are not sourced from a 
pathogen-free environment, which means there is always a risk of introducing 
pathogens during the production process. While a disease-free status cannot be 
guaranteed, only clinically healthy cattle, serologically negative for tick-borne 
diseases are used for vaccine production (OIE, 2008). 
The dose for immunisation must be calculated on the basis of titration due to an 
unknown proportion of parasites losing infectivity during the production process. 
Determining the optimal dose for immunisation is further complicated by the varying 
susceptibility of cattle breeds. Exotic Bos taurus breeds, like the Holstein, develop 
more severe disease than local Bos indicus breeds and their crosses. In a vaccine trial 
with the Marikebuni stock at a location on the Kenyan coast, a higher proportion of 
Jersey than Bos indicus x Bos Taurus cross-bred cattle were observed to be clinical 
reactors following vaccination (Mutugi et al., 1991). Hence, cattle that are most 
likely to develop a severe reaction are generally used for titration of immunising 
stabilates, in order to minimise the chance of clinical reaction following 
immunisation in the field. The potential risk of using a lower dose of the stabilate is 
that parasite genotypes present at low frequency in the immunising stabilate, which 
may contribute to the broad immunity, may not feature at sufficient quantity in every 
vaccine dose. Furthermore, titration of a mixture of stocks of T. parva does not 
ensure optimal doses of each of the component stocks. However, results from 
titrating each of the component stocks separately could not necessarily be 
extrapolated to determine a safe dose of a vaccine mixture (Speybroeck et al., 2008). 
Further losses of infectivity are known to occur when the vaccine is distributed in the 
field and this reduces the effectiveness of each immunising dose. For this reason, it is 
recommended that thawed stabilate be kept on ice and used within eight hours of de-
frosting (Marcotty et al., 2001; Morzaria and Williamson, 1999). 
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1.3 Characterisation of vaccine stabilates 
The Muguga cocktail was originally formulated by selecting parasites based on 
experimental cross-immunity trials conducted in the 1970s (Radley et al., 1975b). At 
that time, before molecular techniques were available, the only hope of ensuring 
consistency among different batches was by adhering to the production protocol. 
Despite these efforts, the consistency of different vaccine batches over the years is 
unknown in terms of both numbers of parasites per dose and the genotypic 
composition of the parasites. 
With advances in immunology and molecular biology, several techniques have been 
used to characterise the three parasite stocks in the Muguga cocktail. Bishop et al. 
(2001) employed three techniques: an indirect fluorescent antibody test (IFAT) with 
a panel of anti-schizont monoclonal antibodies, southern blotting using four T. parva 
repetitive DNA probes and polymerase chain reaction (PCR)-based assays, detecting 
polymorphism within four single-copy genes encoding antigens recognised by 
antibody. Collectively, the data indicated that the Muguga and Serengeti-transformed 
components of the cocktail are genetically closely related but nevertheless distinct, 
while Kiambu 5 was highly distinct from the other two components (Bishop et al., 
2001). 
The availability of the T. parva genome sequence (Gardner et al., 2005) facilitated 
the development of a genome-wide panel of mini (MS) and micro (ms) satellite DNA 
markers for high-resolution genotyping of parasite populations. These were used for 
the analysis of the three components of the Muguga cocktail vaccine (Muguga, 
Serengeti-transformed and Kiambu 5); only four (MS7, MS19, MS25 and MS43) out 
of 31 markers used exhibited alleles that differed between the Muguga and 
Serengeti-transformed component stocks. Using similarity-based analysis, it was 
demonstrated that these two stocks are genetically very closely related (Oura et al., 
2004b). An explanation for this could be that the prolonged passage through cattle 
selected those parasites within the Serengeti-transformed stock that can easily be 
maintained in cattle with the loss of other genotypes that transmit poorly between 
cattle. Other researchers have hypothesised that the original T. parva Serengeti-
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transformed stock has been contaminated with and supplanted by T. parva Muguga 
genotypes over the years (Bishop et al., 2001; Oura et al., 2004b). 
Direct analysis of the FAO1 and FAO2 batches of the Muguga Cocktail using six 
satellite markers provided evidence for at least six alleles at each locus (Oura et al., 
2007b). Comparison of Muguga cocktail batches FAO1 and ILRI0804 produced by 
the Food and Agriculture Organization (FAO) and the International Livestock 
Research Institute (ILRI) demonstrated considerable commonality for the alleles 
identified using five satellite DNA markers. However, the ILRI Serengeti-
transformed stock had an additional allele for four of the five markers compared to 
the FAO Serengeti-transformed stock. These additional alleles in the ILRI Serengeti-
transformed stock had the same size as the alleles found in the Kiambu stock (for 
three of the markers) and the Muguga stock (the remaining marker) (Patel et al., 
2011). If these are true differences between the Serengeti-transformed stocks, it 
means that the relative abundance of alleles in vaccine batches produced using 
different seed stabilates may change. 
A more extensive set of satellite DNA markers was used to analyse the composition 
of the heterogeneous Marikebuni stock (Katzer et al., 2006) with differences in 
marker profiles found among different passages. A large number of genotypically 
distinct clones could be found when all the markers were used for analysis. However, 
for the majority of markers, a single dominant allele with one or two low abundance 
alleles were identified. Clonal analysis of the most recent passage of Marikebuni 
indicated that a specific clonotype had selectively expanded within the stock (Katzer 
et al., 2010). Direct genotyping of stabilates thus provides a reasonable indication of 
the extent of genetic diversity of the parasites present at relatively high frequency in 
the vaccine. However, it is possible that a higher resolution genotyping methodology 
would reveal additional alleles representing minor genotypic components of vaccine 
stabilates, which may contribute to the broad protection provided by the vaccine. The 
differences found by Patel et al. in the two different seed stabilates of the Serengeti-
transformed stock (Patel et al., 2011) highlights the risk that the allelic composition 
of the components of the Muguga Cocktail may vary from generation to generation. 
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1.4 Characterisation of Theileria parva in the field  
The same methods used for the characterisation of T. parva populations in vaccine 
stabilates have been used for the analysis of genotypic diversity of T. parva field 
isolates. Initial characterisation of T. parva isolates was performed using monoclonal 
antibodies raised against three different T. parva stocks, namely Muguga, Kiambu 5 
and Marikebuni (Bishop et al., 1994; Conrad et al., 1989; Conrad et al., 1987). 
Isolates from African buffalo appeared to carry mixed T. parva populations and there 
were marked differences in antigenic diversity between isolates from different 
buffalo and between isolates from the same buffalo taken at different time-points 
(Conrad et al., 1987). 
1.4.1 DNA probes and Restriction Fragment length 
polymorphism (RFLP) 
Other methods used include southern blotting using radio-labeled probes on 
restriction enzyme digested genomic DNA and RFLP-PCR assays targeting 
polymorphic antigen-encoding loci (Bishop et al., 1993; Bishop et al., 1994; Conrad 
et al., 1989; Geysen et al., 1999). Extensive polymorphism was observed among T. 
parva isolates from a variety of geographical areas (Kenya, Tanzania, Zambia, 
Zimbabwe and Uganda) using repetitive ribosomal and telomeric DNA probes and 
anti-schizont monoclonal antibodies (mAbs) (Bishop et al., 1993). RFLP-PCR assays 
using the three antigen-encoding genes p104, p150 and PIM, were used for the 
analysis of Zambian isolates. The majority of the isolates had a similar hybridisation 
pattern, which differed from that of ‘exotic’ stocks such as the Muguga Cocktail 
components (Muguga, Serengeti-transformed, Kiambu 5) (Geysen et al., 1999). 
Different PIM PCR-RFLP profiles were observed in different samples from African 
buffalo from the Kruger National Park, whereas the profiles seen for samples from 
African buffalo from Hluhluwe-iMfolozi Park, Abalingwe Game Reserve and Ithala 
Game Reserve were much more similar to one another (Sibeko et al., 2011). RFLP-
PCR profiles from Zambian cattle isolates were similar to one another but were 
distinct from those of the Muguga Cocktail components (Geysen et al., 1999). 
Relative homogeneity was observed among cattle isolates from Zimbabwe, as 
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assessed using RFLP analysis with the T. parva Tpr repetitive and ribosomal DNA 
probes and the panel of anti-schizont monoclonal antibodies (Bishop et al., 1994). 
1.4.2 Satellite DNA markers 
More recently, a higher resolution genotyping method was developed using a 
genome-wide panel of satellite DNA markers (Asiimwe et al., 2013; Katzer et al., 
2011; Katzer et al., 2006; Katzer et al., 2007; Odongo et al., 2006; Oura et al., 2007b; 
Oura et al., 2004b; Oura et al., 2003; Oura et al., 2011c, d) Across the markers, a 
range of allele sizes were detected in samples from Zambia, Kenya, Zimbabwe and 
Uganda suggesting an overall high level of diversity in the parasite population. 
However, no relationship between genetic similarity and geographical proximity was 
observed (Oura et al., 2003). A high degree of genetic diversity has been found in T. 
parva parasites in Kenyan cattle from different regions with minimal genetic sub-
structuring corresponding to geographical location (Odongo et al., 2006). In contrast, 
there was evidence for geographical sub-structuring in T. parva parasites in cattle in 
Uganda (Oura et al., 2005). 
The T. parva parasites found in African buffalo from Queen Elizabeth National Park 
and Lake Mburo National Park were distinct, indicating there is limited gene flow 
between the populations (Oura et al., 2011a). A higher mean multiplicity of infection 
was observed in buffalo from Queen Elizabeth National Park compared to those from 
Lake Mburo National Park. These values were both much higher than for the 
multiplicity of infection encountered in cattle-derived isolates in Uganda (Oura et al., 
2011a, b). Little genetic differentiation was observed between T. parva isolated from 
cattle within Lake Mburo National Park and cattle outside the park (Oura et al., 
2011b) 
1.4.3 Sequencing of antigens 
Following the identification of CD8+ T cell antigens (Graham et al., 2006), there has 
been an interest in investigating allelic polymorphism in their encoding-genes. For 
example, a large number of allelic sequence variants was found for the genes 
encoding Tp1 and Tp2 in buffalo-derived isolates and isolates from cattle associated 
with buffalo. This diversity was much more limited in cattle-derived parasites from 
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buffalo-free areas, both in terms of the number of alleles found and the differences 
between the different alleles. Allelic polymorphism was evident at the amino acid 
level in CD8+ T cell epitopes identified within these genes (Pelle et al., 2011). 
In addition, sequence analysis has been performed focussing on a number of B cell 
antigen-encoding genes, namely PIM, P67 and P104 antigen genes, for which there is 
evidence the proteins can be recognised by antibody responses (Graham et al., 
2007b; Musoke et al., 2005; Sibeko et al., 2011; Sibeko et al., 2010; Toye et al., 
1995). PCR amplification of the P67 gene of T. parva parasites in African buffalo 
from South Africa resulted in up to four different product sizes in individual animals 
and sequencing of the PCR products demonstrated further polymorphism (Sibeko et 
al., 2010). 
To summarise, a high degree of diversity of T. parva can be found in the field. A 
range of T. parva genotypes have been detected in samples from cattle from different 
countries in Africa (Bishop et al., 1993; Geysen et al., 1999). Relative homogeneity 
was observed among cattle isolates from Zimbabwe (Bishop et al., 1994) and among 
cattle isolates from Zambia (Geysen et al., 1999) whereas isolates from Kenya and 
Uganda were found to be more heterogeneous (Odongo et al., 2006; Oura et al., 
2005; Pelle et al., 2011). There was evidence for geographical sub-structuring in T. 
parva parasites in cattle in Uganda (Oura et al., 2005) although minimal 
geographical sub-structuring was found in parasites in cattle from different regions in 
Kenya (Odongo et al., 2006). The multiplicity of infection found in carrier buffalo is 
much higher than that found in cattle (Conrad et al., 1987b; Oura et al., 2011a; Pelle 
et al., 2011) and the alleles found in buffalo are more distinct from each other 
(Conrad et al., 1987b; Oura et al., 2011a; Pelle et al., 2011). The diversity of T. parva 
parasites in individual buffalo can vary from buffalo to buffalo and this may be 
associated with the sampling location (Oura et al., 2011a; Sibeko et al., 2011; Sibeko 
et al., 2010). 
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13B .5 Next generation sequencing 
Although a number of different methods have been used for the characterisation of 
the Muguga Cocktail and T. parva field isolates, these methods have been hampered 
by the limited level of resolution they could achieve. Next generation sequencing 
(NGS) technologies now offer the opportunity to investigate parasite samples in 
much higher resolution than was previously achievable. These technologies have the 
major advantage that a much higher level of throughput can be achieved at a greatly 
reduced cost per nucleotide compared to traditional Sanger sequencing. One million 
to three billion sequences may be obtained in a single instrument ‘run’ depending on 
the platform used. Several platforms are available including Roche 454 sequencing, 
Illumina Solexa sequencing and ABI Solid sequencing (biosystems, 2010; Illumina, 
2012; Kircher and Kelso, 2010; Liu et al., 2012; Margulies et al., 2005; Roche)). 
Each platform uses a different technical approach and different throughputs, read 
lengths and error rates are associated with each of them. These parameters change 
regularly as each platform is being continually developed and improved.  
Generally, all the platforms have the same advantages and disadvantages if compared 
to Sanger sequencing. The main advantage is that a high throughput can be achieved 
at a greatly reduced cost per nucleotide. However, read lengths are reduced and error 
rates increased in comparison to Sanger sequencing. The increased error rate can 
partly be overcome by the increased sequencing depth and bioinformatic analysis of 
the data. Although a large amount of sequencing data can be obtained in a short 
period of time, sequence analysis can be challenging and requires knowledge of 
bioinformatic processing methods and the availability of good computing 
infrastructure (Kircher and Kelso, 2010; Liu et al., 2012). Each of the platforms has 
its own strengths: the Illumina platform has the lowest cost per nucleotide sequenced, 
SOLid has the highest throughput and Roche 454 the longest read lengths. Each also 
has associated limitations: Illumina has the lowest accuracy in base pair calling, 
SOLid achieves very short read lengths and Roche 454 has homopolymer errors and 
single base pair insertions/deletions (see Table 1.1). Hence, the choice of next-
generation sequence technology depends on the application for which it is intended 
(Kircher and Kelso, 2010; Liu et al., 2012). 
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Table 1.1 Summary of characteristics of three platforms for next generation 
sequencing  
(biosystems, 2010; Illumina, 2012; Kircher and Kelso, 2010; Liu et al., 2012; Roche) 
Characteristic 







HSequencing by ligationHHs 
Read length 700 bp 
MiSeq: 150 bp 
HiSeq: 100 bp 
Up to 50 +35 bp 
Error rate 10-3 - 10-4 10-2 - 10-3 10-2 - 10-3 
Accuracy 99.9% 98% 99.94%




Substitution errors Substitution errors 
Cost/million bases $10 $0.07 $0.13
Reads/run Up to 1 million (24 hrs) 
MiSeq: 3.4 million (27 hrs) 
HiSeq: 3 billion (11 days) 
1.2 billion (12-14 days)  
Total output/run 0.7 Gb 
MiSeq: 1 Gb 





read lengths up to 
1000bp 
Paired-end sequencing, 
read lengths up to 250 bp 
Solid 4hq: 
Accuracy 99.99%, 
read lengths up to 75bp 
Challenges 
Homopolymer errors, 
relatively low throughput 
Short read assembly 




1.6 Immunity against T. parva  
The appearance of CD8+ T cells specific for parasitised lymphocytes following 
immunisation or challenge with T. parva coincides with clearance of the infection 
(Morrison et al., 1981). Further evidence that CD8+ T cells play an important role in 
protection against T. parva was provided by an adoptive transfer experiment 
performed using identical twin calves. Transfer of CD8+ T cells, derived from the 
efferent lymph draining the site of challenge with T. parva in the immune twin, to the 
respective naïve twin provided protection against T. parva infection (McKeever et 
al., 1994). 
Taracha et al. (1995b) investigated the specificity of CD8+ T cells after immunisation 
with two immunologically distinct stocks, Muguga and Marikebuni. CD8+ T cell 
responses in some animals immunised with Muguga recognised both parasites 
whereas in other animals, only the immunising Muguga parasite was recognised. All 
animals that developed cross-reactive CD8+ T cell responses were protected against 
heterologous challenge, whereas the animals that had strain-specific CD8+ T cell 
responses were completely or partially susceptible to heterologous challenge. It was 
hypothesised that this variation in strain specificity of the immune response is due to 
the CD8+ T cell response in different animals being focused on different 
immunodominant antigens which exhibit allelic variation among parasite strains 
(MacHugh et al., 2009a; Taracha et al., 1995b). 
Parasite-specific CD4+ T cells can be detected in immune animals and some of these 
CD4+ T cells have cytolytic activity against T. parva-infected cells. Evidence from in 
vitro studies suggests that the main role of CD4+ T cells is to provide assistance in 
the activation of memory CD8+ T cells (Baldwin et al., 1987; Taracha et al., 1997). 
Although T cell-mediated immunity appears to be the main mechanism for natural 
protective immunity against T. parva, sporozoite-neutralising antibodies can be 
induced after repeated challenge or vaccination using recombinant p67 sporozoite 
surface antigen. However, high antibody titres do not necessary correlate with 
protection upon challenge (Gentschev et al., 1998; Kaba et al., 2004; Musoke et al., 
2005). 
21
1.7 Development of ‘next-generation’ vaccines 
against T. parva 
The fact that cattle may develop protective immunity after natural infection or 
immunisation using the ITM suggests it may, in the future, be feasible to develop a 
subunit vaccine against T. parva. Such a vaccine would have a number of advantages 
over the current live vaccine, i.e. production would be easier, the cost per-dose would 
be lower, quality control would be more straightforward, it would be safer to 
administer and it may not require a liquid nitrogen cold chain for distribution in the 
field. 
Several experiments have been conducted with recombinant p67 sporozoite surface 
antigen using different delivery constructs for immunisation (Gentschev et al., 1998; 
Kaba et al., 2004; Musoke et al., 1992; Musoke et al., 2005). Antibodies against p67 
have been shown to inhibit parasite entry into the cell and neutralise the infection in 
vitro (Musoke et al., 1992). Although high titres of neutralising antibodies could be 
induced in all animals through vaccination, only a proportion of the animals were 
protected against challenge and it has been inferred that this variability is due to 
other immune mechanisms that were not investigated in the experiments (Bishop et 
al., 2003; Gentschev et al., 1998; Kaba et al., 2004; Musoke et al., 1992; Musoke et 
al., 2005). 
Over the last decade, efforts have been directed toward identifying T. parva antigens 
that can be recognised by CD8+ T cells in immune animals, as this cell type is known 
to be important in protective immunity against the parasite. Two different systematic 
approaches have been used to identify high value candidates. Firstly, Theileria 
parva-specific CD8+ T cell lines were used to screen a schizont cDNA library and 
secondly, cDNA candidate genes were selected and tested on the basis of a 
bioinformatic screen of the T. parva genome (Graham et al., 2007a; Graham et al., 
2006). A number of genes were identified whose products can be recognised by 
CD8+ T cell responses and, for some of the genes, epitopes within the proteins were 
identified for cattle of certain major histocompatibility complex class I (MHC I) 





The immune responses of cattle immunised with a cocktail of five CD8+ T cell 
antigens by a heterologous prime-boost regime with recombinant poxvirus vectors 
was examined (Graham et al., 2006). The animals used for the study had been 
identified as expressing a MHC I allele capable of presenting defined antigens to 
CD8+ T cells. Antigen-specific IFN-γ responses were confirmed for the specific 
MHC I haplotypes, but only partial protection in a few of the animals was seen after 
challenge with a lethal dose of T. parva Muguga stock sporozoite stabilate. Only two 
of the six animals expressing the 2*01201 class I allele (the restriction element for 
Tp2) had CD8+ T cell IFN-γ responses against the Tp2 antigen and it was suggested 
that this could be due to a lack of potency of the vaccination protocols rather than an 
inability of the animals to respond to the antigens (Graham et al., 2008b). Despite the 
disappointing results of the vaccine trials, the identified antigens provide an 
opportunity to investigate specificity of CD8+ T cell responses in more detail. 





Chromosome Gene annotation Reference 
Tp1 XP_762973 3 Hypothetical (Graham et al., 2006) 
Tp2 HXP_765583 1 Hypothetical (Graham et al., 2007a) 
Tp3 XP_766389 1 Hypothetical  
Tp4 XP_763228 3 Ɛ-TCP-1 (Graham et al., 2006) 
Tp5 XP_765334 2 eIF-1A (Graham et al., 2006) 
Tp6 XP_765715 1 Prohibitin  
Tp7 XP_764810 2 Hsp90 (Graham et al., 2006) 
Tp8 XP_764709 2 Cysteine protease (Graham et al., 2006) 
Tp9 XP_765463 2 Hypothetical  (Aguado-Martinez et al., 2012) 















MHC I3  
Reference 
Tp1 214-224 VGYPKVKEEML A18  6*01301 (Graham et al., 2008b) 
Tp2 27-37 SHEELKKLGML Animal BW002
2 6*04001 (Graham et al., 2008b) 
Tp2 40-48 DGFDRDALF (Pelle et al., 2011) 
Tp2 49-59 KSSHGMGKVGK A10  2*01201 (Graham et al., 2008b) 
Tp2 50-59 SSHGMGKVGK A10  2*01201 (Graham et al., 2008b) 
Tp2 96-104 FAQSLVCVL Animal BX017
2 T2c (Graham et al., 2008b) 
Tp2 98-106 QSLVCVLMK A10  2*01201 (Graham et al., 2008b) 
Tp2 138-147 KTSIPNPCKW (HPelle et al., 2011H) 
Tp4 328-338 TGASIQTTL A10-KN104  3*00101 (Graham et al., 2008b) 
Tp5 87-95 SKADVIAKY Animal BV050
2 BoLa T5 (Graham et al., 2008b) 
Tp7 206-214 EFISFPISL Animal BW012
2 BoLa T7 (Graham et al., 2008b) 
Tp8 378-388 CGAELNHFL A10-KN104 3*00101 (Graham et al., 2008b) 
Tp9 64-73 AKFPGMKKS A14  1*02301 
Tp10 304-318
1 TNNFNNPELIPVL A10  3*00201  (MacHugh Unpublished) 
1 The minimal epitope length is not yet identified, estimated amino acid composition   
2 Haplotype not defined 
3 Naming of the MHC I molecules was adapted to comply with the new nomenclature 
as described in the ImmunoPolymorphism Database (IPD) (Codner et al., 2012; 
Hammond et al., 2012)  
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1.8 Immunodominance  
MacHugh et al. (2009) provided direct evidence for immunodominance in 
CD8+ T cell responses against T. parva. In MHC I homozygous animals immunised 
with T. parva, a large component of the CD8+ T cell response was found to be 
focused on a single dominant antigen. In animals homozygous for the A18 and A10 
MHC I haplotypes, over 60% of the responding T cell clones were found to 
recognise defined epitopes in the Tp1 and Tp2 antigens respectively (MacHugh et 
al., 2009a). Immunodominance is a common feature in CD8+ T cell responses in 
viral infections; CD8+ T cell responses are preferentially directed towards one or a 
few dominant epitopes despite the presence of a T cell repertoire (TCR) with 
multiple specificities that potentially is capable of responding to a wide range of 
peptides (Yewdell, 2006; Yewdell and Bennink, 1999). 
Immunodominance is the result of a complex combination of factors involved in 
antigen processing and antigen recognition by CD8+ T cells. The relative importance 
of the various factors is likely to differ for different combinations of pathogen and 
host (Yewdell, 2006; Yewdell and Bennink, 1999; Yewdell et al., 2003). Firstly, 
factors that influence the abundance of the peptide epitope associated with MHC I on 
priming antigen-presenting cells play a role. This is dependent on abundance of 
protein prior to antigen processing and the efficiency of peptide processing by the 
MHC I antigen-presenting pathway (Luciani et al., 2013; York et al., 2006). The 
stability of peptide MHC I complex (pMHC) is further dependent on the affinity of 
peptide for the MHC I molecules (Yewdell, 2006). Secondly, immunodominance is 
influenced by factors that influence CD8+ T cell precursor frequency and the affinity 
of the T cell receptors in the T cell repertoire for pMHC. Specific memory CD8 T 
cell will be present at a higher frequency in the memory CD8+ T cell pool after 
initial exposure. Prior experiences can therefore influence the immunodominance 
hierarchy (Cole et al., 1997). Thirdly, so called ‘cross-competition’ can influence 
immunodominance. In cross-competition, CD8+ T cells of different specificities 
compete for interaction with antigen presenting cells (APC) upon challenge with a 
mixture of multiple antigens (such as whole pathogens) (Galea et al., 2012; 
Kastenmuller et al., 2007; Luciani et al., 2013). 
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1.8.1 Immunodominance and sequence 
polymorphism in Theileria parva 
The effect of antigen polymorphism on MHC I presentation and T cell recognition 
has been investigated for two parasite-encoded genes, Tp1 and Tp2. Firstly, an 
epitope was identified (Tp1214-224) in Tp1 of the Muguga genome sequence, which 
can be presented by MHC I allele 6*01301 (Graham et al., 2006). Anchor positions 
involved in peptide binding to MHC I were defined to be P2 (i.e. the residue at 
position 2), P5 and the C-terminal residue. However, alanine substitution at P2 for 
Tp1214-224 did not have an effect on MHC I binding, while substitutions at P5 and the 
C-terminal residue reduced MHC I binding, the latter having the greatest 
effect(Macdonald et al., 2010).  
X-ray crystallography of the pMHC complex (6*01301-Tp1214-224) demonstrated that 
the peptide is presented in a raised conformation. The residue at position nine is 
predicted to be at the point where the main chain of the peptide dips back in the 
binding groove, resulting in several interactions which are critical for the shape and 
stability of the pMHC. Residue changes between P6 and P9 abrogated T cell 
recognition, with alanine substitutions at P9 being most critical. On the basis of the 
crystallographic structure, it was predicted that substitution at P9 would disrupt the 
shape and stability of the complex and thus abrogate TCR recognition (Macdonald et 
al., 2010). However, no amino acid substitutions are found for the P6 and P9 residues 
in natural allelic variants of Tp1 (Pelle et al., 2011). Among allelic sequences of the 
peptide discovered to date, only relatively conserved substitutions of P10 and P11 
have been found (Pelle et al., 2011) and peptides but not cells infected with parasites 
carrying the allelic variants can be recognised by CD8+ T cells in vitro (Steinaa et al., 
2012); (MacHugh et al., 2009a) 
Connelley et al. investigated the role of polymorphism in one of the epitopes in Tp2 
(Tp249-59) (Connelley et al., 2011; Pelle et al., 2011), which is presented by MHC I 
allele 2*01201 (Graham et al., 2008b). The binding of variant epitopes was 
investigated using a series of peptides with alanine substitutions at different positions 
relative to the reference sequence. This was undertaken using a competitive binding 
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assay with the Tp298-106 epitope, which is also presented by the 2*01201 MHC I 
allele.  Serial dilutions of variant peptides were tested for their ability to 
competitively block the binding of the Tp298-106 peptide.  The MHC I binding 
capacity of the Tp249-59 variants was determined by inhibition of cytotoxicity against 
the Tp298-106 epitope. The residue in position eleven was found to be critical for 
MHC I binding and is thus likely to be an anchor residue. All but one of the ten 
allelic variants from the field with substitutions at P11 were still able to bind to MHC 
I, but with varying degrees of efficiency (Connelley et al., 2011). Each of the CD8+ T 
cell clones tested failed to recognise peptide presented with an alanine substitution at 
P8. In addition, none of the natural Tp249-59 variants with amino acid substitutions 
(relative to the reference sequence) at this position were recognised. A proportion of 
the variants with an alanine substitution at P8 retained MHC I binding, indicating that 
the loss of killing activity must be the result of reduced T cell recognition rather than 
MHC I binding (Connelley et al., 2011). 
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1.9 Aims and objectives  
It is clear that allelic polymorphism in Theileria parva antigens recognised by 
CD8+ T cell responses has a profound influence on T cell recognition in vitro. A high 
degree of allelic polymorphism has been observed for some of the antigens that are 
known to be recognised by CD8+ T cell responses (i.e. Tp1 and Tp2), particularly in 
buffalo-derived T. parva. Cattle immunised with the Muguga Cocktail are not solidly 
protected against challenge with buffalo-derived T. parva. It has been hypothesised 
that immunodominance of CD8+ T cell responses against polymorphic antigens is 
responsible for the strain-specificity associated with bovine immunity following ITM 
immunisation using stabilates with limited antigenic diversity. Challenging 
genotypes may have different epitope sequences that may prevent presentation by 
MHC I and/or recognition by CD8+ T cells thus allowing parasites to escape the 
immune response and cause severe clinical disease.
The overall objectives of this project are to investigate antigenic diversity within the 
Muguga Cocktail vaccine and to determine how this relates to antigenic diversity in 
field parasite populations, with particular reference to buffalo-derived T. parva. The 
specific aims of the project were to: 
1. Determine the degree of genetic and antigenic diversity of T. parva parasites
within the Muguga cocktail vaccine 
2. Determine the degree of genetic and antigenic diversity between and within
buffalo-derived Theileria parva in samples from African buffalo from Kenya and 
South Africa 
3. Examine the biological relevance of antigenic diversity by conducting
immunisation and challenge experiments using parasites of known antigenic 
composition 
4. Determine whether parasites of the Theileria genus other than T. parva are present
in African buffalo and sentinel animals 
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4BChapter 2: General Materials and Methods 
14B2.1 Cellular techniques  
32B .1.1 Isolation of peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were obtained as described by 
Goddeeris et al. (Goddeeris and Morrison, 1988). Blood was collected from the 
jugular vein in an equal volume of Alsever’s solution. PBMC were separated by 
density gradient sedimentation over Ficoll-Paque Plus (GE Healthcare, Uppsala, 
Sweden) in 50 ml Falcon tubes and centrifugation at 900 g for 30 minutes. Cells 
were harvested from the Ficoll-Paque interface and mixed with an equal volume of 
Alsever’s solution before centrifuging at 450 g for ten minutes. The pellet was 
washed three times in Alsever’s solution by re-suspending and centrifuged for five 
minutes at 180 g. The final pellet was then re-suspended in standard culture medium 
(referred to as SCM, see Appendix A) and counted using a haemocytometer. 
33B2.1.2 Magnetic-activated cell sorting (MACS) for cell subset 
isolation 
CD8+ cells and blood monocytes were isolated from PBMC by positive selection 
using Magnetic-activated cell sorting (MACS) (Miltenyi Biotec). PBMC were 
obtained as described previously and washed once in phosphate buffered saline 
(PBS) with 2% foetal calf serum (FCS) (PBS-FCS). CD14+ cells were purified from 
PBMC using magnetic beads directly conjugated to goat-anti-human CD14+ IgG 
(Miltenyi Biotec) according to the manufacturer's recommendations. PBMCs were 
mixed with 10 µl CD14 microbeads/107 cells and incubated on ice for 30 minutes. 
CD8+ T cells were purified from PBMC using a mixture of CD8-specific monoclonal 
antibodies (IL-A51 and IL-A105). PBMC were pelleted and re-suspended before 
adding 12.5µl IL-A51/ILA105 (1:500) per 106 cells. The cells were incubated on ice 
for 30 minutes and then washed twice (six to eight minutes at 300 g) in PBS-FCS to 
remove unbound primary antibody. The pellet was re-suspended in PBS-FCS and 
10 μl of anti-mouse IgG microbeads (Miltenyi Biotec) were added per 107 cells. The 
cells were incubated on ice for 30 minutes before transfer to a mini MACS column. 
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The mini MACS column was mounted on the magnet and flushed with 0.5 ml MACS 
buffer (99.5 ml PBS-FCS and 0.5 ml 2 mM Edetic Acid (EDTA)). The cells were 
washed twice in PBS-FCS and re-suspended in 0.5-1 ml MACS buffer. The re-
suspended cells were carefully transferred to the mini MACS column and fluid was 
allowed to pass through the column. The column was washed three times in 0.5 ml 
MACS buffer. Then 2 ml of SCM was added to the column before removal from the 
magnet. The cells were eluted in SCM by removing the column from the magnet and 
inserting the plunger. Flow through was collected in a tube. 
34B2.1.3 Establishment of T. parva-infected cell lines  
Bovine PBMC were infected with T. parva parasites using cryopreserved aliquots of 
sporozoite stabilate. Straws of stabilates were removed from liquid nitrogen, thawed 
rapidly and the contents transferred to a 1.5 ml Eppendorf tube, before adding 1 ml 
of SCM. Particulate tick material was removed by centrifuging at 100 g for five 
minutes and the supernatant containing the sporozoites collected. PBMC were re-
suspended in SCM at 2 x 107/ml and 1 ml of stabilate supernatant added and the 
mixture incubated at 37 C for one hour. The cells were washed once in SCM, re-
suspended at 5 x 106/ml and added to the wells of a 24-well plate. Cultures were 
incubated at 37 C in 5% CO2 (Goddeeris and Morrison, 1988). 
35B2.1.4Generation of cloned Theileria-infected cell lines  
Established Theileria-parasitised cell lines were cloned by limiting dilution in 
conditioned medium (containing 50% SCM and 50% supernatant from established 
buffalo T. parva-infected cell lines) and irradiated bovine PBMC as filler cells. 
Theileria-infected cells were diluted in conditioned medium to a concentration of 
15 cells/ml, 3 cells/ml, 1.5 cells/ml and 0.5 cells/ml. 200 l of cells were distributed 
into wells of 96-well plates to give a concentration of 3 cells/well, 1 cell/well, 
0.3 cells/well and 0.1 cells/well. Irradiated filler cells were added to each well at a 
concentration of 2 x 105 filler cells/well. The plates were then screened 
microscopically and the frequency of wells giving cell growth was determined. Only 
cells from plates showing growth in less than 30% of wells were selected as they 
have a greater than 83% likelihood of being clonal (Goddeeris and Morrison, 1988). 
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Cells from the selected wells were expanded in several wells of a 96-well plate 
before transfer to 24-well plates. The cells from four wells in a 24-well plate were 
then transferred to T25 flasks. 
36B2.1.5 Generation of CD8+ T cell lines   
CD8+ T cell lines were generated in a similar manner to that previously described 
(Goddeeris and Morrison, 1988). Briefly, PBMC were stimulated with autologous 
irradiated parasitised cells in wells of 48-well plates, each well containing 2 x 106 
PBMC (responder cells) and 2 x 105 stimulator cells. All stimulator cells were 
irradiated by exposure to 60Gy of gamma irradiation (ILRI, Nairobi). Cells were 
incubated at 37 C in 5% CO2 for seven days. Viable cells were harvested, washed 
and stimulated a second time as described above, but this time using 1 x 106 
responder cells/well and 4 x 105 stimulator cells/well. Cells from the second 
stimulation were harvested after seven days and enriched by positive selection of 
CD8+ cells by MACS sorting as described previously. Cells were stimulated for a 
third time by distributing 106 responder cells/well with 4 x 105 stimulator cells/well 
in SCM with 100 units recombinant human (rh) IL-2/ml into wells of 48-well culture 
plates. Irradiated autologous T. parva-infected cell lines were used as stimulators (T. 
parva Muguga stabilate 3308). Plates were incubated at 37 C in 5% CO2 for a 
further seven days. The same protocol was used for further re-stimulations of the 
cultures. 
37B2.1.6 Phenotyping of cells by flow cytometry 
Purity of the CD8+ T cell lines was checked by flow cytometry before assaying for 
cytotoxicity. Aliquots of 50 l of cells were distributed in wells of 96-well round-
bottom well plates and pelleted by centrifugation at 900 g for 30 seconds. The 
medium was discarded, the cells re-suspended and 25 l of the required primary 
antibody added. Negative controls were incubated with FACS medium instead of 
primary antibody. The plate was incubated at 4 C for 30 minutes before washing in 
FACS medium (see Appendix A) for a total of three washes. The cells were then re-
suspended in 25 l secondary antibody, 1:100 diluted fluorescein isothiocyanate 
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(FITC)-labelled goat polyvalent anti-mouse-immunoglobulin antibody (Sigma-
Aldrich, UK). The cells were incubated at 4 C for 30 minutes, washed three times as 
previously described, re-suspended in 200 l FACS medium and analysed using a 
BD FACScalibur flow cytometer (Becton Dickinson, USA). The antibodies used for 
typing are listed in Table 2.1. 
Table 2.1 Monoclonal antibodies used for FACS analysis 
Monoclonal antibody Specificity Cell populations identified  
MMIA CD3 All T cells 
IL-A12 CD4 CD4 T cells  
IL-A105/IL-A51 CD8 CD8 T cells, some NK cells  
CC15 or T4 WC1 γ T cells 
IL-A24 SIRP-1A Monocytes
IL-A30 IgM B cells
38B2.1.7 Cytotoxicity assays - Chromium release assay 
CD8+ T cell lines were tested for specificity using a four-hour Chromium release 
cytotoxicity assay. 2 x 106 target cells were labelled with 10 µl 51Chromium and 
incubated for one hour at 37 C in 5% CO2. The cells were washed three times by 
adding 8 ml cytotoxicity medium (see Appendix A) and centrifugation at 180 g for 
five minutes. The pellets were re-suspended in cytotoxicity medium to give a 
concentration of 106 cells/ml. 
For each target cell, 3 x 105 CD8+ T cells were distributed into 96-well plates 
together with 5 x104 of labelled target cells to give an effector to target ratio of 6:1. 
Spontaneous release by each target cell was measured in triplicate wells containing 
100 l cytotoxicity medium instead of effector cells. Maximum release was 
measured in triplicate wells containing 100 l of 0.2% Tween instead of effector 
cells. 
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Plates were centrifuged briefly before incubating at 37 C in 5% CO2 for four hours. 
The plates were centrifuged again and 75 l supernatant of each well harvested using 
a multi-pipette and transferred to 96-well lumaplates (Perkin Elmer, USA) which 
were dried in an oven overnight. The next day the lumaplates were taken from the 
oven and sealed with Top seal-A (Perkin Elmer, USA). Radioactivity release was 
measured using a TopCount NXT machine (Perkin Elmer, USA). 
The percentage cytotoxicity was calculated with the following formula: 
% cytotoxicity =  100   x  (test 51Chromium release - spontaneous 51Chromium release) 
 (maximum 51Chromium release - spontaneous 51Chromium release) 
39B2.1.8 Cytotoxicity assays - Indium release assay 
CD8+ T cell lines were tested for specificity using a four-hour 111Indium release 
cytotoxicity assay. Target cells were labelled by incubation with 5 Ci of Indium for 
30 minutes at 37C in a 15 ml falcon tube. Then the cells were washed six times in 
8 ml cytotoxicity medium (see Appendix A) and centrifuged at 180 g for five 
minutes. The pellets were re-suspended in cytotoxicity medium to give a 
concentration of 105 cells/ml. 50 µl of target cell were added to each of the wells to 
give a concentration of 5 x103 target cells/well. CD8+ T cells were added at different 
concentrations to give effector to target ratios between 20:1 and 0.6:1. A fixed 
effector to target ratio was used when examining the recognition of peptide using an 
autologous T. annulata line as presenter. Peptides were obtained from JPT Peptide 
Technologies GmbH, Germany. The peptide concentration was titrated using ten-fold 
dilutions ranging from 100 ng/ml to 0.01 ng/ml. 
Spontaneous and maximum releases were measured for each of the target cells. 
Spontaneous release was measured in triplicate wells containing 100 l cytotoxicity 
medium instead of effector cells. Maximum release was measured in triplicate wells 
containing 100 l of 0.2% Tween instead of effector cells. Plates were gently 
centrifuged (180 g) for one minute and incubated at 37 C in 5% CO2 for four hours. 
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After four hours the plates were centrifuged in order to pellet the cells and 75 l 
supernatant of each well was transferred into individual gamma counter tubes and a 
small amount of bromophenol blue-stained 1.5% agarose added to capture 
radioactivity in solid form in case of spill. Radioactivity release was measured with a 
Wallac Wizard 1470 Automatic Gamma Counter and percentage cytotoxicity was 
calculated using the following formula: 
% cytotoxicity = 100 x  (test 111In release - spontaneous 111In release)          
(maximum 111In release - spontaneous 111In release) 
40B2.1.9 Ex vivo enzyme-linked immunosorbent spot assay 
(ELISPOT) 
An ex vivo ELISPOT was performed to check whether CD8+ T cells from immunised 
animals were capable of recognising T. parva-infected cells and selected epitopes 
within the Tp2 protein (Tp249-59 and Tp298-106). ELISPOT plates (Millipore, Billerica, 
MA, USA) were pre-coated overnight with a monoclonal anti-bovine IFN-γ antibody 
CC302 (Serotec, Oxford, UK). Plates were washed twice with 200 µl of un-
supplemented minimum essential media (MEM) before blocking with 200 µl of 
Roswell Park Memorial Institute medium (RPMI) supplemented with 10% heat-
inactivated FCS. Plates were incubated at 37 °C for two hours. The RPMI 
supplemented with 10% heat-inactivated FCS was flicked off and replaced with cells 
and incubated in a humidified incubator at 37% with 5% CO2. 
CD8+ T cell and CD14+ cells were isolated from blood as previously described. 
Theileria parva Muguga cell lines were irradiated and left overnight at room 
temperature and washed twice before use. For presentation of peptide, CD14+ cells 
were used at 2.5 × 104 cells/well and peptides were added at a concentration of 1 µM. 
Irradiated and washed T. parva-infected cells were used at 2.5 × 104/well. CD8+ T 
cells were added at 2.5 × 104 cells/well. Controls wells were included that contained 
only CD14+ cells, only CD8+ T cells or only Theileria parva parasitised cells. After 
incubation, well contents were flicked off and plates were washed four times using 
200 µl of distilled water with 0.05% Tween20 (Sigma–Aldrich, USA), followed by 
four washes using 200 µl PBS (Dulbeco) with 0.05% Tween 20 (PBS-T). Then 
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50 μl/well of rabbit anti-bovine IFN-γ anti-sera 1:500 (ILRI, Kenya) was added and 
incubated for one hour at room temperature. The cells were washed four times in 
200 µl PBS-T, before adding 50 μl/well of alkaline phosphatase-conjugated mouse-
anti-rabbit IgG (1:2,000) diluted in PBS + 0.05% Tween20 + 0.1% BSA (Sigma-
Aldrich, USA). Plates were incubated for one hour at room temperature followed by 
six washes in PBS-T. Plates were developed by adding 50 μl/well of substrate 
solution to one tablet of Sigma Fast BCIP/NBT substrate (Sigma–Aldrich, USA) in 
10 ml distilled water. 
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15B2.2 In vivo experiment 
41B2.2.1 Ethical approval 
Ethical permission for the experiment was obtained from the Institute Animal Care 
and Use Committee (IACUC) committee at ILRI, Nairobi, Kenya. The experiment 
was performed as stated in the standard operating procedures for animal 
experimentation, Sections 11 and 20. These SOPs were prepared initially by 
Internationl laboratory for research on animal diseases (ILRAD) IACUC on the 2nd 
of August 1994 and were last revised by ILRI/ IACUC on the 19th March 2004. The 
only exception in this study was that the end-point determination was left to the 
discretion of the institute veterinarian. The SOP was developed for studies using 
cattle-derived T. parva for challenge and decisions on treatment or euthanasia of 
animals were based on an ECF reaction index incorporating parasitological and 
clinical parameters. However, in previous studies using buffalo-derived T. parva 
parasites, disease progression occurred more rapidly. Therefore, decisions to treat or 
euthanize animals were taken when deemed necessary, even when this was not yet 
required on the basis of the ECF index. 
42B .2.2 Screening of animals for in vivo studies  
Animals expressing the MHC I haplotype A10 were selected by workers at ILRI. 
Preliminary selection was performed by immunofluorescence staining of PBMC 
using a monoclonal antibody (IL-A10) specific for the MHC I haplotype A10. This 
was further validated first, by demonstrating recognition by a CD8+ T cell line of a 
peptide known to bind to the 2*01201 A10 class I gene product, following 
incubation of peptide with PBMC from test animals, and second, by sequencing of 
the second A10 class I gene 3*00201. 
43B2.2.3 Infection and treatment 
Animals were immunised by Infection and Treatment using T. parva Muguga 
(stabilate 3308) and long acting oxytetracycline as previously described (Radley et 
al., 1975a). 1.0 ml of stabilate was inoculated subcutaneously below and in front of 
the parotid lymph node using a 1 ml syringe and a 21 G needle. The site was 
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swabbed with 70% alcohol prior to inoculation. At the same time, animals were 
injected with 20 mg/kg of long acting oxytetracycline by deep intra-muscular 
injection. Following immunisation, cattle were examined daily and rectal 
temperatures were taken and recorded. Lymph node smears were taken when the 
rectal temperature was greater than 39.5 °C. Cattle were treated with an anti-
theilerial drug when developing a severe reaction. Blood samples were taken at 
weekly intervals to determine serological responses to immunisation. 
44B2.2.4 Challenge 
Ten weeks after immunisation the animals were challenged, along with two naïve 
controls, with buffalo derived stabilate 3081. Animals were challenged with 1 ml of 
1:20 dilution of Stabilate 3081 by inoculating subcutaneously below and in front of 
the right parotid lymph node using a 1 ml syringe and a 21 G needle. Five straws 
were taken from liquid nitrogen, thawed rapidly and the contents thoroughly mixed 
before diluting 1:20 using vaccine diluent (see Appendix A) while kept on ice. Time 
of thawing was noted. Briefly, animals were inspected three times daily and 
monitored for temperature rise and lymph node enlargement daily. Lymph node and 
blood smears were taken daily when the body temperature was increased and/or 
when the lymph nodes were enlarged. Blood samples were taken at weekly intervals 
to determine serological responses to immunisation. 
In addition, blood samples and lymph node aspirates were taken twice weekly for 
DNA extraction. This frequency was increased to daily when clinical signs were 
detected until the day of treatment or recovery. Haematology was performed every 
two days. 
45B2.2.5 Examination of lymph node and blood smears  
The site for lymph node biopsy was swabbed with 70% alcohol prior to taking the 
biopsy. The lymph node was immobilised between the thumb and forefinger of one 
hand and a 20 G needle on a 2 ml syringe was pushed into the centre of the lymph 
node with the other hand. The plunger of the syringe was carefully withdrawn until a 
small volume of lymph was observed in the hub of the needle. The needle was 
removed, the sample deposited on a microscope slide and a smear made using a drop 
of blood collected in EDTA. 
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Lymph node and blood smears were allowed to dry at room temperature then fixed in 
100% methanol for three minutes and allowed to air dry. The slides were then stained 
using 10% Giemsa diluted in staining buffer (see Appendix A) for twenty minutes. 
The slides were then washed by overflowing the jar containing the stained slides with 
tap water and pouring off the Giemsa stain. They were then washed a further two 
times by filling the jar with tap water and pouring the water off before allowing them 
to dry. The slides were examined under oil immersion using a standard light 
microscope. The criteria used for scoring the levels of parasites (parasitosis) were as 
follows: Ma+, schizonts not easy to find; Ma++, one or two schizonts visible per 
field; Ma+++, more than two schizonts per field. 
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16B2.3 Molecular techniques 
46B2.3.1 Processing samples prior to DNA extraction 
Some pre-processing of samples was required before DNA extraction. Following 
thawing of sporozoite stabilate from liquid nitrogen, excess tick debris was removed 
by centrifuging at 100 g for five minutes. The supernatant containing the sporozoites 
was transferred to a clean Eppendorf tube. The sporozoites were pelleted at 16,000 g 
for ten minutes if a smaller volume was required for DNA extraction. Theileria-
infected cells were harvested from a T25 flask, centrifuged at 900 g for five minutes 
and DNA extracted from the re-suspended pellet. Lymph node aspirates were put in 
PBS and the cells were pelleted by centrifuging at 16,000 g for one minute prior to 
extraction of DNA from the re-suspended pellet. DNA was extracted from 100 µl of 
whole blood collected in EDTA. 
47B2.3.2 DNA extraction  
DNA was extracted from various samples using the Qiagen DNeasy Blood and 
Tissue Kit, according to the manufacturer’s instructions. Briefly, 20 µl of 
proteinase K was added to the sample and the tubes were mixed in a vortex mixer. 
Then 200 µl lysis buffer (AL) was added and tubes incubated at 56 °C for ten 
minutes while shaking. Then 200 µl ethanol was added and tubes mixed thoroughly. 
The mixture was then transferred to a DNeasy mini spin column and centrifuged for 
one minute at 6,000 g. The fluid in the collection tube was discarded and 500 µl of 
washing buffer AW1 was added to the column. The DNeasy mini spin column was 
centrifuged for two minutes at 6,000 g and the flow-through discarded. 500 µl of 
washing buffer AW2 was added and the column centrifuged for three minutes at 
20,000 g. The DNeasy mini spin column was transferred to a clean Eppendorf tube 
and between 100 and 200 µl elution buffer (AE) was added to the membrane of the 
DNeasy mini spin column. The Eppendorf tube and DNeasy mini spin column were 
centrifuged for two minutes at 6,000 g and DNA within the eluate was collected in 
the Eppendorf. DNA was stored at -20 °C until further use. 
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48B2.3.3 PCR 
A number of genes were amplified by PCR in this study. Each PCR reaction was 
comprised 20 pmol forward primer, 20 pmol reverse primer, 0.5 units BIOTAQ 
polymerase (Bioline, UK), 2.0 l 10 x PCR master mix, 50 ng genomic DNA and 
nuclease-free water, to give a final volume of 20 l. A G-storm thermal cycler 
(Genetic Research instrumentation, UK) was used for amplification. The PCR cycle 
programme was as follows: 95C for three minutes, 30 cycles of (95 C for one 
minute, X C for one minute, 72 C for two minutes) and a final extension period of 
72 C for seven minutes. The annealing temperature was adjusted according to the 
primer pair used and was equal to the lowest melting temperature of the primer pair.  
PCR amplification of samples for Roche 454 amplicon sequencing, which used 
fusion primers and DNA polymerase with proofreading capacity, will be discussed in 
Chapter 3. 
49B2.3.4 Purification of PCR products  
PCR products were purified using the Promega Wizard Gel and PCR Clean-up 
System (Promega Corporation, USA). PCR products were visualised by UV on a 
1.5% agarose gel (Bioline, UK) containing SafeView nucleic acid stain (NBS, 
Biologicals Ltd, UK) in Tris-acetate-EDTA buffer (TAE) and bands of the product of 
interest were excised. Membrane-binding solution was added at 10 µl per 10 µg of 
excised product. The agarose was then allowed to melt in a water bath at 60 °C for 
ten minutes. For direct purification, PCR products were mixed with an equal amount 
of membrane-binding solution. The mixture was added to a SV minicolumn fitted on 
a collection tube and incubated for one minute. The SV minicolumn and collection 
tube were centrifuged at 16,000 g for one minute. The flow-through was discarded 
and 700 µl of membrane washing solution added to the column and another spin 
performed at 16,000 g for one minute. The flow-through was discarded and 500 µl of 
membrane washing solution added to the column. The SV minicolumn and collection 
tube were centrifuged at 16,000 g for five minutes. After discarding the flow-through 
the empty SV minicolumn was centrifuged at 16,000 g for one minute. The SV 
minicolumn was transferred to a new Eppendorf tube and between 30 and 50 l of 
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nuclease-free water was added. After another incubation of one minute, the SV 
minicolumn was centrifuged at 16,000 g for one minute. The SV minicolumn was 
discarded and the eluate containing purified DNA stored at -20 C until further use. 
50B2.3.5 Cloning of PCR products 
PCR products were cloned into the pGEM-T Easy vector system (Promega 
Corporation, USA) according to the manufacturer’s instructions. The ligation 
reaction was composed of 5µl 2 x Rapid ligation buffer, 1µl pGEM-T Easy vector, 
1µl T4 DNA ligase (3 Weiss units/µl), ~25 ng PCR product and nuclease-free water 
to give a final volume of 10 l. The reaction mix was incubated for one hour at room 
temperature or overnight at 4 °C. The ligated plasmid/PCR products were 
transformed into JM109 high efficiency competent cells (Promega Corporation, 
USA). Aliquots of 50 µl JM109 cells were added to 2µl of ligation reaction and 
incubated for twenty minutes on ice. The cells were heat-shocked for 45 to 50 
seconds at exactly 42 °C and immediately returned to ice. 950 µl of SOC medium at 
room temperature was added and the cells were incubated for 1.5 hours in a shaking 
incubator at 37 °C and 150 rpm. 100 µl of the transformant was plated on duplicate 
LB/ampicillin/IPTG/X-Gal plates and incubated overnight at 37 °C. Transformed 
colonies were identified on the basis of blue/white screening. Plasmid clones were 
expanded in tubes containing 6 ml of Luria Broth (LB) media containing ampicillin 
at a concentration of 100 µg/ml. Small quantities of individual clones were added to 
the LB/ampicillin using a 10 µl pipette tip. The tubes were incubated overnight in a 
shaking incubator at 37 °C and 150 rpm. 
51B2.3.6 Purification of plasmid clones 
Expanded colonies were purified using the PureYieldTM Plasmid Miniprep System 
(Promega Corporation, USA) according to the manufacturer’s instructions. Briefly, 
600 μl bacterial culture grown in LB medium was transferred to a 1.5 ml Eppendorf 
tube and 100 μl of cell lysis buffer added. This was then mixed by inverting the tube 
six times. Then 350μl of cold neutralisation buffer was added and the contents of the 
tube mixed by inverting until yellow precipitate formed followed by another three 
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inversions. The tube was centrifuged at maximum speed for three minutes and the 
supernatant transferred to a PureYieldTM minicolumn placed in a collection tube. The 
PureYieldTM Minicolumn/collection tube assembly was centrifuged for 15 seconds at 
16,000 g and the flow-through discarded. 200 μl of endotoxin removal wash was 
then added to the PureYieldTM minicolumn and centrifuged for 15 seconds at 
16,000 g, following which 400 μl of column wash solution was added to the 
minicolumn. After a further spin of 30 seconds at 16,000 g, the PureYieldTM 
minicolumn was transferred to a clean 1.5 ml Eppendorf and 30 μl elution buffer was 
added directly to the PureYieldTM minicolumn matrix. The PureYieldTM 
minicolumn/Eppendorf assembly was then centrifuged for 15 seconds at 16,000 g 
after one minute of incubation. Eluted plasmid DNA was stored at -20 °C until 
further use. 
52B .3.7 Bioinformatic sequence analysis 
Purified PCR products or plasmid were sequenced using Sanger technology at DBS 
genomics, University of Durham. Sequencing was carried out using custom primers 
at a concentration of 3.2 pmol/l. Resulting sequence traces were inspected and 
DNA sequences manually corrected and/or trimmed if required. The sequences were 
then analysed using the MEGA5 software package (Tamura et al., 2011). Sequence 
alignments were performed using the default setting of MUSCLE. Phylogenetic 
analysis was performed using MEGA5 (Tamura et al., 2011). Phyogenetic trees were 
inferred using the maximum likelihood method, parsimony method and/or neighbour 
joning method. The optimal nucleotide substitution model was identified using 
Datamonkey (Delport et al., 2010). Phylogenetic trees of the 18S rRNA gene were 
rooted using the 18S rRNA gene sequence of Prororectum micans (M14649), 
Sarcocystic muris (M64244) and Toxoplasma gondii (X68523) as previously done by 
Chaisi et al. (Chaisi et al., 2013) and other more closely related species when 
available. Phylogenetic trees for 5S, Tp6, Tp7 and Tp8 were rooted using sequences 
obtained from the NCBI database, identified using a BLAST search. Heterozygosity 
was calculated using the formula: He = 1 - ΣPi
2 where P is the proportion of allele i. 
The mean diversity in a parasite population was calculated using a maximum 
composite likelihood model in MEGA5; this represents the number of base 
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substitutions per site from averaging over all sequence pairs in the population 
(Tamura et al., 2004; Tamura et al., 2011). Distance matrices were constructed using 
MEGA5 (Tamura et al., 2011) by calculating pair-wise distances using the maximum 
composite likelihood model (Tamura et al., 2004). The rate variation among sites 
was modelled with a gamma distribution (shape parameter = 2). These distance 
matrices were exported for principal co-ordinate analyses using the Genalex plug-in 
for Excel (Peakall and Smouse, 2012). The K-means for the different sub-
populations was calculated using the statistical package, R. 
53B2.3.8 Processing of PCR products for 454 sequencing 
For the 454 sequencing runs, equimolar quantities of purified PCR product, 
generated as described in Chapter 3, were pooled. Purity and product size were 
determined by analysing samples on a Bioagilent DNA1000 chip (Agilent 
technologies, UK) using the Bioanalyser 2100 (Agilent Technologies) and 2100 
expert software (Agilent Technologies) according to the manufacturer’s protocol. 
Preliminary quantification of PCR products was performed by Nanodrop. The PCR 
products were then diluted in triplicate to a concentration of between 20 and 1000 
pg/µl and the DNA concentration determined using a picogreen assay (Invitrogen). 
The concentration of the PCR products was calculated using the standard curve of 
the standards in the picogreen assay. The molarity of the PCR products was 
calculated using the concentration obtained by the picogreen assay and the size 
obtained from the Bioagilent 100 chip, using the following formula: 
Molecules/μl =  (Sample concn in ng/μl) x (6.022 x 1023)  
(656.6 x 109) x (amplicon length in bp) 
Analysis of the sequences obtained by 454 sequencing will be described in Chapter 3 
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54B2.3.9 Satellite DNA typing  
PCR amplification was performed using satellite markers and methods as previously 
described by Oura et al. (Oura et al., 2003). The distribution of the satellite markers 
across the genome is illustrated in Figure 2.1 and their primer sequences are detailed 
in table 2.2. One primer of each primer pair was labelled at the 5' end with the 
fluorophore FAM. Each PCR reaction comprised 10 pmol forward primer, 10 pmol 
reverse primer, 0.5 units BIOTAQ DNA polymerase (Bioline, UK), 1 l of 10 x 
custom PCR buffer (Thermo Fischer, UK), 1 µl of stabilate DNA and nuclease-free 
water to give a final volume of 10 l. The cycling conditions were: 35 cycles of 
denaturation at 94 °C for one minute, annealing at 60 °C for one minute and 
extension at 65 °C for one minute. 
Figure 2.1 Graphical illustration of the satellite loci used in this study 
Adapted from Katzer et al. 2010. Chromosomes 1-4 are denoted by I-IV. Sizes of individual 
chromosomes are identified below. The location of mini satellite (MS) and micro satellite (ms) DNA 
marker is indicated. 
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The PCR products were analysed using capillary flow electrophoresis with the 
fluorophore signal detected using a laser. In the first instance, the presence of PCR 
products was confirmed by running 6 µl of product on a 1.5% agarose gel containing 
ethidium bromide or SafeView nucleic acid stain (NBS, Biologicals Ltd, UK). PCR 
products were then diluted in sterile water (between 1:5 and 1:200 depending on the 
intensity of the band observed on the gel) and 20 µl of each diluted sample was 
transferred to a 96-well non-skirted PCR plate. The plates were sealed with a sterile 
silicon mat and sent to the University of Dundee Sequencing Service for genotyping 
using GenescanTM technology (Applied BioSystems) with GSLIZ500 size standards. 
The peak size, in base pairs (bp), was calculated using Peak Scanner software 
(Applied Biosystems) using the default sizing method with the presence of a primer 
peak and then the data was exported to an Excel spreadsheet. Only peaks in the range 
of 100 to 500 bp were considered for further analysis. In order to measure the 
relative abundance of each of the alleles, the area under the curve was calculated for 
each of peaks separately and for all peaks of a single trace combined. Peaks with an 
area less than 3% of the total area under the curve were excluded from further 
analysis. The relative abundance of individual peaks was expressed as a percentage 
of the total area under the curve for all peaks in a trace. The high-precision peak sizes 
were inspected and then manually adjusted to integer values to facilitate allele 
‘calling’. 
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Table 2.2 Satellite DNA markers used in this study 










































































5BChapter 3: Establishing a deep sequencing 
method to analyse diversity in Theileria parva 
antigens  
3.1 Introduction 
Cattle may be immunised against Theileria parva using the infection and treatment 
method (ITM). The Muguga cocktail vaccine stabilate has been used for ITM and 
consists of three parasite stocks (Radley et al., 1975b): Muguga, Serengeti and 
Kiambu 5. The vaccine has been used under experimental conditions and in the field 
in East Africa and appears to give good protection against challenge from cattle-
derived Theileria parva (Dolan, 1989; ILRAD, 1989; Martins et al., 2010; Musisi et 
al., 1999 ; Radley et al., 1975b; Radley et al., 1979; Uilenberg et al., 1976; Uilenberg 
et al., 1977). The components of the Muguga cocktail have previously been analysed 
using a variety of techniques, including parasite-specific monoclonal antibodies, 
RFLP-PCR of four polymorphic genes and microsatellite markers (Bishop et al., 
2001; Oura et al., 2007a; Oura et al., 2004b; Patel et al., 2011). These analyses 
demonstrated limited diversity in the Muguga cocktail and a high degree of similarity 
between the Muguga and Serengeti-transformed components (Bishop et al., 2001; 
Oura et al., 2007a; Oura et al., 2004b; Patel et al., 2011). It is believed that the 
Muguga cocktail provides broad protection against parasite challenge in the field due 
to the diversity of parasites in the vaccine. It has been hypothesised that some 
parasite genotypes may be present at a low frequency and are beneath the detection 
threshold of currently used methods. 
The different components of the Muguga cocktail should be viewed as individual 
parasite populations with a potential for genotypic diversity within each component 
part. This diversity may be due to a number of genotypes being present when the 
parasite stocks were established and this diversity may be compounded through 
sexual recombination in the tick as the stocks are passaged. Even though discrete 
parasite genotypes may not be preserved over different passages through the tick 
host, allelic diversity could be maintained across the genome within each component. 
However, the influence of genetic drift on a relatively small parasite population may 
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result in a reduction in allelic diversity over the course of multiple passages. 
Assuming that an element of allelic diversity is required for the induction of broad 
protective immunity, for example at key antigen-encoding loci, it is important that 
this diversity is maintained in every new vaccine batch and that methods are 
available for their detection. 
It has been shown that CD8 T cell responses play an important role in the control of 
T. parva in immune animals after vaccination by infection and treatment (McKeever 
et al., 1999; McKeever et al., 1994; Morrison et al., 1981). A number of antigen-
encoding loci have been identified in the parasite genome, alleles of which have been 
shown to be recognised by CD8 T cells. These antigens, referred to as Tp1-Tp10, are 
expressed in the schizont stage of T. parva (Graham et al., 2007a; Graham et al., 
2006). DNA sequencing has revealed that while a number of these antigens are 
highly polymorphic in field populations (Pelle et al., 2011), others show little 
variation among different parasite genotypes. The loci encoding these genes may be 
utilised as markers that can be used to gain an insight into antigenic diversity in T. 
parva. With the development of high-throughput DNA sequencing technology, it is 
now possible to undertake high-resolution characterisation of the different 
components of the Muguga cocktail, targeting genes encoding known CTL antigens 
to provide a multi-locus sequence typing (MLST) system. 
Multi-locus sequence typing was initially developed to analyse genetic diversity in 
prokaryotic and eukaryotic organisms by applying conventional Sanger sequencing 
to determine the sequences of multiple genes in a single organism. Applying MLST 
to a large number of individuals would provide a broad picture of genetic diversity 
within a population. The advantage of MLST over other genotyping methods is that 
DNA sequences can provide precise, discrete, reproducible genetic datasets. 
Importantly, this methodology allows comparison of results between different 
laboratories (Aanensen and Spratt, 2005; Boers et al., 2012), which may be 
challenging or impossible with other techniques. 
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Next generation sequencing strategies offer the opportunity to analyse antigenic 
diversity at far greater depth than traditional Sanger sequencing, due to the large 
number of clonal sequences that can be obtained. In the case of heterogeneous 
samples of T. parva (i.e. stabilates, or DNA extracted from an individual animal or 
tick) this would allow the detection of parasite genotypes present at a low frequency. 
The Roche 454 sequencing platform has the main advantage, compared to other 
high-throughput sequencing platforms that relatively long read lengths of 400-500 bp 
can be achieved (Liu et al., 2012).  
The Roche 454 platform uses a pyrosequencing approach and one of the strategies 
that can be employed using this technology is amplicon sequencing. DNA template 
samples are PCR amplified using ‘fusionprimers’, which consists of three 
components: a sequence-specific primer used for PCR amplification, a multiplex 
identifier (MID), which is a ten nucleotide barcode used for the identification of 
samples, and a 454-adaptor which is required for processing of the PCR products for 
sequencing. The use of these PCR primers is illustrated in Figure 3.1. Following this 
initial amplification, the 454-adaptor region of single-stranded PCR products anneals 
to sequencing beads to allow clonal amplification of products using an emulsion-
based PCR. Following amplification, individual beads are deposited in wells of a 
picotitre plate along with the sequencing reagents. The Roche 454 technology is 
based on a ‘sequencing by synthesis’ approach, which involves ‘flows’ of 
nucleotides being washed over the picotitre plate. When nucleotides are incorporated 
in the growing DNA molecule, a light burst is emitted and the intensity of this signal 
correlates with the number of nucleotides incorporated (Margulies et al., 2005). The 







Figure 3.1 Graphical illustration of 454 amplicon sequencing  
The fusionprimers used for PCR amplification consist of three components: The sequence-specific 
primers, Multiplex IDentifier (MID) and sequencing adaptor.  
 
The work presented in this chapter describes the development of a MLST system 
based on 454 sequencing technology with the capacity to analyse antigenic diversity 
in Theileria parva. This includes the design and validation of PCR primers, 
optimisation of sample preparation protocols and the development of bioinformatic 
workflows for downstream sequence analysis. The overall aim was to develop and 
apply a system that could be used to analyse the composition of parasite vaccine 
stocks and different vaccine batches and to compare diversity in vaccine stocks with 
that of field parasite populations 
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3.2 Material and Methods 
A system was developed to PCR amplify segments of genes encoding T. parva 
antigens from a variety of DNA samples and to determine the nucleotide sequence of 
these amplicons using Roche 454 FLX Titanium technology. A bioinformatics 
pipeline was developed to allow removal of artefacts from the raw sequencing data 
and to summarise the results. Development of the system involved the following 
steps: 
 Design of PCR primers
 Selection of parasites for primer validation
 Primer validation and optimisation of PCR conditions
 DNA extraction of sporozoite stabilate and carrier animals
 Sample preparation
 Bioinformatic analysis
These steps are described in detail below. 
3.2.1 Design of PCR primers 
Primers were designed to amplify 300-500 bp segments of a number of genes known 
to encode antigens recognised by CD8 T cells (Tp1-Tp10). The amplicons included 
epitope regions, where epitopes within the antigens had been identified. The genomic 
reference sequences of the T. parva (Muguga) antigen genes and additional 
sequences of allelic variants provided by R. Pelle (ILRI, Kenya) and C. Sugimoto 
(Hokkaido University, Japan) were used to facilitate primer design. Available 
sequences were aligned using the MUSCLE algorithm in the Mega5 software 
package (Edgar, 2004; Tamura et al., 2011) and primers were designed to match 
regions of the genes that were conserved among the different T. parva parasites. 
Primer sequences were BLASTed against the NCBI nucleotide database to ensure 
they only matched the sequence of the gene of interest and would not anneal to other 
loci in the T. parva or the bovine genome. Additional primers were designed when a 
given primer set failed to amplify all DNA samples in the test panel or non-specific 
amplification was observed. Redesign of primers was necessary for most genes for a 
variety of reasons. The most frequent reason for failure to obtain a PCR product was 
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polymorphism in one or both of the primer binding sites in certain genotypes. Other 
reasons for re-designing primers included non-specific amplification of DNA from 
uninfected bovine PBMC and/or from bovine samples infected with other Theileria 
species. On one occasion, a primer was found to anneal to the adaptor part of the 
fusion primer. In most cases these problems were solved by testing alternative 
primers. 
Due to sequence variation among genotypes, the use of degenerate primers was 
required for the Tp1, Tp2, Tp4 and Tp10 genes. For Tp2, two different forward 
primers and two different degenerate reverse primers were used in order to amplify 
each of the parasite clones in the test panel. The aim was to amplify products 
between 300 and 500 bp as this is the optimal length for the Roche 454 Titanium 
platform. For Tp2 it was impossible to design a product smaller than 500bp due to 
the high degree of polymorphism within the gene. The primers selected for use in 
subsequent studies are listed in Table 3.1. 
 It proved impossible to identify primers that would amplify the Tp9 gene from the 
majority of clones in the test panel. The gene is known to be highly polymorphic in 
the population and exhibits a variety of insertions and deletions. This, together with 
the size limitations of 454 amplicon sequencing, made it impossible to design 
primers that would amplify most alleles and for this reason Tp9 was excluded from 
the study. 
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Table 3.1 Primers selected for amplification of T. parva antigen genes and the 
predicted amplicon size  
The amplicon size was predicted based on the T. parva Muguga genome reference 
sequence. xxxxxxxxx represents the sequence of the Multiplex Identifier (MID) as can be 
found in the Roche Technical bulletin (TCB013-2009) ‘Amplicon Fusion Primer Design 
Guidelines for GS FLX Titanium Series Lib-A Chemistry’. 
3.2.2 Selection of parasites for primer validation  
It was essential to ensure that the primers were capable of amplifying a high 
proportion of the allelic variants of the genes of interest. To this end, a panel of DNA 
samples from cloned parasitised cell lines was established in order to test the 
designed primers. The use of DNA from clonal parasites was considered essential, 
because failure to amplify alleles containing polymorphism in the primer binding 
sites could be disguised when attempting to amplify from DNA derived from mixed 
parasite populations. 
Primer name Fusion primer sequence 



































Primers were initially tested using a set of ten T. parva (Marikebuni) clones of 
diverse genotypes as defined by satellite DNA typing (Katzer et al., 2006). A further 
set of cloned cell lines was established by the limiting dilution of five cell lines 
derived from African buffalo from the Masai Mara and Laikipia districts in Kenya 
(Conrad et al., 1987b). Further cloned cell lines were established from cell lines 
isolated from cattle that were used in a vaccine trial on the Marula farm near lake 
Naivasha, Rift Valley District, Kenya (Pelle et al., 2011; Young et al., 1992). The 
pastures of the farm were frequented by buffalo thus disease breakthrough was 
attributed to buffalo-derived T. parva challenge. The use of buffalo-derived T. parva 
parasites provided a rigorous test of the ability of the primers to amplify a wide range 
of parasite allelic variants, because there is evidence that these parasites are 
genotypically more diverse than cattle-derived T. parva parasites (Conrad et al., 
1989; Oura et al., 2011b; Pelle et al., 2011). DNA was extracted from all the cloned 
cell lines using the DNeasy Blood & Tissue Kit (Qiagen) and a number of clones 
from each isolate were used for primer testing The DNA concentrations were 
adjusted to a standard concentration of 50 ng/µl. For 7 of the 39 cloned cell lines in 
the original test panel, PCR amplification failed for most genes. Further investigation 
demonstrated that these lines were infected with Theileria sp (buffalo) rather than 
Theileria parva. All the remaining clonal cell lines in the test panel (see Table 3.2). 
were subsequently sequenced at the 18S rRNA locus to ensure they were T. parva 
(Gubbels et al., 1999; Oura et al., 2004a). To test primer specificity, DNA 
preparations derived from uninfected Rhipicephalus appendiculatus ticks, uninfected 
bovine PBMC and samples infected with Theileria taurotragi, Theileria buffeli, 
Theileria sp. (buffalo) and T. annulata were included in the test panel. DNA samples 
from bovine PBMC were derived from a Bos indicus animal at ILRI, Kenya and a 
Bos taurus animal at the University of Edinburgh, United Kingdom (see Table 3.3). 
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Table 3.2 List of cloned T. parva cell lines used to validate primers 
UoE University of Edinburgh, UK; ILRI International Livestock Research Institute, Nairobi, Kenya 
UoE University of Edinburgh, UK; ILRI International Livestock Research Institute, Nairobi, Kenya 
Location or name Clone Country Origin Material Source 
Marikebuni A3 Kenya bovine In vitro culture UoE 
Marikebuni A7 Kenya bovine In vitro culture UoE 
Marikebuni B12 Kenya bovine In vitro culture UoE 
Marikebuni E43 Kenya bovine In vitro culture UoE 
Marikebuni F31 Kenya bovine In vitro culture UoE 
Marikebuni F44 Kenya bovine In vitro culture UoE 
Marikebuni F53 Kenya bovine In vitro culture UoE 
Marikebuni I8 Kenya bovine In vitro culture UoE 
Marikebuni I38 Kenya bovine In vitro culture UoE 
Marikebuni J17 Kenya bovine In vitro culture UoE 
Marula N33 1 Kenya bovine In vitro culture ILRI 
Marula N33 3 Kenya bovine In vitro culture ILRI 
Marula N33 4 Kenya bovine In vitro culture ILRI 
Marula N33 5 Kenya bovine In vitro culture ILRI 
Marula N43 1 Kenya bovine In vitro culture ILRI 
Marula N43 3 Kenya bovine In vitro culture ILRI 
Marula N43 5 Kenya bovine In vitro culture ILRI 
Marula N43 6 Kenya bovine In vitro culture ILRI 
Mara 3 3 Kenya buffalo In vitro culture ILRI 
Mara 3 6 Kenya buffalo In vitro culture ILRI 
Mara 3 7 Kenya buffalo In vitro culture ILRI 
Mara 3 9 Kenya buffalo In vitro culture ILRI 
Mara 30 2 Kenya buffalo In vitro culture ILRI 
Mara 30 5 Kenya buffalo In vitro culture ILRI 
Mara 30 8 Kenya buffalo In vitro culture ILRI 
Mara 30 11 Kenya buffalo In vitro culture ILRI 
Mara 42 2 Kenya buffalo In vitro culture ILRI 
Mara 42 5 Kenya buffalo In vitro culture ILRI 
Mara 42 8 Kenya buffalo In vitro culture ILRI 
Mara 42 12 Kenya buffalo In vitro culture ILRI 
Mara 6998 9 Kenya buffalo In vitro culture ILRI 
Mara 6998 11  Kenya buffalo In vitro culture ILRI 
Table 3.3List of samples to test primer specificity 
Genus and species Location or name Country Origin Material Source 
T. buffeli Marula Kenya buffalo blood ILRI
T. taurotragi - Kenya bovine culture ILRI
T. sp (Buffalo) Buffalo 6834 clone 3 Kenya buffalo  culture  ILRI 
T. annulata Ankara C9 Turkey bovine culture UoE 
R. appendiculatus Muguga Kenya tick tick ILRI
Bos indicus ILRI Kenya bovine PBMC ILRI
Bos taurus Edinburgh UK bovine PBMC UoE
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3.2.3 Primer validation and optimisation of PCR conditions 
PCR conditions were optimised using DNA from a T. parva Muguga cell line 
employing different primer concentrations and different cycling conditions. The 
optimised conditions were then used to amplify DNA from the test panel of T. parva 
clones. At least three PCR products per primer pair were sequenced to ensure that the 
amplified products were indeed amplicons of the gene of interest. Following this, 
fusion primers were used for amplification, as these would be required to facilitate 
454 sequencing. The use of different combinations of MIDs allowed the reads to be 
identified as belonging to specific samples when different templates are sequenced 
together on the same region of the picotitre plate. 
Two different polymerases with proofreading ability were used in an attempt to 
reduce PCR error: Fast start high fidelity enzyme blend (Roche, Mannheim, 
Germany) and PFU DNA polymerase (Promega, Madison, USA). The reaction 
mixtures are detailed in Table 3.4. However, for a number of genes, amplification 
using these proofreading polymerase was poor and in these cases, a combination of 
Pfu DNA polymerase and BIOTAQtm (Bioline, UK) was used at a ratio of 1:1. PCR 
conditions were optimised by testing a range of temperatures, primer concentrations 
and cycling conditions. Both the use of fusion primers and the use of proofreading 
polymerases reduced the efficiency of the PCR amplification and the reaction mix 
used was adapted to the polymerase used (see Table 3.5). 
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Table 3.4 Components of PCR reaction mix for sample preparation 
X* For primer concentration see table 3.5. Recommended quantity of DNA: 50 ng for parasitised cell 
lines, DNA equivalent to 5µl of whole blood or tick stabilate. 
Roche FastStart High Fidelity PCR system (cat no. 03553426001 or 03553400001) 
5 µl FastStart High Fidelity Reaction buffer 10x with 18mM MgCl2 
1 µl dNTPs (10mM) 
X* Forward primer
X* Reverse primer
2.5 units Fast Start High fidelity enzyme blend 
water
1 µl DNA 
50 µl total reaction volume 
BIOTAQ + PFU 
5 µl µl 10x custom PCR Master mix (ThermoScientific SM-005) 
X* Forward primer
X* Reverse primer
1 unit BIOTAQ DNA polymerase (Bioline BIO 21040) 
1 unit PFU DNA polymerase (Promega M7741) 
water
1 µl DNA 
50 µl total reaction volume 
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Table 3.5  Summary of primer conditions for sample preparation for 454 
amplicon sequencing 
Only the sequence-specific regions of the fusion primers are displayed. PCR conditions are indicated 







reaction Cycling conditions 
Tp1 F  CTGGTGTACAATTTGGTGGG     
R  AACTTNMCTTCTTGCGAACC 
20 
20 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 55°C 
for 30 s, 72°C for 30 s) 
72°C for 7 min 








95°C for 3 min 
35 cycles (95°C for 1 min, 49°C 
for 1 min, 72°C for 2 min) 
72°C for 7 min 
Tp2 








95°C for 3 min 
35 cycles (95°C for 1 min, 49°C 
for 1 min, 72°C for 2 min) 
72°C for 7 min 
Tp3 F  AGCAGATTTCACTCAAGCTGC 
R  TCCCCCAGAACATTAAACGG 
20 
20 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 54°C 
for 30 s, 72°C for 30 s) 
72 °C for 7 min 
Tp4 F  GCAACACAATACTTTGCAGG 
R  CCTCAAACACWCCACAAGTTCC 
10 
10 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 54°C 
for 30 s, 72°C for 30 s) 
72 °C for 7 min 
Tp5 F  GTATGCTCGGTAATGGCAG 
R  GATTTTGGTCGCTTCAGGC 
10 
10 
Roche 95°C for 5 min 
30 cycles (95°C for 30 s, 55°C 
for 30 s, 72°C for 30 s) 
72°C for 7 min 
Tp6 F  CGTCCAATAATTTACGATGTGAG 
R  GCTTAAGTGGGTTAAGGAGACA 
10 
10 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 55°C 
for 30 s, 72°C for 30 s) 
72°C for 7 min 
Tp7 F  TGAAGAAGGACGACTCGCAC 
R  TCCTCGTCAGTGACGTCGG  
20 
20 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 58°C 
for 30 s, 72°C for 30 s) 
72 °C for 7 min 
Tp8 F  ATCCACAACCAAGTGCCCAG 
R  TGCTATTGCGAGTCAACAG 
10 
10 
Roche 95°C for 3 min 
30 cycles (95°C for 30 s, 54°C 
for 30 s, 72°C for 30 s) 
72°C for 7 min 
Tp10 F  GGTCGTCTGACAATAACC 





95°C for 3 min 
35 cycles (95°C for 1 min, 49°C 
for 1 min, 72°C for 2 min) 
72°C for 7 min  
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3.2.4 DNA extraction from sporozoite stabilate and carrier 
animals 
Amplification using the sporozoite stabilate derived DNA was poor compared to that 
using DNA derived from cell lines (see Figure 3.2), which is likely to be due to the 
relative low abundance of parasites in the T. parva sporozoites stabilates. 
Figure 3.2 PCR amplification using Tp8 specific primers and DNA extracted from stabilate and 
T. parva infected cell line 
1. T. parva Muguga stabilate 4230; 2. T. parva Muguga cocktail stabilate ILRI0801; 3. Positive
control: T. parva Muguga cell line; 4. Negative control: H2O 
A number of different protocols for extracting DNA were investigated in an attempt 
to improve PCR amplification (see Figure 3.3). DNA was extracted from Stabilate 93 
(T. parva Muguga, produced at CTVM) using a variety of DNA extraction kits 
according to the manufacturers’ instructions: Wizard® Genomic DNA Purification 
Kit (Promega), DNeasy Blood & Tissue Kit (Qiagen) and ChargeSwitch® gDNA 
Micro Tissue Kit (Invitrogen™). The efficiency of PCR following DNA extraction 
with the DNeasy Blood & Tissue Kit was comparable with DNA extraction using 
ChargeSwitch® gDNA Micro Tissue Kit. The efficiency of PCR was slightly lower 
with DNA extracted using the Wizard® Genomic DNA Purification Kit. It was 
therefore decided that DNA extraction would continue to be performed using the 
DNeasy Blood & Tissue Kit. Stabilate 93 provided a higher yield of PCR product 
than the Muguga cocktail component stabilates regardless of the method of DNA 
extraction. 
 1     2    3    4    
310bp → 
 1      2     3     4 
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Figure 3.3 PCR amplification using Tp8-specific fusion primers and DNA extracted from 
stabilate using different methods 
1. Promega kit; 2. Charge switch kit; 3. Qiagen column, using water for elution; 4. Qiagen column,
using AE buffer for elution; 5. positive control DNA from T. parva Muguga cell line; 6. Negative 
control H2O 
A modified protocol for processing tick stabilate material for DNA extraction had 
been developed at ILRI. This protocol involved an additional centrifugation step to 
discard particulate tick material present in the stabilates. Thawed stabilate was 
centrifuged at 500 x g for 5 min and the supernatant, which contained the sporozoites 
was used for further processing using the Qiagen DNeasy Blood and tissue kit, 
according to the manufacturer’s instructions. DNA extracted using this modified 
protocol produced a more abundant product following PCR amplification (see 
Figure 3.4).  
3     4     5    6   
 3     4     5     6 
380bp → 
 1       2        3       4       5      6   
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Figure 3.4 PCR amplification of the Tp8 gene before and after removal of excess tick material 
by centrifugation  
DNA was extracted from the Muguga (St4230), Serengeti-transformed (St4229) and Kiambu 5 
(St4228) stabilates by using stabilate material directly or by using material obtained after a centrifuge 
step and removal of particulate tick material (spin). Negative control is water. Postive control is DNA 
from T. parva Muguga cell line.   
1. St4230 directly 5. St4229 directly 9. St4228 directly
2. St4230 spin 6. St4229 spin 10. St4228 spin
3. Negative control 7. Negative control 11. Negative control
4. Postive control 8. Postive control 12. Positive control
3.2.5 Sample preparation  
Genes of interest were amplified from each sample using a unique combination of 
MID tags, employing the PCR conditions detailed in Tables 3.4 and 3.5. The PCR 
products were purified by gel extraction using the Wizard® PCR Preps DNA 
Purification System (Promega Corporation, USA) according to the manufacturer’s 
instructions. The purity of PCR products was assessed using Agilent DNA1000 chips 
on a 2100 Bioanalyzer (Agilent Technologies, USA). A more accurate quantification 
of the PCR product was performed using a picogreen assay (Thermo Fischer 
Scientific, USA) before equimolar quantities of PCR products were pooled. Products 
were pooled such that amplicons did not differ in size by more than 50 bp in a single 
pool. In some cases it was necessary to submit several pools of different size to the 
sequencing centre. The pools of PCR product were submitted to commercial 454 
sequencing centres, initially Genepool, University of Edinburgh and later to the 
Centre for Genomics Research (CGR), University of Liverpool, where amplicon 
pools of different size were processed in separate emulsion-based PCRs (emPCR). 
The pools of different sizes of amplicons were themselves pooled following emPCR. 




3.2.6.1 De-multiplexing sequence reads 
A large number of samples may be combined in a single 454 sequencing run 
providing that individual samples are uniquely identified. Amplicons from different 
animals or different parasite isolates may therefore be pooled and analysed 
simultaneously and this is facilitated by the use of primers incorporating unique 
Multiplex Identifier (MID) tags. The MID tags allow identification of the source of 
the sequences and different combinations of 5' and 3' MID tags may be used to 
provide unique identifiers where larger numbers of template samples are being 
processed. A bioinformatics pipeline was developed to de-multiplex read data from 
the raw sequencing files into files corresponding to individual PCR reactions. This 
bioinformatics pipeline is illustrated in Figure 3.5. Briefly, the raw reads (contained 
within flowgram files) were first segregated on the basis of the MID tag identified at 
the 5' end of the read using a script provided by Roche, ‘sfffile’. The sff files were 
then converted to FASTA files using another script provided by Roche, ‘sffinfo’, and 
further segregation was done by identifying the MID tag at the 3' end of the read 
using a script provided by Genepool, ‘split_by_end_MID_exact_match_only.sh’. 
The reads in these FASTA files were further partitioned on the basis of the primer 
sequence identified using another script provided by Genepool, 
‘split_by_fasta_file.sh’ and a reference file containing the primer sequences, e.g. 
‘hannekesprimers.txt’. The reads were all oriented in the direction they were 
sequenced, from either the adaptor A-side or the adaptor B-side. This meant that 
reads with a specific MID tag at the 5' end of the adaptor A-side needed to be 
differentiated from reads with the same MID tag at the 5' end of the adaptor B-side. 
Therefore, reads derived from the same sample (i.e. PCR reaction) but sequenced 
from a different adaptor side were combined in a single file. The names of the reads 
belonging to an individual sample were extracted using a script provided by Dr 
Willie Weir, University of Glasgow, ‘extract_readnames.pl’. The read names were 
then used to extract the raw reads from the original flowgram file using the sfffile 
script provided by Roche. 
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Figure 3.5 Illustration of bioinformatics pipeline for generating files with reads from individual 
samples.   
The files were generated using the sequences of the adaptor, MID and sequence specific components 
of the fusion primers (See figure 3.1)The adaptor parts of the fusion primers at the end of the reads are 
displayed in red for adaptor A and in blue for Adaptor B. The MID sequence in the fusionprimer is 
displayed in either yellow or orange depending on the MID combination used for amplification of the 
sample. The sequence specific part of the fusion primer is displayed in green, light green for the 
forward primer and dark green for the reverse primer.  
3.2.6.2 Segregating reads Tp2  
Due to the high level of polymorphism in the Tp2 gene, it was impossible to design 
primers that would generate amplicons of less than 500 bp. Therefore, primers were 
used which amplified a PCR product of around 560 bp, including fusion primers and 
adaptors. Although read lengths of up to 600 bp may sometimes be achieved using 
Roche 454 FLX Titanium chemistry, in practice many reads fall short of this length 
and this renders them too short to identify both the 5' and 3' MID tag. Therefore, for 
Tp2 the same unique MID tag was used in the both the 5' and 3' primers for PCR 
from each sample, allowing assignment of reads to a specific PCR reaction on the 
basis of the presence of a single primer and MID tag. Since sequencing quality 
deteriorates toward the end of a read, it was decided to analyse the forward and 
reverse reads separately and to only use the first 350 nucleotides of sequence data for 
variant identification. Noise reduction in the sequence dataset was undertaken using 
the Mothur platform, which is an open-source platform which incorporates a suite of 
bioinformatic tools that are useful for the analysis of microbial ecology data (see 
below) (Schloss et al., 2009). 
3.2.6.3 Reducing ‘noise’ in the sequencing data 
Large amounts of data can be generated using high throughput sequencing platforms. 
However, due to limitations of the technology combined with the very high number 
of reads generated, the absolute number of errors is considerable. For the purpose of 
genome assembly, these errors can largely be eliminated as a consensus sequence 
may be created when sufficient sequencing depth is achieved. However, these errors 
present a challenge when using high throughput sequencing to discover novel allelic 
variants in specific genes. It can be difficult to determine whether minor sequence 
variations are simply errors introduced during sample processing or whether they 
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represent genuine allelic variants. Errors can be divided into those introduced during 
PCR and those which arise during the sequencing process. Mis-incorporation of 
nucleotides during the polymerisation process of PCR is a common source of error 
and it is known that different DNA polymerases are associated with different error 
rates. For most genes Roche high fidelity polymerase was used for amplification, 
which has six-fold higher accuracy than Taq polymerase. Chimaera formation during 
PCR may also introduce additional false sequence variants. Chimaeras are formed 
when an incompletely extended DNA strand functions as a primer and anneals to a 
second DNA strand of different sequence in a subsequent round of the reaction. This 
results in a product which is a hybrid of two or more target sequences. Lastly, a bias 
toward particular variants may be introduced during the sample preparation process 
and PCR and this may be related to DNA extraction methodology and primer 
specificity. While not a source of sequence error, as such, the proportion of different 
amplicon species in the PCR product may not accurately reflect the composition of 
the template material (Schloss et al., 2011). 
For Roche 454 pyrosequencing, the error rate per nucleotide base introduced during 
the sequencing process is comparable with that of conventional Sanger sequencing 
(Liu et al., 2012) and is lower than that of other sequencing platforms such as 
Illumina and Solid v4. 454 pyrosequencing utilised the sequencing by synthesis 
process where ‘flows’ of nucleotides are washed over the picotitre plate. When 
nucleotides are incorporated in the growing DNA molecule, a light signal is emitted 
and the intensity of this light signal correlates with the number of nucleotides 
incorporated (Margulies et al., 2005). This correlation is less precise when there is 
sequential incorporation of a high number of the same nucleotide and this frequently 
results in mis-calling the number of single nucleotides incorporated. This is a well-
recognised phenomenon and is termed a ‘homopolymer error’. In addition, spurious 
single base-pair insertions and deletions are known to occur. A bioinformatics 
pipeline was developed to account for these types of error in the raw sequencing 
data.  
65
The most common application for 454 FLX Titanium amplicon sequencing is the 
analysis of 16S subunit rRNA gene sequences in microbial ecology studies. A 
frequently used platform for the processing of 16S RNA deep sequencing data is 
Mothur. The platform, which incorporates a suite of bioinformatic tools that are 
useful for the analysis of microbial ecology data, is continuously improved and 
updated (Schloss et al., 2009). The algorithms utilised by the software have been 
developed to either correct errors in the reads or by entirely removing erroneous 
reads. Quince et al. wrote the ‘Pyronoise’ and ‘SeqNoise’ algorithms (Quince et al., 
2009; Quince et al., 2011). Pyronoise operates by clustering the raw flowgram data 
and aims to remove errors introduced during the sequencing process. The distribution 
of observed light intensities is used to define distances between the flowgrams within 
a cluster and the probability that a flowgram was generated by a given sequence is 
calculated. The most likely sequence is then calculated using an expectation-
maximisation algorithm (Quince et al., 2009). Although the algorithm was written 
for the analysis of 16S rRNA data, it can be used for other loci that have been 
subjected to pyrosequencing (Quince et al., 2009). The algorithm was re-
implemented in a more accessible and robust format in the Mothur software package 
as ‘shhh.flows’ (Schloss et al., 2011). This package employs a modified single-
linkage clustering algorithm, which clusters sequences within a specified distance of 
each other. It assumes that sequences that are more abundant are correct (Huse et al., 
2010; Schloss et al., 2011). A second noise-removal step utilises a program called 
‘shhh.seqs’, which is a re-implementation of the Seqnoise algorithm written by 
Quince et al. (Quince et al., 2011). This algorithm deals with single base pair errors 
by clustering sequences with a set maximum difference between sequences. The 
nucleotide transition probabilities are calculated and used to define a distance 
between sequences that reflects the probability that a given read could have been 
generated from a true sequence, given PCR error. This was done using a mixture 
model to cluster sequences; all sequences within a cluster are considered to 
correspond to a true sequence about which observed noisy reads are distributed. 
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Lastly, the mothur platform incorporates several chimera detection algorithms (Edgar 
et al., 2011; Haas et al., 2011; Quince et al., 2011). Perseus was written for the use of 
detecting chimeras in the absence of a reference database, the algorithm is trained 
using a set of sequences similar to the sequences of interest (Quince et al., 2011). 
Uchime and Perseus outperform Chimera slayer when used without a reference 
database (Schloss and Westcott, 2011). All three programs were used in order to 
minimise the chance of false variant calling due to the presence of chimera.  
A shell script, ‘process_sfffiles.sh’, was written by Dr Willie Weir to automate the 
analysis of multiple flowgram files using Mothur. This script requires an input 
directory with flowgram files of individual PCR reactions and subjects the sequence 
data in each of these files to a series of bioinformatics steps. The minimum number 
or minimum percentage of variant reads to be considered a genuine allelic variant 
can be set. The sequence data representing the output of the bioinformatic pipeline 
could then be manually inspected using a MUSCLE alignment using MEGA5 
(Edgar, 2004; Tamura et al., 2011). Further manual correction of homopolymer 
errors was performed as deemed appropriate. This was achieved by adding or 
deleting single nucleotides when the length of the homopolymer tract differed from 
that of the most common allele(s); not correcting such errors would have lead to 
frame shifts and thus a radical change to the translated sequence and the appearance 
of spurious stop codons. In the case of single base pair insertions and deletions, reads 
were discarded if this resulted in non-coding sequence. A number of the genes have 
introns (Tp4, Tp5 and Tp10) and this issue was taken into consideration when 
translating to amino acid sequence. 
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3.3 Results 
3.3.1 Performance of bioinformatic pipeline on clonal 
samples 
In order to gain an insight into the efficiency of the bioinformatics pipeline in 
accounting for noise in the sequence dataset, amplicons from a cloned parasite were 
sequenced. This cloned parasite was obtained by in vitro cloning of a T. parva 
infected cell line. The reads for individual PCR reactions were obtained by 
identification of one MID tag and one primer and this was possible as the sample was 
amplified using the same MID tag in both the forward and reverse primers. The files 
were then processed using Mothur. A summary of the file for the Mothur pipeline is 
shown in Table 3.6. For the majority of genes, the bioinformatics pipeline was 
capable of removing the noise and a single, genuine, allele was determined following 
execution of the pipeline. However, for some of the genes (Tp3, Tp5 and Tp7) there 
were still two sequences present, meaning that the bioinformatics pipeline had not 
fully resolved all the PCR and/or sequencing errors that occurred during processing. 
The type of error varied between different genes (See figure 3.6-3.8). For Tp3, single 
base-pair insertions were found for the control sample and for other samples 
sequenced in the same run as the control. However, the same type of error was not 
encountered for Tp3 for other samples in different sequencing runs. When translating 
the nucleotide sequence to amino acid sequence, insertions lead to frame shifts and 
premature stop codons. These erroneous reads could be filtered out by discarding 
reads in which single base pair insertions and deletions lead to incomplete coding 
sequence.  
For Tp5, differences in the length of homopolymer were found, despite the 
application of algorithms for homopolymer correction in the bioinformatics pipeline. 
These homopolymer errors, which also resulted in altered open reading frames, were 
corrected manually by removing or adding single nucleotides to adjust the length to 
that of the most common allele. These errors were not reproduced in samples 
sequenced on other sequencing runs. 
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For Tp7, three single base-pair substitutions were found, which were difficult to 
identify as errors when manually inspecting the resulting sequencing reads. The 
reads with errors were present at a low frequency (7/2196 = 0.32%). In light of this 
result, the script was adapted to allow a minimum percentage of reads before a 
variant was deemed genuine. Thus, assuming that a 0.32% error rate is 
representative, a cut-off of 0.4% would remove the reads with potential errors but 
still allow detection of allelic variants at a frequency as low as 1 in 250. The errors 
were not reproduced in a repeat of sequencing Tp7 product using the same clone in a 
different sequencing run (see Table 3.6). Gilles et al. estimated that a minimum of 
five sequences are required to be able to effectively correct errors (Gilles et al., 2011) 
and therefore a minimum of five reads was applied in addition to the minimum of 
0.4%.  
Table 3.6 Summary of bioinformatics processing of sequences obtained for the 
control clone 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the 
results before manual editing. 1st, 2nd and CLUS refer to the stages of noise removal. Chimaera 
detection was performed using three different algorithms: S = Chimaera Slayer P = Perseus 
U = Uchime. Sensitivity was calculated as the probability of identifying a minor allele present at 
1:100, 1:200, 1:500 and 1:1000. ‘>min no. reads’  = the number of variants found after removal of 
variants with less than 3 reads; ‘>min%’ = the number of variants found after removal of variants 
which are present at a frequency of less than 0.3% of the total good reads; ‘Total good reads’ = the 
number of reads maintained after filtering of reads in the bioinformatics pipeline; Hz= heterozygosity; 
Counts = the number of reads for each of the alleles detected. 
No. of unique 
sequences after 
de-noising





















control.Tp1.sff 334 87 11 11 0 0 0 94.94 76.9 44.5 25.4 1 1 294 0 294 
Control_Forward.
Tp2.sff 718 203 26 26 0 0 0 99.82 95.7 71.44 46.13 1 1 625 0 625 
Control_Reverse.
Tp2.sff 858 481 114 112 0 0 0 99.91 96.78 74.92 49.7 1 1 690 0 690 
control.Tp3.sff 3159 443 45 45 0 0 0 100 100 99.7 94.6 2 2 2921 0.014 2899 22 
control.Tp4.sff 1206 241 36 36 0 0 0 99.99 99.6 88.8 66.3 1 1 1087 0 1087 
control.Tp5.sff 979 121 22 22 0 0 0 99.99 99.0 83.7 59.9 2 2 912 0.228 792 120 
control.Tp6.sff 1787 136 5 5 0 0 0 100 99.9 96.7 81.6 1 1 1701 0 1701 
control.Tp7.sff 2246 141 16 16 0 0 0 100 100 98.8 89.1 2 2 2196 0.007 2188 8 
control.Tp7II.sff 4353 131 3 2 0 0 0 100 100 99.98 98.7 1 1 4327 0 4327 
control.Tp8.sff 2505 160 20 19 0 0 0 100 100 99.3 91.3 1 1 2444 0 2444 
control.Tp10.sff 1577 154 16 16 0 0 0 100 99.9 95.2 78.1 1 1 1517 0 1517 
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Figure 3.6 Alignment of Tp3 sequences after bioinformatic processing of 
sequences obtained from the control clone 
Figure 3.7 Alignment of Tp5 sequences after bioinformatic processing of 
sequences obtained from the control clone 
Figure 3.8 Alignment of Tp7 sequences after bioinformatic processing of 
sequences obtained from the control clone  
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In summary, analysis of sequences from the cloned parasite revealed a low incidence 
of errors that were not identified and removed by the bioinformatics pipeline. 
However, it proved possible to remove any remaining errors by manually inspecting 
and adjusting suspect read data and by adjusting the minimum number (or 
percentage) of reads that is required before a variant is deemed genuine. 
3.3.2 Performance of bioinformatic pipeline on 
heterogeneous samples  
The PCR amplification of the cloned parasite as described in the previous section 
was unlikely to result in chimaeric sequences. Moreover, sequencing errors would 
theoretically be easier to detect given that the one ‘genuine’ variant is present at a 
very high frequency and therefore, it was important to further test the bioinformatics 
pipeline. A second sequencing run was performed and this included amplicons of 
Tp1, Tp3, Tp5, Tp7 and Tp8 from two samples; Kiambu 5 a component of the 
Muguga cocktail vaccine and SC06, a sample derived from a carrier buffalo from the 
Kruger National Park. It was anticipated that Kiambu 5 would show limited diversity 
whereas the sample from the carrier buffalo would display more extensive diversity, 
thus providing examples of the different types of data that will be analysed in 
subsequent studies. 
3.3.2.1 De-multiplexing reads on the basis of MID tags 
The samples described above were amplified using the same MID tag at the 5' and 3' 
end of the amplicon. The sequence reads were segregated first by finding the 5' MID 
tag and subsequently by finding the 3' MID tag. The percentages of reads that had 
MID tags on both ends in forward and reverse reads are shown in Table 3.7; 86% of 
the sequences in this sequencing run were full-length. Thus, if both MIDs were 
required to assign reads to a specific sample (e.g. when relying on combinations of 
different 5' and 3' MIDs), only 86% of the reads could be used for further analysis.  
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Table 3.7 Summary of number of reads after partitioning the raw reads by 
5' MID only or by 5' MID and 3' MID subsequently 
3.3.2.2 De-multiplexing reads on the basis of primer sequence 
To obtain the reads corresponding to individual PCR reactions the sequence data 
required to be further partitioned using the primer sequences. This was done using a 
script provided by Stephen Bridgett, Genepool, University of Edinburgh. In some 
cases, the sequence quality decreases towards the end of the read and permitting 
mismatches with the primer sequence can be used to maximise the number of 
sequence reads obtained for each PCR reaction. Reads were processed using four 
different methods in an attempt to establish the optimal parameters for bioinformatic 
processing (see Table 3.8) to produce files that can be used for further processing 
using Mothur (Tables 3.9 and 3.10). Two methods, which required the identification 
of MIDs at both the 5' and 3' end of the reads, reduced the number of reads that could 
be used for final analysis in Mothur. Methods which involved allowing mismatches 
in the primer region increased the number and percentage of identified reads for the 
different PCR reactions. This increase was more pronounced for Tp1 and Tp3. These 
genes corresponded to the two longest amplicons of the five genes amplified during 
this analysis; amplicon sizes for Tp1 were between 510 and 560 nucleotides and  for 
Tp3 were approximately 485 nucleotides. 
5' MID 5' MID and 3' MID 
% reads with both 
MIDs 
Total 37,530 32,342 86%
5' MID1 19,442 17,119 88%
5' MID2 18,088 15,223 84%
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Table 3.8 Summary of the characteristics of the four read groups tested 
Reads were processed in four different ways: 1 The reads were assigned to a sample by the 
identification of one Multiplex Identifier (MID) and the identification of one primer (either forward or 
reverse), which was identical to the primer used for PCR (no-mismatches). 2) Reads were assigned by 
the identification one MID and the identification of both the reverse and forward primer used for PCR 
amplification. Up to two mismatches were allowed to identify the primer sequences. 3) Reads were 
assigned to a sample by the identification of both MIDs (at adaptor A and adaptor B)  and one primer 
(either forward or reverse) 4) Reads were assigned to a sample by the identification of both MIDs and 
both primers, allowing up to two mismatches for the identification of primers.  
Tables 3.9 and 3.10 show a summary of the progress of the different steps of the 
Mothur bioinformatics pipeline, including the number of unique variants remaining 
after the different steps and the number of chimaeric variants detected. It also details 
the number of variants present that exceed the minimum threshold number of reads 
(n = 5) and the number of variants present above a minimum frequency value (0.4%).  
Gilles et al. estimated that a minimum of five sequences are required to be able to 
effectively correct errors (Gilles et al., 2011). Based on this and the analysis of 
sequences obtained for the control clone a minimum threshold of 5 reads was set 
together with a minimum threshold of 0.4% of the total number of good quality reads 
before a variant was deemed genuine. These thresholds led to the rejection of a 
considerable number of variants. However, for the buffalo sample, the number of 
variants was still high even when these thresholds were applied (see Table 3.10). The 
method used for de-multiplexing reads had little impact on the number of variants 
found. Therefore, it was decided to use method 4 for de-multiplexing reads as 
identification of both MIDs and both primers was the most stringent filtering of the 
four methods assessed. 
Read group Number of MIDs Number of primers Mismatches in primer(s) 
1 1 1 0
2 1 2 2
3 2 1 0
4 2 2 2
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Table 3.9 Summary of the file generated by processing reads from Kiambu 5 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the 
results before manual editing. 1st, 2nd and CLUS refer to stages of noise removal. Chimaera detection 
was performed using three different algorithms: S = Chimaera Slayer P = Perseus U = Uchime. 
Sensitivity  was calculated as the probability of identifying minor allele variants present at 1:100 and 
1:200. ‘>min no.reads’ = the number of variants found after removal of variants with less than 5 reads. 
‘>min%’ = the number of variants found after removal of variants which are present at a frequency of 
less than 0.4% of the total good reads. ‘Total good reads’= the number of reads maintained after 
filtering of reads in the bioinformatics pipeline Hz= heterozygosity  
No. of unique sequences 








1st 2nd Pre 
Clus









1 890 135 12 12 0 0 0 100 98.3 2 2 820 0.015 
2 823 112 11 11 0 0 0 100 98.0 2 2 776 0.013 
3 803 108 12 12 0 0 0 99.9 97.8 2 2 757 0.016 
Tp1 
4 762 96 12 12 0 0 0 99.9 97.4 2 2 729 0.016 
1 2760 672 75 74 7 1 0 100 99.9 14 2 2238 0.117 
2 2473 594 79 79 6 1 0 100 99.9 11 2 2062 0.108 
3 2372 604 79 78 6 1 0 100 99.9 12 4 1934 0.113 
Tp3 
4 2195 522 78 78 7 1 0 100 99.9 11 2 1848 0.122 
1 5477 732 38 38 0 0 0 100 100 4 1 5079 0 
2 4933 602 38 38 0 0 0 100 100 5 1 4714 0 
3 4886 616 37 37 0 0 0 100 100 2 1 4591 0 
Tp5 
4 4636 527 38 38 0 0 0 100 100 2 1 4464 0 
1 5800 420 16 15 0 0 0 100 100 4 1 5551 0 
2 5275 323 16 15 0 0 0 100 100 4 1 5169 0 
3 5309 347 18 17 0 0 0 100 100 3 1 5115 0 
Tp7 
4 4983 287 17 16 0 0 0 100 100 3 1 4890 0 
1 4062 614 50 50 0 0 0 100 100 6 1 3809 0 
2 3633 512 51 51 0 0 0 100 100 5 1 3496 0 
3 3709 544 47 47 0 0 0 100 100 4 1 3514 0 
Tp8 
4 3458 464 47 47 0 0 0 100 100 3 1 3353 0 
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Table 3.10 Summary of the file generated by processing reads from SC06 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the 
results before manual editing. 1st, 2nd and LCUS refer to stages of noise removal. Chimaera detection 
was performed using three different algorithms: S = Chimaera Slayer P = Perseus U = Uchime. 
Sensitivity  was calculated as the probability of identifying minor allele variants present at 1:100 and 
1:200. ‘>min no.reads’ = the number of variants found after removal of variants with less than 5 reads. 
‘>min%’ = the number of variants found after removal of variants which are present at a frequency of 
less than 0.4% of the total good reads. ‘Total good reads’= the number of reads maintained after 
filtering of reads in the bioinformatics pipeline Hz= heterozygosity  
The number of acceptable reads after the bioinformatics process differed per gene 
and sample (Table 3.11). For Tp1, the percentage of reads available after the 
bioinformatics processing was dramatically reduced for the buffalo sample, mainly 
due to the detection of chimaeric sequences. The percentage of reads available after 
bioinformatics processing was relatively high in both samples for Tp5, Tp7 and Tp8. 
No. of unique sequences 
after de-noising 




chimaera removal & 








1st 2nd Pre 
Clus 








1 4395 1811 195 195 2 60 0 100 100 22 16 2519 0.89 
2 3799 1633 207 206 0 53 0 100 100 20 15 2236 0.89 
3 3240 1511 200 199 0 49 0 100 100 18 15 1888 0.88 
Tp1 
4 3058 1383 203 202 0 50 0 100 100 19 15 1846 0.88 
1 939 335 86 86 1 0 0 100 97.4 20 17 732 0.89 
2 842 278 88 88 1 0 0 99.9 96.9 23 17 687 0.89 
3 801 297 84 84 1 0 0 99.8 96.2 22 18 636 0.89 
Tp3 
4 746 254 84 84 1 0 0 99.8 95.7 21 17 621 0.89 
1 3167 743 133 129 0 0 0 100 100 30 20 2759 0.91 
2 2846 618 133 127 0 0 0 100 100 28 20 2587 0.91 
3 2715 624 129 124 0 0 0 100 100 25 20 2435 0.90 
Tp5 
4 2579 546 129 123 0 0 0 100 100 24 20 2382 0.90 
1 5639 879 87 76 0 0 0 100 100 25 13 5181 0.81 
2 5072 693 98 87 0 0 0 100 100 25 13 4811 0.81 
3 5044 735 93 83 0 0 0 100 100 25 14 4703 0.83 
Tp7 
4 4742 609 94 84 1 0 0 100 100 25 14 4527 0.83 
1 3682 565 70 68 0 0 0 100 100 7 5 3415 0.25
2 3340 470 74 71 0 0 0 100 100 6 4 3179 0.26
3 3367 514 77 75 0 0 0 100 100 8 5 3146 0.26
Tp8 
4 3188 452 76 73 0 0 0 100 100 8 5 3038 0.31
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Table 3.11 Percentage of reads in which both MIDs and both primers could be 
identified 










Tp1 890 729 82 4,395 1,846 42
Tp3 2,760 1,867 68 939 629 67
Tp5 5,477 4,464 82 3,167 2,391 75
Tp7 5,800 4,890 84 5,639 4,527 80
Tp8 4,062 3,353 83 3,682 3,038 83
3.3.2.3 Assessment of chimaera detection by sequencing a mixture of 
two cloned parasites 
For Tp1, the number of chimaeras detected was high in the buffalo sample and only a 
single chimaera was detected for Tp3. In contrast, for Kiambu 5, no chimaeras were 
detected for Tp1 and several were identified for Tp3. The Tp1 chimaeras were 
detected using Perseus and the Tp3 chimaeras using Chimaera Slayer. The different 
programs use different algorithms for detecting chimaeras. For the genes used in this 
study, the optimal chimaera detection algorithm appears to differ among genes. The 
number of chimaeras detected also appears to be influenced by the number of 
nucleotide changes between reads and the total number of variants present in a 
sample. However, the precise genetic composition of the Kiambu 5 and SC06 
samples used in this experiment is unknown. To increase the likelihood chimaeras 
will be detected, it was decided that all three chimaera detection algorithms would be 
applied to every dataset. For some of the genes no chimaeras were detected. This 
could be because chimaeras were not present or because chimaeras were not 
detected. These genes are relatively conserved and the differences between the two 
different sequences might be too small to be marked as chimaeras using the chimaera 
detection algorithms. The formation and detection of chimaeras was further tested for 
Tp1, Tp3 and Tp5 using an artificial mix consisting of equal DNA concentrations (as 
determined by Nanodrop) of two cloned parasites. The two clones were Marula 
N43-5 and Marula N33-4. To provide accurate baseline data for these two clones, the 
sequences of the antigen genes were determined by Sanger sequencing. The results 
of the Mothur pipeline are summarised in Table 3.12. 
76
Perseus detects four chimaeras in the Tp1 gene, removing true variant as well as true 
chimaeras. This means there is a risk that true variants could also be removed from 
other samples. No chimaeras were detected in the reads obtained for Tp5. The two 
most frequent reads correspond to the sequences identified using conventional 
Sanger sequencing. The sequences of the two clones differed in 6 nucleotides (see 
figure 3.9). The other four sequences appear to be chimaeras of these two reads. This 
demonstrates that none of the three algorithms is capable of detecting the chimaeras 
in this dataset. No chimaeras were detected in the reads for Tp3 either. Interestingly, 
chimaeras were detected in both the reads obtained for SC06 (see Table 3.10) and 
Kiambu 5 (See Table 3.9). This clearly indicates that the efficiency of the algorithms 
depends on the dataset being analysed. Chimaera detection is presently sub-optimal, 
despite several different algorithms being available and this issue needs to be taken 
into account when interpreting results
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Table 3.12 Summary of Mothur pipeline of sequencing of an equal mixture of two clones 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the results before manual editing. 1st, 2nd and CLUS refer to stages of 
noise removal. Chimaera detection was performed using three different algorithms: S = Chimaera Slayer P = Perseus U = Uchime. ‘>min no.reads’ = the number of 
variants found after removal of variants with less than 5 reads. ‘>min%’ = the number of variants found after removal of variants which are present at a frequency of 
less than 0.4% of the total good reads. ‘Total good reads’= the number of reads maintained after filtering of reads in the bioinformatics pipeline ‘Read counts’= the 
number of reads for each of the alleles detected.  
No. of unique 
sequences after 
de-noising 
No. of chimaeras 
detected 
Variants after 
chimaera removal & above 
thresholds 
Gene Initial no. of 
reads 
1st 2nd Clus S P U 
>min  





Tp1 1520 285 13 13 0 4 0 1 1 1272 1272 
Tp3 780 211 21 19 0 0 0 5 5 319 176, 91, 23, 14, 8 
Tp5 1145 190 26 25 0 0 0 9 7 1007 382, 334, 152, 119, 8, 6, 6 
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Figure 3.9 Alignment of nucleotide sequences of Tp5 amplicons generated from a mixture of two clones 
Nucleotides that differed between different identified alleles are highlighted.  
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3.4 Discussion 
A multi-locus sequence typing system was developed for the analysis of genetic 
diversity among Theileria parva antigen-encoding genes using Roche 454 amplicon 
sequencing technology. A total of nine genes known to be recognised by CD8+ T cell 
responses in immune animals were selected for the typing system. During 
development of the system, PCR amplicons were generated from a vaccine stabilate 
and blood from a carrier African buffalo. These were then successfully subjected to 
454 sequencing and the derived sequences were analysed using a custom 
bioinformatics pipeline. 
3.4.1 Generation of amplicons 
Extensive primer validation was necessary during the development of the system and 
each candidate primer set was tested on a panel of T. parva clones. This was essential 
in order to ensure that the PCR primers were able to amplify the majority of, if not 
all, allelic variants of T. parva. The clones were derived from parasitised cell lines 
isolated from buffalo or from cattle undergoing clinical theileriosis after infection 
with buffalo-derived T. parva. The test panel used in this study was an ideal resource 
for the validation of primers, as buffalo-derived T. parva is known to be more 
genotypically diverse than the cattle-derived parasite. For the majority of genes, 
several primer combinations required testing before a primer combination could be 
found that would amplify every clone in the test panel. For the primer validation 
process, the DNA concentration was standardised to 50 ng/µl. However, the amount 
of amplicon yielded varied among clones, as judged by the intensity of bands on the 
agarose gel. While this suggests that the efficiency of PCR may not equivalent for 
different template sequences, it is unknown whether the host/parasite DNA ratio was 
equivalent for all clones and whether better amplification was associated with a 
higher parasite load. Nevertheless, it is appreciated that primer specificity and 
sensitivity may potentially be an issue and that ‘imperfect’ template sequences may 
be associated with lower yield. The PCR protocol should therefore be regarded as 
semi-quantitative, with caveats applied when drawing inferences on the relative 
abundance of allelic variants. 
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Amplification from sporozoite stabilates was poor compared to amplification of 
DNA derived from parasitised cell lines. This may be improved by removal of 
particulate tick material using an additional centrifugation step before DNA 
extraction. It was desirable to use DNA extracted directly from sporozoite stabilates, 
as maintaining parasites in vitro is likely to exert a selective pressure on the parasite 
population under study (Sutherland et al., 1996; Taylor et al., 2005). 
Polymerase with proofreading capacity was used in order to minimise the number of 
errors introduced during PCR amplification and the number of PCR cycles was kept 
as low as reasonably possible. Unfortunately, amplification using fusion primers 
together with proofreading polymerase was inefficient and for most samples only 
small quantities of template DNA were available. The number of cycles required to 
obtain sufficient PCR products for all the genes was relatively high and varied 
between 30 and 35 cycles. Chimaeras were detected for Tp3 in both Kiambu 5 and 
SC06 and for Tp1 in SC06. The number of sequences available for further analysis 
was greatly reduced for Tp1 from SC06, with only 42% of raw reads passing quality 
control. Ideally, PCR conditions should be optimised to reduce the number of 
chimaeras when sufficient DNA is available for optimisation. 
3.4.2 Bioinformatics pipeline 
A bioinformatics pipeline was established for the processing of the sequences 
obtained and to identify and account for PCR and sequencing errors. Reads were 
assigned to a sample following identification of both MID tags and both primers. The 
next step in the pipeline was to remove ‘noise’ from the dataset, using algorithms to 
either correct errors in situ or to discard potentially erroneous reads. Sequencing of 
the control clone demonstrated that the bioinformatics pipeline could not account for 
all the PCR and/or sequencing errors introduced during sample processing and it was 
shown that the type of error differed among target genes. This agrees with other 
studies, which have documented differences in the type of error and error rate when 
sequencing different gene products (Gilles et al., 2011). 
It is clear that 454 amplicon sequencing gives rise to non-random sequencing errors 
(Niklas et al., 2013; Schloss et al., 2011; Skums et al., 2012). Homopolymer errors 
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may be found throughout reads, whereas single nucleotide insertions and nucleotide 
substitutions are more common towards the end of long reads (Gilles et al., 2011). 
Errors can vary between sequencing centres and even between sequencing runs 
(Schloss et al., 2011). Gilles et al. estimated that a minimum of five sequences are 
required to be able to effectively correct errors (Gilles et al., 2011). 
Homopolymer errors are relatively easy to detect and manually correct, but manual 
correction is impossible for single nucleotide insertions and substitutions. Based on 
Gilles estimation that a minimum of five sequences are required for error correction 
(Gilles et al., 2011) and the error rate observed in sequencing the control clone, a 
minimum threshold of five reads and 0.4% abundance before a sequence was deemed 
genuine. It is possible that some genuine variants are rejected using this threshold, 
thereby underestimating the true number of variants present in a sample. It is 
advisable to include an internal control in each sequencing run in order to estimate 
the sequence error rate and the rate of chimaerism in that run (Schloss et al., 2011; 
Skums et al., 2012) and, ideally, the control should have a level of complexity 
similar to the other samples in the run (Skums et al., 2012). 
3.4.3 Chimaera detection 
Three different algorithms were used for chimaera detection in the bioinformatics 
pipeline to maximise the chance of detecting chimaeras - Chimaera Slayer, Perseus 
and Uchime (Edgar et al., 2011; Haas et al., 2011; Quince et al., 2011). For the 
samples analysed in this study, it was found that Perseus and Chimaera Slayer 
detected chimaeras in the same datasets, while chimaeras were not detected by 
Uchime. As these algorithms were used successively, the results do not necessarily 
indicate that Uchime was ineffective and in previous studies, Perseus and Uchime 
were shown to have a similar efficiency (Edgar et al., 2011; Schloss et al., 2011). 
Perseus identified a genuine variant as chimaeric in sequences obtained for Tp1 in a 
mixture of two clones. None of the chimaeric sequences were detected in a mixture 
of two clones for Tp3 and Tp5. However, chimaeras were detected in Tp3 amplicons 
using Chimaera Slayer for both Kiambu 5 and SC06. Perseus also detected a 
chimaera in Tp3 for Kiambu 5. These database-independent methods of chimaera 
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detection use sequences within the dataset as a reference and thus the reference 
sequences vary between different samples. It is important to be aware that some 
genuine sequences may be identified as chimaeric while some chimaeric sequences 
may escape detection despite the use of three different algorithms. 
Chimaera formation is commonly encountered in the field of population genetics and 
has been increasingly observed when using high throughput sequencing (Haas et al., 
2011; Quince et al., 2009; Schloss et al., 2011). It is estimated that individual 
sequence libraries for environmental bacterial diversity studies can contain over 45% 
chimaeric sequences (Haas et al., 2011) and such sequences can lead to 
overestimation of species diversity in habitats when targeting the16S ribosomal RNA 
gene, although this has been partially overcome with the use of 16S rRNA reference 
databases. Unfortunately, databases are not available for the allelic variants of the 
genes used in this study. 
Theileria parva undergoes sexual recombination in the tick gut and it is possible that 
recombination break-points may lie within the loci of interest, with such break-points 
relating to ancient and/or recent recombination events. Katzer et al (2011) performed 
a genetic cross of two cloned isolates of T. parva (Muguga and Marikebuni) and 
identified 35 recombinant progeny using a panel of 79 satellite DNA markers. The 
rate of recombination differed across the chromosomes (between 0.12 and 0.34 
cm/Kb) and hot and cold spots were identified (Katzer et al., 2011). A high number 
of cross-over events were observed in two recombinant T. parva clones using 
comparative genomics. The distribution of cross-over events (CO) differed among 
the four chromosomes and between the two recombinant clones, varying from one 
cross-over per 0.3 Mb to one cross-over per 1.3 Mb (Henson et al., 2012). Thus, it is 
possible that some genuine recombinant allelic sequences may be mis-indentified as 
‘chimaeric’, particularly if the putative ‘parental’ alleles can be identified in the 
dataset. The effect of such mis-identification is that the multiplicity of infection 
would be underestimated. However, for the present study, it was decided to 
implement each of the chimaera detection methods in order to minimise the chance 
of designating artefactual sequences as real.  
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3.4.4 Adaptation of amplification and bioinformatics pipeline 
for Tp2 
The amplicons for Tp2 were relatively large and only a small proportion of the reads 
were sufficiently long to span both MID tags. This necessitated Tp2 being amplified 
using the same MID tag on both the forward and reverse primer in order to assign 
reads to a specific sample and this allowed sequences obtained in the forward and 
reverse direction to be analysed separately. Errors increase toward the ends of long 
reads and these cannot always be corrected accurately by a bioinformatics pipeline. 
Schloss et al. truncated reads at 720 flows, which corresponds to around 400 bp to 
remove this noise (Schloss et al., 2011). In the case of Tp2, sequence reads were 
truncated around 350 flows. 
In summary, a MLST typing system was developed for the analysis of the antigenic 
diversity of Theileria parva using Roche 454 amplicon sequencing technology. 
Amplicons were successfully generated and sequenced from vaccine stabilate and 
carrier animals. Noise was removed from sequencing reads using a bioinformatic 
pipeline constructed around the Mothur software package. The pipeline was able, for 
the most part, to adequately identify and remove ‘noise’ from the dataset, but further 
manual editing was required in some cases and chimaeric sequences were not always 
detected. A threshold of a minimum of five reads and least 0.4% abundance was 
determined to differentiate between genuine allelic variants and erroneous reads. 
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6BChapter 4: Analysis of the Muguga cocktail 
vaccine 
17B4.1 Introduction 
The Muguga cocktail is the most widely used parasite preparation for immunisation 
against Theileria parva by the ‘infection and treatment’ method (ITM) and 
incorporates three parasite stocks: Muguga, Serengeti-transformed and Kiambu 5. 
Since the initial testing of the components of the Muguga cocktail in the 1970s, each 
has been passaged a number of times. A consistent protocol for production of 
different passages of the vaccine components has been strictly followed in an 
attempt to maintain the consistency of the vaccine. Stabilates used for vaccination 
are derived from seed stabilates that are in turn derived from master seed stabilates. 
In other words, a master seed parasite population will go on to complete the life-
cycle twice before it forms an actual vaccine stabilate. Reference stabilates are 
produced alongside the production of the immunising stabilates. Although several 
molecular typing methods have been used to characterise T. parva parasites in the 
Muguga cocktail (Bishop et al., 2001; Geysen et al., 1999; Oura et al., 2007a; Oura 
et al., 2004b; Patel et al., 2011), these have provided limited information on the 
detailed composition of the individual stocks, in particular the presence of minor 
genotypes. Little detail is available on the level of consistency between different 
passages of the three components and among different batches of the Muguga 
cocktail produced from the same passage. 
Studies of another T. parva stock (Marikebuni), known to be genetically 
heterogeneous (Katzer et al., 2010), illustrate the necessity to monitor parasite 
composition. Analyses using a large panel of satellite DNA markers revealed major 
differences in profile among different passages of this stock. Patel et al. used a subset 
of five satellite DNA markers to compare two batches of the Muguga cocktail 
vaccine (FAO1 and ILRI0804) and the corresponding reference stabilates. All the 
reference stabilates were produced using the same seed stabilates (Stabilate 68, 69 
and 73) (see Figure 4.1). Differences in allele sizes were found for four out of five 
satellite loci between the two Serengeti transformed reference stabilates (stabilate 
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4229 and 4139) produced from the same seed stabilate (stabilate 69) (Patel et al., 
2011). 
The Global Alliance for Veterinary Medicine (Galvmed) is aiming to facilitate the 
more widespread use of the Muguga cocktail vaccine, which includes the production 
of new vaccine batches at the Centre for Ticks and Tick-Borne Diseases (CTTBD) in 
Malawi. For the production of future vaccine batches of the Muguga cocktail 
vaccine, the current reference stabilates (Stabilate 4228, Stabilate 4229 and 4230) 
will be used as the new seed stabilates (see figure 4.1). Hence, future vaccine batches 
will be derived from a different passage compared to the two most recent large 
vaccine production rounds, FAO in 1993 and ILRI08 in 2008. This could potentially 
alter the composition of the parasites in the vaccine and possibly influence the 
immunity induced. 
Figure 4.1 Relationship between the different Muguga cocktail seed, reference and vaccine 
stabilates.  
Each arrow represents a single passage through cattle/ticks. Muguga cocktail batches are displayed in 
the red boxes and were formulated by mixing ticks infected with the Kiambu 5, Serengeti-transformed 
and Muguga stock after a passage through cattle/ticks  
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While satellite DNA typing provides a profile of the major components within a 
parasite stock, it does not allow detection of minor components. The multilocus 
sequence typing system based on 454 technology developed in this study can be used 
for high resolution characterisation of parasite populations and thus we now have the 
capacity to identify minor components. The main aim of the work described in this 
chapter was to use multilocus sequence typing in combination with satellite DNA 
typing to determine the extent of parasite diversity in components of the Muguga 
cocktail, focusing on the masterseed stabilates that will be used for future vaccine 
production. The profiles generated for the seed stocks may be used for comparison 
with progeny vaccine stabilates, other vaccine stabilates and field parasite 
populations. 
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18B4.2 Material and Methods 
55B4.2.1 Samples 
DNA was extracted from stabilates used for infection and treatment as previously 
described in Chapter 2. Details of the stabilates can be found in Table 4.1. 






Muguga   4230  73  ILRI 
Muguga  N57  147  CTTBD 
Serengeti transformed  4229  69  ILRI 
Kiambu 5  4228  68  ILRI 
ECF MC ILRI  0801  68,69,73  ILRI 
ECF MC ILRI  0802  68,69,73  ILRI 
ECF MC ILRI  0803  68,69,73  ILRI 
ECF MC ILRI  0804  68,69,73  ILRI 
Marikebuni  3014  2 cattle‐tick passages  RVC (made at ILRAD) 
Marikebuni  128  3014  CTVM, UoE 
Katete   KL4 CTTBD 
Chitongo   CL20 CTTBD 
ILRI= International Livestock Research Institute, Nairobi, Kenya; CTTBD= Centre 
for ticks and tick borne diseases, Lilongwe, Malawi; RVC= Royal Veterinary 
college, University of London; ILRAD= Internationl laboratory for research on 
animal diseases, Nairobi, Kenya; CTVM, UoE= Centre of tropical veterinary 
medicine, University of Edinburgh 
56B4.2.2 Satellite DNA typing 
Satellite DNA typing was performed as described in Chapter 2 on all the stabilates 
listed in Table 4.1 except for stabilates 57 and 3014, for which a limited amount of 
DNA was available. Satellite markers were distributed across the genome (See figure 
2.1). Allele sizes were determined by capillary flow electrophoresis and detection of 
the fluorophore signal from a labelled primer in each amplicon. The relative 
abundance of individual peaks was expressed as percentage of the total area under 
the curve for all peaks in a trace combined. Peaks with an area of less than 3% of the 
total area under the curve for all peaks were excluded. 
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57B4.2.3 454 amplicon sequencing 
Amplicons were generated for the genes Tp1 through to Tp8 and Tp10 for the 
Muguga (stabilate 4230), Serengeti transformed (stabilate 4229), Kiambu 5 (stabilate 
4228) and Marikebuni (stabilate 3014) stocks. The amplicons were generated and 
pooled as described in Chapter 3 and submitted for sequencing. In addition, 
amplicons were generated for Marikebuni stabilate 128 for the genes Tp1, Tp5 and 
Tp10. Reads derived from different sequencing runs were combined when 
sequencing data were available from more than one sequencing run. Sequencing 
results were analysed as previously described in Chapter 3. Resulting sequences were 
aligned using MUSCLE and were visualised using Jalview (Edgar, 2004; 
Waterhouse et al., 2009). 
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19B4.3 Results 
58B4.3.1 Satellite genotyping 
81B4.3.1.1 Comparison of the Muguga cocktail components and batches 
Genotypic diversity within batches of the Muguga cocktail and the three components 
of the Muguga cocktail was assessed using a panel of satellite DNA markers. Product 
size and relative abundance were determined using capillary electrophoresis (see 
figure 4.2 for an example of histograms). Products were successfully obtained for 
eleven of the satellite DNA markers (See figure 4.3). The data obtained was used to 
calculate a heterozygosity value for each stock (See table 4.2). 
Figure 4.2 Example of representative histograms obtained for MS7 for samples Kiambu 5  and 
Muguga cocktail. Blue peaks represent sample peaks, the estimated allele size are indicated below 
the peaks. The allele size was estimated using a standard curve (red line), which was obtained using 
the peaks obtained for the LIZ500 size standard (peaks in orange) 
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 For each of the satellite markers, between one and four alleles were found in 
individual samples representing the components of the Muguga cocktail vaccine 
batches and the reference stabilates. The four batches of the Muguga cocktail had a 
very similar satellite profile, both in terms of which alleles were found and the 
relative abundance of each of these alleles. Small differences in relative abundance 
of alleles between different batches of parasites produced from the same stabilates 
using similar batches of ticks were observed. This could be a result of stochastic 
variation among straws and may be related to clumping of sporozoites within the 
sample. As PCR is not a fully quantitative process, it is possible that minor 
differences in template composition may be magnified during amplification. In 
general terms, however, this genotyping methodology is capable of providing highly 
reproducible results. In a related experiment, different straws representing the same 
Serengeti –transformed reference stabilate (stabilate 4229) were genotyped by 
another worker at another institution using the same satellite reagents (University of 
Glasgow). The results were very similar to those generated in the present study, 
indicating that the methodology is robust and the results are repeatable (see figure 
4.4). 
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Figure 4.3 Results of satellite DNA typing of four Muguga cocktail vaccine batches and reference stabilates using 11 DNA Satellite markers 
Muguga cocktail vaccine batches (ILRI0801-ILRI0804) and reference stabilates Kiambu 5 (Stabilate 4228), Serengeti-transformed (Stabilate 4229) and Muguga 
(Stabilate 4230) were produced in the same vaccine production run using stabilates 68, 69 and 72 as seed stabilates. In the last column the results are displayed for an 
old Muguga cocktail stabilate (Stabilate N57) (the result for MS21for stabilate N57 is missing). Different allele sizes are displayed in a different colour and the relative 
abundance of each of the alleles is displayed in the stacked bars, estimated allele sizes for each of the markers are displayed next to the diagrams. For more information 
on the stabilates see figure 4.1. 
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Figure 4.4 Comparison of repeats for three markers for the Serengeti transformed stock. 
Allele sizes and relative abundance for the Serengeti-transformed stock using three satellite DNA 
markers (MS8, MS21, MS30) obtained in this study (I) (see figure 4.3) were compared with allele 
sizes and relative abundance obtained at the University of Glasgow (II).  
A few inconsistencies were observed in the typing results obtained in the present 
study for different batches of the Muguga cocktail. For MS7 applied to ILRI0804, an 
extra peak corresponding to 214 bp was identified which was not present in the other 
batches of the Muguga cocktail (ILRI0801-ILRI0803). For MS9 applied to 
ILRI0803, an extra peak corresponding to 245 bp was found and for MS40 applied to 
ILRI0801, an extra peak of 227 bp was found. These extra peaks are likely to 
represent contamination, as the sizes corresponded to allelic sizes of other markers 
that were processed in the same 96-well plate used for Genescan. For ILRI0801, a 
minor peak at 149 bp was missing for MS27 compared to the other ILRI08 batches, 
which may reflect either a failure to detect a low concentration of the PCR product, 
or a failure for this locus to prime due to low template concentration. The assays for 
these markers need to be repeated in order to resolve these anomalies. Nevertheless, 
overall the composition of the four vaccine batches produced in the same vaccine 
production run (i.e. ILRI0801-ILRI0804) appeared to be consistent. The satellite 
DNA profiles were similar in allele size and abundance and the allele sizes identified 
corresponded with those found in the three reference stabilates. However, for marker 
MS8, by applying an area threshold of 3% for a peak to be considered a genuine 
allele, allele d would not be identified/accepted in the Serengeti transformed stock, as 
this allele was only present at 1.7%. 
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Table 4.2 Heterozygosity in the Muguga cocktail vaccine and reference stabilates 
The heterozygosity of the different batches of the Muguga cocktail and the reference stabilates was 
calculated for each of the loci. The average heterozygosity is displayed.  
Based on satellite typing, the diversity within the reference stabilates and the 
Muguga cocktail appeared to be limited. The higher heterozygosity observed for 
ILRI0803 compared to the other vaccine batches is due to the higher heterozygosity 
for the ms9 locus, which is likely to be caused by a contaminant. The heterozygosity 
is conserved between the other Muguga cocktail vaccine batches. The heterozygosity 
for each of the components is low (Hz between 0.012 and 0.120)  
Two alleles were detected using MS25 for Kiambu 5; In contrast, only a single allele 
was found using each of the remaining ten successfully amplifying markers for 
Kiambu 5. Four of these alleles were unique to the Kiambu 5 stocks. At another four 
loci, the Kiambu 5 allele was also found as a minor component of the Serengeti-
transformed stock. For the remaining two markers, the Kiambu 5 allele was also 
present in all the components of the Muguga cocktail. A single allele was also found 
in the Muguga stock for eight loci and two alleles for the remaining three loci. For 
the Serengeti-transformed stock, a single allele was detected at seven of the eleven 
loci, two alleles at two loci and three alleles at the remaining two loci.  
The Muguga (St 4230) and Serengeti (St 4229) stocks differed from each other at 
four loci, although one or two relatively abundant alleles were shared at these loci. 
The Kiambu 5 stock differed from the Muguga stock at eight of the ten loci and from 
the Serengeti transformed stock at seven of the ten loci. 










DNA from Muguga stabilate N57 was available for this study and was genotyped 
using the satellite markers. Historically, this stabilate was used to produce Muguga 
stabilate 73, from which the Muguga reference stabilate 4230 was produced (see 
figure 4.1). Differences between stabilate N57 and 4230 were found across three of 
the eleven markers. For two of the markers, MS7 and MS40, alleles present at 6-58% 
in stabilate N57 appear to be lost in stabilate 4230. However, for MS8, stabilate 4230 
had an extra allele, at a relative abundance of 15%, compared to stabilate N57. The 
composition of parasite stocks can thus change over passage.  
82B4.3.1.2 Comparison of the Muguga cocktail with other vaccine stabilates 
The same eleven satellite markers were used to investigate the degree of genotypic 
diversity in other stabilates used for vaccination in the field (see figure 4.5) and the 
diversity of the stabilates was estimated by calculating the average heterozygosity 
over all the successfully amplified markers (see Table 4.3). The Marikebuni stock 
was originally isolated from a collection of ticks from the coastal region in Kenya 
and has been used in vaccine trials in Kenya. The Katete and Chitongo stocks were 
isolated in Zambia and have been used for vaccination in Malawi and Zambia 
(Geysen et al., 1999).  
Table 4.3 Average heterozygosity in vaccine stabilates 
The heterozygosity was highest for the Muguga cocktail (HZ 0.288). The 
heterozygosity was very low for both Zambian stocks (Katete and Chitongo) (Hz 
0,00 and 0,032), while the Marikebuni stock had an intermediate level of 
heterozygosity (Hz 0.132) 
Sample Average Hz 
ILRI0802 0.288
Katete  0.000 
Chitongo  0.032 
Marikebuni 0.132 
95 
Figure 4.5 Results of DNA satellite typing of four different ITM stabilates using 11 markers 
The four stabilates are the Muguga cocktail (ILRI0802), the Katete stock (stabilate KL4), the Chitongo stock (CL20) and the Marikebuni stock (stabilate 128). Data is 
missing for MS21 for the Chitongo stabilate and MS25 for the Katete stabilate due to shortage of material available for analysis. Different allele sizes are displayed in a 
different colour and the relative abundance of each of the alleles is displayed in the stacked bars, estimated allele sizes for each of the markers are displayed next to the 
diagrams.
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Very limited diversity was detected within the Zambian stocks (Katete and 
Chitongo), but differences were found between the two stocks. Identical alleles were 
detected for three satellite DNA markers (MS7, MS8 and MS27); the Chitongo stock 
had an additional allele for ms9, besides a shared allele; different alleles were 
detected for the other five successfully obtained amplified markers (MS3, MS30, 
MS33, MS39 and MS40).  The Katete stock and the Muguga cocktail shared alleles 
at two of the ten loci (MS21 and MS27), whereas the Chitongo stock and the 
Muguga cocktail had alleles in common at six of the ten loci (ms9, MS27, MS30, 
MS33, MS39 and MS40) 
The Marikebuni stock was found to be more heterogenous than the Zambian stock, 
but less so than the Muguga cocktail; two alleles were detected at six of the eleven 
loci. With the exception of MS3, alleles were shared between the Marikebuni stock 
and the Muguga cocktail. For five of the loci, a second non-shared allele was found 
in the Marikebuni stock (MS7, MS21, MS25, MS30, MS40).   
59B4.3.2 ‘Deep’ multilocus sequence typing  
83B4.3.2.1 Muguga cocktail reference stabilates  
The satellite genotyping results indicated that genotypic diversity within the Muguga 
cocktail vaccine batches and reference stabilates is limited. To examine diversity in 
greater depth, the three stabilates that will be used as seed stabilates for future 
vaccine batches were subjected to multilocus sequence typing using deep sequencing 
technology. This offers the facility to generate high resolution allelic profiles which 
can be used as a reference to compare against future seed stabilates. The aim was to 
obtain a minimum of 1,000 reads for each of the genes examined, to facilitate 
detection of allelic variants present at a frequency of 0.5% with a confidence of  
>99%. A summary of the number of reads obtained for each of the samples/genes 
and the number of sequences processed at the different points in the bioinformatics 
pipeline can be found in Table 4.4.  
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The alleles identified in different components of the Muguga cocktail were compared 
by aligning resulting DNA sequences using MUSCLE (Edgar, 2004) and a number 
was assigned to each allele identified. Alignments of the different alleles can be 
found in Appendix B. The frequencies of the different alleles in the different 
reference stabilates of the Muguga cocktail are illustrated in Figure 4.6. 
Figure 4.6 Allelic composition of the three components of the Muguga cocktail based on 
nucleotide sequence of nine Theileria parva antigens.  
Despite the high sequencing depth achieved, the number of allelic variants identified 
was low. In the Muguga stock only a single allele was detected at each locus, except 
for a minor second allele in Tp6 with an abundance of 0.77%. Across the loci, the 
same alleles found in Muguga dominated the Serengeti-transformed stock, but a 
second allele was detected for four genes at a frequency of less than 10%. For the 
Kiambu 5 stock, three genes had a single allele identical to the allele found in the 
Muguga and Serengeti-transformed stocks. Four genes had a single allele identical to 
the minor alleles found in the Serengeti-transformed stock. For the remaining genes, 
between two and four alleles were found. One allele of Tp7, two alleles of Tp3 and 
three alleles of Tp4 were not represented in either the Muguga or Serengeti-
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transformed stocks. In summary, multilocus sequence typing identified between one 
and four alleles across the nine genes examined within the combined components of 
the Muguga cocktail, revealing a similar level of diversity to that found using 
satellite genotyping. 
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Table 4.4 Summary of the bioinformatic processing of the sequencing reads obtained from the 
Muguga cocktail  













No. of reads obtained 


















1 2 3 4 
Tp1 MC_Test_AB 2195 361 22 22 0 0 0 100 99.9 2 1 2039 0 2039 
Tp2F MC 906 377 48 48 0 0 0 99.9 97.3 2 2 721 0.01 716 5 
Tp2R MC 941 573 153 152 0 0 0 99.9 97.5 3 3 731 0.11 688 36 7 
Tp3 MC_Test 4976 959 120 120 8 1 0 100 100 6 4 4309 0.53 2179 1979 118 33
Tp4 MC_AB 1282 213 20 20 1 0 1 100 99.7 4 4 1172 0.21 1039 60 39 34
Tp5 MC_Test_AB 13310 952 50 50 0 0 0 100 100 2 1 12934 0 12934 
Tp6 MC 1118 123 12 12 0 0 0 100 99.5 1 1 1055 0 1055 
Tp7 MC_Test 7575 655 33 32 0 0 0 100 100 3 2 7361 0.02 7304 57
Tp8 MC_Test 6453 919 87 87 0 0 0 100 100 1 1 6146 0 6146 
Kiambu 
St4228 
Tp10 MC_AB 5146 411 13 13 0 0 0 100 100 1 1 5036 0 5036 
Tp1 MC 2182 447 38 38 0 0 0 100 100 1 1 1942 0 1942 
Tp2F MC 559 256 56 56 0 0 0 98.3 86.6 3 3 403 0.14 372 21 10  
Tp2R MC 817 477 123 123 0 0 0 99.9 95.9 1 1 637 0 637 
Tp3 MC 1794 277 34 34 0 0 0 100 100 3 2 1626 0.01 1617 9
Tp4 MC 1697 370 47 47 0 0 0 100 100 1 1 1493 0 1493 
Tp5 MC 1954 331 34 33 0 0 0 100 100 2 2 1817 0.08 1746 71
Tp6 MC 1259 142 14 14 0 0 0 100 99.7 2 2 1158 0.06 1123 35
Tp7 MC 2432 307 25 24 0 0 0 100 100 1 1 2310 0 2310 
Tp8 MC 3205 388 37 37 0 0 0 100 100 2 2 3012 0.01 2997 15
Serengeti 
St4229 
Tp10 MC 256 64 8 8 0 0 0 90.5 68.9 2 2 233 0.16 213 20 
Tp1 MC 2394 419 25 25 0 0 0 100 100 1 1 2175 0 2175 
Tp2F MC 586 199 41 40 0 0 0 99.1 90.7 2 2 472 0.07 455 17
Tp2R MC 843 393 92 92 0 0 0 99.9 96.9 2 2 693 0.03 682 11
Tp3 MC 1394 230 25 25 0 0 0 100 99.8 2 2 1261 0.01 1252 9
Tp4 MC 1863 378 26 26 0 0 0 100 100 1 1 1649 0 1649 
Tp5 MC 1577 264 33 33 0 0 0 100 99.9 1 1 1463 0 1463 
Tp6 MC 2200 226 9 9 0 0 0 100 100 2 2 2050 0.02 2025 25
Tp7 MC_AB 3827 172 11 10 0 0 0 100 100 3 1 3715 0 3715 
Tp8 MC 2345 330 46 46 1 0 0 100 100 2 2 2206 0.01 2194 12
Muguga 
St4230 
Tp10 MC_AB 7299 523 42 42 0 0 0 100 100 1 1 7091 0 7091 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the 
results before manual editing. Reads of different sequencing runs were combined when available 
(MC=Run with samples of the Muguga cocktail, Test=Testrun (see chapter 3), AB=Run with samples 
from African Buffalo (Chapter 5). 1st, 2nd and CLUS refer to the stages of noise removal. Chimaera 
detection was performed using three different algorithms: S = Chimaera Slayer P = Perseus 
U = Uchime. Sensitivity was calculated as the percentage chance of identifying a minor allele present 
at 1:100 and 1:200. ‘>min no. reads’  = the number of variants found after removal of variants with 
less than 5 reads; ‘>min%’ = the number of variants found after removal of variants which are present 
at a frequency of less than 0.4% of the total good reads; ‘Total good reads’ = the number of reads 
maintained after filtering of reads in the bioinformatics pipeline; Hz= heterozygosity; The number of 
reads obtained for each of the alleles detected are displayed. 
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84B .3.2.2 Marikebuni stabilates  
A high resolution multilocus sequencing profile was obtained for another T. parva 
stock, Marikebuni stabilate 3014, which has also been used successfully as a single 
component ITM vaccine, mainly in the coastal region of Kenya. The same genes 
analysed in the Muguga cocktail components were examined in Marikebuni 3014. 
Additionally, sequencing was performed on Marikebuni stabilate 128 for four of 
these genes, Tp1, Tp2, Tp5 and Tp10. Marikebuni 128 was produced at the 
University of Edinburgh by a single tick passage from an animal infected with 
stabilate 3014. A summary of the number of reads obtained for each of the 
samples/genes and the number of sequences processed at the different points in the 
bioinformatics pipeline can be found in Table 4.5. 
Table 4.5 Summary of the bioinformatic processing of the sequencing reads obtained from 
Marikebuni stabilates 3014 and 128 
The number of reads at the different stages of the bioinformatics pipeline are shown together with the results 
before manual editing. Reads of different sequencing runs were combined when available (MC=Run with 
samples of the Muguga cocktail, Test=Testrun (see chapter 3)AB=Run with samples from African Buffalo 
(Chapter 5)) 1st, 2nd and Clus refer to the stages of noise removal. Chimaera detection was performed using three 
different algorithms: S = Chimaera Slayer P = Perseus U = Uchime. Sensitivity was calculated as the percentage 
chance of identifying a minor allele present at 1:100 and 1:200. ‘>min no. reads’  = the number of variants found 
after removal of variants with less than 5 reads; ‘>min%’ = the number of variants found after removal of variants 
which are present at a frequency of less than 0.4% of the total good reads; ‘Total good reads’ = the number of 
reads maintained after filtering of reads in the bioinformatics pipeline; Hz= heterozygosity; The number of reads 
obtained for each of the alleles detected are displayed. 
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Allele 1 2 3 4 5
Tp1 339 63 4 4 0 0 0 95.8 79.3 2 2 315 0.15 290 25 
Tp2for 1679 444 25 24 1 1 2 100 100 3 3 1644 0.18 1484 106 54 
Tp2rev 4416 1193 40 39 0 0 0 100 100 5 4 4372 0.09 4169 127 58 18
Tp3 374 45 4 4 0 0 0 97.1 82.9 1 1 352 0.00 352 
Tp4 543 60 7 7 0 0 0 99.5 93.0 1 1 530 0.00 530 
Tp5 5518 231 14 13 0 0 0 100 100 7 5 5076 0.11 4771 227 31 24 23
Tp6 2027 137 4 4 0 0 0 100 100 1 1 1933 0.00 1933 
Tp7 1910 87 4 3 0 0 0 100 100 2 2 1875 0.05 1826 49 
Tp8 15949 298 5 5 0 0 0 100 100 2 1 15445 0 15445 
Marikebuni 
St 3014 
Tp10 14003 947 53 53 0 0 0 100 100 4 4 13145 0.13 12267 463 216 199
Tp1 524 123 21 21 0 0 0 98.7 57.8 3 3 426 0.090315 406 15 5
Tp2for 62 29 7 7 0 0 0 13.0 6.8 1 1 14 0 14 
Tp2rev 418 196 31 29 0 0 0 97.85 84.96 1 1 378 0 378 
Tp5 1265 92 7 7 0 0 0 100 99.8 2 2 1217 0.10842 1147 70 
Marikebuni 
St 128 
Tp10 897 145 26 25 0 0 0 100 98.3 1 1 813 0 813 
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The frequency of the different alleles in the Marikebuni stabilates is illustrated in 
figure 4.7 (allele colours correspond with the colours used in figure 4.6).
Figure 4.7 Allelic composition of Marikebuni stabilates 3014 and 128 based on nucleotide 
sequence of nine Theileria parva antigens 
In Marikebuni stabilate 3014, single alleles were detected for three of the genes (Tp3, 
Tp4 and Tp6), and these were identical to the alleles found in Muguga and Serengeti. 
For Tp5 and Tp10, a second allele was detected which was identical to the allele in 
Kiambu 5. A minor allele of Tp7, which is identical to the allele in Muguga and 
Serengeti-transformed stocks, was found along with a second major allele, which is 
unique to the Marikebuni stock. For Tp2for, Tp2rev and Tp10, three or four alleles 
were found for stabilate 3014. However, only a single allele was detected in 
sequence reads obtained for these genes in stabilate 128. This single allele was 
identical to the major allele in stabilate 3014, Muguga and Serengeti. The number of 
reads obtained for stabilate 128 was considerably lower than that for stabilate 3014 
despite aiming for a similar sequencing depth. The reduced sequencing depth 
coupled with the requirement to identify a minimum of five reads to define an allele 
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may be responsible for the failure to detect some of the additional alleles.The same 
two alleles were found for Tp1 and Tp5 in the two Marikebuni stabilates, but the 
relative proportion of the two alleles differed between the two stabilates. In stabilate 
3014, Tp1 allele 1 was represented by 7.9% of the reads and allele 2 by 82.1% of the 
reads. For stabilate 218, allele 1 was represent by 96.5% of the reads and allele 2 by 
3.5%. For Tp5, allele 1 was present at 95.5% and allele 2 at 4.5% in stabilate 3014 
compared to 5.8% and 94.2% respectively in stabilate 128. Despite the relatively low 
number of reads obtained for stabilate 128, the results indicate that tick passage of 
this T. parva stock results in changes in the composition of the parasite population in 
the Marikebuni stock. 
60B4.3.3 Antigenic diversity in the Muguga cocktail reference 
stabilates and Marikebuni stabilate 
Multilocus sequence typing of the Muguga cocktail and Marikebuni stocks resulted 
in the identification of between one and four alleles per locus at the nucleotide level. 
The nucleotide sequences were translated into predicted amino acid sequences in 
order to investigate allelic diversity at the protein level and this resulted in the 
identification of between one and three alleles at each locus. For Tp1, T2rev, Tp4, 
Tp5, Tp6, Tp8 and Tp10, a single allele was found at each locus in the Muguga 
cocktail. Two alleles that differed by two amino acid residues were found in the 
Tp2for sequences. These residues, which were found within the Tp227-37 epitope 
region (H→D for residue Tp228 and K→N for residue Tp232), were outwith the 
sequences generated by the Tp2rev primer. Two alleles were found for Tp7, which 
differed by one amino acid (P →A). Three alleles were found for Tp3, involving 
differences in seven amino acid residues. 
A series of epitopes recognised by CD8+ T cell responses have been identified within 
the proteins encoded by seven of these genes. A summary of the allelic variants of 
the epitopes found in the Muguga cocktail components and the two Marikebuni 
stabilates, based on predicted amino acid sequences, is shown in Table 4.6. For all 
but one of the genes, only a single allele of the epitopes was found in the Muguga 
cocktail. A second variant allele was found for the Tp227- 37 epitope in the Serengeti 
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and Kiambu 5 stocks. The Marikebuni stocks were found to contain between one and 
three variant epitopes for the genes examined: one allele was found for the Tp2 138-
147, Tp4 328-338, Tp5 87-95, Tp7 206-214, Tp8 378-388 and Tp10304-318 epitopes. Two alleles 
were found for Tp1 214-224 and three alleles for Tp2 27-37, Tp2 40-48, Tp2 49-59, Tp2 50-59,
Tp2 96-104 and Tp2 98-106. The epitope variants differed by one to six amino acid 
residues from the reference sequence
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Table 4.6 Epitope variants found in vaccine stabilates used for infection and treatment against T. par va   
A) Muguga cocktail (Muguga stabilate 4230, Serengeti stabilate 4229 and Kiambu 5 stabilate 4230). Amino acid residues that differ from the T. parva Muguga
reference genome are highlighted in red.  
B) Marikebuni (stabilate 3014). Amino acid residues that differ from the T. parva Muguga reference genome are highlighted in red.
Var. Tp1214-224 Tp4328-338 Tp587-95 Tp10304-318 
V1 VGYPKVKEEML TGASIQTTL SKADVIAKY TNNFNNPELIPVL 
Var. Tp227-37 Tp240-48 Tp249-59 Tp250-59 Tp296-104 Tp298-106 Tp2138-147 
V1 SHEELKKLGML DGFDRDALF KSSHGMGKVGK SSHGMGKVGK FAQSLVCVL QSLVCVLMK KTSIPNPCKW 
V2 SDEELNKLGML 
Var. Tp1214-224 Tp4328-338 Tp587-95 Tp10304-318 
V1 VGYPKVKEEML TGASIQTTL SKADVIAKY TNNFNNPELIPVL 
V2 VGYPKVKEEII 
Var. Tp227-37 Tp240-48 Tp249-59 Tp250-59 Tp296-104 Tp298-106 
V1 SHEELKKLGML DGFDRDALF KSSHGMGKVGK SSHGMGKVGK FAQSLVCVL QSLVCVLMK 
Tp2138-147 
KTSIPNPCKW 
V2 SDEELETLGML LTSKAMMTVGK TSKAMMTVGK  
V3 SEAELRKMGMI KSSHGMGKIGK SSHGMGKIGK  
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20B4.4 Discussion  
The aim of the work in this chapter was to generate a reference profile for the 
masterseed stocks of the Muguga cocktail using satellite DNA typing and multilocus 
sequence typing using 454 technology. This profile can be used for comparison with 
progeny vaccine stabilates, other vaccine stabilates and field parasite populations. 
Satellite DNA typing has previously been used for characterization of T. parva 
parasites, including the components of the Muguga cocktail (Oura et al., 2004b; Oura 
et al., 2003; Patel et al., 2011). In this study, satellite DNA typing was used to 
examine consistency of content of the three reference stabilates and the 
corresponding Muguga cocktail vaccine batches. In order to obtain higher resolution, 
a larger panel of satellite DNA markers was used than in the previous study by Patel 
et al. (Patel et al., 2011). The benefits of using satellite typing are that this method is 
relatively low-cost and rapid and that data analysis is comparatively straightforward. 
However, the method may fail to detect differences between closely related parasites 
and its sensitivity is limited in detecting minor alleles present at low abundance. 
Furthermore, results between labs cannot easily be compared unless the methods 
used for product size determination and product quantification are carefully 
standardised (Oura et al., 2004b; Patel et al., 2011). 
61B4.4.1 Comparison of methods for satellite DNA typing 
Multiple alleles were identified at a number of satellite markers for the individual 
components of the Muguga cocktail (Stabilate 4228-4230). Patel et al. also detected 
a second allele with four markers (MS7, MS19, MS25 and MS39) in the ILRI 
Serengeti reference stabilate (Stabilate 4229) and for two markers (MS7 and MS19) 
in the ILRI and FAO Muguga reference stabilates (Stabilate 4229 and 4139) (Patel et 
al., 2011). However, Oura et al. detected single alleles for each of the 31 satellite 
markers used in infected cell lines established in vitro by infecting PBMC with 
stabilates 68,69 and 73 (see figure 4.1 ) (Oura et al., 2007b). This discrepancy is 
probably due to the use of cell lines which are frequently dominated by individual 
genotypic components, which overgrow other components following in vitro 
passage. Alternatively, the discrepancy could be due to the analysis of PCR products 
using Spreadex gels rather than the capillary flow electrophoresis. Capillary flow 
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electrophoresis allows detection of low abundance products not visible on agarose 
gel. 
In this study, allele sizes were determined by capillary flow electrophoresis and 
fluorophore detection, as was done in the study by Patel et al. (Patel et al., 2011). 
Overall, the estimated allele sizes were very similar in each study, but some minor 
differences in allele size did arise and this is likely due to minor differences in allele 
calling methodology and the use of different instruments. In the present study, the 
relative abundance of alleles was determined by calculating the area under the curve 
in the traces and this was shown to be relatively reproducible between laboratories 
(Edinburgh and Glasgow). The most accurate method in terms of allele sizing and 
determining the relative abundance of alleles is therefore capillary flow 
electrophoresis. 
62B4.4.2 Satellite DNA profile of the Muguga cocktail  
The ILRI Muguga and Serengeti-transformed stocks had identical single alleles at 
seven out of the eleven markers. For the remaining four markers (MS7, MS8, MS25 
and MS30), one or two major alleles were found, which were shared between the 
Muguga and Serengeti-transformed stocks and in some cases an additional allele was 
found in one of the stocks. Differences between the two stocks were also detected in 
the study by Patel et al., which utilised four satellite markers (MS7, MS8, MS25 and 
MS39). Oura et al. detected different single alleles for four of the 31 satellite markers 
used (MS7, MS19, MS25 and MS43) (Oura et al., 2007b). Two of these satellites 
(MS19 and MS43) were not examined in the current study. The results from the 
present study indicate that the Kiambu 5 component is genotypically distinct from 
Muguga and Serengeti. It has a distinct and unique single allele for four of the ten 
markers that successfully amplified. The single alleles found at four other markers 
were also found as minor components in the Serengeti-transformed stock. All three 
components of the Muguga cocktail were identical at the remaining two markers. 
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The diversity in the Muguga cocktail batches is limited, with between one and four 
alleles present for each of the eleven satellite DNA markers used and this reinforces 
the previous finding that diversity within the Muguga cocktail is limited (Oura et al., 
2004b; Patel et al., 2011). The satellite DNA profiles were similar for the four 
batches of the Muguga cocktail vaccine, ILRI 0801-ILRI0804, and the alleles 
identified corresponded with those found in the three reference stabilates, which 
were produced simultaneously with the Muguga cocktail vaccine batches. This 
indicates that there is consistency between vaccine batches produced in the same 
vaccine production run. 
Comparison of two Muguga reference stabilates two passages apart demonstrated 
differences involving loss or gain of minor alleles at three of the ten loci (Stabilate 
N57 and Stabilate 4230). Patel et al. also demonstrated additional alleles in the ILRI 
Serengeti reference stock compared to the FAO Serengeti reference stock (Patel et 
al., 2011). Differences in satellite profiling following tick passage have previously 
been observed in studies with Marikebuni T. parva stocks (Katzer et al., 2006). 
These findings highlight the potential for changes in the precise composition of 
parasite populations following tick passage. The components of the Muguga Cocktail 
are, in effect, small recombining parasite populations based on small founder 
populations represented by the initial isolates. Consequently, low frequency alleles 
are at particular risk of drifting out of the populations and particular alleles have 
becoming fixed at many loci. Current vaccine components therefore have a low, but 
measurable, level of diversity. It is therefore desirable to produce large quantities of 
seed stabilates for vaccine production to minimise such variation during the 
production process. The satellite DNA profiles established in this study can be used 
for comparison with future progeny reference stabilates. 
 108
63B4.4.3 Deep multilocus sequence typing – quantification of 
abundance of allelic variants 
The deep multilocus sequence typing system was applied to establish a high-
resolution profile of the antigenic composition of the current reference stabilates and 
future seed stabilates. The depth of this analysis was limited by the relatively high 
error rate inherent in the process, as observed while sequencing control samples (see 
Chapter 3). A conservative cut-off of 0.4% abundance was chosen to differentiate 
between true variants and potentially erroneous reads. This still afforded a high of 
level of resolution in assessing the composition of parasites used for vaccination. 
Moreover, alleles present beneath this threshold in a population/generation may not 
always be present in a single dose of vaccine stabilate as the effective vaccination 
dose is relatively low as discussed in the section below. 
64B .4.4 Estimation of effective number of sporozoites in a 
single ITM dose  
The Muguga cocktail vaccine stabilate batches produced at ILRI in 2008 contained 
275.53 infected salivary gland acini/vaccine component/ ml of stabilate, based on the 
average number of infected acini per tick and the number of ground-up ticks per ml 
of stabilate (personal communication Ekta Patel, ILRI). Based on the dimensions of 
sporozoites and mature infected salivary gland cells, Fawcett et al. estimated that 
each infected acinus contains up to 4 x104 sporozoites (Fawcett et al., 1982a). It is 
unlikely that all these sporozoites would have been mature and capable of infecting 
bovine cells in vivo when they were harvested for stabilate production. The number 
of sporozoites maturating depends on the length of time ticks pre-feed on rabbits; the 
highest number of mature sporozoites in the salivary gland, before their release into 
the saliva, is observed after four days of feeding on rabbits (Kimbita et al., 1997). If 
we assume 90% of the sporozoites are mature and infective when harvested at four 
days, then 1 ml of undiluted vaccine stabilate can be estimated to contain 1 x 107
viable sporozoites (= 275.53 x 4 x104 x 90%). Major losses in infectivity are 
predicted to occur at different stages of the vaccine production process. For example, 
for the production of Theileria annulata stabilate it has been estimated that only 24% 
of sporozoites are recovered after the grinding process (Walker et al., 1983). 
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Theileria sporozoites are very fragile and considerable further losses of sporozoites 
occur through the freezing and thawing process. In T. parva, there is an estimated 
infectivity loss of 30- to 100-fold when frozen stabilate is thawed compared to the 
use of fresh sporozoites (Personal communication Daniel Ngugi, RVC). 
Extrapolating from a 100-fold loss in infectivity, each ml of undiluted stabilate may 
be estimated to contain 105 viable sporozoites per stock, which will result in 103
sporozoites per stock for each vaccination dose after a 100-fold dilution (ie. a total 
dose of 3,000 sporozoites). However, the proportion of these infective sporozoites 
that successfully infect bovine cells in vivo following inoculation into an animal is 
unknown. Further loss of infectivity can occur in the field, as it is difficult to 
maintain a cold chain at all stages of vaccine delivery in the field. An in vitro 
infectivity loss of between 1% and 4% per hour, depending on the parasite stock, was 
found for stabilates stored in an ice bath (Mbao et al., 2007). A proportion of the 
animals vaccinated with parasites kept on ice for eight hours or more did not 
withstand subsequent parasite challenge (Marcotty et al., 2001). It was therefore 
recommended that stabilate be used within eight hours of thawing (Marcotty et al., 
2001; Morzaria et al., 1999). The absolute loss of infectivity in the field has not been 
quantified, but if we assume a modest loss of 20% takes place, then each dose will 
contain approximately 800 infective parasites. Based on these assumptions, variant 
genotypes/alleles detected at 0.4% frequency by methods used in the current study 
would equate to 3.2 infective parasites per vaccine dose. Given the numerous factors 
that can potentially result in variation in the dose of parasites delivered to an animal, 
it is likely that not all animals will receive minor parasite genotypes present at 0.4% 
in the bulk vaccine. These calculations indicate that, for practical purposes, the level 
of resolution provided by the deep sequencing procedure used in this study is 
sufficient to assess the composition of the parasites used for vaccination. 
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65B4.4.5 Deep multilocus sequence typing - Muguga cocktail 
components 
The deep multilocus sequence typing system focused on genes encoding CD8+ T cell 
target antigens. Previous studies of CD8+ T cell responses to T. parva have shown 
that these frequently exhibit parasite strain specificity and analyses of allelic 
sequences of two of the parasite antigen genes in field isolates of T. parva revealed 
extensive diversity (Pelle et al., 2011; Taracha et al., 1995a). However, the parasites 
in the Muguga cocktail show relatively limited diversity for each of the loci 
examined in this study, with each component appearing to contain one predominant 
allele plus, in some cases, one or more minor components. The differences between 
the alleles were, in most cases, minimal, with only a few variant nucleotides. 
Moreover, in five of the genes, the nucleotide variation did not result in any amino 
acid changes in the protein. In the Muguga cocktail reference stabilates, allelic 
variation was found in the encoded protein for Tp2, Tp3, and Tp7. This did not result 
in variation in the epitopes identified in Tp7 and only a single allelic variant was 
identified in one of the seven epitopes identified in Tp2 (Tp2 27-37). These findings 
coupled with the results from the DNA satellite typing indicate that diversity within 
the Muguga cocktail is very limited both in terms of the number of alleles and the 
differences between the alleles. Despite this limited diversity within the Muguga 
cocktail, it appears to give broad protection against a range of T. parva parasites. 
This contrasts with the high degree of diversity for Tp1 and Tp2 genes that was 
documented in field isolates from both cattle and buffalo (30 and 41 alleles for Tp1 
and Tp2 respectively). Diversity was especially high in buffalo-derived and buffalo-
associated parasite isolates with between 18 and 25 variants found for the CD8 
epitopes within the Tp2 gene (Pelle et al., 2011). 
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66B4.4.6 Deep multilocus sequence typing - Marikebuni vaccine 
stabilate 
A second parasite population used for vaccinating cattle in Kenya, the Marikebuni 
stock, also showed limited genotypic diversity based on satellite DNA typing. 
However, there was a higher degree of diversity in the Marikebuni stock compared to 
the Muguga cocktail based on the antigens sequenced in this study. Multilocus 
sequencing identified the presence of two variants of the Tp1 epitope and three 
variants in six of the epitopes in Tp2 (Tp2 27-37, Tp2 40-48 Tp2 49-59, Tp2 50-59, Tp2 
96-104, Tp2 98-106). Differences in satellite profile following tick passage have been 
observed in previous studies with the Marikebuni stock (Katzer et al., 2006). A 
marked difference in the allelic composition between passages was detected in the 
present study by deep sequencing the Tp1 and Tp5 loci. Thus, for the Marikebuni 
stock, deep multilocus sequence typing gave a higher degree of resolution compared 
to satellite DNA typing. 
67B4.4.7 Composition of the Muguga cocktail 
The Muguga cocktail was formulated in the 1970s based on cross-immunity studies. 
The inClusion of the Serengeti-transformed component gave better protection than 
Kiambu 5 and Muguga used as a bivalent vaccine (Radley et al., 1975b). However, 
the Muguga and Serengeti-transformed stocks appear very similar using multilocus 
sequence typing and DNA satellite typing, confirming the findings of several 
previous studies (Bishop et al., 2001; Geysen et al., 1999; Oura et al., 2007b). It has 
been speculated that the original T. parva Serengeti-transformed stock has been 
contaminated with and supplanted by T. parva Muguga genotypes over the years 
(Bishop et al., 2001; Oura et al., 2004b).  Buffalo often demonstrate a high 
multiplicity of infection with T. parva with individual animals harbouring 
genotypically diverse parasites (Oura et al., 2011a, b; Pelle et al., 2011). While it is 
likely that passage of a buffalo-derived parasite stock through cattle by tick 
transmission would result in loss of genetic diversity, it seems unlikely that such a 
parasite would end up being so genetically similar to the cattle-derived Muguga 
stock. Unfortunately, stabilate material representing early passages of the Serengeti 
transformed stock are not available and therefore it is impossible to confirm whether 
 112
the composition of current parasite stocks is the same as those tested in the 1970s. 
Repeating of the cross-immunity experiments with the current parasite stocks would 
confirm whether the current parasite stocks induce a similar cross-protection profile. 
If so this might suggest that the minor components of the Serengeti-transformed 
stock, which are distinct from Muguga, are important in the broad protection 
provided by the Muguga cocktail.   
Even though the Muguga cocktail appears to protect against a range of cattle-derived 
T. parva parasites and provides protection in the field, there are some reports 
indicating that not all animals are protected against parasites from different areas of 
Africa (Lynen et al., 1991). As suggested before by Bishop et al. and Oura et al., the 
formulation of the Muguga cocktail should be validated, as better protection might be 
provided by formulating an alternative cocktail (Bishop et al., 2001; Oura et al., 
2007a). If minor components in the parasite stocks contribute to the breadth of 
immunity, it is important to know whether their presence or absence within a vaccine 
can explain in variation in the protection elicited. When two passages of the 
Marikebuni stock were analysed, at certain markers, particular alleles were identified 
in only one of the passages (This study and (Katzer et al., 2010) and there is some 
indication that there is variation in composition of components of the Muguga 
cocktail (This study and (Patel et al., 2011). A more standardised composition could 
be achieved by using carefully selected, genotypically distinct, T. parva clones. The 
use of clones would make quality control easier as the presence of minor components 
would not need to be monitored and maintained. The inClusion of clones that are 
genotypically more distinct may make the cocktail more suitable for deployment 
over a wider geographical area.  
Two local stocks (Katete and Chitongo) are currently used for immunisation against 
ECF in Malawi and Zambia. The stocks are genotypically quite different from the 
stocks in the Muguga cocktail (This study; (Geysen et al., 1999; Hayashida et al., 
2013). Interestingly, breakthroughs were seen when the Katete stock was used to 
challenge Muguga cocktail-immunised animals (Geysen, 2000), whereas Muguga 
cocktail-immunised animals were immune against challenge from the Chitongo stock 
(Geysen, 2000). The Katete and Chitongos stocks had alleles in common with the 
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Muguga cocktail for two out of ten and six out of ten DNA satellite markers 
respectively.  
The techniques used in this study may be used for preliminary screening of candidate 
parasites stocks for inClusion in an improved formulation of a cocktail vaccine. 
Although it would be relatively easy to identify a number of genotypically distinct 
parasite clones, it will, unfortunately, be necessary to perform extensive in vivo 
cross-immunity experiments to confirm the utility of the novel components. 
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7BChapter 5: Theileria parva in African buffalo  
5.1 Introduction 
African buffalo are considered to be a reservoir host for T. parva and can be infected 
with high levels of the parasite in the absence of clinical disease (Oura et al., 2011a; 
Young et al., 1978). In contrast, cattle develop severe clinical disease with a high 
mortality rate when infected with buffalo-derived T. parva (Lawrence, 1979). 
Previous studies have shown that only a proportion of animals ITM-immunised using 
cattle-derived T. parva stocks, including the Muguga Cocktail, were protected 
against buffalo-derived T. parva (Lohre, 1978; Radley et al., 1975c; Radley et al., 
1979). This lack of protection against buffalo-derived parasites is believed to be due 
to strain specificity in the immunity induced by infection and treatment. In particular, 
this has been attributed to the use of vaccine stabilates with limited parasite diversity 
and subsequent challenge with a mixture of strains representing a variety of allelic 
variants in epitopes recognised by the immune system. 
A series of experiments have been conducted using buffalo-derived T. parva 
stabilates for the infection and treatment method of vaccination of cattle. These 
stabilates were produced by either collecting ticks from the ground of paddocks 
frequented by buffalo (Dolan, 1984; Latif et al., 2001) or by feeding ticks on infected 
buffalo (Cunningham et al., 1974; Mutugi et al., 1988a; Mutugi et al., 1988b; Young 
et al., 1977a). In most cases, vaccination with these stabilates led to the induction of 
protective immunity against buffalo-derived T. parva challenge. Furthermore, cross-
protection was noted between buffalo-derived stabilates from different locations in 
Kenya when cattle were immunised with a single buffalo-derived T. parva stabilate 
(Mutugi et al., 1988a; Mutugi et al., 1988b). These results clearly show that cattle 
can develop immunity against buffalo-derived T. parva and that there is the potential 
for a single buffalo-derived stabilate to be used effectively in different geographical 
areas (Mutugi et al., 1988a; Mutugi et al., 1988b). 
The multiplicity of infection with T. parva in carrier buffalo has been found to be 
much higher than that in cattle (Conrad et al., 1987b; Oura et al., 2011a; Pelle et al., 
2011). Oura et al. (2011) found evidence for the presence of at least nine alleles at a 
single locus in an individual African buffalo, indicating that a minimum of nine 
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parasite genotypes were present. Marked differences in antigenic diversity have been 
noted between isolates from different buffalo and between isolates from the same 
buffalo taken at different time-points (Conrad et al., 1987). Microsatellite-based 
analysis of T. parva maintained in African buffalo in Uganda indicated the presence 
of distinct parasite populations in Lake Mburo National Park and Queen Elizabeth 
National Park (Oura et al., 2011a). Variation in PIM PCR-RFLP profiles was 
observed among samples from buffalo from the Kruger National Park, whereas the 
profiles from buffalo from Hluhluwe-iMfolozi Park, Abalingwe Game Reserve and 
Ithala Game Reserve were much more similar to one another (Sibeko et al., 2011). 
Recent work characterising the parasite has focused on Tp1 and Tp2, two genes 
known to encode antigens that can be recognised by bovine CD8+ T cell responses. A 
large number of allelic sequence variants were found for these genes among buffalo-
derived isolates and buffalo-associated cattle-derived isolates from Kenya (Pelle et 
al., 2011). 
The main aim of this chapter is to gain an insight into genotypic diversity between 
and within buffalo-derived T. parva populations from two geographically distinct 
areas in South Africa and Kenya. Genotypic diversity of buffalo-derived T. parva 
will be analysed using a multi-locus sequence typing system based on Roche 454 
technology, the development of which is detailed in Chapters 3 and 4. This system 
has the major advantage that it will allow the identification of multiple allelic 
variants of the parasite within individual animals. The antigenic diversity found in 
the samples from buffalo will then be compared to antigenic diversity found in the 
Muguga Cocktail vaccine. 
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5.2 Material and methods 
5.2.1 Samples from buffalo 
DNA from African buffalo was provided by Nicholas Yules, Pirbright Institute and 
ILRI, Kenya. Genomic DNA was extracted from the whole blood of buffalo from the 
Kruger National Park (South Africa) and from blood clots of buffalo from the Ol 
Pejeta conservancy (Kenya). The buffalo were found in different parts of the 
conservancies and varied in age and sex (see Table 5.1). 





Sex Location Park Country 
SC01 18 months F Crocodile bridge Kruger National Park South Africa 
SC02 2 years M Crocodile bridge Kruger National Park South Africa 
SC03 2 years F Mnyeleni Kruger National Park South Africa 
SC04 3 years F Mnyeleni Kruger National Park South Africa 
SC05 3.5 years M Sekurakwane Kruger National Park South Africa 
SC06 3 years M Sekurakwane Kruger National Park South Africa 
301 5 years M 
Sweet waters 
N 00° 02.752' E 36° 56.165' 
Ol Pejeta Conservancy Kenya 
302 2 years M 
Sweet waters 
N 00° 01.331' E 36° 56.104' 
Ol Pejeta Conservancy Kenya 
303 3 years F 
Sweet waters  
N 00° 01.332' E 36° 56.104' 
Ol Pejeta Conservancy  Kenya 
304 1 year M 
West of Ewaso Ngiro river 
N 00° 01.332' E 36° 56.050' 
Ol Pejeta Conservancy Kenya 
305 5 years F 
West of Ewaso Ngiro river  
N 00° 02.225' E 36° 51.224' 
Ol Pejeta Conservancy Kenya 
306 > 6 years  M 
Sweet waters  
N 00° 00.799' E 36° 57.797' 
Ol Pejeta Conservancy Kenya 
307 6 years F 
Sweet waters 
N 00° 01.668' E 36° 55.446' 
Ol Pejeta Conservancy Kenya 
308 5 years F 
Sweet waters  
N 00° 01.668' E 36° 55.489' 
Ol Pejeta Conservancy Kenya 
5.2.2 Amplicon sequencing using Roche 454 technology  
Amplicons were generated of the Tp1, Tp2, Tp4, Tp5, Tp6 and Tp10 genes using the 
PCR conditions and ‘fusionprimers’ as described in Chapter 3. The raw sequencing 
data was processed using the bioinformatics pipeline described in Chapter 3. The 
resulting sequences were subjected to a number of analyses described in chapter 2; 
these include: calculation of the number of polymorphic sites in nucleotide and 
amino acid sequences, heterozygosity, mean distance between variants, principal co-
ordinate analysis (PCoA) and construction of phylogenetic trees. 
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5.3 Results 
Deep multi-locus sequence typing was performed on one of the buffalo samples from 
the Kruger National Park, using all nine T. parva loci previously used to characterise 
the Muguga Cocktail components. Polymorphism was found in each of the genes, 
with between three and 19 alleles identified at each locus (see Figure 5.1). 
Figure 5.1 Proportion of different alleles found at nine loci representing the parasite population 
in a single buffalo. The sequences were obtained using DNA from a buffalo from the 
Kruger national Park (SC06) 
Following the analysis of a single buffalo parasite population, multi-locus sequence 
typing was performed on all the buffalo samples available using a set of six genes, 
namely Tp1, Tp2, Tp4, Tp5, Tp6 and Tp10. The resulting sequences were subjected 
to a number of analyses to estimate diversity for the different genes in the different 
buffalo populations. These include: calculation of the number of polymorphic sites in 
nucleotide and amino acid sequences, heterozygosity and mean distance between 
variants; the results can be found in Table 5.2. Further investigation of the 
relationship between sequences was undertaken using principal co-ordinate analysis 
and the construction of phylogenetic trees. 
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Table 5.2 Diversity of buffalo-derived T. parva at six loci 
1 number of polymorphic sites shown does not include residues in insertion/deletion regions (ind); 
2 only the first 252 bp of Tp2 forward reads for were used for analysis; 3 heterozygosity could not be 
calculated for Tp2 as the number of reads obtained for some of the animals was low. The number of 
variants based on the nucleotide sequence and the mean divergence between sequence variants and the 
corresponding standard error (S.E.M) and mean heterozygosity (Hz) are shown. The Tp4, Tp5 and 
Tp10 gene contain introns and the number of polymorphic sites in the coding sequence (CDS) is 
shown. The number of polymorphic sites in the predicted protein sequence and the number of allelic 
variants is shown. 
Overall, a high number of variant nucleotide sequences was detected for each of the 
genes in this study combined, ranging from 27 alleles for Tp6 to 76 alleles for Tp1. 
The number of alleles was highest in Tp1, Tp2 and Tp4, which led to a high number 
of amino acid variants for Tp1 and Tp2 (Table 5.2). For all the genes, many of the 
alleles were ‘private’ to either African buffalo from the Kruger National Park or to 
African buffalo from the Ol Pejeta conservancy. A limited number of alleles was 
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shared between African buffalo from the two locations (between 1 and 4 depending 
on the gene). For Tp5 and Tp10 nucleotide changes in the coding region did not 
result in amino acid changes. The number of nucleotide changes was proportionally 
higher in the intron segments of the amplicons representing spliced genes, i.e. Tp4, 
Tp5 and Tp10 (based on data presented in Table 5.2). Within the different buffalo 
parasite populations the highest diversity was observed for the Tp2 gene, as 
expressed by the mean distance between sequences. The distance between sequences 
within a population was much lower for the other genes (see Figure 5.2). The high 
mean heterozygosity found for Tp1, Tp4, Tp5 and Tp6 indicates that each buffalo 
carries multiple parasite genotypes and no one genotype dominates the mixture 
(Table 5.2). 
Figure 5.2 Mean distance between sequences obtained for T. parva populations from African 
buffalo from Ol Pejeta and the Kruger National Park 
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5.3.1 Number of allelic variants in buffalo from Kruger 
National Park and the Ol Pejeta conservancy 
The average number of alleles detected in individual animals was high for all of the 
genes for African buffalo from both the Kruger National Park and the Ol Pejeta 
conservancy (see XFigure 5.3 X). Although the total of number of alleles found in 
African buffalo the Kruger National Park and the Ol Pejeta conservancy was similar, 
the number of allelic variants for Tp4, Tp5 and Tp10 within an individual African 
buffalo appears to be higher for African buffalo from the Kruger National Park (see 
Figure 5.3). This difference cannot be explained by a difference in the number of 
reads obtained. A similar trend was observed for the Tp10 gene, but unfortunately 
only five of the eight datasets from the Ol Pejeta buffalo had sufficient reads for 
further analysis (the other three were excluded from further analysis); substantial 
variation was found in the remaining datasets. Unfortunately, the number of reads 
obtained for Tp2 in individual buffalo was too low for analysis of the number of 
alleles in individual animals and could not be included in the analysis. Nevertheless, 
it appears that the allelic diversity of T. parva is greater in buffalo from the Kruger 
National Park than from the Ol Pejeta conservancy. 
Figure 5.3 Number of alleles found in individual buffalo and read depth for Tp1, Tp4, Tp5, Tp6 
and Tp10 
a) The average number of allelic variants and standard deviation are shown for buffalo samples from
the Kruger National Park and the Ol Pejeta conservancy. Only datasets that contained > 400 reads 
after bioinformatic processing were used for the analysis. b) The average number of reads and 
standard deviations for the datasets used to make Figure 5.3a. 
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5.3.2 Comparison of T. parva maintained in buffalo from the 
Kruger National Park and the Ol Pejeta conservancy  
The sequences obtained for the different T. parva genes from buffalo from the 
Kruger National Park and the Ol Pejeta conservancy were used for principal co-
ordinate analysis. For Tp2, Tp4, Tp5, Tp6 and Tp10, no meaningful sub-clustering 
was observed using PCoA analysis; no Clustering was observed among sequences 
from individual animals, nor between sequences derived from African buffalo from 
the two locations. However, the fact that many ‘private’ alleles were identified in 
each location from more than one buffalo suggests that the parasite populations have 
differentiated, despite the lack of discrimination in the PCoA analysis. As an 
example, the results for Tp5 are illustrated in Figure 5.4.  
A degree of sub-Clustering can be seen for T. parva from buffalo from the Ol Pejeta 
conservancy and the Kruger National Park using sequences obtained for Tp1 and this 
is illustrated in Figure 5.5. Sequences from each sampling location are largely 
discriminated by the first axis of the graph, which explains 30.1 % of the variation in 
the dataset. Individual buffalo were associated with a variety of sequences and 
clustering was not observed among sequences derived from individual animals. A 
number of cattle-derived Tp1 sequences (n = 22) from a previous study by Pelle et 
al. (2011) were incorporated into a PCoA (see Figure 5.6). The extensive diversity 
among the buffalo-derived sequences contrasts with the limited diversity among 
those derived from cattle. The cattle-derived sequences clustered around the edges of 
the buffalo-derived sequences obtained. 
Similarly, a number of cattle-derived Tp2 sequences (n = 22) from a previous study 
by Pelle et al. (2011) and this study (Muguga Cocktail and Marikebuni vaccine 
stock, see Chapter 3) were incorporated into a PCoA and this is shown in Figure 5.7. 
The extensive diversity among the buffalo-derived sequences contrasts with the 
limited diversity among those derived from cattle. For this gene the cattle-derived 
sequences also cluster around the edges of the buffalo-derived sequences obtained.
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Figure 5.4 PCoA of Tp5 allelic diversity in T. parva in African buffalo 
Illustration of the relationship between T. parva present in buffalo from the Kruger National Park (SC01-SC06) and the Ol Pejeta conservancy (301-308) 
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Figure 5.5 PCoA of Tp1 allelic diversity in buffalo 
Illustration of the relationship between T. parva present in buffalo from the Kruger National Park (SC01-SC06) and the Ol Pejeta conservancy (301-308) 
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Figure 5.6 PCoA of the Tp1 Allelic diversity in T. parva in African buffalo and cattle 
This diagram illustrates the relationship between T. parva present in African buffalo from the Kruger National Park, the Ol Pejeta conservancy and cattle from different 
regions in Kenya (Kilifi, Nyairo and Kakuzi) (Pelle et al., 2011)  
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Figure 5.7 PCoA of Tp2 allelic diversity in T. parva in African buffalo and cattle  
 This diagram illustrates the relationship between T. parva present in African buffalo from the Kruger National Park, the Ol Pejeta conservancy and cattle from 
different regions in Kenya (Kilifi, Nyairo and Kakuzi) (Pelle et al., 2011)
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Phylogenetic trees were constructed to further investigate the relationship between 
the different sequences obtained. Two exemplar phylogenetic trees are shown in 
Figures 5.8 and 5.9. Additional trees can be found in Appendix C. For each of the 
genes there appears to be a degree of sub-clustering between sequences obtained 
from African buffalo from the Kruger National Park and the Ol Pejeta conservancy. 
However, the bootstrap support of the constructed trees was very low, so no firm 
conclusions can be drawn on the phylogenetic relationship between sequences of the 
different parasites. The lack of bootstrap support of the constructed trees might be 
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 Figure 5.8 Phylogenetic tree constructed using buffalo Tp1 sequences 
The tree was constructed using a maximum likelihood method using 1,000 bootstrap replicates. The 
bootstrap values indicate the degree of support for each of the nodes. Sequences were obtained from 
buffalo from the Kruger National Park and the Ol Pejeta conservancy, all unique sequences obtained 
within the Kruger National Park or the Ol Pejeta conservancy are displayed. The location (Ol Pejeta 
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Figure 5.9 Phylogenetic tree constructed using buffalo Tp5 sequences 
The tree was constructed using a maximum likelihood method using 1,000 bootstrap replicates. The 
bootstrap values indicate the degree of support for each of the nodes. Sequences were obtained from 
buffalo from the Kruger National Park and the Ol Pejeta conservancy. The location (Ol Pejeta (∆) or 
Kruger NP (□)), animal number and allele ranking are displayed.  
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5.3.3 Antigenic diversity in buffalo-derived T. parva 
A series of epitopes recognised by CD8+ T cell responses have been identified within 
the proteins encoded by Tp1, Tp2, Tp4, Tp5 and Tp10. A large number of epitope 
variants was found for the epitopes within the Tp2 gene (see Table 5.3). Between 31 
and 42 allelic variants were found at the amino acid level for the epitopes within the 
forward reads of this gene, some of which were shared between buffalo from the 
Kruger National Park and the Ol Pejeta conservancy. The alleles of the Tp249-59 
epitope are detailed in XTable 5.4X. For the other genes, the antigenic diversity was 
more limited despite the high number of allelic variants at the nucleotide sequence 
level. Many nucleotide changes were found to be synonymous and did not lead to 
coding changes. No diversity was found for either Tp587-95 or Tp10304-318, two alleles 
were found for Tp4328-338 and three alleles were found for Tp1214-224. The alleles for 
the Tp1214-224 and Tp4328-338 epitopes include the reference alleles found in the 
Muguga Cocktail. The two newly discovered variants of the Tp1214-224 epitope have 
relatively subtle residue changes in the last two residues of the epitope compared to 
the reference sequence, i.e. Tp1223 (M →I) and Tp1224 (L→I), and this is shown in 
Table 5.3. Tp7 and Tp8 were only examined for one sample from a buffalo from the 
Kruger National Park (see Figure 5.1) and no epitope variants were found for Tp7206-
214 and Tp8378-388 in this sample (data not shown)
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Table 5.3 Epitope variants found in samples from buffalo from the Kruger National Park and 
the Ol Pejeta conservancy 
Var. Tp1214-224 Tp227-37 Tp240-48 Tp249-59 Tp4328-338 Tp587-95 Tp10304-318 
V1 VGYPKVKEEML NDDELENLGML DGFDKEKLF KSSHGMGKIGR TGASIQTTL SKADVIAKY TNNFNNPELIPVL 
V2 VGYPKVKEEMI NDDELKKLGML DGFDKELLF KSSHGMGKVGK SGASIQTTL 
V3 VGYPKVKEEII NDDELKRMGMV DGFDKETLF KSSHGMGKVGR 
V4 NDDELNKLGML DGFDRDALF KSSHGMGMVGR 
V5 NDDELRKLGMV DGFDREKLF KSSKAMTTTGK 
V6 NDEELENLGML DGFDRELLF KSSKGLTAVGK 
V7 SDDDLKKLGML DGFDRQRLF KSSKGMTAVGK 
V8 SDDDLNKLGML DGFEKERLF KSSKSMGIVGR 
V9 SDDELDTLGML DKLDKDKLF KTSHSMGMIGK 
V10 SDDELETLGML DNLDKDKLF KTSKAMTATGR 
V11 SDDELKKLGML DNLNKERLF KTSKAMTMTGR 
V12 SDDELKKMGLI EGFDKEKLF KTSKAMTSTGR 
V13 SDDELNKLGML EGFEKEKLF KTSKGMTEVGK 
V14 SDDELRKLGML EGLDMEALF KTSKGMTKVGR 
V15 SDDELRKLGMV GNFDRELLF KTSKSMGQVGR 
V16 SDDELSKMGML GNFNKETLF LSSHGMGKVGK 
V17 SDEELDTLGML PDFEKERLF LTSHGMGEVGK 
V18 SDEELESLGML PDLDKNRLF LTSHGMGKIGR 
V19 SDEELETLGML PDPDKERLF LTSHGMGKVGR 
V20 SDEELKELGML PDPDKETLF LTSHGMGRIGR 
V21 SDEELKKMGML PDPNKDRLF LTSKAMGAVGR 
V22 SDEELKKLGML PDPDKQRLF LTSKAMMTVGK 
V23 SDKELDTLGML PDPNKERLF LTSKAMSTVGK 
V24 SDNELDTLGLL PDPVKERLF LTSKAMTHVGK 
V25 SDSELETLGML PGFDKELLF LTSKAMTHVGR 
V26 SEAELRKMGMI PGFDKEVLF LTSKAMTTVGK 
V27 SEDELKKMGMV PHPDKERLF LTSKAMTTVGR 
V28 SEEELRKMGMI PNPDKEKLF LTSKCMTEVGR 
V29 SHEELKKLGML PNPDKEKLF LTSKGMAAVGR 
V30 TDEELENLGML QDPDKETLF LTSKGMTKIGK 
V31 TDEELREMGMI SNFDRESLF LTSKGMTKIGR 
V32 TEDELKKLGML TDPVKERLF LTSKSMMTVGK 
V33 TEDELKKLGMV LTSKSMSEVGR 
V34 TEDELKNMGLI MTSKAMTATGR 









Epitope variants highlighted in grey were found in a previous study by Pelle et al (2011). 
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Table 5.4 Variants of Tp249-59 epitope found in African buffalo from the Kruger National Park, 




Ol Pejeta Kenyan study1 
1 KSSHGMGKIGR KSSHGMGKIGR KSSHGMGKIGR 
2 KSSHGMGKVGK KSSHGMGKVGK KSSHGMGKVGK 
3 KSSHGMGKVGR KSSHGMGKVGR KSSHGMGKVGR 
4 KSSHGMGMVGR 
5 KSSKAMTTTGK KSSKAMTTTGK KSSKAMTTTGK 
6 KSSKGLTAVGK 
7 KSSKGMTAVGK KSSKGMTAVGK 
8 KSSKSMGIVGR KSSKSMGIVGR 
9 KTSHSMGMIGK KTSHSMGMIGK 
10 KTSKAMTATGR KTSKAMTATGR KTSKAMTATGR 
11 KTSKAMTMTGR KTSKAMTMTGR 
12 KTSKAMTSTGR 
13 KTSKGMTEVGK KTSKGMTEVGK KTSKGMTEVGK 






20 LTSHGMGRIGR LTSHGMGRIGR LTSHGMGRIGR 
21 LTSKAMGAVGR 
22 LTSKAMMTVGK LTSKAMMTVGK 
23 LTSKAMSTVGK LTSKAMSTVGK LTSKAMSTVGK 
24 LTSKAMTHVGK LTSKAMTHVGK 
25 LTSKAMTHVGR 
26 LTSKAMTTVGK LTSKAMTTVGK LTSKAMTTVGK 
27 LTSKAMTTVGR 
28 LTSKCMTEVGR 
29 LTSKGMAAVGR LTSKGMAAVGR 
30 LTSKGMTKIGK 
31 LTSKGMTKIGR LTSHGMGKIGR 
32 LTSKSMMTVGK LTSKSMMTVGK LTSKSMMTVGK 
33 LTSKSMSEVGR LTSKSMSEVGR LTSKSMSEVGR 
34 MTSKAMTATGR MTSKAMTATGR 
35 MTSKAMTMTGR MTSKAMTMTGR 






1 Pelle et al (2011) 
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5.4 Discussion 
5.4.1 Diversity in T. parva in African buffalo from the Kruger 
National Park and the Ol Pejeta conservancy 
The multiplicity of infection was high in both buffalo from the Kruger National Park 
and the Ol Pejeta conservancy. Using deep multilocus sequence typing of Tp1, Tp2, 
Tp4, Tp5, Tp6 and Tp10, an average of between 8.8 and 21.5 alleles were found in 
individual animals for each of the loci for buffalo from the Kruger National Park and 
between 6.8 and 17.6 alleles for buffalo from the Ol Pejeta conservancy. In a 
previous study, a maximum of nine alleles was found at a single locus using satellite 
DNA markers in individual samples from buffalo from national parks in Uganda 
(Oura et al., 2011a). While it is possible that the buffalo sampled in Uganda simply 
had a lower multiplicity of infection, it is likely that the lower number of alleles per 
locus identified in that study was due to the use of a different genotyping technology, 
both in terms of the locus type and the method of allele-calling. The multi-locus 
typing system used in this study is capable of detecting single nucleotide differences 
between alleles and thus provides a very high level of resolution. 
It has been hypothesised that T. parva was introduced into South Africa at the 
beginning of the twentieth century through the importation of cattle from East Africa 
for the purpose of restocking, following the rinderpest epidemic at the end of the 19th 
century (Mbizeni et al., 2013; Norval et al., 1991a; Norval et al., 1992). It has been 
argued that the local T. parva population was decimated at the end of the 19th century 
due to the death of considerable numbers of cattle and buffalo during the rinderpest 
epidemic, thus causing a severe bottleneck of the T. parva population. The imported 
cattle were hypothesised to carry T. parva from East Africa, thereby re-introducing 
East Coast fever to the region with subsequent transmission into African buffalo 
(Mbizeni et al., 2013). Current evidence indicates that T. parva in cattle in East 
Africa is much less diverse than that in African buffalo (Pelle et al., 2011). Given the 
high multiplicity of infection and genotypic diversity of T. parva within individual 
South African buffalo revealed in the study, the hypothesis that African buffalo 
became infected with T. parva after introduction from cattle from East Africa 
appears unlikely. 
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A simpler explanation is that the remaining South African buffalo population acted 
as a reservoir for the local T. parva population. The size of the buffalo population in 
the Kruger National Park alone, as measured by the 2009 census, was 27,000. Even 
if the buffalo population fell to a few thousand following the rinderpest epidemic, the 
effective size of the parasite population would still have been very large and 
sufficient to ensure the maintenance of a parasite population with a high level of 
genotypic diversity. Analysis of the major histocompatibility complex gene, DRB3, 
in buffalo revealed high allelic diversity for buffalo from four national parks in 
Africa, including the Kruger National Park. It was hypothesised that following 
decimation of the buffalo population in South Africa because of the rinderpest 
epidemic, the population was restored by the rapid re-colonisation of buffalo from 
unaffected to affected areas (Wenink et al., 1998). It seems likely, therefore, that the 
re-colonising buffalo would still be infected with the vestiges of the local population 
and this would re-establish in the country.  
Over six loci, the mean distance between alleles sequences was surprisingly similar 
in each of the three sample sets: (1) buffalo from Ol Pejeta and Kruger National Park 
combined, (2) buffalo from the Ol Pejeta conservancy and (3) buffalo from the 
Kruger National Park. Figure 5.2 illustrates the fact there was a good agreement over 
the three ‘populations’ and taken together with the relatively small error bars, this 
data demonstrates converging results, which in turn suggests that each population 
was sampled with adequate depth to meaningfully calculate this metric. It had been 
expected that sequences obtained from T. parva parasites from buffalo in the Kruger 
National Park would display less diversity than that those from Eastern Africa 
buffalo ( HMbizeni et al., 2013H) for two reasons: firstly, the suggested bottleneck due to 
the rinderpest as mentioned above and secondly, differences in climatic conditions 
and tick behaviour (Mbizeni et al., 2013). Ticks have adapted to the harsh climatic 
conditions during the dry season in South Africa by developing the ability to go into 
‘diapause’, a predetermined state of low activity and metabolism. This state is under 
neurohormonal control and is initiated, maintained and terminated by changes in 
daylight length and other factors (Young et al., 1994). As a consequence of this 
behaviour, Rhipicephalus appendiculatus completes only one life-cycle within a 
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calendar year. Parasites must be maintained long enough in the mammalian host to 
allow ticks to pick up infection following diapause (Young et al., 1994) and not all T. 
parva genotypes are capable of inducing a long-term carrier state in the cattle host 
(Skilton et al., 2002). However, buffalo can carry T. parva for long periods of time, 
up to 888 days (Grootenhuis et al., 1987), which will allow parasite diversity to be 
maintained in the buffalo host over the dry season. When ticks feed on buffalo after 
their diapause, they will readily become infected with a mixture of parasites. 
Seasonality of ticks thus does not necessarily hamper the maintenance of parasite 
diversity in the buffalo host. 
5.4.2 Sub-structuring of T. parva in Kruger National Park and 
the Ol Pejeta conservancy 
A degree of geographical sub-structuring was observed between the parasites in the 
Kruger National Park and the Ol Pejeta conservancy. This sub-structuring was most 
evident for the Tp1 gene, based on both phylogenetic and PCoA analysis. This 
suggests the parasite populations have differentiated and the simplest explanation is 
that of genetic drift. 
The estimated average genetic ‘distance’ (as measured by the number of nucleotide 
substitutions per site from averaging over all sequence pairs) between any two alleles 
in the Kruger National Park and within the Ol Pejeta conservancy was very similar 
for all six genes examined, i.e. Tp1, Tp2, Tp4, Tp6 and Tp10. Principal co-ordinate 
analysis using Tp2, Tp4, Tp5, Tp6 and Tp10 did not reveal any obvious partitioning 
of the dataset.  Phylogenetic analysis also did not provide evidence for the parasite 
populations in the Kruger national park and the Ol Pejeta conservancy evolving 
separately. Sequences from the two parks can be found in the same clades.  However, 
many of the identified alleles were ‘private’ to either the African buffalo from Ol 
Pejeta or to African buffalo from the Kruger National Park. The fact that several of 
these ‘private’ alleles were identified in each location suggests that the parasite 
populations have differentiated, despite the lack of discrimination in the PCoA 
analysis. Identical sequences were found in several buffalo from one area, which 
suggests a degree of homogeneity in local populations, i.e. little evidence of a high 
rate of novel mutations in the locality. The diversity observed has probably been 
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around for a long time. This pattern may be consistent with a lot of ‘ancient’ 
diversity in combination with present day geographical sub-structuring, which may 
be at a fine level.  
5.4.3 Antigenic diversity in T. parva maintained in African 
buffalo 
For buffalo-derived T. parva, a moderate to very high degree of allelic 
polymorphism was observed for the genes targeted for deep multi-locus sequence 
typing even within single buffalo. This diversity within an individual animal allows 
feeding ticks to pick up several genotypically distinct parasites that can sexually 
recombine in the tick to give rise to novel parasite genotypes. A large number of 
allelic variants of Tp1 and Tp2 have previously been identified in isolates from 
buffalo (Pelle et al., 2011). In the present study, additional allelic variants were 
identified and this was anticipated as the population was sampled in greater depth. 
The diversity in the epitope regions within the Tp1 and Tp2 gene was high in 
buffalo-derived T. parva from both the Kruger National Park and the Ol Pejeta 
conservancy. Many of the allelic variants of the epitopes in the Tp2 gene were shared 
between Ol Pejeta and the Kruger National Park, but a number of private alleles were 
found in each area. 
Although many variants of the Tp1 gene were found, the most notable feature of this 
variation was perhaps the difference in copy number of the proline-rich repeats 
towards the end of the reads. Only three alleles of the Tp1214-224 epitope were found 
in both Ol Pejeta and the Kruger National Park. Only one allele was detected for the 
Tp587-95 and Tp10304-318 epitopes and two alleles were found for the Tp4328-338
epitope. Most nucleotide changes in these genes did not result in amino acid changes 
when translated into amino acid sequences. This level of conservation at the amino 
acid level suggests that the encoding nucleotide sequences are largely under 
purifying selection and suggest that conservation of these genes is required for 
parasite fitness. Moreover, the data indicates that these epitopes have not been 
influenced either by positive diversifying or balancing selection and this in turn 
suggests they are not under strong immune selection by the African buffalo host. 
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Animals immunised by infection and treatment using the Muguga Cocktail are not in 
every case protected against challenge with buffalo-derived T. parva parasites. The 
diversity within the Muguga Cocktail is known to be limited, based on DNA satellite 
typing (see Figure 4.3)  and deep multi-locus sequence typing (see Figure 4.6). 
Although the allelic variants of the Tp2 gene differed somewhat between the Kruger 
National Park and the Ol Pejeta conservancy, many allelic variants were detected in 
each population which were very different from the Muguga alleles of Tp2. Previous 
work has shown that CD8+ T cell clones derived from animals immunised with T. 
parva Muguga could not recognise peptides with a substitution at P8 of the Tp249-59 
epitope (Connelley et al., 2011). In this study, a substitution with respect to the 
Muguga allele at P8 was found for many of the Tp249-59 variants (see Table 5.4) and 
it is therefore likely they will not be recognised by CD8 T cells induced by the T. 
parva Muguga stock. For the other epitopes in the Tp2 gene, the relationship of 
allelic polymorphism to immune recognition is unknown. However, it seems likely 
that the high degree of polymorphism in the epitopes and specificity of CD8+ T cell 
responses in immunity will prevent or reduce recognition by CD8+ T cells, leading to 
failure of the Muguga Cocktail to protect against buffalo-derived parasites. 
In contrast, epitopes in other genes were relatively conserved among parasite 
genotypes and should these genes be investigated in the future, it may be concluded 
that immunisation using a stabilate with a more limited diversity (such as the 
Muguga Cocktail) can be used for successful vaccination against buffalo-derived T. 
parva. The conservation of some of the antigens recognised by bovine CD8+ T cells 
is promising for the design of a next-generation vaccine. The use of conserved genes 
would overcome the issue of genetic diversity between different parasites and would 





8BChapter 6: Investigating the role of antigenic 
polymorphism in immune protection  
21B6.1 Introduction 
Immunity against Theileria parva is mediated by a CD8+ T cell response (McKeever 
et al., 1994) and the strain-specificity of the response has been shown to correlate 
with the strain-specificity of immunity upon parasite challenge (Taracha et al., 
1995a). A number of T. parva antigens recognised by CD8+ T cells from cattle 
immunised by ITM have been identified (Graham et al., 2007a; Graham et al., 2006). 
It has been shown in animals of defined MHC I haplotypes that antigens recognised 
by the CD8+ T cell response are determined by the host MHC phenotype and a large 
component of responding CD8+ T cells (up to 75%) is specific for a single antigen 
and usually only one or two epitopes (MacHugh et al., 2009a). Such 
immunodominance is a common feature in CD8+ T cell responses in viral infections; 
CD8+ T cell responses are preferentially directed towards one or a few dominant 
epitopes despite the presence of a T cell repertoire with multiple specificities, which 
is potentially capable of responding to a wide range of peptides (Yewdell, 2006; 
Yewdell and Bennink, 1999). 
Immunodominance results from a complex combination of factors involved in 
antigen processing and antigen recognition. The relative importance of the different 
factors is likely to differ for different pathogen/host combinations (Yewdell, 2006; 
Yewdell and Bennink, 1999; Yewdell et al., 2003). The mechanisms that determine 
immunodominance in CD8+ T cell responses against T. parva are unknown, but the 
immunodominant nature of these responses has important implications for the design 
of effective vaccines (MacHugh et al., 2009a). When CD8+ T cell responses are 
focused on only one or a few antigens, polymorphism in the epitopes can result in 
failure of CD8+ T cells to recognise heterologous parasite strains, resulting in 
susceptibility to challenge with such parasites (MacHugh et al., 2009a). At least 
some of the identified T. parva antigens show a high degree of sequence 
polymorphism (Pelle et al., 2011). 
The effect of polymorphism on MHC I presentation and T cell recognition has been 
investigated for two of the identified epitopes recognised by CD8+ T cell responses 
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in Holstein cattle. Using specific CD8+ T cell clones and synthetic peptides 
containing alanine substitutions at each amino acid residue, it was possible to 
identify MHC I binding residues and residues that affected T cell recognition. Some 
residue changes had little effect on MHC I binding or T cell recognition, whereas 
substitution at other residues had a detrimental effect on both types of interaction 
(Connelley et al., 2011; Macdonald et al., 2010). Animals homozygous for the A10 
MHC I haplotype and immunised with T. parva Muguga have been shown to mount 
an immunodominant CD8+ T cell response against epitopes in the Tp2 antigen 
(MacHugh et al., 2009a). The Tp2 antigen is highly polymorphic; two epitopes, 
Tp249-59
 and Tp298-106 both presented by MHC I allele 2*01201, are recognised 
(Graham et al., 2008a). Studies with single alanine substituted peptides and peptides 
representing allelic variants of the Tp249-59 epitope using specific CD8
+ T cell clones, 
demonstrated that the residue at position eleven influences MHC I binding, that the 
residue eight is essential for T cell recognition and that several other residues have 
variable effects on T cell recognition (Connelley et al., 2011). 
It has been proposed that sequence polymorphism in T. parva antigens combined 
with immunodominance in CD8+ T cell responses allows particular parasites to 
escape CD8+ T cell responses in vivo. To address this hypothesis, the current study 
sought to determine whether immunisation with a clonal population of T. parva that 
induces CD8+ T cell responses to a dominant polymorphic antigen will result in 
selective breakthrough of parasite genotypes expressing alternate alleles of this 
antigen following challenge with an antigenically diverse T. parva isolate, i.e. 
containing the homologous allele and heterologous alleles of the dominant antigen. 
Animals expressing the MHC I A10 haplotype were used, which (as discussed 
above) recognises two dominant epitopes in the reference sequence of the Tp2 
antigen, Tp249-59
 and Tp298-106 (Graham et al., 2008a). The initial aim of the study 
was to identify a challenge stabilate containing allelic variants of Tp249-59
 and Tp298-
106, including the reference allele. The selected stabilate was then used to challenge 
animals immunised with the Muguga stock and the breakthrough population of 
parasites in the immunised animals, along with parasites in control animals, were 
analysed by 454 amplicon sequencing of the Tp2 gene. Figure 6.1 illustrates the 
experimental design. 
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Figure 6.1 Conceptual design of challenge experiment, illustrating the 
anticipated ‘knock-down’ of homologous genotypes 
Only the Tp2 49-49 epitope is shown for illustration purposes.
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22B6.2 Material and methods  
68B .2.1 Sequence analysis of the Tp2 gene 
The Tp2 gene was PCR amplified from samples of DNA prepared from two 
stabilates of T. parva 3081 and 4110 produced from infected buffalo. The PCR 
products were cloned into the P-GEM-T vector and plasmid clones were purified 
using the PureYieldTM Plasmid Miniprep System (Promega Corporation, USA) as 
previously described in Chapter 2. The Tp2 gene was also amplified from nine 
cloned T. parva-infected cell lines derived from a cell line infected with the 
Marikebuni stock (A3, A7, B12, F31, F44, F53, I8, I38 and J17). The purified 
plasmids or PCR products were sent to Durham Genomics for sequencing using 
Sanger technology. Chromatograms were converted into FASTA sequences and 
alignment was undertaken using MUSCLE in the MEGA5 software package (Edgar, 
2004; Tamura et al., 2011). The nucleotide sequences were translated into amino acid 
sequences and the sequences for the epitopes Tp249-59 and Tp298-106
 were extracted. 
69B .2.2 Recognition of Tp2 variants present in T. parva 
Marikebuni 
A CD8+ T cell line from animal 011 was tested for specificity with respect to the Tp2 
epitope variants found in the T. parva Marikebuni stock using a four-hour 111Indium 
release cytotoxicity assay. CD8+ T cells from this animal have been shown to 
recognise both epitopes in the reference sequence of theTp2 antigen (MacHugh et al., 
2009b). Theileria parva Muguga and two T. parva Marikebuni lines (B12 and F53) 
containing epitope variants of Tp249-59 and Tp298-106
 were used as targets at effector-
to-target ratios between 20:1 and 0.6:1 (see Chapter 2). The recognition of peptide 
was examined using autologous T. annulata-infected cells as antigen presenting cells 
and peptide concentrations ranging from 100 ng/ml to 0.01 ng/ml. 
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70B6.2.3 In vivo challenge experiment 
All experimental work was performed with the help of Thomas Njoroge and Stephen 
Mwaura, ILRI, Kenya. Seven animals carrying MHC I haplotype A10 were selected 
as described in Chapter 2 (see Table 6.1 for further information). Animals were 
transported to the ILRI farm and received acaricide treatment on arrival, three days 
after arrival and subsequently once a week. Animals were tested for evidence of 
exposure to Theileria parva, Theileria mutans, Anaplasma and Babesia bigemina 
using parasite species-specific ELISAs. Samples for ELISA were taken on the day of 
arrival, day of immunisation, day of challenge and six weeks after challenge. The 
ELISAs were performed by Alice Njeri, ILRI, Kenya. 
Table 6.1 Animals used for the challenge experiment 
Animal 
number Breed Sex Age ITM vaccinated 
BG040 Friesian/Ayrshire M 1 year yes 
BG041 Friesian M 7 months yes
BG044 Friesian M 9 months no
BF080 Ayrshire M 2.3 years yes
BF083 Friesian M 2.5 years no
BF085 Ayrshire M 2.5 years yes
BF086 Friesian M 2.5 years yes
Animals were immunised by infection and treatment (ITM) using T. parva Muguga stabilate 3308. 
Two weeks after arrival at ILRI, five of the animals were immunised by infection 
and treatment with T. parva Muguga Stabilate 3308. Ten weeks after immunisation, 
these animals, along with two unimmunised controls, were challenged with buffalo-
derived T. parva stabilate 3081 at a dilution of one in twenty. Animals were 
monitored closely after challenge. Briefly, animals were inspected three times a day 
and temperature and lymph node enlargement were monitored daily. Smears of 
lymph node aspirates and blood were taken daily when body temperature increased 
and/or when lymph node enlargement was observed. Animals were treated with 
buparvaquone when they developed severe disease. 
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71B6.2.4  Tp2 specificity of CD8+ T cell responses of immunised 
animals 
The specificity of CD8+ T cell responses of immunised animals was investigated 
using a 51Chromium release cytotoxicity assay and an ex vivo ELISPOT assay. 
CD8+ T cells were cultured by stimulation with irradiated autologous T. parva-
infected cells as previously described in Chapter 2 and specificity was then 
determined by assaying cytotoxic activity using autologous T. parva cell lines, an 
MHC I-mismatched T. parva cell line and an A10-homozygous cell line (592 T. 
parva Muguga) as target cells. The ex vivo ELISPOT assay was performed with the 
help of Rosemary Saya, ILRI, Kenya. Purified CD8+ cells were used as effector cells 
and purified CD14+ cells pulsed with peptides as target cells. The peptides used were 
T. parva Muguga Tp249-59 KSSHGMGKVGK and Tp298-106 QSLVCVLMK. 
72B6.2.5 Analysis of allelic variants of Tp2 ex vivo 
DNA was extracted from blood and lymph node samples obtained from the animals 
undergoing clinical reactions upon challenge, using the DNeasy Blood and Tissue 
Kit (Qiagen, UK). Amplicons of the Tp2 gene were generated by PCR amplification 
using fusion primers and resulting PCR products were pooled and submitted for 454 
Sequencing (see Chapter 3). Sequence reads were partitioned into those belonging to 
individual samples after which the bioinformatic pipeline described in Chapter 3 was 




73B6.3.1 Assessment of T. parva Marikebuni as the challenge 
parasite 
For the proposed challenge, a stabilate was required that contained the Muguga Tp2 
allele in addition to allelic variants of Tp2 that are likely not to be recognised by 
CD8+ T cells induced by immunisation with Muguga. Ideally, a challenge stabilate 
would represent a genotypically diverse parasite population and the Tp2 reference 
allele would be present on a number of different genotypes. This would mean that 
any immune-selection acting upon other undefined antigen-encoding loci would not 
result in appreciable selection at the Tp2 locus and confound the planned analysis.  
The Marikebuni stock is genotypically diverse as judged by satellite DNA typing of 
clones derived from CTVM stabilate 72 (Katzer et al., 2010) and has previously also 
been shown to be antigenically heterogeneous (Goddeeris et al., 1990). Sequencing 
of the Tp2 gene in nine cloned T. parva Marikebuni lines, shown previously by 
satellite DNA typing to be genotypically distinct (Katzer et al., 2011), demonstrated 
the presence of two alleles; seven of the clones possessed the reference Muguga 
allele, while the remaining two clones had a variant allele, which differed from the 
Tp249-59 and Tp298-106 reference sequences at two and three amino acid residues 
respectively (see Table 6.2). 
Table 6.2 Sequences of Tp249-59 and Tp298-106 obtained from nine clonal T. parva Marikebuni 
infected cell lines 
Cell line Tp249-59 Tp298-106 
T. parva Muguga  KSSHGMGKVGK QSLVCVLMK
T. parva Marikebuni 
A3, A7, F31, F44, I8, I38, J17 
KSSHGMGKVGK QSLVCVLMK 
T. parva Marikebuni 
B12, F53 
KSSHGMGKIGR QSIVCVVSK 
An un-cloned CD8+ T cell line available from an immune animal, homozygous for 
MHC I A10 (Animal 1011) and known to recognise Tp2 (MacHugh et al., 2009a), 
was used to determine whether the allelic variants of the Tp2 epitopes in these cloned 
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lines are recognised by Muguga-induced CD8+ cells. The CD8+ T cell line 
recognised autologous T. parva Muguga but not an MHC I-mismatched T. parva 
line. One of the clonal T. parva Marikebuni lines (F53) was lysed, but at a lower 
percentage than the T. parva Muguga line. The other T. parva Marikebuni line (B12) 
was not lysed, even at higher effector-to-target ratios (see Figure 6.2). The absence 
of killing of the B12 line indicates that the Tp2 allelic variant is not recognised 
efficiently by the Muguga-induced CD8+ T cell response. Differential killing of the 
two clonal T. parva Marikebuni cell lines, which have identical sequence of the Tp2 
gene, could be due to recognition of another gene product that is conserved between 
F53 and Muguga but has a different allele in B12.  
Figure 6.2 Specificity of CD8 T cells from animal 1011 tested against T. parva-parasitised cell 
lines that carry different allelic variants of the Tp2 gene  
Four cell lines were assayed by Indium release assay: autologous and MHC I mismatched T. parva 
Muguga and two MHC I matched T. parva Marikebuni parasitised cell lines (B12 and F53) both of 
which carry an allelic variant of the Tp2 gene (See Table 6.2). 
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The uncloned CD8+ T cell line was able to recognise peptides representing both the 
T. parva Muguga and the T. parva Marikebuni alleles of the Tp249-59 epitope, 
although the latter was recognised less efficiently (see Figure 6.3). This reduced 
efficiency may account for the apparent lack of recognition of the Marikebuni-
infected cells. Nevertheless, in view of the observed cross-reactivity the T. parva 
Marikebuni stock was considered unsuitable for the proposed challenge experiment.   
Figure 6.3 Specificity of CD8 T cells from animal 1011 tested against target cells pulsed with 
different concentrations of Tp2 peptide 
Specificity was assayed by Indium relese assay. Peptides were presented by an autologous T. annulata 
Ankara parasitised cell line (TAA). Peptide sequences were reference Tp2 49-59: KSSHGMGVGK, 







74B6.3.2 Assessment of buffalo-derived T. parva as the challenge 
parasite 
Subsequently, two buffalo stabilates (Stabilate 3081 and 4110) were examined for 
their potential to be used as a challenge stabilate. Buffalo are known to have a high 
multiplicity of infection with parasites that are genetically and antigenically diverse 
and extensive sequence polymorphism has been found in alleles of the Tp2 gene 
among buffalo-derived T. parva (Pelle et al., 2011); data presented in Chapter 4). 
The Tp2 gene of these two buffalo-derived stabilates was amplified and sequenced 
after cloning in the P-GEM-T vector. Both stabilates showed a high degree of allelic 
diversity at the protein level; twelve and nine allelic variants of the Tp2 gene were 
found in fourteen and eleven sequences obtained by Sanger sequencing, respectively, 
from stabilates 3081 and 4110; eleven variants of both CD8+ T cell epitopes were 
found in stabilate 3081, while stabilate 4110 contained nine allelic variants of Tp249-
59 and eleven and eight variants for Tp298-106 (see Tables 6.3 and 6.4). The T. parva 
Muguga (i.e. reference) allele of Tp249-59 and Tp298-106 was found to be present in 
both stabilates in sequences obtained by Sanger sequencing. A single Muguga allelic 
sequence was obtained for both stabilates,  out of a total of twelve 4110 sequences 
and fourteen 3081sequences. 
The allelic diversity of Tp2 in Stabilate 3081 was also examined using Roche 454 
amplicon sequencing. Six allelic variants of Tp249-59 and twelve allelic variants of 
Tp298-106 were found corresponding to 481 and 603 reads respectively (see 
Figure 6.4). Allelic variants that were found by both Sanger and Roche 454 amplicon 
sequencing are denoted by an asterisk in Table 6.4. Interestingly, the number of 
variants detected was lower using Roche 454 sequencing compared to Sanger 
sequencing and the T. parva Muguga allele of Tp249-59 was not detected using 454 
sequencing. This might indicate the T. parva Muguga allele is present at a very low 
frequency and the detection of this allele by Sanger sequencing was fortuitous. This 
low frequency could be a problem using Roche 454 sequencing, as a minimum of 
five reads is required before a putative 454 sequence-variant is accepted.  
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Table 6.3 Sequences for Tp249-59 and Tp298-106 obtained for buffalo stabilate 4110 
Tp249-59 Tp298-106 
V1 (1) KSSHGMGKVGK FAQSLVCVLMK
V2 (2) KSSHGMGKIGR LAQSIVCVVSK 
V3 (1) KSSKGMTAVGK FAKSIKCVSQH 
V4 (1) KTSKGMTKVGR FGQSIKCVAQH 
V5 (1) KTSRSMGQVGR LAASIKCVSQH 
V6 (1) KTSKGMTRVGR FGQSIKCVAQH 
V7 (1) KTPKGMTKVGR FGQSIKCVAQH 
V8 (1) LTSKSMSEVGR FAQSIYCVVKN 
V9 (2) LTSHGMGRIGR FAASIKCVAQY 
Variant sequences of the Tp249-59 and Tp298-106 are displayed, the number of sequences is displayed in 
parentheses. Residues that differ from Tp249-59 and Tp298-106 of T. parva Muguga are displayed in red. 
Table 6.4 Sequences for Tp249-59 and Tp298-106 obtained for buffalo stabilate 3081 
Tp249-59 Tp298-106 
V1 (1) KSSHGMGKVGK QSLVCVLMK*
V2 (1) KSSHGMGKVGR*  ESIMCVIKK 
V3 (1) KSSKGMTAVGK* QSIYCVANN 
V4 (1) KSSKGMTAVGK  QSIYCVVKN* 
V5 (1) KTSKGMTKVGR* QSIKCVAQH 
V6 (2) LTSKAMTTVGK* QSIKCVAHH* 
V7 (1) LTSKAMTHVGR  QSIYCVAKN 
V8 (1) LTSKAMTHVGK  QSIYCVAKN* 
V9 (1) LTSKAMTTVGK  QSIKCVSQH* 
V10 (1) LTSKAMSTVGK* QSIYCVANN 
V11 (1) KTSKGMTEVGK  ASIHCVSNK* 
V12 (1) LTSKGMAAVGR  QSIQCVSKY* 
Variant sequences of the Tp249-59 and Tp298-106 are displayed, the number of sequences is displayed in 
parentheses.  Residues that differ from Tp249-59 and Tp298-106 of T. parva Muguga are displayed in red. 
Sequences that were also obtained using 454 sequencing are marked * (see Figure 6.4) 
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Figure 6.4 Allelic diversity of the Tp249-59 and Tp 98-106 epitopes found in Stabilate 3081 using 
Roche 454 amplicon sequencing 
The percentage of reads of Tp249-59 allelic variant found in the forward reads (481 reads) or Tp298-106 
allelic variants in reverse reads (603 reads) are displayed. The Muguga Tp249-59 allele 
(KSSHGMGKVGK) was not detected whereas the Muguga Tp298-106 allele (QSLVCVLMK) was 
detected at ~11% of the reads (underlined). 
The infectivity of different sporozoite stabilates can vary greatly. Estimation of 
infection rates with T. parva in ticks used to produce the stabilate provide an 
indication of the likely infectivity for cattle and in vitro titrations provide data on 
infectivity for blood lymphocytes in vitro. However, the only definite way to 
establish infectivity in vivo is to perform in vivo titration. Unfortunately, very limited 
information was available on the in vivo infectivity of the two available buffalo 
stabilates, as titration was performed using only a few animals. It was considered 
important that the stabilate used for challenge in this study produced sufficiently 
severe reaction in vivo to ensure breakthrough parasites could be isolated ex vivo. 
Ngumi et al. used stabilate 3081 for evaluating whether buffalo-derived T. parva 
stabilates could be safely used for immunisation by infection and treatment (Ngumi 
et al., 1992). Control animals that did not receive treatment were included in this 
experiment and it was shown that the stabilate was highly infective at a 1/10 dilution 
and remained infective at a 1/100 dilution (Ngumi et al., 1992). Given this 
information, it was decided to utilise stabilate 3081 for challenge and a 1/20 dilution 
of the stabilate was used in an attempt to limit the severity of disease while still 
having a reasonable probability that each dose contains sufficient parasite numbers to 
represent all the allelic variants present in the stabilate. 
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75B6.3.3 Immunisation and challenge of cattle 
Animals were immunised with T. parva Muguga (Stabilate 3801) with success 
assessed by the detection of a serological response. The results showed that animals 
BG040, BF080 and BF085 developed significant titres of antibody against T. parva, 
indicating successful immunisation. The titre of antibody in animal BF086 was 
inconClusive. Unfortunately, animal BG041 seroconverted before immunisation and 
could therefore not be used for the remainder of the study. 
Table 6.3 Serological screening for antibodies against Anaplasma marginale, Babesia bigemina, 
Theileria mutans and Theileria parva  
Samples were taken on day of arrival (two weeks pre-immunisation), on the day of immunisation, on 
the day of challenge (ten weeks after immunisation) and at six weeks post-challenge. Seropositivity 
was determined using a pathogen-specific ELISA. Values in green are considered seronegative, values 
in red are considered seropositive and values in black are considered inconClusive. 
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CD8+ T cell lines were isolated from the immunised animals and stimulated in vitro 
using autologous T. parva Muguga cell lines as previously described in Chapter 2. 
The specificity of the CD8+ T cells was tested using a 51Cr release assay. 
Unfortunately, only a limited number of targets could be tested using in this assay 
with relatively low effector-to-target ratios, due to limited proliferation in vitro. Low 
levels of killing against autologous T. parva cell lines were found for each of the 
immunised animals with a maximum killing between 8 and 24% (see Figure 6.5). 
Low levels of killing were also seen against the A10-homozygous T. parva line for 
animals BG040, BF080 and BF085. Animal BF086 did not show reactivity with the 
A10 homozygous line and was therefore considered unlikely to recognise Tp249-59 or 
Tp298-106.
Figure 6.5 MHC I restriction of CD8 T cell lines from T. parva Muguga immune animals.   
A chromium release assay was used to test the ability of CD8+ T cell lines of T. parva immunised 
animals BG040, BF080, BF085 and BF086, to lyse autologous T. parva (-◊-), MHC I A10 T. parva 
Muguga line (592 Tpm A10/A10)  (-∆- ) and a MHC I  mis-matched T. parva Muguga (2229 Tpm 
A18/A18) (-□-) 
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The ability of the immunised animals to recognise Tp249-59 and/or Tp298-106 was 
further investigated using an ex vivo IFN-γ ELISPOT assay (see Figure 6.6). All 
immunised animals recognised autologous T. parva Muguga cells, indicating that 
immunisation successfully induced CD8+ responses against T. parva. CD8+ cells 
from both animal BG040 and BF085 were able to recognise Tp298-106. CD8
+ cells 
from animal BG040 also recognised Tp249-59. Thus, two animals were suitable for 
investigating the selective breakthrough of non-T. parva Muguga Tp2 variants. 
Figure 6.6 Recognition of T. parva Muguga and Tp249-59 and Tp298-106 of CD8
+ T cells ex vivo six 
weeks after immunisation by infection and treatment 
An IFN-γ ELISPOT was used to test the reactivity of isolated CD8+ T cells (2.5x 104 cells) with 
autologous T. parva-infected cells (2.5 x 104 cells) or autologous monocytes (2.5 x 104 cells) pulsed 
with either the Tp249-59 or the Tp298-106 peptide at a concentration of 1 μM. Autologous T. parva 
Muguga cell line, CD14+ cells and CD8+ cells in combination with CD14+ were used as negative 
controls. 
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76B .3.4 Reaction of animals upon challenge with buffalo 
stabilates 3081 
Animals were then challenged with 1 ml of a 1:20 dilution of buffalo-derived 
stabilates 3081. The clinical reaction of each animal was very different despite great 
effort to ensure homogenisation of the stabilates before challenge. The reactions 
differed in terms of the time to first detection of schizonts in the lymph nodes, the 
levels and duration of detectable parasites and the severity of clinical signs (see 
Table 6.6 and appendix D). 
Table 6.6 Clinical parameters for immune and naive animals after challenge with stabilate 3081 
I = Animal was immunised by infection and treatment using T. parva Muguga stabilate 3308, 
C = Naïve control. Fever was defined as a body temperature (≥ 39.5°C) and the days on which 
animals had a fever and the maximum body temperature are displayed. NPS= No parasites seen 
The clinical reactions of the two non-immunised animals (BG044 and BF083) were 
very different. Parasites were detected from day seven for animal BF044 and 
treatment was required at day 15 after challenge. Interestingly, fever, an early and 
consistent feature of infections with cattle-derived T. parva, only developed a week 
after the detection of the first parasites, but the animal showed obvious clinical signs 
before the onset of fever. The other control animal (BF083) showed only a delayed 
transient mild reaction, with fever between 19 and 24 days after infection and 
detectable parasites on days 20 and 22. 
Fever (>39.5°C)
Animal number 














BF085 I NPS 24,25 40 -  - 
BF080 I 9,10,17,23 18-20 41.2 - Slight anorexia 





BG044 C 7-9,11-15 14,15 41.1 15 
Recumbent, anorexia, 
neurological signs  
BF083 C 20,22 19-24 40.5 24 Slight anorexia 
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Among the immunised animals the reactions were also very variable. Schizonts were 
detected in lymph node smears from animal BG040 twelve days after challenge and 
this animal required treatment at 16 days after challenge. Animal BF085 only 
developed fever 24 days after challenge, which disappeared by day 26 without 
intervention. No parasites could be detected in lymph node and blood smears from 
this animal, but parasite-positive samples were found using PCR at day 17, 18 and 
25. For animal BF080, parasites were intermittently detected from day 9 to day 23.
The animal showed only very mild clinical signs and did not require treatment. The 
first parasites were detected at day 13 after challenge for animal BF086. This animal 
developed a severe clinical reaction and required treatment at day 16. 
Overall, the clinical signs observed after challenge with this stabilate were different 
from those following the commonly used T. parva Muguga stabilates: the lymph 
node enlargement was limited in all the animals and in some animals fever was 
detected days after the first parasites were detected in the lymph nodes. The number 
of parasites found in lymph node smears was generally very low despite, in some 
instances, severe clinical reactions. 
77B6.3.5 Analysis of allelic variants of Tp2 in challenge animals 
The number of samples available for the analysis of Tp2 allelic variants of T. parva 
parasites ex vivo was limited due to one animal sero-converting before immunisation 
and the variability observed in the responses following immunisation and challenge. 
Only two animals recognised Tp249-59 or Tp298-106 and the added variability of the 
reaction in the control and immunised animals made it difficult to compare parasites 
in naïve controls and breakthrough parasites in immune animals that responded to 
Tp2. Therefore, the scale and objectives of the experimental plan were reduced to 
that of a preliminary study designed to compare the parasites at the beginning of the 
infection with those at the time of treatment in a single pair of animals. It was 
anticipated that the Tp2-specific T cell response in the immune animal would alter 
the composition of Tp2 alleles. 
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Samples were chosen from one naïve animal and one immune animal that had 
CD8+ T cells capable of recognising Tp2. Theileria parva PCR-positive samples 
taken at the beginning of the infection (day 8) and on the day of treatment (day 15) 
were examined from control animal BG044. Samples from the immune animal, 
BF085 taken on days 18 and 25 following challenge were also selected for analysis. 
Thus, the time interval between each pair of samples was equivalent for the naïve 
and the immune animal. The Muguga Tp249-59 epitope KSSHGMGKVGK was not 
detected in samples from either the immune or the naïve animal at either time-point 
(see Figure 6.7). In the immune animal certain alleles in the breakthrough appear to 
reduce in frequency between the two time points examined (KTSKAMTMTGR and 
KSSHGMGKVGR), whereas others are boosted (eg. KSSKGMTAVGK). 
Conversely, the allele frequencies in the naïve animal are more similar between the 
time points.  
The percentage of reads representing the Muguga Tp298-106 QSLVCVLMK epitope 
was lower at both time-points in the immunised animal (BF085) compared to the 
naïve animal (see Figure 6.8). In this animal, the percentage of reads was also lower 
for a number of other allelic variants, i.e. QSIKCVAHH, ASIHCVSNK, 
ASIKCVSQH and QSIKCVSQH. The frequency of reads that had a valine (V) in 
position seven, a lysine (K) in position eight or an asparagine (N) in position nine of 
the Tp298-106 epitope, was higher in samples from the immune animal (BF085) 
compared to the naïve animal (BF044) (see Table 6.7). However, no obvious 
difference was observed between the pairs of samples from individual animals. 
Hence, it was impossible to draw any clear conClusions from the results of this 
experiment. 
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Figure 6.7 Percentage of reads representing different alleles of Tp249-59  forward reads in 
parasites isolated ex vivo 
Reads are shown for one control animal (BG044) and one immune animal (BF085) at the beginning of 
infection (day 8 and 18 respectively) and at time of treatment (BG044, day 15) or at the peak of the 
response (BF085, day 25). 
Figure 6.8 Percentage of reads representing different alleles of Tp298-106 reverse reads of 
parasites obtained ex vivo 
Reads are displayed for one control animal (BG044) and one immune animal (BF085) at the 
beginning of infection (day 8 and 18 respectively) and at time of treatment (BG044, day 15) or at the 
peak of the response (BF085, day 25). 
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Table 6.7 Proportion of reads displaying certain amino acid residues of the Tp298-106 epitope in 
T. parva isolated ex vivo 
Position 1  Q A E K
4423 72.2 21.9 1.1 4.8
4427 61.7 36.8 0.5 0.9
8506 53.6 41.3 2.4 2.8











Position 4  V H K L M Q Y
4423 9.7 7.5 38.8 3.4 3.8 4.0 32.8
4427 6.2 14.7 49.0 0.0 0.5 2.4 27.3
8506 2.0 0.0 22.2 0.0 2.4 38.9 34.5











Position 7 L A I S V
4423 9.7 17.3 7.2 37.2 28.7
4427 6.2 20.6 0.5 43.5 29.2
8506 2.0 7.5 2.4 2.8 85.3
8507 4.5 9.5 1.4 8.5 76.1
Position 8 M N H K Q
4423 9.7 16.7 7.4 34.7 31.4
4427 6.2 14.7 12.2 30.2 36.8
8506 2.0 0.0 2.4 75.8 19.8
8507 4.5 0.0 10.3 66.6 18.5
position 9  K H N T Y
4423 22.2 33.7 38.1 0.0 6.0
4427 22.7 39.2 31.0 0.0 7.1
8506 16.3 7.9 73.4 0.0 2.4
8507 14.5 14.7 65.0 2.6 3.2
The background of cells was coloured from no colour to dark red to indicate a low to high percentage 
of reads with a certain amino acid residue in a certain position of the Tp2 98-106 epitope. 
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24B6.4 Discussion  
78B6.4.1 Selection of animals 
This study set out to investigate whether CD8+ T cell responses to a dominant T. 
parva antigen (Tp2) coincide with non-recognition of parasites with a different Tp2 
genotype and, consequently, the immune ‘escape’ of such genotypes. Animals 
expressing a MHC I A10 haplotype, known to recognise epitopes within the 
dominant Tp2 antigen (Graham et al., 2008b; MacHugh et al., 2009b), were used for 
this study. Unfortunately, not all immunised animals in this study recognised the Tp2 
epitopes. The animals were heterozygous for the MHC I A10 haplotype and the lack 
of recognition of Tp2 epitopes by some of the animals is likely a reflection of 
differences in the immunodominance hierarchy among animals of different MHC I 
backgrounds. During the course of these studies, other researchers in the Morrison 
Bovine Immunology Group (University of Edinburgh) have also found that only a 
proportion of the MHC I A10 heterozygous animals have detectable CD8+ T cell 
responses to Tp2. Moreover, A10-homozygous animals recognise both Tp2 epitopes 
while A10-heterozygous animals only gave detectable responses to the Tp298-106 
epitope (Xaioying Li and Tim Connelley, unpublished). A similar phenomenon has 
been observed in immune responses to influenza; immune responses to several 
H2Db- and H2Kb-restricted influenza epitopes were diminished in H2bxk F1 versus 
homozygous mice (Day et al., 2011). Graham et al. (2008 ) examined immune 
responses of cattle immunised with a cocktail of five CD8+ T cell antigens by a 
heterologous prime-boost regime with recombinant poxvirus vectors. The animals 
used for the study had been identified as expressing a MHC I allele capable of 
presenting defined antigens to CD8+ T cells. Only two of the six animals expressing 
2*01201 had CD8+ T cell IFN-γ responses against the Tp2 gene. It was suggested 
that this could be due to a lack of potency of the vaccination protocols rather than an 
inability of the animals to respond to the antigens (Graham et al., 2008b). For future 
studies, it would be informative to use MHC I homozygous animals or a larger 
number of heterozygous animals in order to obtain sufficient numbers of animals 
responding to the antigen under examination. Alternatively, another as yet 
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unidentified polymorphic antigen that induces more consistent reactions in 
heterozygous animals could be used. 
The reaction upon challenge with the buffalo-derived stabilate 3081 was very 
variable in both immune and naïve animals. There is evidence that the Muguga stock 
which was used for immunisation contains very little antigenic diversity. It was 
therefore anticipated that immune animals would only recognise a small proportion 
of the challenge parasites and that they would suffer severe reactions upon challenge. 
Differences in reactions in immune animals could occur due to different antigen 
specificities of CD8+ T cells induced by the immunisation using Muguga. However, 
this cannot explain the differences in the control animals. One explanation could be 
that animals used were not truly immunologically naïve, despite the fact that only 
animals that were serological negative for T. parva were used. One animal was 
excluded from further analysis as it seroconverted before immunisation (BG041). All 
the animals were transported from the same farm and the presence of one 
seropositive animal indicates that the animals had a chance of being exposed to 
Theileria parva prior to the start of the experiment. Another explanation is that prior 
exposure to other tick-borne pathogens such as Theileria mutans and Babesia 
bigemina could have induced a degree of cross-immunity in some of the animals.  
79B6.4.2 Challenge dose  
Great efforts were made to homogenise the stabilate before inoculation to ensure 
consistency of the dose and content of parasites administered to each animal. 
Previously available data indicated that the stabilate was highly pathogenic at a 1/10 
dilution and led to fatality in five challenged animals at an average of 16.4 days 
(Ngumi et al., 1992).  The most likely explanation, perhaps, is that variability of 
reaction is due to a reduction in infectivity of the stabilate compared to when it was 
used previously. A further two-fold dilution of the dose used in previous studies, 
which resulted acute disease and rapid death, would not have been expected to result 
in the substantial reduction in disease severity in a proportion of the animals 
observed in the present study. Stabilates can lose infectivity during long-term storage 





the 1980s and it has been more than twenty years since the last infectivity data, it is 
likely that a degree of infectivity has been lost in the material used in the present 
study. While a higher dose may have yielded a more homogenous reaction on 
challenge it would likely also have elicited more severe clinical signs. As the animals 
were expected to have immunity against only a proportion of the challenge parasites, 
increased severity of disease may have resulted in an overwhelming parasite load 
which may in turn have dysregulated the immune response. This may have resulted 
in failure of the immune response despite the presence of CD8+ T cells capable of 
recognising a proportion of challenge parasites. Thus, the specific ‘knock-down’ of 
genotypes recognised by the CD8+ T cell response would not be observed. 
80B6.4.3 Selective removal of genotypes 
A previous study using satellite DNA markers provided evidence that selective 
removal, or filtering, of certain genotypes occurred following challenge of animals 
previously immunised with a cloned population of the Marikebuni stock and then 
challenged with the parental Marikebuni stock. Filtering was not observed following 
challenge of naïve animals (Katzer et al., 2007). Different parasite genotypes 
emerged at different time-points after challenge and in immune animals of different 
MHC I backgrounds (Katzer et al., 2007). The filtering appeared to be focused on a 
few genomic loci although it could not be related to specific antigens. The present 
study set out to determine whether the emergence of the different parasite genotypes 
in challenged animals is related to CD8+ T cell responses directed to 
immunodominant polymorphic antigens. 
Due to the variability discussed above, a limited number of samples were available 
for analyses, and therefore the study was reduced to a preliminary analysis in a single 
pair of immune and naïve animals. The Muguga Tp249-59 epitope KSSHGMGVGK 
was not detected in either immune or naïve animal and thus no preferential filtering 
could be seen for this epitope. This is probably a reflection of the low proportion of 
Muguga Tp249-59 epitope KSSHGMGVGK in the challenge stabilate and thus a 
stabilate with a higher proportion of the ‘immunising’ epitope would be desirable. In 
the immune animal certain alleles in the breakthrough appear to be reduced in 
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frequency whereas others were boosted. In contrast, the allele frequencies in the 
naïve animal were more similar between the time points. The differences in the 
breakthrough parasite populations at the different timepoint, may be evidence that 
immunity has disrupted the challenge populations. As animal BF085 did not 
recognise Tp249-59 peptide, this could be evidence for strain specificity acting on an 
additional unidentified antigen. 
The Muguga Tp298-106 epitope was detected in both the immune (BF085) and naïve 
animal (BG044). The proportion in animal BG044 was similar to that found in the 
stabilate at both the start of the infection and at the time of treatment. The proportion 
appeared to be reduced in animal BF085 at both 18 and 25 days after challenge. 
CD8+ T cells of this animal recognised Tp298-106 peptide using the ELISPOT assay 
and thus genotypes with this epitope would be expected to be preferentially removed 
after memory CD8+ T cell responses become effective Effector function of memory 
CD8+ T cells can be detected from 8 days after challenge (Graham et al., 2006) and 
thus filtering due to CD8 + T cell responses might have occurred prior to day 18 after 
challenge The results indicate that there might be a degree of filtering, but as samples 
were derived from only a single immune animal and the fact that the Muguga Tp2 
allelic variants of Tp249-59 and Tp298-106 were only present at a low proportion in the 
challenge stabilate, no firm conClusions can be drawn from this experiment. In an 
ideal study, a challenge stabilate consisting of a mixed parasite population containing 
a lower number of more distinct allelic variants of the target CD8+ T cell antigen 
would be used. The CD8+ T cell responses induced by immunisation should be 
focused on an allelic variant that is present in higher abundance in the stabilate than 
in the current study, thus making it easier to detect ‘knock-down’ following 
challenge. No such stabilate is currently available, although one could be synthesised 
by mixing different cloned parasites and co-transmitting them through ticks as 
utilised by Katzer et al. (2011). This would allow a round of sexual reproduction to 
take place in the tick and thus the predicted re-assortment of genes encoding different 
polymorphic CD8+ T cell target antigens (Katzer et al., 2011). 
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Chapter 7: Haemoparasites in cattle and African 
buffalo 
7.1 Introduction 
Buffalo are commonly infected with a range of Theileria species, including Theileria 
parva, Theileria velifera, Theileria mutans, Theileria buffeli and T. sp (buffalo) 
(Allsopp et al., 1999; Oura et al., 2011a, b; Young et al., 1978). Grazing of cattle and 
buffalo in proximity to each other provides the opportunity for transmission of 
pathogens from buffalo to cattle via ticks. Different Theileria species are transmitted 
by a number of different tick species, but the vector for T. sp (buffalo) and T. buffeli 
have not yet been identified (see Table 7.1) (Norval et al., 1992). Severe disease is 
seen in cattle after infection with buffalo-derived T. parva (Norval et al., 1991a). 
However, the role of other haemoparasites transmitted from buffalo in causing 
disease in cattle is less clear. 
Table 7.1 Theileria spp found in cattle and/or African buffalo in Africa and corresponding tick 
vectors 
1 (Thompson et al., 2008) 2 (Norval et al., 1992) 3(Jongejan et al., 2004)4 (Ngumi et al., 1994) 
Parasite species Tick vector  Mammalian host  
T. parva1,2,3  R. appendiculatus,  
R. zambeziensis  
R. duttoni 
(other Rhipicephalus spp) 
(Hyalomma spp.).  
Bovine, African buffalo 
T. taurotragi2 R. appendiculatus 
R. zambeziensis 
R. pulchellus 
Cattle, sheep, goats,  
wild ungulates (e.g. eland, 
Bushbuck) 






Cattle, African buffalo, eland, 
bushbuck 
T. velifera2 A. variegatum
A. hebraem 
A. astrion 
A. lepidum  
Cattle, African buffalo 
T. sp (buffalo) Unknown African buffalo 






Theileria mutans and Theileria velifera can infect cattle and are generally considered 
to be non-pathogenic, although there are some reports of clinical disease associated 
with T. mutans infection in cattle (Irvin et al., 1972; Paling et al., 1981; Snodgrass et 
al., 1972). Until recently, Theileria buffeli and Theileria sp. (buffalo) were thought to 
be exclusive to buffalo and incapable of infecting cattle. However, Oura et al. were 
able to detect Theileria buffeli in young calves grazing in Lake Mburo National Park 
in Uganda using a reverse line blot assay (Oura et al., 2011b). Young et al. also 
found a then unidentified parasite in cattle with clinical theileriosis on the Marula 
Estate, Nakuru district, Kenya (Young et al., 1992). Only a few macroschizonts were 
present and large piroplasms were detected in erythrocytes with veils and bars 
(Young et al., 1992).Later studies demonstrated that T. sp Marula was, in fact, 
T. buffeli (Allsopp et al., 1993; Ngumi et al., 1994). Theileria sp (buffalo) was not 
detected in any of the cattle tested in Oura’s study, whereas most buffalo examined 
were found to be infected with this species (Oura et al., 2011b). The cattle examined 
by Oura et al did not have signs of clinical disease but many had carrier infections 
with T. parva, suggesting that T.sp (buffalo) had not established carrier infections in 
these animals. However, it is possible that an acute infection can establish in cattle, 
which does not lead to a carrier state. Similarly, in South Africa, T. sp (buffalo) was 
not detected in around 2,500 cattle samples tested with a real-time hybridisation PCR 
assay during routine diagnostic screening (Mans et al., 2011a).  
Evidence for the existence of Theileria sp (buffalo) as a distinct species was first 
reported by Conrad et al. (1987) who used monoclonal antibodies and restriction 
fragment length polymorphism profiles, employing a T. parva-specific repetitive 
DNA probe, to try to differentiate between cattle- and buffalo-derived Theileria 
parva-parasitised cell lines. DNA from sub-clones of the buffalo 6834 cell line 
hybridised poorly with the IgTPM-23 and IgTpM probes and the buffalo-derived 
sub-clones showed a somewhat different reaction pattern to that of the cattle-derived 
ones using monoclonal antibodies (Allsopp et al., 1993; Conrad et al., 1987a; Conrad 
et al., 1989; Conrad et al., 1987b). Sequencing of the 18S ribosomal subunit from 
these lines indicated that the cells were infected with a novel species of Theileria that 
was closely related to but distinct from T. parva and this was provisionally named 
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Theileria sp (buffalo) (Allsopp et al., 1993). A cell line infected with the same 
species has subsequently been isolated from a buffalo in South Africa (Zweygarth et 
al., 2009). In the present study, cloned cell lines infected with T. sp (buffalo) were 
identified among clones generated from two Theileria-parasitised cell lines derived 
from buffalo. The isolation of T. sp (buffalo)-infected cell lines from buffalo 
indicates that the parasite is able to transform buffalo leukocytes. Whether T. sp 
(buffalo) is also able to transform cattle cells is unknown. Co-infections with T. 
parva and T. sp (buffalo) are very common in buffalo in Eastern Africa and Southern 
Africa (Allsopp et al., 1993; Oura et al., 2011a, b; Pienaar et al., 2011b). These co-
infections present a challenge to the diagnosis of T. parva in buffalo in South Africa, 
where a real-time PCR diagnostic test is used. The test is based on the 18S ribosomal 
RNA gene, the DNA sequence of which is very similar for the two parasites (Sibeko 
et al., 2008). Pienaar et al. examined the effect of mixed T. sp (buffalo)/T. parva 
infection on the accuracy of the diagnostic test and estimated that about 10% of T. 
parva infections are misdiagnosed (Pienaar et al., 2011). A further complication is 
the detection in South African buffalo of additional 18S ribosomal RNA gene 
sequences that differ by a few nucleotides from T. sp (buffalo) (Chaisi et al., 2011; 
Mans et al., 2011b). This led to questioning whether the two sequence types 
represented different species of Theileria. Mans et al. used the 5S ribosomal subunit 
gene, which shows greater sequence divergence, to successfully differentiate the two 
parasites (Mans et al., 2011a).  
As described in Chapter 3 of this thesis, analyses of a set of cloned buffalo 
parasitised cell lines with a panel of PCR primers designed to amplify antigen genes 
of T. parva identified several lines that failed to yield PCR products with many of the 
primers. These cell lines were subsequently shown to be infected with T. sp (buffalo).  
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The aims of the studies described in this chapter were: 
- To examine the phylogenetic relationship of T. sp (buffalo) and T. parva utilising 
clonal cell lines  
- To investigate the presence of T. sp (buffalo) in cell lines and samples from cattle 
with clinical theileriosis after grazing on pastures shared with African buffalo 
- To identify Theileria species present in African buffalo, which could potentially 
be transmitted to cattle 
- To identify Theileria species present in tick-stabilate produced by feeding 
R. appendiculatus on African buffalo 
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7.2 Material and Methods 
7.2.1 Analysis of T. sp (buffalo) in Theileria-infected cell lines 
DNA from 18 uncloned Theileria-infected cell lines derived from cattle on the 
Marula farm in the Rift valley region of Kenya were examined. These DNA samples 
were provided by David Odongo, ILRI, Kenya. The Marula farm is located close to 
Naivasha National Park and animals were grazed in an area known to be frequented 
by buffalo. The cell lines were established from animals that showed clinical signs 
characteristic of East Coast fever and schizonts were detected in lymph node 
aspirates. 
The 18S subunit was amplified from genomic DNA samples with Theileria/Babesia-
specific primers as described previously (Gubbels et al., 1999; Oura et al., 2004a). 
1 µl of PCR product was then used in a semi-nested PCR reaction using a T. parva 
and a T. sp (buffalo)-specific reverse primer and visualised following electrophoresis 
on a 1.5% agarose gel. The presence of T. sp (buffalo)-specific sequence was 
confirmed for some of the cell lines by sequencing of PCR products amplified using 
the Theileria/Babesia species-specific primers, which were cloned using the pGEM-
T Easy vector system (Promega Corporation, USA) as previously described in 
Chapter 2. A very small quantity of culture was used directly for PCR amplification 
using the T. sp (buffalo)-specific reverse primer. T. sp (buffalo) positive molecular 
clones were further expanded and purified using the PureYield Plasmid Miniprep 
System (Promega Corporation, USA). Sequencing of PCR products was performed 
by Durham Genomics. 
Table 7.2  Primers used for amplification of the 18S rRNA gene 
Specificity Name Sequence 5'-3'
18s_Forward_Gub  GAGGTAGTGACAAGAAATAACAATA
Pan Theileria/Babesia primers 
18s_reverse_Our2 CTAAGAATTTCACCTCTGACAGT
T. parva-specific  
reverse primer 
18s_ parva_HH1 CTTATTTCGGACGGAGTTCG 




7.2.2 454 Sequencing of 18S ribosomal RNA subunit 
Samples examined for the presence of Theileria and Babesia species were as follows: 
(i) Nine DNAs from blood samples from a group of twelve sentinel Boran cattle that 
developed clinical theileriosis following introduction into an area grazed by African 
buffalo on the Ol Pejeta conservancy, Laikipia district, Kenya. DNA from these 
samples was extracted by ILRI staff from whole blood; (ii) DNA derived from blood 
samples of African buffalo collected in the Ol Pejeta conservancy in Kenya (blood 
clots) and the Kruger National Park in South Africa (whole blood); (iii) DNA 
extracted from two previously generated stabilates of sporozoites, which had been 
produced by feeding R. appendiculatus ticks on carrier buffalo that were captured as 
calves. Stabilate 3081 was prepared from R. appendiculatus ticks which fed on a T. 
parva carrier buffalo (7014) captured on Ol Pejeta Ranch, Nanyuki, Kenya. Stabilate 
4110 was prepared from R. appendiculatus ticks which fed on a T. parva carrier 
buffalo (7752).DNA samples from the sentinel cattle and African buffalo in the Ol 
Pejeta conservancy and buffalo-derived stabilates were supplied by ILRI, Kenya. 
DNA from buffalo from the Kruger National Park was provided by Dr Nick Juleff, 
Pirbright Institute, UK. 
The presence of different species of Theileria and Babesia in samples described 
above was investigated by sequencing a 375bp segment of the 18S ribosomal RNA 
gene using Roche 454 amplicon sequencing technology. The 18S ribosomal RNA 
gene was amplified from samples of genomic DNA using fusion primers that 
generate a product from all Theileria and Babesia species, as described in Chapter 3. 
Fusion primer sequences are detailed in Table 7.3. Further processing of the samples 
and bioinformatic processing was performed as described in Chapter 3. 
Table 7.3  Sequences of fusion primers used for amplification of the 18S rRNA gene for 
sequencing using Roche 454 technology 
Name Adaptor  MID tag Sequence 
18s_for_gub_Ax CGTATCGCCTCCCTCGCGCCATCAG xxxxxxxxxx GAGGTAGTGACAAGAAATAACAATA 
18s_rev_Our2_Bx CTATGCGCCTTGCCAGCCCGCTCAG xxxxxxxxxx CTAAGAATTTCACCTCTGACAGT 
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7.2.3 PCR amplification for phylogenetic analysis of T. sp 
(buffalo) and T. parva 
Selected genes of T. sp (buffalo) and T. parva clones were amplified for phylogenetic 
analysis. At least four clones were sequenced for each of 4 categories of Theileria 
parasites: cattle-associated T. parva, cattle-derived buffalo-associated T. parva, 
buffalo-derived T. parva and buffalo-derived T. sp (buffalo) (see Table 7.4). The 
genes amplified were 5S ribosomal RNA gene (Mans et al., 2011a) and three genes 
encoding T cell antigens in T. parva: Tp6, Tp7 and Tp8 (see Table 7.5). The primers 
for the amplification of Tp6, Tp7 and Tp8 and their T.sp (buffalo) orthologues were 
designed when trying to design primers that would amplify all/most Theileria parva 
variants (See chapter 3), but were not used for this purpose because the primers also 
amplified genes from T. sp (buffalo) clones. The amplified PCR products were 
cleaned using the Promega Wizard Gel and PCR Purification Kit (Promega 
Corporations, USA) and sent to Durham Genomics for Sanger sequencing. Sequence 
analysis was performed as described in Chapter 2. 
Table 7.4 Samples used for the phylogenetic analysis of T. sp (buffalo) and T. parva 
Name/Animal Clone Location
Cattle derived T. parva 
Muguga  Reference genome Kenya 
Marikebuni  A3, A7, B12, E43, 
F44, F53, I8, I38, J17 
Kenya 
Mariakani St 3231 clone 2/3 Kenya 
Boleni St3230 clone 1:1 Zimbabwe
Uganda St 3645clone 1/2 Uganda
Cattle associated with African buffalo T. parva 
Marula N33 Clone 2, 4, 5, 7 Nakuru, Kenya 
Marula N43 Clone 1, 2, 5, 6 Nakuru, Kenya 
Buffalo-derived T .parva 
Mara 3 Clone 3 Maasai Mara, Kenya 
Mara 30 Clone 5, 8, 11 Maasai Mara, Kenya 
Mara 42 Clone 2,5 Maasai Mara, Kenya 
Buffalo 6998 Clone 2,4,9 Kenya 
Buffalo-derived T. sp (buffalo)  
Buffalo 6998 Clone 3,8,10 Kenya 
Buffalo 6834 Clone 1,5,7,10 Laikipia, Kenya 
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Table 7.5 List of primers and primer sequences to amplify the 5S ribosomal RNA gene , Tp6, 
Tp7 and Tp8 
*(Mans et al., 2011a) 
Gene Primer name Primer sequence 












7.3.1 Demonstration of T. parva and T. sp (buffalo) in cell 
lines derived from naturally infected cattle 
Eighteen parasitised cell lines were obtained from cattle undergoing clinical disease 
after grazing in an area frequented by buffalo on the Marula estate, Kenya. Theileria 
parva was detected in 15 of the samples and T. sp (buffalo) was detected in seven of 
the samples using a semi-nested PCR with reverse primers specific for either T. 
parva or Theileria sp (buffalo) in a second round of amplification (see Figure 7.1). 
Figure7.1 Results of a semi-nested PCR assay of 18S ribosomal subunit using primers specific 
for T. parva and T. sp (buffalo) in the second round of PCR.  
The presence of T. parva and T. sp (buffalo) in samples from 18 cattle from the Marula farm is 
illustrated. Three T. parva and three T. sp (buffalo) clones were used as controls to confirm species-
specificity. M = molecular weight marker 
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That the PCR products were derived from T. sp (buffalo) was confirmed by 
sequencing two of the products obtained for the 18S rRNA gene after cloning into 
the P-GEM-T cloning vector. Sequences obtained for animals N18 and N86 are 
shown in Figure 7.2. 
Figure 7.2 Nucleotide alignment of a 50 bp region of the 18S rRNA gene amplified from samples 
from cattle from the Marula farm  
Sequences are aligned with sequences of Theileria parva (AF013418 and HQ684067) and T. sp 
(buffalo) (HQ895982 and DQ641260) obtained from the NCBI database. Nucleotides that were not 
conserved between sequences were highlighted.  
7.3.2 Phylogenetic analysis of T. parva and T. sp (buffalo)  
A set of clonal T. parva and T. sp (buffalo) parasitised cell lines was used for further 
analysis of the phylogeny of the two parasites. The 5S rRNA gene used in a previous 
study to analyse samples from South African buffalo was examined (Mans et al., 
2011a). The other genes used in the present study were Tp6 (predicted to encode 
prohibitin), Tp7 (predicted to encode heat shock protein 90) and Tp8 (predicted to 
encode a cysteine protease). These three antigen genes are relatively conserved 
among T. parva genotypes and do not appear to have been subject to immune 
selection (see chapter 5). Four groups of cloned parasitised cell lines were used, each 
group consisting of a minimum of four cloned parasitised cell lines: (1) buffalo-
derived T. parva, (2) T. parva from cattle co-grazed with buffalo (buffalo-
associated), (3) T. parva from cattle in buffalo-free areas and (4) buffalo-derived 
T. sp (buffalo). 
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Phylogenetic trees constructed for all four genes demonstrate that T. sp (buffalo) 
sequences form a cluster distinct from the T. parva sequences, with high levels of 
bootstrap support at the node separating the species. This provides further evidence 
that T. sp (buffalo) might represent a distinct species. No clear demarcation can be 
found between buffalo-derived T. parva and buffalo-associated T. parva on 
phylogenetic trees based on any of the markers. There is a tendency for cattle-
derived T. parva to cluster separately from the buffalo-derived and buffalo-
associated T. parva, but the phylogenetic distance is small and much smaller than the 
distance between T. parva and T. sp (buffalo) (see Figures 7.3-7.10). Moreover, the 
Tp6 sequence from one buffalo-derived T. parva clusters with the cattle-derived T. 






Figure 7.3 Principal component analysis of Tp8 and Tp8 orthologues in T. sp (buffalo). This 
diagram illustrates the relationship between buffalo-derived (◊), buffalo-associated (□) and cattle-
derived T. parva (∆) isolates and buffalo-derived T. sp (buffalo (o), suggesting T. sp (buffalo) isolates 
form a distinct population. The datapoints in the PCoA correspond with the samples displayed in the 
phylogenetic tree in figure7.4  
 
Figure 7.4 Phylogenetic tree showing the relationship between T. parva and T. sp (buffalo) based 
on Tp8 sequences. Sequences for Tp8 were used to construct a maximum likelihood tree using 1,000 
bootstrap replicates. The percentage of bootstrap values indicating the degree of support for each node 
are shown. The tree was rooted using an orthologue of Tp8 found in Babesia equi (CP001669). The 
samples used were buffalo-derived (◊), buffalo-associated (□) and cattle-derived T. parva (∆) isolates 
and buffalo-derived T. sp (buffalo) (o).   
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Figure 7.5 Principal component analysis of Tp7 and Tp7 orthologues in T. sp (buffalo) 
This diagram illustrates the relationship between buffalo-derived (◊), buffalo-associated (□) and 
cattle-derived T. parva (∆) isolates and buffalo-derived T. sp (buffalo (o), suggesting T. sp (buffalo) 
isolates form a distinct population. The datapoints in the PCoA correspond with the samples found in 























 Theileria annulata(TA12105)(XM 947380)
 Toxoplasma gondii (AY344115)











Figure 7.6 Phylogenetic tree showing the relationship between T. parva and T. sp (buffalo) based 
on Tp7 sequences  
Sequences for Tp7 were used to construct a tree by maximum likelihood analysis using 1,000 
bootstrap replicates. The bootstrap values indicating the degree of support for each node are shown. 
The tree was rooted using the putative Heat shock protein 90 gene sequence for Toxoplasma gondii 
(AY344115), Babesia bovis (AK442026) and Theileria annulata (XM_947380). The samples used 
were buffalo-derived (◊), buffalo-associated (□) and cattle-derived T. parva (∆) isolates and buffalo-
derived T. sp (buffalo) (o).   
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Figure 7.7 Principal component analysis of Tp6 and Tp6 orthologues in T. sp (buffalo). This 
diagram illustrates the relationship between buffalo-derived (◊), buffalo-associated (□) and cattle-
derived T. parva (∆) isolates and buffalo-derived T. sp (buffalo (o), suggesting T. sp (buffalo) isolates 
form a distinct population. The datapoints in the PCoA correspond to the samples in the phylogenetic 
tree in figure 7.8. 
Figure 7.8 Phylogenetic tree showing the relationship between T. parva and T. sp (buffalo) based 
on Tp6 sequences of Tp6 
The tree was constructed by maximum likelihood analysis using 1,000 bootstrap replicates. The 
bootstrap values indicating the degree of support for each node are shown. The tree was rooted using 
the prohibitin gene sequence for Babesia bovis (XM001609045) and Theileria orientalis 
(AB161472).The samples used were buffalo-derived (◊), buffalo-associated (□) and cattle-derived T. 
parva (∆) isolates and buffalo-derived T. sp (buffalo) (o).   
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Figure 7.9 Principal component analysis of 5S rRNA gene sequences of T. parva and T. sp 
(buffalo) 
This diagram illustrates the relationship between buffalo-derived (◊), buffalo-associated (□) and 
cattle-derived T. parva (∆) isolates and buffalo-derived T. sp (buffalo (o), suggesting T. sp (buffalo) 
isolates form a distinct population. The datapoints in the PCoA correspond with the samples found in 
the phylogenetic tree in figure 7.10. 
Figure 7.10 Phylogenetic tree showing the relationship between T. parva and T. sp (buffalo) 
based on the 5S rRNA gene 
The tree was constructed by maximum likelihood analysis using 1,000 bootstrap replicates. The 
bootstrap values indicating the degree of support for each node are shown. The tree was rooted using 
the 5S rRNA gene sequence for Babesia bovis (AK441686.1) and Toxoplasma gondii 
(XM_002366722.1). The samples used were buffalo-derived (◊), buffalo-associated (□) and cattle-
derived T. parva (∆) isolates and buffalo-derived T. sp (buffalo (o).   
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7.3.3 Investigation of Theileria species in sentinel cattle 
grazed in proximity of African buffalo 
Twelve sentinel cattle were introduced into a fenced area within the Ol Pejeta 
Conservancy and became infected, developing disease from 14 days after 
introduction. Ten out of twelve animals were detectably infected by day 16 after 
introduction. Animals were treated within 2-3 days of the first detection of parasites 
in lymph node smears. 454 sequencing of the 18S rRNA gene was conducted on nine 
samples obtained immediately prior to treatment and two samples obtained 27 days 
after treatment. In the samples obtained immediately prior to treatment, T. parva was 
detected in all nine animals and was the only detectable Theileria species (see 
Table 7.6). Co-infection with Babesia bigemina and another undefined Theileria 
species, which did not share a high percentage of 18S identity with other known 
Theileria species, was detected in one of the sentinel animals. Samples from this 
animal (32) and another animal (35) were also examined 27 days after treatment. In 
both of these samples, Babesia bigemina sequences represented the majority of the 
reads, with the proportion of T. parva sequences correspondingly reduced. Sequences 
representing Theileria taurotragi and the undefined Theileria species referred to 
above were found in animal 32, while T. sp (buffalo) sequences were detected in 
animal 35. 
Table 7.6  Theileria and Babesia species detected in sentinel cattle at the Ol Pejeta conservancy 
Animal Theileria Theileria Theileria T.sp Theileria Theileria Babesia Theileria Undefined 
number parva velifera mutans (buffalo) buffeli seninsis bigemia taurotragi Theileria sp 
Ol Pejeta 23 895
Sentinel cattle 25 2237
27 3232
28 1402
32 1942 84 33




35* 31 22 1516
36 2876
The numbers in the table represent the number of reads obtained for each of the different Theileria 
species in each of the samples. * Samples were taken 27 days after treatment 
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7.3.4 Theileria parasites in African buffalo 
DNA samples obtained from African buffalo on the Ol Pejeta conservancy provided 
an opportunity to examine the Theileria species carried by buffalo, which could 
potentially be transmitted to cattle. The eight African buffalo examined were all 
found to be infected with T. parva, T. velifera and T. sp (buffalo) (see Table 7.7). A 
low number of reads were obtained for T. mutans for two of the eight buffalo. One 
animal had co-infections with both T. sinensis and T. buffeli. One animal was co-
infected with T. buffeli only and two animals with T. sinensis only. 
Samples were also available from African buffalo from the Kruger National Park, 
South Africa. Five of the six buffalo sampled were found to be co-infected with T. 
parva, T. velifera, T. mutans and T. sp (buffalo) (see Table 7.7). One animal (SC02) 
only yielded sequences for T. mutans and T. sp (buffalo), but only a small number of 
sequence reads were obtained from the sample from this buffalo. Minor sequence 
variation was observed among the 18S rRNA sequences obtained for all of the 
Theileria species. These will be discussed further. 
Table 7.7 Theileria and Babesia species found in African buffalo from the 
Kruger National Park, South Africa and the Ol Pejeta conservancy, Kenya 
Animal Theileria Theileria Theileria T.sp Theileria Theileria Babesia Theileria Undefined 
number parva velifera mutans (buffalo) buffeli seninsis bigemia taurotragi Theileria sp 
Kruger National park SC01 27 116 118 89
South Africa SC02 10 13
SC03 6 97 13 357
SC04 23 50 23 29
SC05 149 370 72 455
SC06 59 96 62 242
Ol Pejeta Conservancy 301 691 465 691 277
Kenya 302 187 111 246
303 463 134 869
304 139 99 5 492
305 400 173 8 786
306 8 11 44 39 25
307 300 42 188 0 244
308 56 37 71 542
The numbers in the table represent the number of reads obtained for each of the 
different Theileria species in each of the samples 
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7.3.5 Heterogeneity of T. parva and T. sp (buffalo) in African 
buffalo 
Previous work examining the diversity of Theileria species in buffalo in South 
Africa, demonstrated the presence of sequence variants among the 18S rRNA gene 
sequences attributed to T. parva and T. sp (buffalo); in each case the sequences were 
very closely related to, but distinct from both T. parva and T. sp (buffalo) (Chaisi et 
al., 2011; Mans et al., 2011). Sequences similar to the 18S rRNA sequences of T. 
parva/T. sp (buffalo) were obtained by 454 sequencing in the present study. The 
sequences were obtained from DNA samples of five African buffalo in the Kruger 
National Park (represented by 264 reads) and from eight African buffalo in the Ol 
Pejeta conservancy (2,244 reads). There were only three nucleotide differences 
between T. parva and T. sp (buffalo) reference sequences over the 375 bp amplicon 
examined. Sequence variants were present that differ in one nucleotide from the T. 
parva reference sequence and in two nucleotides from the T. sp (buffalo) reference 
sequence. Due to the limited number of nucleotide changes over the amplicon 
examined, no clear clustering was seen of the sequences on alignment and 
phylogenetic analyses of T. parva and T. sp (buffalo) sequences (see figure 7.11 and 
appendix E) This is in agreement with previously published data (Chaisi et al., 2011).  
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Figure 7.11 Phylogenetic analysis of T. sp (buffalo) and T. parva sequences obtained from 
African buffalo 
The tree was constructed using a maximum likelihood method using 1,000 bootstrap replicates. The 
bootstrap values indicating the degree of support for each node are shown. The tree was rooted using 
the 18S rRNA gene sequence for T. annulata (HM628582.1). Samples from African buffalo from the 
Kruger National Park are labelled KNP Buffalo, followed by the animal number (SC01-SC06), and 
followed by the number of reads obtained for the allele. Samples from African buffalo from the Ol 
Pejeta conservancy are labelled Ol Pejeta Buffalo, followed by the animal number (301-308) and the 
number of reads obtained for the allele.  
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7.3.6 Heterogeneity in the 18S rRNA gene of T. velifera 
Twenty-five distinct 18S rRNA sequences similar to Theileria velifera were obtained 
from thirteen buffalo samples, corresponding to 1,801 reads. The BLASTN sequence 
homology searches indicated that the seventeen sequences obtained from samples 
from buffalo from the Kruger National Park (corresponding to 729 reads) were 
identical or similar to previously identified 18S rRNA sequences of T. velifera 
(JN5272701.1- JN5272705) and only differed by a few nucleotides from each other. 
However, the sequence homology searches indicated that T. velifera-like sequences 
obtained from buffalo on the Ol Pejeta conservancy (corresponding to 1,072 reads) 
formed a distinct cluster from previously identified 18S rRNA sequences of this 
organism. In all the samples from African buffalo from the Ol Pejeta conservancy, 
only one T. velifera-like variant was found, which had 6 unique nucleotide changes 
in the amplified gene segment compared to previously identified T. velifera-like 
variants (see figure 7.12 and Appendix E). Overall, polymorphism was found in 11 
nucleotides over the amplicons when looking at all the T. velifera-like sequences for 
African buffalo from both Kenya and South Africa.  
Figure 7.12 Alignment of T. velifera-like sequence variants 
The alignment was made using a representative sequence obtained in this study from each T. velifera-
like clade together with T. velifera-like sequences from the NCBI database; T. velifera (JN572703) 
and T. velifera-like 1 (JN572704) 
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Figure 7.13 Phylogenetic tree showing the relationship between T. velifera 18S rRNA gene 
sequence variants 
The tree was constructed using a maximum likelihood method using 1,000 bootstrap replicates. The 
bootstrap values indicating the degree of support for each cluster are shown. The tree was rooted using 
rRNA gene sequences for Prororectum micans (M14649), Sarcocystic muris (M64244), Toxoplasma 
gondii (X68523), Theileria parva (HQ684067.1) and Theileria sp ex Syncerus caffer (HQ895982.1). 
Samples from African buffalo from the Kruger National Park are labelled KNP Buffalo, followed by 
the animal number (SC01-SC06) and the number of reads obtained for the allele. Samples from 
African buffalo from the Ol Pejeta conservancy are labelled Ol Pejeta Buffalo, followed by the animal 
number (301-308) and the number of reads obtained for the allele.  
7.3.7 Heterogeneity in the 18S rRNA gene of T. mutans 
Eighteen distinct 18S rRNA sequences (corresponding to a total of 311 reads 
detected in eight buffalo) similar to T. mutans were obtained using BLASTN 
sequence homology searches. Most of these sequences were identical or similar to 
previously identified 18S rRNA sequences of T. mutans and T. mutans-like 
sequences (JN573694.1, FJ213585.1, FJ213586.1, JN572700.1, JN572696.1, 
AF078815.1, JN572694.1). For the samples from the Kruger National Park, 
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T. mutans, T. mutans-like 1 and T. mutans-like 2 sequences were found as previously 
described for buffalo samples from South Africa (Chaisi et al., 2013). Unfortunately, 
only a low number of T. mutans-like reads was obtained from two buffalo from the 
Ol Pejeta conservancy. These were all found to be identical to another variant found 
previously in South African buffalo (JN572700; T. mutans-like X in Figure 7.14 and 
Appendix E) by (Chaisi et al., 2013). 
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Figure 7.14 Phylogenetic tree showing the relationship between T. mutans-like 18S rRNA 
sequence variants 
The tree was constructed using a maximum likelihood method using 1,000 bootstrap replicates. The 
bootstrap values indicating the degree of support for each node are shown. The tree was rooted using 
the 18S rRNA gene sequence for Prororectum micans, Sarcocystic muris, T. gondii and T. parva 
(HQ684067.1). Samples from African buffalo from the Kruger National Park are labelled KNP 
Buffalo, followed by the animal number (SC01-SC06), and followed by the number of reads obtained 
for the allele. Samples from African buffalo from the Ol Pejeta conservancy are labelled Ol Pejeta 





7.3.8 Theileria species in buffalo-derived sporozoite 
stabilates 
To investigate whether R. appendiculatus could be a vector for T. sp (buffalo), deep 
amplicon sequencing of the 18S rRNA gene was performed on DNA prepared from 
two buffalo-derived T. parva stabilates. The stabilates had been produced previously 
by feeding laboratory R. appendiculatus ticks on buffalo that were captured from the 
field when they were young. Stabilate 3081 was produced by feeding ticks on a 
buffalo captured at the Laikipia district, Kenya, whereas stabilate 4110 was produced 
by feeding ticks on a buffalo captured in Kenya. DNA from a buffalo from the 
Kruger National Park and DNA from a parasitised bovine cell line from an animal on 
the Marula estate were also sequenced as positive controls. It was shown in a 
previous sequencing run that the sample from the buffalo from the Kruger National 
Park contained T. parva, T. sp (buffalo), T. mutans and T. velifera (see Table 
7.8).The cattle cell line sample from the Marula estate contained both T. parva and T. 
sp (buffalo) based on the semi-nested PCR assay (see Figure 7.1). Samples from both 
controls yielded 18S sequences for the expected Theileria species. In the sequences 
obtained from the African buffalo from Kruger National Park (467 reads), T. parva, 
T. sp (buffalo), T. mutans and T. velifera were all demonstrated. Only Theileria 
parva could be demonstrated in the two buffalo-derived stabilates (represented by 
1,479 and 607 reads in each stabilates) (see Table 7.8). However, for both stabilates, 
a number of variant sequences of the T. parva 18S rRNA gene (111 and 58 
sequences for one of the variants for respectively stabilate 3081 and stabilate 4110, 
and 45 sequences for a second variant in stabilates 4110) were found differing by one 
nucleotide from T. parva sequences and two or three nucleotides from T. sp (buffalo) 





Table 7.8 Sequencing of the 18S rRNA gene from two buffalo-derived stabilates  
 
The number of reads representing each of the Theileria species is indicated for the samples used; The 
two buffalo-derived stabilates used were stabilate 3081(HNgumi et al., 1992H) and Stabilate 4110; As 
positive controls a blood sample from buffalo SC06 from the Kruger national Park and a Theileria 
infected cell line from bovine N79 from the Marula farm were used.  
 
 
Stabilate name T. parva T. sp (buffalo) T. mutans T. velifera 
Buffalo-derived stabilate 3081 1,479 0 0 0 
Buffalo-derived stabilate 4110 607 0 0 0 
Buffalo SC06 49 203 94 121 




Figure 7.15 Alignment of 18S rRNA sequences obtained for buffalo-derived stabilates 3081 and 4110  
Representatives of the different sequence varaints obtained for buffalo-derived stabilates 3081 and 4110 were aligned with sequences for T. parva (HQ895970) and T. 




7.4.1 Detection of Theileria sp (buffalo) in parasitised cell 
lines isolated from cattle 
The presence of T. sp (buffalo) was demonstrated in seven out of 18 cell lines 
derived from cattle that had been introduced into an area of the Marula estate known 
to be grazed by buffalo. The parasite can thus infect and transform bovine 
lymphocytes and can be maintained in vitro in mixed cultures that also contain 
Theileria parva. Further clonal analyses of these lines are required to confirm that 
the T. sp (buffalo)-transformed bovine cells can be maintained in vitro in the absence 
of T. parva. However, this seems likely, since cloned T. sp (buffalo)-infected cell 
lines could be established from buffalo-derived cultures. Given the ability of this 
parasite to transform bovine lymphocytes, a role in pathology in cattle could be 
expected. 
The cell lines were isolated from animals with clinical disease and the presence of 
both T. parva and T. sp (buffalo) in cultures suggest that both parasites were 
abundant in the infected animal, which might imply that T. sp (buffalo) contributes to 
the pathogenesis of disease in cattle. The contribution of T. sp (buffalo) either alone 
or in combination with T. parva may have been overlooked in the past because the 
parasites are morphologically similar and are serologically cross-reactive (Conrad et 
al., 1987b). There is a need to obtain a T. sp (buffalo) sporozoite stabilate to test its 
pathogenicity in cattle. 
The transforming parasites Theileria parva and Theileria annulata are able to cause 
severe disease in cattle. Candidate genes potentially involved in transformation have 
been identified by comparative genomic analysis of T. orientalis (a non-transforming 
Theileria), T. parva and T. annulata (transforming Theileria species) (Hayashida et 
al., 2012). Theileria sp (buffalo) provides an additional transforming species that 
could be added to comparative genome studies to provide further insight into the 
genes that are important for transformation. 
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Differences in cell tropism can be found between and within Theileria species. 
Theileria parva parasites can generally infect lymphocytes of different lineages, 
including CD4+ T cells, CD8+ T cells, γδ T cells and B cells (Baldwin et al., 1988). 
However, a Zambian stock of T. parva (Chitongo) reported to be of relatively low 
virulence could only infect CD8+ T cells (Tindih et al., 2012). Studies of the cell 
tropism of T. parva in relation to disease have indicated that infected T cells are able 
to cause disease, whereas infected B cells give rise to self-limiting infections 
(Morrison et al., 1996). Theileria annulata infects cells of the monocyte/macrophage 
and B cell lineages (Spooner et al., 1988) and clinical signs are generally milder than 
infection with T. parva. Since T. sp (buffalo) is more closely related to T. parva than 
T. annulata, its cell tropism might be expected to be similar to T. parva. Future work 
should attempt to examine the cell tropism of this parasite both in cattle and in 
buffalo. Cloned infected buffalo cell lines are available for such studies while cloned 
bovine lines could be generated from the mixed infection lines isolated from Marula 
cattle. 
7.4.2 Phylogenetic analysis of T. parva and T. sp (buffalo) 
Theileria parva and T. sp (buffalo) have been shown to be genetically closely related 
based on analysis of the DNA sequence of the 18S rRNA gene (Chaisi et al., 2011; 
Mans et al., 2011a). The phylogenetic relationship between the two species was 
analysed further in the present study using sequences obtained for four other genes: 
5S rRNA, Tp6, Tp7 and Tp8. This analysis demonstrated that for all four genes T. sp 
(buffalo) sequences form a distinct Cluster separate from T. parva, with high levels 
of bootstrap support. However, since T. sp (buffalo) clonal cell lines were available 
from only two buffalo and thus the analysis was performed with a limited number of 
sequences, these findings will need to be confirmed with a larger sample of parasites. 
If the clear differentiation between the two Theileria species is confirmed upon 
examination of additional samples, these genes could be candidates for an improved 
differential diagnostic test to distinguish T. parva and T. sp (buffalo) in African 
buffalo and cattle (Pienaar et al., 2011; Sibeko et al., 2008). 
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The phylogenetic analysis of buffalo-derived T. parva and buffalo-associated cattle 
T. parva showed that these parasites Cluster together. The sequences from buffalo-
derived T. parva and buffalo-associated cattle T. parva also Clustered together on 
PCoA. This is in agreement with the results obtained by Pelle et al., where samples 
from cattle on the Marula estate Clustered with buffalo-derived T. parva in principal 
component analysis based on Tp2 allelic sequences (Pelle et al., 2011). A study of 
samples collected in Lake Mburo National Park in Uganda employing microsatellite 
DNA typing found that the T. parva genotypes obtained from buffalo and cattle were 
distinct from each other (Oura et al., 2011b). However, the cattle in the Ugandan 
study did not have clinical theileriosis and since buffalo-derived parasites do not 
readily establish a carrier state in cattle (Lawrence, 1979), the cattle parasites 
examined were likely to represent a more restricted subset of cattle-maintained 
parasites compared to those examined in the current study. This is consistent with the 
observation that in the current study, the non-buffalo-associated cattle T. parva 
appear to form a sub-Cluster within the overall T. parva population based on allelic 
sequences at each of the four loci. Pelle et al. (2011) also detected a limited subset of 
alleles in cattle compared to buffalo for Tp1 and Tp2.  There is modest bootstrapping 
support for the separation of the groups and the tree is unstable. The distances 
between the groups are small, suggesting that limited differentiation has occurred 
and this supports the concept of a relatively recent adaptation of a sub-population of 
T. parva to the cattle host. The collection of samples used in the current analysis was 
too small to determine definitively the overall relationship between the three 
categories of T. parva. A large panel of sympatric samples would be required and 
therefore to begin to address this issue, a number of sentinel calves located in a 





7.4.3 Theileria species in blood of cattle grazed in proximity 
to buffalo 
Most of the sentinel animals introduced to the buffalo-grazed area on the Ol Pejeta 
conservancy only had detectable infection with T. parva at the time they received 
theileriacidal treatment. Oura et al. studied haemoparasites in resident cattle grazed 
in proximity to wildlife in Uganda and, in addition to T. parva, found T. mutans, 
T. velifera, T. taurotragi, A. marginale and E. bovis (Oura et al., 2011b). However, 
most of these animals would have had prolonged exposure to the local parasites and 
had persistent carrier infections. The sentinel animals introduced at the Ol Pejeta 
conservancy were maintained tick-free in the period before their introduction and as 
a precautionary measure were also treated with acaricide on the day of arrival in the 
conservancy. All animals became heavily infested with ticks (>1000 ticks/animal) 
over the following two weeks, clinical/parasitological evidence of theileriosis was 
first observed for most animals from 16 days after acaricide treatment, and treatment 
for Theileria was required for these animals by day 19. Hence, the time-frame 
between the acaricide losing residual effect and anti-Theileria treatment was 
relatively short and might not have allowed the development of infection with other 
Theileria species that were present at lower levels in the ticks and/or were 
transmitted by a different tick species. In addition, since the animals all had acute 
infections with T. parva, low levels of infections with other parasites might not have 
been detectable because of the much higher frequency of T. parva 18S sequence 
reads.  
The rapid development of disease in the sentinel animals is likely due to a 
combination of very high levels of exposure to buffalo-derived T. parva and the lack 
of immunity. The large number of ticks found on the cattle might have further 
stressed the animals making them more susceptible to disease. Since this area of the 
conservancy is fenced to exclude cattle, ticks will have fed exClusively on wildlife. 
The levels of infection with Theileria parasites in the ticks were not examined in the 
current study. Theileria parva was found in all the samples of African buffalo 
examined and this persistent parasitaemia, in the absence of clinical signs, likely 
results in high infection rates in buffalo-fed ticks. 
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Two of the sentinel animals on the Ol Pejeta conservancy were found to be infected 
with Babesia bigemina. This parasite is transmitted by a number of species of 
Rhipicephalus (R. decoloratus, R. microplus and R. annulatus) (Jongejan and 
Uilenberg, 2004). No Babesia bigemina was detected in any of the African buffalo 
examined in this study, indicating that African buffalo are unlikely to be the source 
of Babesia bigemina in the sentinel cattle.   
7.4.4 Heterogeneity of Theileria species in African buffalo 
In previous studies, allelic variation has been identified in the 18S rRNA gene of T. 
parva, T. sp (buffalo), T. mutans and T. velifera from African buffalo from different 
National Parks and ranches in South Africa (Chaisi et al., 2013; Chaisi et al., 2011; 
Mans et al., 2011a). The Theileria parva and T. sp (buffalo) sequences were closely 
related, differing at eleven nucleotide positions over the 18S rRNA gene over the 
length of 1,505 bp. One to three nucleotide differences were detected among allelic 
variants of T. parva, whereas, between one and ten nucleotide differences were 
detected between alleles of the T. sp (buffalo) group (Chaisi et al., 2013; Mans et al., 
2011a). Four T. mutans-like alleles were found, including a previously obtained 
sequence variant which was named T. sp (Strain MSD) (Chae et al., 1999). The other 
variants identified in the present study were named T. mutans-like 1, T. mutans-like 2 
and T. mutans-like 3. Between 18 and 30 nucleotide differences were observed 
among different T. mutans-like sequences over a region of 1,562 base pairs. For 
T. velifera, between one and seven base pair differences were found between the 
T. velifera-like sequences (Chaisi et al., 2011; Mans et al., 2011a).  
In this study, all buffalo were found to be infected with T. parva, T. sp (buffalo) and 
T. velifera. The amplicons sequenced were shorter than those in previous studies 
(~375 base pairs), but over this region the T. parva and T. sp (buffalo) species 
possessed a very similar 18S rRNA gene sequence to sequences reported in previous 
studies (Chaisi et al., 2011; Mans et al., 2011a; Sibeko et al., 2008). Theileria 
mutans, T. mutans-like 1, T. mutans like-2, T. mutans-like 3 sequences were obtained 
from buffalo from the Kruger National Park and these had been previously found in 
South Africa buffalo (Chaisi et al., 2013; Mans et al., 2011a). In this study, more 
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than one T. mutans-like variant was found within an individual animal. In all the 
samples from African buffalo from the Ol Pejeta conservancy, only one T. velifera-
like variant was found, which had 6 unique nucleotide changes over the size of the 
amplicons compared to previously identified T. velifera-like variants. Polymorphism 
was found in 11 nucleotides over the amplicons size when looking at all the 
T. velifera-like sequences for African buffalo from the Ol Pejeta conservancy and 
Kruger National Park combined.  
There are no universal criteria for species classification on the basis of variation in 
the 18S rRNA gene (Norval et al., 1991a) and no data are available on the 
morphology of the parasites, their possible vectors or their role in clinical disease 
that would support speciation. Thus, Chaisi et al. suggested that the variants of the 
different Theileria species should be classified as variants of the Theileria species 
(Chaisi et al., 2011) until further evidence for speciation is available. Ultimate 
species definition would require the loss of capability of sexual recombination in the 
tick vector, if transmitted by the same tick species. However, should parasites be 
transmitted by separate tick species, this in itself would imply a degree of 
differentiation has already taken place and there would clearly exist a barrier to 
sexual recombination. This scenario would facilitate parasite populations evolving in 
isolation, a driving force for speciation. Further studies of the biology of these 
parasites coupled with genetic analyses are required to address this question. 
The lack of diversity of Theileria velifera and T. mutans species in African buffalo 
from the Ol Pejeta conservancy could have a number of reasons. Firstly, the Ol 
Pejeta conservancy is relatively small and is well fenced. This could have resulted in 
small founder populations of Theileria spp establishing at the conservancy. The 
effects of genetic drift are more pronounced in small populations and certain variants 
of a species might be able to become dominant or disappear from a population due to 
random fluctuations and competition for tick vectors. The Ol Pejeta conservancy has 
a large wildlife-proof electric fence and the integrity of the fence is checked daily, 
preventing the introduction of parasites by wildlife outside the conservancy. 
However, cattle from neighbouring communities are fattened and slaughtered on the 
conservancy. Thus, the introduction of ticks with new Theileria genotypes is likely to 
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be limited to those brought in with cattle. The animals are generally healthy animals 
and thus only parasites which can induce a carrier state in cattle will be introduced. 
Even though ticks in theory could move across the fence, in the absence of 
movement of mammalian hosts this will be at a low level. Cattle at fenced wildlife-
livestock interfaces in southern African were reported not to have T. parva, whereas 
animals in unfenced areas were infected (Caron et al., 2013), indicating that the 
transmission of T. parva and presumably other tick-borne pathogens is limited in the 
presence of adequate fencing. Secondly, the limited diversity of Theileria sp could be 
possibly due to differences in availability of the different tick vectors at the Ol Pejeta 
conservancy, due to environmental factors, due to the relatively small area of the 
conservancy or due to the changes in tick population due to the regular acaricide 
treatment of all cattle on the conservancy. Around 7,000 head of cattle are present in 
the conservancy, which receive frequent acaricide treatment (every three to five days 
depending on the season). The rigorous acaricide treatment regime could greatly 
reduce the tick burden on the conservancy and impact on the tick populations present 
in the conservancy and consequently the transmission dynamics of tick-borne 
pathogens. 
7.4.5 Tick vector of T. sp (buffalo)  
Theileria sp (buffalo) was not detected in two T. parva tick stabilates derived 
previously by feeding clean ticks on naturally infected buffalo. No information is 
available on whether the buffalo from which the stabilates were derived were 
infected with T. sp (buffalo). However, it is of note that one of the stabilates was 
prepared from a buffalo captured on the Ol Pejeta site in the mid-1980s (Morzaria et 
al., 1995). Moreover, each of the buffalo examined in the present study, including the 
animals on Ol Pejeta, were infected with T. sp (buffalo), as were most buffalo in 
previously published papers (Mans et al., 2011a; Oura et al., 2011a). In this study, 
the proportion of reads corresponding to T. sp (buffalo) and T. parva varied between 
individual buffalo. However, for the majority of the buffalo from Ol Pejeta, the 
number of reads obtained for T. sp (buffalo) and T. parva were roughly equivalent. In 
contrast, for African buffalo from the Kruger National Park, the number of sequences 
obtained for T. sp (buffalo) was many times greater than the number of sequences 
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obtained for T. parva. Thus, although the results of the current study do not exclude 
the possibility that R. appendiculatus can act as a vector for T. sp (buffalo), they 
suggest that it is transmitted by another tick species, with differential level of 
challenge in each area.  
Theileria sp. (buffalo) has been found in buffalo in South Africa, Kenya and Uganda 
and often occurs in combination with T. parva. This would indicate that the tick 
vector (if not R. appendiculatus itself) requires climatic conditions similar to 
R. appendiculatus, has a wide geographical distribution, is relatively abundant and 
frequently feeds on buffalo. Pienaar et al. have suggested Amblyomma hebraeum, 
Amblyomma marmoreum, Hyalomma truncatum, Rhipicephalus appendiculatus, 
Rhipicephalus evertsi evertsi or Rhipicephalus simus as potential vectors for T. sp 
(buffalo) based on the fact that these tick species were found on African buffalo at 
the Kruger National Park (Horak et al., 2007; Pienaar et al., 2011). A large number 
of other tick species are present in both Eastern and Southern Africa (see Table 7.9) 
(Anderson et al., 2013; Fyumagwa et al., 2011; Horak et al., 2007; Kariuki et al., 
2012; Lynen et al., 2007; Pascucci et al., 2011; Walker et al., 2001) and could be 
potential vectors for T. sp (buffalo), in addition to the vectors suggested by Pienaar et 
al. (Pienaar et al., 2011). Further studies to analyse ticks collected from field sites 
where T. sp (buffalo) is known to be present are required to identify the vector(s) of 
this parasite. 
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Table 7.9 Tick species found in East and Southern Africa 
A= Anderson et al., 2013 F=Fyumagwa et al., 2011 H=Horak et al., 2007 L= Lynen et al., 2007 W=Walker et al., 2001 



















































































































































9BChapter 8: General discussion  
The most significant findings of this study were: 
 The three components of the T. parva Muguga Cocktail vaccine show limited
genotypic and antigenic diversity.
 Extensive diversity was found for buffalo-derived T. parva both at the
population level and within individual animals.
- Buffalo parasites examined from South Africa and Kenya showed a
similarly high level of diversity. 
- A subset of CD8+ T cell antigens examined exhibited antigenic 
polymorphism. 
- Other CD8+ T cell antigens were highly conserved at the amino acid 
level. 
 Theileria sp (buffalo) was identified in cell lines isolated from cattle,
indicating that this parasite can transform bovine lymphocytes.
25B8.1 Limited diversity within the Muguga Cocktail 
Vaccine  
Based on the deep multilocus sequence typing, the diversity of the Muguga Cocktail 
was found to be limited; each of the components contained a predominant allele with 
in some cases one or two minor alleles. The Muguga and Serengeti-transformed 
stocks showed a high level of similarity in antigen gene sequence content and 
satellite DNA profiles, confirming the findings of several previous studies (Bishop et 
al., 2001; Geysen et al., 1999; Oura et al., 2007b). Because of this similarity, other 
workers have speculated that the original T. parva Serengeti-transformed stock has 
been contaminated with and supplanted by T. parva Muguga genotypes over the 
years (Bishop et al., 2001; Oura et al., 2004b). The inClusion of two parasites stocks 
that are genotypically very similar may not be optimal for obtaining broad immunity. 
In the present study, minor components found in the Serengeti-transformed stock 
were not detected in the Muguga stock. These minor components may represent 
remnants of the parasites present in the original Serengeti-transformed stock. If these 
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minor components are important for the induction of broad immunity, their presence 
in different preparations of the vaccine needs to be monitored. Information on the 
broad protective activity of the Muguga Cocktail is based on experiments conducted 
in the 1970s (Radley et al., 1975b). Because the original stocks used in these studies 
are no longer available, it is impossible to determine whether their composition has 
changed in the intervening period. Hence, there is a case for repeating some of the 
cross-protection experiments to determine whether the Muguga Cocktail shows 
broad protection similar to that reported by Radley and colleagues (Radley et al., 
1975b; Young et al., 1973). 
There is evidence from the current study and previous studies that there is a risk that 
the composition of vaccine stocks can vary between batches or with tick passage. 
The composition of vaccine batches produced in the same vaccine production run 
was very similar, but some variation was observed with tick passage. It is thus 
important to monitor the consistency of parasite stocks used for vaccination, 
especially when an additional passage through ticks is involved. The results 
generated from the current generation of parasite stocks in the present study provide 
a useful baseline with which future vaccine batches can be compared for consistency 
of composition. 
In this study, the components of the Muguga Cocktail were characterised by deep 
multilocus sequencing using 454 technology and satellite DNA typing, using a 
modified protocol in comparison to previous studies. Deep sequencing revealed very 
limited diversity in the three components of the Muguga Cocktail. This technique is 
relatively costly and laborious with data analysis being technically challenging and 
requiring sophisticated bioinformatic support. Satellite DNA typing, although having 
somewhat lower resolution in detecting low frequency alleles, proved to be a more 
practical method for characterising the parasites in the Muguga Cocktail stocks. The 
method used in this study to determine allele sizes and relative abundance of the 
alleles on satellite DNA typing (capillary flow electrophoresis) was shown to be 
relatively reproducible between laboratories. However, deep sequencing can provide 
greater level of resolution when investigating the genetic composition of parasite 
stocks and remains an immensely useful tool for experimental research. Its resolution 
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in the current study was limited by the subsequent finding that some of the antigens 
targeted were highly conserved at the amino acid level and it is clear this approach 
would be more fruitful if additional polymorphic antigens were analysed. 
To overcome the potential inconsistencies in the composition of the Muguga 
Cocktail, consideration should be given to developing an alternative cocktail vaccine 
based on the use of clonal parasites. Formulation of a new cocktail vaccine 
containing three parasite clones selected on the basis of genotypic and antigenic 
divergence may well provide protection comparable to that obtained with the 
Muguga Cocktail. The components of such a vaccine could readily be distinguished 
and the composition of vaccine batches monitored, thus allowing improved quality 
control and greater consistency of the vaccine. 
26B8.2 Extensive diversity in buffalo-derived T. parva  
A high level of genetic diversity was detected in T. parva in African buffalo both at 
the population level and within individual animals. Although the average number of 
nucleotide sequence alleles detected at each locus in individual animals was slightly 
lower for the Kenyan buffalo in Ol Pejeta compared to the South African animals in 
the Kruger National Park, the diversity was still very high in both populations. The 
mean distance between sequences of parasites in the two locations was very similar. 
No differentiation was observed for sequences from the different locations in PCoA 
analysis for the majority of the genes. However, a degree of geographical sub-
Clustering was observed in the PCoA analysis of the Tp1 gene. A phylogenetic tree 
was constructed to investigate the evolutionary relationships among Tp1 alleles and 
this provided evidence that particular lineages have evolved separately in each 
population. Although population-specific lineages could not be identified among Tp5 
sequences, identical alleles were identified within a multiple buffalo hosts from the 
same population, either the Kruger National Park or Ol Pejeta. Taken together, this 
suggests the two buffalo populations have differentiated and this is most readily 
observed in a ‘fast-evolving’ gene such as Tp1. 
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It has been hypothesised that South African buffalo were infected with T. parva at 
the beginning of the 20th century. This was attributed to the introduction of T. parva 
from cattle imported from Kenya for restocking purposes after the rinderpest 
pandemic killed the vast majority of South African cattle and buffalo (Mbizeni et al., 
2013; Norval et al., 1991b; Norval et al., 1992). Given the high degree of diversity 
found in individual African buffalo from the Kruger National Park in the current 
study and the limited antigenic diversity in isolates from cattle in Kenya (Pelle et al., 
2011), it seems more likely that the low number of surviving African buffalo in the 
Kruger National Park would have been sufficient to ensure the maintenance of a 
diverse parasite population. 
27B8.3 High level of genetic diversity in buffalo-derived T. 
parva at some antigen-encoding loci 
A high level of antigenic diversity in the Tp2 gene was found, as previously reported 
by Pelle et al. (2011). A large number of allelic variants of the epitopes in the Tp2 
gene were identified, many of which were shared between African buffalo from the 
Kruger National Park and the Ol Pejeta conservancy. A number of novel variants 
were identified in addition to those reported by Pelle et al. (2011). For Tp1, although 
the extent of nucleotide polymorphism was lower than for Tp2, it often resulted in 
changes in amino acid residues and a large number of amino acid sequence variants 
were detected. Consequently, three alleles of the Tp1214-224 epitope were detected, 
which were similar to those reported previously by Pelle et al. (2011). 
The identification of a large number of alleles of the sequenced genes in individual 
animals indicates that they have acquired infection from multiple tick infection 
events and that ticks feeding on the animals are likely to become infected with a 
genotypically mixed parasite population. This will provide the opportunity for 
frequent sexual recombination between genetically distinct parasites in the tick, 
which can result in the generation of further heterogeneity in the parasite population. 
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28B .4 Tp4, Tp5, Tp6 and Tp10 antigens are highly 
conserved in buffalo-derived T. parva 
The other four genes, namely Tp4, Tp5, Tp6 and Tp10, were highly conserved at the 
amino acid level despite the diversity observed at the nucleotide level. Only a single 
allele was found for the epitopes in Tp5 and Tp10 and two alleles for the Tp4328-338 
epitope. The CD8+ T cell responses induced by infection and treatment frequently 
display parasite strain specificity, indicating that the target antigens are polymorphic. 
This may reflect the greater dominance of the more polymorphic antigens in 
induction of the CD8+ T cell responses, with responses to the conserved antigens not 
being of sufficient magnitude to confer protection. Further studies are required to 
determine the relative contribution of responses to these conserved antigens to the 
overall CD8+ T cell response and their role in protection. 
These conserved genes may represent good candidates for the development of next 
generation vaccines as no strain specificity in immunity would be expected. 
However, it is unknown which cattle MHC I genotypes are capable of presenting 
these epitopes and this may limit their effectiveness when applied to populations of 
cattle in the field. Nevertheless, if protective CD8+ T cell responses could be 
generated using these conserved antigens, this would potentially overcome the 
problem of strain specificity of immunity associated with vaccination using live 
parasites, and enable the use of sub-unit vaccines in areas where cattle co-graze with 
African buffalo. 
29B8.5 Implication of buffalo parasite diversity for 
vaccination  
Immunisation of cattle with several cattle-derived parasites stocks, including the 
Muguga Cocktail, has failed to protect against challenge with buffalo-derived 
parasites under field and experimental conditions. Although in some cases the 
mortality was slightly reduced or delayed, the mortality and severity of disease 
remained high in the majority of cases (Cunningham et al., 1974; Latif et al., 2001; 
Lohre, 1978; Radley et al., 1975a; Radley et al., 1979; Snodgrass et al., 1972; Young 





with success in cattle of pastoralist communities in the Ngoro Ngoro conservancy 
region in Tanzania, where buffalo are present and are infected with T. parva (Di 
Giulio et al., 2009; Martins et al., 2010). This apparent variation in the efficacy of 
vaccination raises questions about the T. parva diversity in its broadest sense and 
further studies are required to understand the epidemiology of the parasite in areas 
where the land is co-grazed by cattle and buffalo. In particular there is a need to 
understand parasite challenge at the level of the tick vector. The availability of 
epidemiological data on infections in ticks and the cattle and buffalo mammalian 
hosts would enable the development of mathematical models of the transmission of 
T. parva in different epidemiological settings. 
An important question is - how likely are cattle in different epidemiological 
situations to encounter an infected tick that has acquired its infection by feeding on a 
buffalo compared to an infected tick that acquired infection from a cow? In areas 
with buffalo where no or very limited tick control is employed, it is possible that 
most ticks feeding on cattle may have fed in their previous stage on cattle. If the 
chance of an animal encountering a tick that previously fed on a buffalo is low, it can 
be envisaged that challenge of Muguga Cocktail-vaccinated cattle with infected ticks 
predominantly fed previously on cattle could boost and broaden the antigenic 
specificity of immunity and hence provide greater protection against challenge with 
both cattle-fed and buffalo-fed ticks. 
In areas with buffalo where livestock management includes regular acaricide 
treatment of cattle, the numbers of ticks that complete feeding on cattle and are able 
to transmit T. parva will be greatly reduced. Although this may also result in 
reduction in overall tick burden, the proportion of infected ticks that have acquired 
their infections from buffalo will increase. This, coupled with reduced boosting of 
immunity by challenge with cattle-fed infected ticks, may result in an increased 
likelihood of vaccine breakthroughs in Muguga Cocktail-vaccinated animals. 
Vaccination with buffalo-derived parasites could be considered. Previous studies 
have provided evidence that vaccination of cattle by ITM with buffalo-derived T. 
parva provides protection against challenge with buffalo-derived T. parva. 
(Cunningham et al., 1974; Dolan, 1984; Latif et al., 2001; Mbizeni et al., 2013; 
 201
Mutugi et al., 1988a; Mutugi et al., 1988b; Radley et al., 1975c; Young et al., 
1977b). However, in view of the requirement of buffalo for tick feeding to produce 
stabilates of these parasites, the practicality of this approach is questionable. 
30B8.6 Infection of cattle with Theileria sp. (buffalo)  
Theileria parva, T. sp (buffalo), T. velifera were detected in all African buffalo 
examined in this study, based on sequencing of the 18S ribosomal RNA gene. 
Theileria mutans and T. mutans–like sequences were detected in all buffalo from the 
Kruger National Park and in some animals from the Ol Pejeta conservancy. In 
addition, T. sinensis and T. buffeli were detected in buffalo from the Ol Pejeta 
conservancy and these parasites have the potential to be transmitted from buffalo to 
cattle. Theileria parva is generally considered the only species of Theileria 
pathogenic for cattle in Africa. However, a potential role of T. mutans in disease in 
cattle has been described (Snodgrass et al., 1972) and T. buffeli has been detected in 
cattle grazed in proximity of buffalo in Kenya and Uganda (Oura et al., 2011b; 
Young et al., 1992), although it was not associated with disease. 
Of particular interest in the present study was the detection of T. sp (buffalo) in in 
vitro cell lines isolated previously from cattle with clinical disease, which had grazed 
alongside buffalo. This parasite was also detected in blood from one of the sentinel 
cattle at the Ol Pejeta conservancy. The demonstration of T. sp (buffalo) in cattle cell 
lines indicates that T. sp (buffalo) is capable of infecting and transforming bovine 
cells and may thus be involved in pathology in cattle. It is difficult to differentiate 
between T. parva and T. sp. (buffalo) parasites microscopically or serologically and 
therefore the role of T. sp (buffalo) in pathology in cattle may be underestimated. The 
establishment of T. sp (buffalo) sporozoite stabilates will be required to investigate 
the role of this parasite in disease in cattle. Examination of available buffalo-derived 
sporozoites stabilates would suggest Rhipicephalus appendiculatus is not the tick 
vector for T. sp (buffalo) and therefore further efforts to identify the tick vector of 
T. sp (buffalo) are required. 
The 18S rRNA sequences of T. parva and T. sp (buffalo) are very similar and mixed 





T. parva (Pienaar et al., 2011; Sibeko et al., 2008). In this study, phylogenetic 
analysis of sequences obtained for Tp6, Tp7, Tp8 and the 5S rRNA gene and their 
orthologues in T. sp (buffalo) showed a clear distinction between each species. These 
genes could thus be considered as candidates for an improved diagnostic test for T. 
parva in South Africa. 
31B8.7 Main conclusions 
The results of these studies have demonstrated that the three T. parva components of 
the Muguga Cocktail live vaccine (Muguga, Serengeti, Kiambu 5), as well as the 
combined cocktail, contain very limited genotypic diversity. The vaccine was found 
to contain a number of minor components present at low levels within some of the 
individual parasite stocks. This finding has highlighted the risk that such components 
could be lost during tick passage of these parasites, thus altering the composition of 
the vaccine and potentially reducing its ability to induce broad protection against 
field challenge. To overcome this problem, it is proposed that an improved cocktail 
vaccine should be produced using a mixture of clonal parasites, to ensure consistency 
of parasite composition and immune protection. A mixture of three parasites 
carefully selected on the basis of genotypic and antigenic divergence could be used 
for such a vaccine. 
Buffalo-derived T. parva genotypes showed a high level of diversity both at the 
population level and within individual buffalo. In particular, there was extensive 
antigenic diversity in the epitopes recognised by bovine CD8+ T cells in the Tp1 and 
Tp2 antigens. However, despite allelic variation at the nucleotide level, the amino 
acid sequences of the remaining four genes, namely Tp4, Tp5, Tp6 and Tp10, 
showed a high level of conservation. The strain specificity of CD8+ T cell responses 
in immunity in animals immunised by ITM indicate that the immune responses are 
directed predominantly to polymorphic antigens. The identification of antigens that 
are conserved between parasite isolates offers the potential to explore the possibility 
of induction of protective immunity using these molecules, in order to obtain 





Standard Culture Medium (SCM) 
RPMI 1640 medium + 25 mM HEPES + L-glutamine (Gibco, Paisley, UK) 
10% (heat-inactivated) foetal bovine serum (Gibco)  
100 U/ml penicillin, 100 g/ml streptomycin, 293 g/ml L-glutamine (penicillin-
streptomycin-glutamine 100 x solution) (Gibco) 
5 x 10-4 M 2-Mercaptoethanol  
Alsever’s solution (10 x stock) 
D-glucose 205.0g (113.8 mM) 
citric acid 5.5 g (2.9 mM) 
sodium chloride 42.0g (71.9 mM) 
tris-sodium citrate di-hydrate 80.0 g (27.2 mM) 
Made up to a volume of 1 litre with DDW. Made up to 1 x solution by filter 
sterilising 0.1 litre stock solution using 0.45µm Minisart® single use filter 
(Sartorious, Germany) and adding 0.9 litre of DDW. 
FACS Medium 
RPMI 1640 medium + 25 mM HEPES + L-glutamine (Gibco) 
5% (heat-inactivated) foetal bovine serum (Gibco)  
0.2% sodium azide 
Cytotoxicity Medium 
RPMI 1640 medium + 25 mM HEPES + L-glutamine (Gibco) 
5% (heat-inactivated) foetal bovine serum (Gibco) 
II
Tris-Acetate/EDTA electrophoresis buffer - TAE buffer (50 x stock) 
Trizma base 242 g (2M) 
Glacial acetic acid 59.1ml (2M) 
EDTA 100ml of 0.5M solution (50mM) 
pH adjusted to 7.7-8.0 with glacial acetic acid if required. Made up to a volume of 
1 litre with DDW. 
Buffer for Giemsa staining 
potassium di-hydrogen phosphate 3 g 
di-sodium hydrogen phosphate 15 g 
Made up to a volume of 5 litres with distilled water. pH adjusted to 7.2 using either 
sodium hydroxide or hydrochloric acid. 
Stabilate diluent 
Minimum essential media (MEM) with Hanks’ salts, L-glutamine and nonessential 
amino acids (Sigma Aldrich) supplemented with sodium hydrogen carbonate 
(0.35 g/L) 
3.5% of volume BSA – albumin bovine fraction V, pH 7, standard grade (Serva 
electrophoresis) 
7.5% of volume glycerol, pH 7.2 
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Figure 1 Nucleotide alignment of Tp1 within the Muguga Cocktail and the Marikebuni stabilates 
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Figure 3 Nucleotide alignment of Tp2 reverse reads within the Muguga Cocktail and the Marikebuni stabilates 
VI 
Figure 4 Nucleotide alignment of Tp3 reads within the Muguga Cocktail and the Marikebuni stabilates 
 VII 
Figure 5 Nucleotide alignment of Tp4 within the Muguga Cocktail and Marikebuni stabilates 
 VIII 
Figure 6 Nucleotide alignment of Tp5 within the Muguga Cocktail and Marikebuni stabilates 
IX 
Figure 7 Nucleotide alignment of Tp6 within the Muguga Cocktail and Marikebuni stabilates 
X 
Figure 8 Nucleotide alignment of Tp7 within the Muguga Cocktail and Marikebuni stabilates 
XI 
Figure 9 Nucleotide alignment of Tp8 within the Muguga Cocktail 
 XII 
Figure 10 Nucleotide alignment of Tp10 within the Muguga Cocktail and Marikebuni stabilates 
 XIII 
Figure 11 Amino acid alignment of Tp1 within the Muguga Cocktail and Marikebuni stabilates.  
The position of the Tp1214-224 epitope is indicated above the sequences 
Figure 12 Amino acid alignment of Tp2 forward reads within the Muguga Cocktail and Marikebuni stabilates.  
The positions of CD8 T cell epitopes is indicated above the sequences.  
Figure 13 Amino acid alignment of Tp2 reverse reads within the Muguga Cocktail and Marikebuni stabilates. 
The positions of CD8 T cell epitopes is indicated above the sequences.  
 XIV 
Figure 14 Amino acid alignment of Tp3 within the Muguga Cocktail and Marikebuni stabilates 
Figure 15 Amino acid alignment of Tp4 within the Muguga Cocktail and Marikebuni stabilates 
The position of the Tp4328-338 epitope is indicated above the sequences 
Figure 16 Amino acid alignment of Tp5 within the Muguga Cocktail and Marikebuni stabilates 












Figure 183 Amino acid alignment of Tp7 within the Muguga Cocktail and Marikebuni stabilates 
The position of the Tp7206-214 epitope is indicated above the sequences 
 
 
Figure 19 Amino acid alignment of Tp8 within the Muguga Cocktail and Marikebuni stabilates 
The position of the Tp8378-388 epitope is indicated above the sequences 
 
 XVI 
Figure 20 Amino acid alignment of Tp10 within the Muguga Cocktail and Marikebuni stabilates 
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Figure 1 Phylogenetic tree showing the relationship between Tp1 (buffalo) 
sequences obtained from African buffalo – Maximum Parsimony method.  
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. There were a total of 312 positions in the final dataset. 
Samples from African buffalo from the Kruger national park are labelled Kruger NP, 
followed by the animal number (SC01-SC06), the allele number and the number of 
sequences obtained for the allele. Samples from the African buffalo from the Ol 
Pejeta conservancy are labelled Ol Pejeta, followed by the animal number (301-306) 
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Figure 2 Phylogenetic tree showing the relationship between Tp1 (buffalo) 
sequences obtained from African buffalo- Neighbor Joining method  
The phylogenetic relationship was inferred using the Neighbor-Joining method. The 
bootstrap consensus tree inferred from 1000 replicates is shown. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test are 
shown next to the branches. The tree is drawn to scale, with branch lengths in the 
same units as those of the evolutionary distances used to infer the phylogenetic tree. 
The evolutionary distances were computed using the Maximum Composite 
Likelihood method and are in the units of the number of base substitutions per site. 
The rate variation among sites was modelled with a gamma distribution (shape 
parameter = 2). ). The analysis involved 76 nucleotide sequences. Samples from 
African buffalo from the Kruger national park are labelled Kruger NP, followed by 
the animal number (SC01-SC06), the allele number and the number of sequences 
obtained for the allele. Samples from the African buffalo from the Ol Pejeta 
conservancy are labelled Ol Pejeta, followed by the animal number (301-306), allele 
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Figure 3 Phylogenetic tree showing the relationship between Tp2 (buffalo) 
sequences obtained from African buffalo - Maximum likelihood method.  
The tree was constructed using a maximum likelihood method using 1,000 bootstrap 
replicates. The bootstrap values indicate the degree of support for each of the nodes. 
Sequences were obtained from buffalo from the Kruger National Park and the Ol 
Pejeta conservancy, all unique sequences obtained within the Kruger National Park or 
the Ol Pejeta conservancy are displayed. Samples from African buffalo from the 
Kruger national park are labelled □ Kruger NP, followed by the animal number 
(SC01-SC06), the allele number and the number of sequences obtained for the allele. 
Samples from the African buffalo from the Ol Pejeta conservancy are labelled ∆ Ol 
Pejeta, followed by the animal number (301-306), allele number and the number of 
sequences obtained. Samples from laboratory maintained parasites are labelled ◊, 
followed by the stabilate name, the allele number and the number of sequences 
obtained. Sequences from cattle from a previous study are labelled ◊, followed by the 
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Figure 4 Phylogenetic tree showing the relationship between Tp2 (buffalo) 
sequences obtained from African buffalo- Maximum Parsimony method.  
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. The evolutionary distances were computed using the 
Maximum Composite Likelihood method and are in the units of the number of base 
substitutions per site. The rate variation among sites was modelled with a gamma 
distribution (shape parameter = 2). The analysis involved 84 nucleotide sequences. 
All positions containing gaps and missing data were eliminated. There were a total of 
249 positions in the final dataset. Samples from African buffalo from the Kruger 
national park are labelled □ Kruger NP, followed by the animal number (SC01-SC06), 
the allele number and the number of sequences obtained for the allele. Samples from 
the African buffalo from the Ol Pejeta conservancy are labelled ∆ Ol Pejeta, followed 
by the animal number (301-306), allele number and the number of sequences 
obtained. Samples from laboratory maintained parasites are labelled ◊, followed by 
the stabilate name, the allele number and the number of sequences obtained. 
Sequences from cattle from a previous study are labelled ◊, followed by the name and 
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Figure 5 Phylogenetic tree showing the relationship between Tp2 (buffalo) 
sequences obtained from African buffalo- Neighbor Joining method 
The phylogenetic relationship was inferred using the Neighbor-Joining method. The 
bootstrap consensus tree inferred from 1000 replicates is shown. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test are 
shown next to the branches. The evolutionary distances were computed using the 
Maximum Composite Likelihood method and are in the units of the number of base 
substitutions per site. The rate variation among sites was modelled with a gamma 
distribution (shape parameter = 2). The analysis involved 84 nucleotide sequences. 
Samples from African buffalo from the Kruger national park are labelled □ Kruger 
NP, followed by the animal number (SC01-SC06), the allele number and the number 
of sequences obtained for the allele. Samples from the African buffalo from the Ol 
Pejeta conservancy are labelled ∆ Ol Pejeta, followed by the animal number (301-
306), allele number and the number of sequences obtained. Samples from laboratory 
maintained parasites are labelled ◊, followed by the stabilate name, the allele number 
and the number of sequences obtained. Sequences from cattle from a previous study 
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Figure 6 Phylogenetic tree showing the relationship between Tp5 (buffalo) 
sequences obtained from African buffalo- Maximum Parsimony method.   
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. There were a total of 309 positions in the final dataset. 
Samples from African buffalo from the Kruger national park are labelled □ Kruger 
NP, followed by the animal number (SC01-SC06), the allele number and the number 
of sequences obtained for the allele. Samples from the African buffalo from the Ol 
Pejeta conservancy are labelled ∆ Ol Pejeta, followed by the animal number (301-
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Figure 7 Phylogenetic tree showing the relationship between Tp5 (buffalo) 
sequences obtained from African buffalo- Neighbor-Joining method.  
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. The evolutionary distances were computed using the 
Maximum Composite Likelihood method and are in the units of the number of base 
substitutions per site. The rate variation among sites was modelled with a gamma 
distribution (shape parameter = 2). The analysis involved 139 nucleotide sequences. 
Samples from African buffalo from the Kruger national park are labelled □ Kruger 
NP, followed by the animal number (SC01-SC06), the allele number and the number 
of sequences obtained for the allele. Samples from the African buffalo from the Ol 
Pejeta conservancy are labelled ∆ Ol Pejeta, followed by the animal number (301-
306), allele number and the number of sequences obtained.  
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Table 4 Monitoring of parasitological parameters in lymph nodes and blood after challenge with 
Stabilate 3081 
BG040 0 1 2 3 4 5 6 7 8 9 10 11 12 
right parotoid ln - - - - - - - - - - - - - 
left parotoid ln - - - - - - - H++ H++ H++ H++ H++ MA+ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - - - - - - 
blood - - - - - - - - - NPS NPS - 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - - 
H+ MA+ MA+ MA+ - - - - - - - - - - - 
- - - - - - - - - - - - - - - 
H++ H++ MA+ MA+ - - - - - - - - - - - 
- NPS NPS - - NPS NPS - - NPS - - - - - 
BG044 0 1 2 3 4 5 6 7 8 9 10 11 12 
right parotoid ln - - - - - - - - - - - - - 
left parotoid ln - - - - - - - MA+ MA++ MA+ H+ MA+ MA+ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - H+ H+ H+ - - 
blood - - - - - - - - - NPS NPS NPS 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - - 
MA+ MA+ MA++ - - - - - - - - - - - - 
- - - - - - - - - - - - - - - 
MA++ MA+ MA+ - - - - - - - - - - - - 
- NPS NPS - - NPS - - - NPS - - - - - 
BF080 0 1 2 3 4 5 6 7 8 9 10 11 12 
right parotoid ln - - - - - - - - - - - - - 
left parotoid ln - - - - - - - - H+ MA+ MA+ H+ H+ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - - - - - - 
blood - - - - - - - - - - - - - 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - 
H+ H++ H+ - MA+ H+ H+ H+ H+ - MA+ H+ - - - 
- - - - - - - - - - - - - - - 
- - - - - - - - - - - - - - - 
- - - - NPS NPS NPS - - NPS - - - - - 
 XXV
BF083 0 1 2 3 4 5 6 7 8 9 10 11 12 
left parotoid ln - - - - - - - - - H++ H++ H+ H++ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - - - - - - 
blood - - - - - - - - - - - - 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - - 
H++ H++ H++ H+ H++ H++ H+ H+ H+ H+ H+ H+ - - - 
- - - - - - - - - - - - - - - 
- - - - - - - - - - + - - - - 
BF085 0 1 2 3 4 5 6 7 8 9 10 11 12 
right parotoid ln - - - - - - - - - - - - - 
left parotoid ln - - - - - - - - - - - H+ H+ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - - - - - - 
blood - - - - - - - - - - - - - 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - - 
- H+ H+ - H+ H+ - - H+ H++ H++ H++ - - - 
- - - - - - - - - - - - - - 
- - - - - - - - - - - - - - 
- NPS - - - NPS - - - NPS NPS NPS - - - 
BF086 0 1 2 3 4 5 6 7 8 9 10 11 12 
right parotoid ln - - - - - - - - - - - - - 
left parotoid ln - - - - - - - - - - H+ H+ H++ 
right prescapular ln - - - - - - - - - - - - - 
left prescapular ln - - - - - - - - - - - - - 
blood - - - - - - - - - - - - 
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 
- - - - - - - - - - - - - - - 
MA+ MA+ MA+ MA++ MA+ MA+ - H+ - - - - - - - 
- - - - - - - - - - - - - - - 
- MA+ MA+ MA+ - - - - - - - - - - - 
- NPS NPS - - NPS - - - NPS - - - - - 
Animals were monitored for 27 days after challenge and the day of measurement is 
shown. The presence of parasites was examined in lymph nodes (ln) and blood. H+ 
slight hyperplasia of lymphocytes, H++ mild hyperplasia of lymphocytes, Ma+ 
schizonts not easy to find, Ma++ 1 to 2 schizonts visible per field, Ma +++ > 2 
schizonts per field, NPS no parasites seen.  
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Table 5 Body temperature of animals after challenge with stabilate 3081 
The body temperature for each of the animals is shown in °C 
 Animal 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
BG040 38.2 39.2 38.2 38.2 38.6 39.4 38.3 38.2 39.7 38.7 40.6 38.6 38.6 39.2 39.3 
BG044 38.6 38.6 38.4 38.5 38.6 39 39.1 39.3 39.2 39.2 39.1 38.9 39.5 39.6 41.1 
BF080 38.5 39.1 38.3 38.2 38.4 38.4 38.1 37.8 38.3 38.5 38.8 38.8 38.5 38.1 38.1 
BF083 38.5 39.3 38.3 38.3 37.9 38.8 38.2 38.2 38.3 38.7 38.9 38.7 38.4 38.3 38.1 
BF085 38.5 38.9 38.3 38.2 38.4 38.5 38.2 38.4 38.4 38.8 38.8 38.8 38.7 38.4 38.5 
BF086 38.2 39.6 38.1 38.1 38.4 38.4 37.9 38.7 38.6 38.5 38.6 38.8 38.7 38 39.6 
 Animal 16 17 18 19 20 21 22 23 24 25 26 27 28 29 
BG040 40.9 40.9 40.4 39.7 39.1 38.7 38.7 38 38.4 38.2 38.3 38.4 38.3 38.1  
BG044 41.1 39.4 39.1 38.9 38.6 38.8 38.7 38.2 38.7 38.3 38.7 38.4 38.4 38.4  
BF080 38.6 38.9 40.3 41.2 40.2 38.8 38.6 38.6 39.1 39 38.7 38.6 38.7 38.1  
BF083 39.1 39.1 38.9 40.1 40.5 40.1 39.5 40.1 40 40.1 39.6 39.1 39 38.6  
BF085 39 38.7 38.9 38.7 38.5 38.6 38.6 38.9 39.8 40 38 38.5 38.6 38.4  
BF086 41 40.8 39.7 39.6 38.9 38.5 38.3 38.4 38.4 38.4 38.5 38.6 38.7 38.3  
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Appendix E 
Figure 1 Phylogenetic tree showing the relationship between T. parva and T.sp 
(buffalo) sequences obtained from African buffalo.  
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. The tree was rooted using rRNA gene sequences for 
Prororectum micans (M14649), Sarcocystic muris (M64244), T. gondii (X68523),T. 
parva (HQ684067.1) and T. annulata (HM628582.1) Samples from African buffalo 
from the Kruger national park are labelled KNP buffalo, followed by the animal 
number (SC01-SC06), followed by the number of sequences obtained for the allele. 
Samples from the African buffalo from the Ol Pejeta conservancy are labelled Ol 
Pejeta buffalo, followed by the animal number (301-306), followed by the number of 
sequences obtained for the allele. Bovine samples from the Ol Pejeta conservancy are 
labelled Ol Pejeta bovine, followed by the animal number and followed by the 
number of sequences obtained for the allele 
 B15e (HQ895972.1)
 Mz6c (HQ895971.1)
 KNP 102 (HQ684067.1)
 KNP Buffalo SC05 133
 KNP Buffalo SC01 27
 OlPejeta Buffalo 303 463
 OlPejeta Buffalo 301 691
 OlPejeta Bovine 25 2237
 OlPejeta Bovine 32 1942
 OlPejeta Buffalo 308 30
 Mz13j (HQ895985.1)
OlPejeta Bovine 27 
T. parva
 OlPejeta Bovine 32 18
 KNP Buffalo SC06 5
T.sp X
 OlPejeta Buffalo 303 862
 KNP Buffalo SC05 70
 T. sp ex Syncerus caffer (DQ641260)
 KNP Buffalo SC03 347
 OlPejeta Buffalo 307 11
 KNP Buffalo SC05 16
 KNP Buffalo SC05 8
 OlPejeta Buffalo 308 10
 A21 (HQ895978.1)
 OlPejeta Bovine 35 22
 V8b (HQ895982.1)
 OlPejeta Buffalo 307 177
 OlPejeta Buffalo 305 779
T.sp buffalo group 1
 Q15c (HQ895983)
 K1c (HQ895977.1)
T.sp buffalo group 2
 T. annulata(HM628582.1)
 P. micans (M14649)
 T .gondii (X68523)































Figure 2 Phylogenetic tree showing the relationship between T. velifera like 
sequences obtained from African buffalo.  
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. The tree was rooted using rRNA gene sequences for 
Prororectum micans (M14649), Sarcocystic muris (M64244), T. gondii (X68523). 
Samples from African buffalo from the Kruger national park are labelled KNP 
Buffalo, followed by the animal number (SC01-SC06) and the number of sequences 
obtained for the allele. Samples from the African buffalo from the Ol Pejeta 
conservancy are labelled Ol Pejeta Buffalo, followed by the animal number (301-
306), followed by the number of sequences obtained for the allele.  
 Theileria velifera clone H22d (JN572702.1)
 Theileria velifera clone A4d (JN572703.1)
 KNP BuffaloSC04 34
 Theileria velifera clone BovKZNd (JN572705.1)
 KNP Buffalo SC03 67
 KNP Buffalo SC01 52
 KNP Buffalo SC06 43
 KNP Buffalo SC05 222
T. velifera
 KNP Buffalo SC01 36
 KNP Buffalo SC06 108
 Theileria cf. velifera clone H4a (JN572701.1)
 Theileria cf. velifera B  (GU733376.1)
 KNP Buffalo SC03 15.
 KNP Buffalo SC05 103
 Theileria cf. velifera clone Q15a (JN572704.1)
T. velifera like 1
 KNP Buffalo SC01 12
 KNP Buffalo SC06 52
 KNP Buffalo SC03 15
 KNP Buffalo SC01 16
 KNP Buffalo SC06 9
T. velifera like 2
 KNP Buffalo SC04 5
 KNP Buffalo SC04 8
 KNP Buffalo SC05 28
 Ol Pejeta Buffalo 305 173
 Ol Pejeta Buffalo 306 11
 Ol Pejeta Buffalo307 42
 Ol Pejeta Buffalo308 37
 Ol Pejeta Buffalo 301 465
 Ol Pejeta Buffalo 302 111
 Ol Pejeta Buffalo303 134
 Ol Pejeta Buffalo 304 99
T.velifera like Ol Pejeta
 P.micans (M14649)
 T.gondii (X68523)































































Figure 3 Phylogenetic tree showing the relationship between T. mutans-like 18S 
rRNA sequence variants 
The phylogenetic relationship was inferred using the Maximum Parsimony method. 
The bootstrap consensus tree inferred from 1000 replicates is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test is 
shown next to the branches. The tree was rooted using rRNA gene sequences for 
Prororectum micans (M14649), Sarcocystic muris (M64244), T. gondii (X68523) T. 
parva (HQ684067.1), T.velifera (JN572703.1) and T. mutans (AF078815.1). Samples 
from African buffalo from the Kruger National Park are labelled KNP Buffalo, 
followed by the animal number (SC01-SC06) and the number of reads obtained for 
the allele. Samples from African buffalo from the Ol Pejeta conservancy are labelled 
Ol Pejeta Buffalo, followed by the animal number (301-308) and the number of reads 
obtained for the allele. 
 Theileria sp (JN572700.1)
 Ol Pejeta Buffalo 305 8
 Ol Pejeta Buffalo 304 5
T. mutans like X 
 Theileria cf. mutans 2 (JN572696.1)
 KNP Buffalo SC04 9
 KNP Buffalo SC06 14
 Theileria mutans like 2 (FJ213586.1)
T. mutans like 2 
 KNP Buffalo SC02 .5
 KNP Buffalo SC03 6
 KNP Buffalo SC06 32
 Theileria mutans-like 1 (FJ213585.1)
 KNP Buffalo SC05 36
 KNP Buffalo SC01 22
T. mutans like 1 
 Theileria cf mutans 3 (JN572694.1)
 KNP Buffalo SC05 25
 KNP Buffalo SC06 5
 KNP Buffalo SC04 8
 KNP Buffalo SC03 7
 KNP Buffalo SC01 7
 KNP Buffalo SC05 30
 KNP Buffalo SC06 11
 KNPBuffalo SC02 5
T. mutans like 3 
 Theileria mutans (AF078815.1)
 KNP Buffalo SC01 5
T. mutans
 Theileria parva KNP102 (HQ684067.1)
 Theileria velifera clone A4d  (JN572703.1)
 P.micans (M14649)





























12BAppendix F  
DNA of cloned T. parva infected cell lines used for PCR 
Sample Name  Species of 
isolation 
Animal Id Source Chapter 
Marula N33  Clone 1 Bovine N33 ILRI 3 
Marula N33  Clone 3 Bovine N33 ILRI 3 
Marula N33  Clone 4 Bovine N33 ILRI 3 
Marula N33  Clone 5 Bovine N33 ILRI 3 
Marula N43  Clone 1 Bovine N43 ILRI 3 
Marula N43  Clone 3 Bovine N43 ILRI 3 
Marula N43  Clone 5 Bovine N43 ILRI 3 
Marula N43  Clone 6 Bovine N43 ILRI 3 
Mara 3          Clone 3 Buffalo Mara 3 ILRI 3 
Mara 3 Clone 6 Buffalo Mara 3 ILRI 3, 6 
Mara 3 Clone 7 Buffalo Mara 3 ILRI 3 
Mara 3 Clone 9 Buffalo Mara 3 ILRI 3 
Mara 30 Clone 2 Buffalo Mara 30 ILRI 3 
Mara 30 Clone 5 Buffalo Mara 30 ILRI 3,6 
Mara 30 Clone 8 Buffalo Mara 30 ILRI 3, 6 
Mara 30 Clone 11 Buffalo Mara 30 ILRI 3,6 
Mara 42 Clone 2 Buffalo Mara 42 ILRI 3,6 
Mara 42 Clone 5 Buffalo Mara 42 ILRI 3,6 
Mara 42 Clone 8 Buffalo Mara 42 ILRI 3 
Mara 42 Clone 12 Buffalo Mara 42 ILRI 3 
Mara 6998 Clone 9 Buffalo Mara 6998 ILRI 3,6 
Mara 6998 Clone 11  Buffalo Mara 6998 ILRI 3 
Marikebuni Clone A3 Bovine 592 UoE 3, 6 
Marikebuni Clone A7 Bovine 592 UoE 3, 6 
Marikebuni Clone B12 Bovine 592 UoE 3, 6 
Marikebuni Clone E43 Bovine 592 UoE 3, 6 
Marikebuni Clone F31 Bovine 592 UoE 3, 6 
Marikebuni Clone F44 Bovine 592 UoE 3, 6 
Marikebuni Clone F53 Bovine 592 UoE 3, 6 
Marikebuni Clone I8 Bovine 592 UoE 3, 6 
Marikebuni Clone I38 Bovine 592 UoE 3, 6 
Marikebuni Clone J17 Bovine 592 UoE 3, 6 
 XXXI
DNA from blood samples of African buffalo (Syncerus caffer) used for 
PCR 
Animal ID Location  Source Chapter 
SC01 Kruger National Park, South 
f
Pirbright 5,7 
SC02 Kruger National Park, South 
Af i
Pirbright 5,7 
SC03 Kruger National Park, South 
Af i
Pirbright 5,7 
SC04 Kruger National Park, South 
Af i
Pirbright 5,7 
SC05 Kruger National Park, South 
Af i
Pirbright 5,7 
SC06 Kruger National Park, South 
Af i
Pirbright 3,5,7 
301 Ol Pejeta Conservancy, Kenya ILRI 5,7 
302 Ol Pejeta Conservancy, Kenya ILRI 5,7 
303 Ol Pejeta Conservancy, Kenya ILRI 5,7 
304 Ol Pejeta Conservancy, Kenya ILRI 5,7 
305 Ol Pejeta Conservancy, Kenya ILRI 5,7 
306 Ol Pejeta Conservancy, Kenya ILRI 5,7 
307 Ol Pejeta Conservancy, Kenya ILRI 5,7 
308 Ol Pejeta Conservancy, Kenya ILRI 5,7 
DNA from lymphnode samples of sentinel cattle after field exposure 
used for PCR  
Animal ID Location  Source Chapter 
023 Ol Pejeta Conservancy, Kenya ILRI 7 
025 Ol Pejeta Conservancy, Kenya ILRI 7 
027 Ol Pejeta Conservancy, Kenya ILRI 7 
028 Ol Pejeta Conservancy, Kenya ILRI 7 
032 Ol Pejeta Conservancy, Kenya ILRI 7 
033 Ol Pejeta Conservancy, Kenya ILRI 7 
034 Ol Pejeta Conservancy, Kenya ILRI 7 
035 Ol Pejeta Conservancy, Kenya ILRI 7 
036 Ol Pejeta Conservancy, Kenya ILRI 7 
 XXXII
DNA from sporozoite stabilates used for molecular biology 
Stabilate name Stabilate 
number 
Source Chapter 
Muguga  4230 ILRI 4 
Muguga N57 CTTBD 4
Serengeti transformed 4229 ILRI 4 
Kiambu 5 4228 ILRI 3,4 
ECF MC ILRI 0801 ILRI 4 
ECF MC ILRI 0802 ILRI 4 
ECF MC ILRI 0803 ILRI 4 
ECF MC ILRI 0804 ILRI 4 
Marikebuni 3014 RVC 
( ILRAD) 
4 
Marikebuni 128 UoE 4
Katete  KL4 CTTBD 4 
Chitongo  CL20 CTTBD 4 
Marikani  3231 clone 2/3 ILRI 7 
Boleni 3230 clone 1/1 ILRI 7 
Uganda 3645 clone 1/2 ILRI 7 
Buffalo-derived T. parva 3081 ILRI 6, 7 
Buffalo-derived T. parva 4110 ILRI 6, 7 
 XXXIII 
Other DNA’s used for PCR 
Genus and 
species 
Location or name Country Species of 
isolation
Material Source Chapter
T. buffeli Marula Kenya Buffalo blood ILRI 3
T. taurotragi - Kenya Bovine In vitro culture ILRI 3 
T. sp (Buffalo) Buffalo 6834 clone 3 Kenya Buffalo  In vitro culture  ILRI 3 
T. annulata Ankara C9 Turkey Bovine In vitro culture UoE 3 
R. appendiculatus Muguga Kenya Tick tick ILRI 3
Bos indicus ILRI Kenya Bovine PBMC ILRI 3
Bos taurus Edinburgh UK Bovine PBMC UoE 3
Animals used for in vivo experiment 
Animal 
number  
Breed  Sex  Age MHC Source Chapter 
BG040 Friesian/Ayshire M 1 year A10/.. ILRI 6 
BG041 Friesian M 7 months A10/.. ILRI 6 
BG044 Friesian M 9 months A10/.. ILRI 6 
BF080 Ayshire M 2.3 years A10/.. ILRI 6 
BF083 Friesian M 2.5 years A10/.. ILRI 6 
BF085 Ayshire M 2.5 years A10/.. ILRI 6 
BF086 Friesian  M 2.5 years A10/.. ILRI 6 
 XXXIV 
In vitro established T. parva infected cell lines used for immunological assays 
Sample name  Animal 
ID 
MHC I  
haplotype 
Used for  Source Chapter 
011 Muguga 011 A10/A10 Cytotoxicity assay  UoE 6
641 Muguga 641 A18/A18 Cytotoxicity assay  UoE 6 
Marikebuni clone B12 592 A10/A10 Cytotoxicity assay UoE 6 
Marikebuni clone F53 592 A10/A10 Cytotoxicity assay UoE 6 






























Aanensen, D.M., and Spratt, B.G. (2005). The multilocus sequence typing network: 
mlst.net. Nucleic acids research 33, W728-733. 
Aguado-Martinez, A., MacHugh, N., and Morrison, I. (2012). Identification of a 
parasite antigen recognised by both CD4 and CD8 T cells specific for lymphoblasts 
infected with Theileria parva. Immunology 137, 626-627 Abstract P1420. 
Allsopp, B.A., Baylis, H.A., Allsopp, M.T., Cavalier-Smith, T., Bishop, R.P., 
Carrington, D.M., Sohanpal, B., and Spooner, P. (1993). Discrimination between six 
species of Theileria using oligonucleotide probes which detect small subunit 
ribosomal RNA sequences. Parasitology 107 ( Pt 2), 157-165. 
Allsopp, M.T., Theron, J., Coetzee, M.L., Dunsterville, M.T., and Allsopp, B.A. 
(1999). The occurrence of Theileria and Cowdria parasites in African buffalo 
(Syncerus caffer) and their associated Amblyomma hebraeum ticks. The 
Onderstepoort journal of veterinary research 66, 245-249. 
Anderson, K., Ezenwa, V.E., and Jolles, A.O. (2013). Tick infestation patterns in free 
ranging African buffalo (Syncerus caffer): Effects of host innate immunity and nice 
segregration among tick species. International Journal for Parasitology: Parasites and 
wildlife 2, 1-9. 
Anonymous (1981). The eradication of East Coast fever in South Africa. Journal of 
the South African Veterinary Association 52, 71-73. 
Anonymous (1988). Nomenclature. In Theileriosis in Eastern, Central and Southern 
Africa, T.T. Dolan, ed. (Lilongwe, Malawi, The International Laboratory for research 
on animal diseases), pp. 182-186. 
Anonymous (2002). Disease risk management directive for buffalo (Syncerus caffer) 
in South Africa. ( 2002/09/19). 
Asiimwe, B.B., Weir, W., Tait, A., Lubega, G.W., and Oura, C.A. (2013). 
Haemoparasite infection kinetics and the population structure of Theileria parva on a 
single farm in Uganda. Veterinary parasitology 193, 8-14. 
 XXXVI
Baldwin, C.L., Goddeeris, B.M., and Morrison, W.I. (1987). Bovine helper T-cell 
clones specific for lymphocytes infected with Theileria parva (Muguga). Parasite 
immunology 9, 499-513. 
Baldwin, C.L., Black, S.J., Brown, W.C., Conrad, P.A., Goddeeris, B.M., Kinuthia, 
S.W., Lalor, P.A., MacHugh, N.D., Morrison, W.I., Morzaria, S.P., and et al. (1988). 
Bovine T cells, B cells, and null cells are transformed by the protozoan parasite 
Theileria parva. Infection and immunity  56, 462-467. 
Bishop, R.P., Sohanpal, B.K., Allsopp, B.A., Spooner, P.R., Dolan, T.T., and 
Morzaria, S.P. (1993). Detection of polymorphisms among Theileria parva stocks 
using repetitive, telomeric and ribosomal DNA probes and anti-schizont monoclonal 
antibodies. Parasitology 107 ( Pt 1), 19-31. 
Bishop, R.P., Spooner, P.R., Kanhai, G.K., Kiarie, J., Latif, A.A., Hove, T., Masaka, 
S., and Dolan, T.T. (1994). Molecular characterization of Theileria parasites: 
application to the epidemiology of theileriosis in Zimbabwe. Parasitology 109 ( Pt 5), 
573-581. 
Bishop, R., Geysen, D., Spooner, P., Skilton, R., Nene, V., Dolan, T., and Morzaria, 
S. (2001). Molecular and immunological characterisation of Theileria parva stocks 
which are components of the 'Muguga cocktail' used for vaccination against East 
Coast fever in cattle. Veterinary parasitology 94, 227-237. 
Bishop, R., Nene, V., Staeyert, J., Rowlands, J., Nyanjui, J., Osaso, J., Morzaria, S., 
and Musoke, A. (2003). Immunity to East Coast fever in cattle induced by a 
polypeptide fragment of the major surface coat protein of Theileria parva sporozoites. 
Vaccine 21, 1205-1212. 
Blouin, E.F., and Stoltsz, W.H. (1989). Comparative infection rates of Theileria parva 
lawrencei in salivary glands of Rhipicephalus appendiculatus and Rhipicephalus 
zambeziensis. The Onderstepoort journal of veterinary research 56, 211-213. 
Boers, S.A., van der Reijden, W.A., and Jansen, R. (2012). High-throughput 






Caron, A., Miguel, E., Gomo, C., Makaya, P., Pfukenyi, D.M., Foggin, C., Hove, T., 
and de Garine-Wichatitsky, M. (2013). Relationship between burden of infection in 
ungulate populations and wildlife/livestock interfaces. Epidemiology and infection  
141, 1522-1535. 
Chae, J.S., Allsopp, B.A., Waghela, S.D., Park, J.H., Kakuda, T., Sugimoto, C., 
Allsopp, M.T., Wagner, G.G., and Holman, P.J. (1999). A study of the systematics of 
Theileria spp. based upon small-subunit ribosomal RNA gene sequences. Parasitology 
research 85, 877-883. 
Chaisi, M.E., Sibeko, K.P., Collins, N.E., Potgieter, F.T., and Oosthuizen, M.C. 
(2011). Identification of Theileria parva and Theileria sp. (buffalo) 18S rRNA gene 
sequence variants in the African Buffalo (Syncerus caffer) in southern Africa. 
Veterinary parasitology 182, 150-162. 
Chaisi, M.E., Collins, N.E., Potgieter, F.T., and Oosthuizen, M.C. (2013). Sequence 
variation identified in the 18S rRNA gene of Theileria mutans and Theileria velifera 
from the African buffalo (Syncerus caffer). Veterinary parasitology 191, 132-137. 
Codner, G.F., Birch, J., Hammond, J.A., and Ellis, S.A. (2012). Constraints on 
haplotype structure and variable gene frequencies suggest a functional hierarchy 
within cattle MHC class I. Immunogenetics 64, 435-445. 
Cole, G.A., Hogg, T.L., Coppola, M.A., and Woodland, D.L. (1997). Efficient 
priming of CD8+ memory T cells specific for a subdominant epitope following 
Sendai virus infection. Journal of immunology 158, 4301-4309. 
Connelley, T.K., MacHugh, N.D., Pelle, R., Weir, W., and Morrison, W.I. (2011). 
Escape from CD8+ T cell response by natural variants of an immunodominant epitope 
from Theileria parva is predominantly due to loss of TCR recognition. Journal of 
immunology 187, 5910-5920. 
Conrad, P.A., Iams, K., Brown, W.C., Sohanpal, B., and ole-MoiYoi, O.K. (1987a). 
DNA probes detect genomic diversity in Theileria parva stocks. Molecular and 
biochemical parasitology 25, 213-226. 
 
 XXXVIII
Conrad, P.A., ole-MoiYoi, O.K., Baldwin, C.L., Dolan, T.T., O'Callaghan, C.J., 
Njamunggeh, R.E., Grootenhuis, J.G., Stagg, D.A., Leitch, B.L., and Young, A.S. 
(1989). Characterization of buffalo-derived theilerial parasites with monoclonal 
antibodies and DNA probes. Parasitology 98 Pt 2, 179-188. 
Conrad, P.A., Stagg, D.A., Grootenhuis, J.G., Irvin, A.D., Newson, J., Njamunggeh, 
R.E., Rossiter, P.B., and Young, A.S. (1987b). Isolation of Theileria parasites from 
African buffalo (Syncerus caffer) and characterization with anti-schizont monoclonal 
antibodies. Parasitology 94 ( Pt 3), 413-423. 
Cunningham, M.P., Brown, C.G.D., Burridge, M.J., Musoke, A.J., Purnell, R.E., 
Radley, D.E., and Sempebwa, C. (1974). East Coast Fever - Titration in cattle of 
suspensions of Theileria parva derived from ticks. British Veterinary Journal 130, 
336-345. 
Day, E.B., Charlton, K.L., La Gruta, N.L., Doherty, P.C., and Turner, S.J. (2011). 
Effect of MHC class I diversification on influenza epitope-specific CD8+ T cell 
precursor frequency and subsequent effector function. Journal of immunology 186, 
6319-6328. 
De Deken, R., Martin, V., Saido, A., Madder, M., Brandt, J., and Geysen, D. (2007). 
An outbreak of East Coast Fever on the Comoros: a consequence of the import of 
immunised cattle from Tanzania? Veterinary parasitology 143, 245-253. 
Delport, W., Poon, A.F., Frost, S.D., and Kosakovsky Pond, S.L. (2010). Datamonkey 
2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 
26, 2455-2457. 
Di Giulio, G., Lynen, G., Morzaria, S., Oura, C., and Bishop, R. (2009). Live 
immunization against East Coast fever- current status. Trends in parasitology 25, 85-
92. 
Dolan, T.T. (1984). Immunization against Theileriosis on Ol Pejeta ranch, laikipia 
Kenya. In Immunization against theileriosis in Africa (Nairobi, Kenya). 
Dolan, T.T. (1989). Theileriosis in Eastern, Central and Southern Africa, proceedings 
of a workshop on East Coast fever immunization held in Lilongwe, Malawi 20-22 
September 1988 (Nairoby, Kenya: The International Laboratory for Research on 
Animal Diseases). 
 XXXIX
Edgar, R.C. (2004). MUSCLE: multiple sequence alignment with high accuracy and 
high throughput. Nucleic acids research 32, 1792-1797. 
Edgar, R.C., Haas, B.J., Clemente, J.C., Quince, C., and Knight, R. (2011). UCHIME 
improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194-2200. 
Fawcett, D., Musoke, A., and Voigt, W. (1984). Interaction of sporozoites of Theileria 
parva with bovine lymphocytes in vitro. I. Early events after invasion. Tissue Cell 16, 
873-884. 
Fawcett, D.W., Buscher, G., and Doxsey, S. (1982a). Salivary gland of the tick vector 
of East Coast fever. III. The ultrastructure of sporogony in Theileria parva. Tissue 
Cell 14, 183-206. 
Fawcett, D.W., Doxsey, S., Stagg, D.A., and Young, A.S. (1982b). The entry of 
sporozoites of Theileria parva into bovine lymphocytes in vitro. Electron microscopic 
observations. European journal of cell biology 27, 10-21. 
Fyumagwa, R.D., Simmler, P., Meli, M.L., Hoare, R., Hofmann-Lehmann, R., and 
Lutz, H. (2011). Molecular detection of Anaplasma, Babesia and Theileria species in 
a diversity of tick species from Ngorongoro Crater, Tanzania. South African journal 
of wildlife research 41, 79-86. 
Galea, I., Stasakova, J., Dunscombe, M.S., Ottensmeier, C.H., Elliott, T., and 
Thirdborough, S.M. (2012). CD8+ T-cell cross-competition is governed by peptide-
MHC class I stability. European journal of immunology  42, 256-263. 
Gardner, M.J., Bishop, R., Shah, T., de Villiers, E.P., Carlton, J.M., Hall, N., Ren, Q., 
Paulsen, I.T., Pain, A., Berriman, M., et al. (2005). Genome sequence of Theileria 
parva, a bovine pathogen that transforms lymphocytes. Science 309, 134-137. 
Gauer, M., Mackenstedt, U., Mehlhorn, H., Schein, E., Zapf, F., Njenga, E., Young, 
A., and Morzaria, S. (1995). DNA measurements and ploidy determination of 
developmental stages in the life cycles of Theileria annulata and T. parva. 
Parasitology research 81, 565-574. 
 XL
Gentschev, I., Glaser, I., Goebel, W., McKeever, D.J., Musoke, A., and Heussler, V.T. 
(1998). Delivery of the p67 sporozoite antigen of Theileria parva by using 
recombinant Salmonella dublin: secretion of the product enhances specific antibody 
responses in cattle. Infection and immunity  66, 2060-2064. 
Geysen, D. (2000). The application of Molecular Biology techniques to analyse 
diversity in Theileria parva populations in Zambia. In Department of Biology and 
Biochemistry (London, Brunel University). 
Geysen, D. (2008). Live immunisation against Theileria parva: spreading the disease? 
Trends in parasitology 24, 245-246. 
Geysen, D., Bishop, R., Skilton, R., Dolan, T.T., and Morzaria, S. (1999). Molecular 
epidemiology of Theileria parva in the field. Tropical medicine and international 
health 4, A21-27. 
Gilles, A., Meglecz, E., Pech, N., Ferreira, S., Malausa, T., and Martin, J.F. (2011). 
Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC 
genomics 12, 245. 
Giulio, G.D., Lynen, G., Morzaria, S., Oura, C., and Bishop, R. (2009). Live 
immunization against East Coast fever- current status. Trends in parasitology 25, 85-
92. 
Goddeeris, B.M., Katende, J.M., Irvin, A.D., and Chumo, R.S. (1982). Indirect 
fluorescent antibody test for experimental and epizootiological studies on East coast 
fever (Theileria parva infection in cattle). Evaluation of a cell culture schizont antigen 
fixed and stored in suspension. Research in veterinary science 33, 360-365. 
Goddeeris, B.M., and Morrison, W.I. (1988). Techniques for the generation, cloning 
and characterization of bovine cytotoxic T cells specific for the protozoan Theileria 
parva. Journal of Tissue Culture Methods 11, 101-110. 
Graham, S.P., Honda, Y., Pelle, R., Mwangi, D.M., Glew, E.J., de Villiers, E.P., Shah, 
T., Bishop, R., van der Bruggen, P., Nene, V., and Taracha, E.L. (2007a). A novel 
strategy for the identification of antigens that are recognised by bovine MHC class I 
restricted cytotoxic T cells in a protozoan infection using reverse vaccinology. 





Graham, S.P., Pellé, R., Honda, Y., Mwangi, D.M., Tonukari, N.J., Yamage, M., 
Glew, E.J., Villiers, E.P.d., Shah, T., Bishop, R., et al. (2006). Theileria parva 
candidate vaccine antigens recognized by immune bovine cytotoxic T Lymphocytes. 
Proceedings of the National Academy of Sciences of the United States of America 
103, 3286-3291. 
Graham, S.P., Pelle, R., Yamage, M., Mwangi, D.M., Honda, Y., Mwakubambanya, 
R.S., de Villiers, E.P., Abuya, E., Awino, E., Gachanja, J., et al. (2008). 
Characterization of the fine specificity of bovine CD8 T-cell responses to defined 
antigens from the protozoan parasite Theileria parva. Infection and immunity  76, 
685-694. 
Graham, S.P., Saya, R., Awino, E., Ngugi, D., Nyanjui, J.K., Hecker, R., Taracha, 
E.L., and Nene, V. (2007b). Immunostimulatory CpG oligodeoxynucleotides enhance 
the induction of bovine CD4+ cytotoxic T-lymphocyte responses against the 
polymorphic immunodominant molecule of the protozoan parasite Theileria parva. 
Veterinary immunology and immunopathology 115, 383-389. 
Grootenhuis, J.G., Leitch, B.L., Stagg, D.A., Dolan, T.T., and Young, A.S. (1987). 
Experimental induction of Theileria parva lawrencei carrier state in an African 
buffalo (Syncerus caffer). Parasitology 94 ( Pt 3), 425-431. 
Gubbels, J.M., de Vos, A.P., van der Weide, M., Viseras, J., Schouls, L.M., de Vries, 
E., and Jongejan, F. (1999). Simultaneous detection of bovine Theileria and Babesia 
species by reverse line blot hybridization. Journal of clinical microbiology 37, 1782-
1789. 
Hammond, J.A., Marsh, S.G., Robinson, J., Davies, C.J., Stear, M.J., and Ellis, S.A. 
(2012). Cattle MHC nomenclature: is it possible to assign sequences to discrete class I 
genes? Immunogenetics 64, 475-480. 
Haas, B.J., Gevers, D., Earl, A.M., Feldgarden, M., Ward, D.V., Giannoukos, G., 
Ciulla, D., Tabbaa, D., Highlander, S.K., Sodergren, E., et al. (2011). Chimeric 16S 
rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR 
amplicons. Genome research 21, 494-504. 
 
 XLII
Hayashida, K., Abe, T., Weir, W., Nakao, R., Ito, K., Kajino, K., Suzuki, Y., 
Jongejan, F., Geysen, D., and Sugimoto, C. (2013). Whole-genome sequencing of 
Theileria parva strains provides insight into parasite migration and diversification in 
the African continent. DNA research 20, 209-220. 
Hayashida, K., Hara, Y., Abe, T., Yamasaki, C., Toyoda, A., Kosuge, T., Suzuki, Y., 
Sato, Y., Kawashima, S., Katayama, T., et al. (2012). Comparative Genome Analysis 
of Three Eukaryotic Parasites with Differing Abilities To Transform Leukocytes 
Reveals Key Mediators of Theileria-Induced Leukocyte Transformation. Mbio 3, (5) 
e00204-12. 
Henson, S., Bishop, R.P., Morzaria, S., Spooner, P.R., Pelle, R., Poveda, L., Ebeling, 
M., Kung, E., Certa, U., Daubenberger, C.A., and Qi, W. (2012). High-resolution 
genotyping and mapping of recombination and gene conversion in the protozoan 
Theileria parva using whole genome sequencing. BMC genomics 13, 503. 
Horak, I.G., Golezardy, H., and Uys, A.C. (2007). Ticks associated with the three 
largest wild ruminant species in southern Africa. The Onderstepoort journal of 
veterinary research 74, 231-242. 
Hove, T., Musisi, F.L., Kanhai, G.K., Latif, A., Masaka, S., Munatswa, F.C., Pegram, 
R.G., Kamwendo, S.P., Quiroga, J.C., Mwangondwe, R., and et al. (1995). Challenge 
of Theileria parva (Boleni) immunised cattle with selected east African Theileria 
stocks. Tropical animal health and production 27, 202-210. 
Huse, S.M., Welch, D.M., Morrison, H.G., and Sogin, M.L. (2010). Ironing out the 
wrinkles in the rare biosphere through improved OTU clustering. Environmental 
microbiology 12, 1889-1898. 
Illumina (2012). An introduction to Next-generation sequencing technology.  
(www.ilumina.com/NGS).  
ILRAD (1989). Theileriosis in Eastern, Central and Southern Africa: Proceedings of a 
Workshop on East Coast Fever Immunization held in Lilongwe, Malawi20-22 





Irvin, A.D., Brown, C.G., Burridge, M.J., Cunningham, M.P., Musoke, A.J., Pierce, 
M.A., Purnell, R.E., and Radley, D.E. (1972). A pathogenic theilerial syndrome of 
cattle in the Narok District of Kenya. I: Transmission studies. Tropical animal health 
and production 4, 220-229. 
Jongejan, F., and Uilenberg, G. (2004). The global importance of ticks. Parasitology 
129, S3-14 
Jongejan, F., Nene, V., de la Fuente, J., Pain, A., and Willadsen, P. (2007). Advances 
in the genomics of ticks and tick-borne pathogens. Trends in parasitology 23, 391-
396. 
Kaba, S.A., Schaap, D., Roode, E.C., Nene, V., Musoke, A.J., Vlak, J.M., and van 
Oers, M.M. (2004). Improved immunogenicity of novel baculovirus-derived Theileria 
parva p67 subunit antigens. Veterinary parasitology 121, 53-64. 
Kariuki, D., Young, A., Morzaria, S., Lesan, A., Mining, S., Omwoyo, P., Wafula, J., 
and Molyneux, D. (1995). Theileria parva carrier state in naturally infected and 
artificially immunised cattle. Tropical animal health and production 27, 15-25. 
Kariuki, E.K., Penzhorn, B.L., and Horak, I.G. (2012). Ticks (Acari: Ixodidae) 
infesting cattle and African buffaloes in the Tsavo conservation area, Kenya. The 
Onderstepoort journal of veterinary research 79. 
Kastenmuller, W., Gasteiger, G., Gronau, J.H., Baier, R., Ljapoci, R., Busch, D.H., 
and Drexler, I. (2007). Cross-competition of CD8+ T cells shapes the 
immunodominance hierarchy during boost vaccination. Journal of experimental 
medicine 204, 2187-2198. 
Katende, J., Morzaria, S., Toye, P., Skilton, R., Nene, V., Nkonge, C., and Musoke, 
A. (1998). An enzyme-linked immunosorbent assay for detection of Theileria parva 
antibodies in cattle using a recombinant polymorphic immunodominant molecule. 
Parasitology research 84, 408-416. 
Katzer, F., Ngugi, D., Oura, C., Bishop, R.P., Taracha, E.L., Walker, A.R., and 
McKeever, D.J. (2006). Extensive genotypic diversity in a recombining population of 
the apicomplexan parasite Theileria parva. Infection and immunity  74, 5456-5464. 
 XLIV
Katzer, F., Ngugi, D., Schnier, C., Walker, A.R., and McKeever, D.J. (2007). 
Influence of host immunity on parasite diversity in Theileria parva. Infection and 
immunity  75, 4909-4916. 
Katzer, F., Ngugi, D., Walker, A.R., and McKeever, D.J. (2010). Genotypic diversity, 
a survival strategy for the apicomplexan parasite Theileria parva. Veterinary 
parasitology 167, 236-243. 
Katzer, F., Lizundia, R., Ngugi, D., Blake, D., and McKeever, D. (2011). 
Construction of a genetic map for Theileria parva: Identification of hotspots of 
recombination. International journal for parasitology 41, 669-675. 
Kimbita, E.N., and Silayo, R.S. (1997). Use of an in vitro infectivity assay in 
comparison with histological techniques in the study of Theileria parva sporozoite 
maturation. Veterinary parasitology 70, 83-97. 
Kircher, M., and Kelso, J. (2010). High-throughput DNA sequencing- concepts and 
limitations. BioEssays : news and reviews in molecular, cellular and developmental 
biology 32, 524-536.  
Latif, A.A., Hove, T., Kanhai, G.K., and Masaka, S. (2001). Exposure of cattle 
immunized with different stocks of Theileria parva to buffalo-associated Theileria 
challenge on two game parks in Zimbabwe. The Onderstepoort journal of veterinary 
research 68, 197-201. 
Latif, and Jongejan, F. (2002). The wide-use of acaricide control of livestock diseases 
in Africa needs a re-appraisal. In Newsletter intergrated control pathogen 
trypanosomasis vectors. 
Latif, A.A., and Hove, T. (2011). History and critical review of Theileria parva 
(Boleni), the vaccine stock against Zimbabwean cattle theileriosis. Ticks and tick-
borne diseases 2, 163-167. 
Lawrence, J.A. (1977). The serological relationship between Theileria parva 
(Muguga) and Theileria lawrence from Rhodesia. The Veterinary record 100, 470-
471. 
Lawrence, J.A. (1979). The differential diagnosis of the bovine theilerias of Southern 





Lawrence, J.A., Norval, R.A., and Uilenberg, G. (1983). Rhipicephalus zambeziensis 
as a vector of bovine Theileriae. Tropical animal health and production 15, 39-42. 
Liu, L., Li, Y., Li, S., Hu, N., He, Y., Pong, R., Lin, D., Lu, L., and Law, M. (2012). 
Comparison of next-generation sequencing systems. Journal of biomedicine & 
biotechnology 2012, 251364. 
Lohre (1978). In Tick-borne diseases and their vectors, J.H. Wilde, ed. (Univeristy of 
Edinburgh). 
Luciani, F., Sanders, M.T., Oveissi, S., Pang, K.C., and Chen, W. (2013). Increasing 
viral dose causes a reversal in CD8+ T cell immunodominance during primary 
influenza infection due to differences in antigen presentation, T cell avidity, and 
precursor numbers. Journal of immunology 190, 36-47. 
Lynen, G., Makala, L.H.C., and Pas, W.M., (1991) East Coast fever immunization in 
Eastern Province, Zambia. In Ticks and Tick-Borne Disease Control (ed. T. T. Dolan) 
Proceedings of a Joint OAU, FAO and ILRAD Workshop held in Kampala, Uganda, 
12–14 September 1991.(ILRAD, Nairobi, Kenya) , pp. 16–21. 
Lynen, G., Zeman, P., Bakuname, C., Di Giulio, G., Mtui, P., Sanka, P., and Jongejan, 
F. (2007). Cattle ticks of the genera Rhipicephalus and Amblyomma of economic 
importance in Tanzania: distribution assessed with GIS based on an extensive field 
survey. Experimental & applied acarology 43, 303-319. 
Macdonald, I.K., Harkiolaki, M., Hunt, L., Connelley, T., Carroll, A.V., MacHugh, 
N.D., Graham, S.P., Jones, E.Y., Morrison, W.I., Flower, D.R., and Ellis, S.A. (2010). 
MHC class I bound to an immunodominant Theileria parva epitope demonstrates 
unconventional presentation to T cell receptors. PLoS pathogens 6, e1001149. 
MacHugh, N.D., Connelley, T., Graham, S.P., Pelle, R., Formisano, P., Taracha, E.L., 
Ellis, S.A., McKeever, D.J., Burrells, A., and Morisson, W.I. (2009). CD8+ T-cell 
responses to Theileria parva are preferentially directed to a single dominant antigen: 
Implications for parasite strain-specific immunity. European  journal of immunology  
39, 2459-2469. 
 XLVI
Mans, B.J., Pienaar, R., Latif, A.A., and Potgieter, F.T. (2011a). Diversity in the 18S 
SSU rRNA V4 hyper-variable region of Theileria spp. in Cape buffalo ( Syncerus 
caffer) and cattle from southern Africa. Parasitology 38, 766-779. 
Mans, B.J., Pienaar, R., Potgieter, F.T., and Latif, A.A. (2011b). Theileria parva, T. 
sp. (buffalo) and T. sp. (bougasvlei) 18S variants. Veterinary parasitology 182, 382-
383. 
Marcotty, T., Billiouw, M., Chaka, G., Berkvens, D., Losson, B., and Brandt, J. 
(2001). Immunisation against East Coast fever by the infection and treatment method: 
evaluation of the use of ice baths for field delivery and appraisal of an acid 
formulation of long-acting tetracycline. Veterinary parasitology 99, 175-187. 
Margulies, M., Egholm, M., Altman, W.E., Attiya, S., Bader, J.S., Bemben, L.A., 
Berka, J., Braverman, M.S., Chen, Y.J., Chen, Z., et al. (2005). Genome sequencing 
in microfabricated high-density picolitre reactors. Nature 437, 376-380. 
Martins, S.B., Di Giulio, G., Lynen, G., Peters, A., and Rushton, J. (2010). Assessing 
the impact of East Coast Fever immunisation by the infection and treatment method in 
Tanzanian pastoralist systems. Preventive veterinary medicine 97, 175-182. 
Mbao, V., Berkvens, D., Dorny, P., Van den Bossche, P., and Marcotty, T. (2007). 
Comparison of the survival on ice of thawed Theileria parva sporozoites of different 
stocks cryoprotected by glycerol or sucrose. The Onderstepoort journal of veterinary 
research 74, 9-15. 
Mbizeni, S., Potgieter, F.T., Troskie, C., Mans, B.J., Penzhorn, B.L., and Latif, A.A. 
(2013). Field and laboratory studies on Corridor disease (Theileria parva infection) in 
cattle population at the livestock/game interface of uPhongolo-Mkuze area, South 
Africa. Ticks and tick-borne diseases 4, 227-234. 
McKeever, D.J., Taracha, E.L.N., Innes, E.L., MacHugh, N.D., Awinl, E., Goddeeris, 
B.M., and Morrison, W.I. (1994). Adoptive transfer of immunity to Theileria parva 
int he CD8+ fraction of responding efferent lymph. Proceedings of the National 
Academy of Sciences of the United States of America 91, 1959-1963. 
McKeever, D.J., Taracha, E.L., Morrison, W.I., Musoke, A.J., and Morzaria, S.P. 
(1999). Protective immune mechanisms against Theileria parva: evolution of vaccine 
development strategies. Parasitology today 15, 263-267. 
 XLVII
Minjauw, B., and McLeod, A. (2003). Tick-borne diseases and poverty. The impact of 
ticks and tick-borne diseases on the livelihood of small-scale and marginal livestock 
owners in India and eastern and southern Africa. In Research report, DFID animal 
health programme, (Centre for Tropical veterinary medicine, university of Edinburgh, 
UK). 
Morrison, W.I., Buscher, G., Murray, M., Emery, D.L., Masake, R.A., Cook, R.H., 
and Wells, P.W. (1981). Theileria parva: kinetics of infection in the lymphoid system 
of cattle. Experimental parasitology 52, 248-260. 
Morrison, W.I., MacHugh, N.D., and Lalor, P.A. (1996). Pathogenicity of Theileria 
parva is influenced by the host cell type infected by the parasite. Infection and 
immunity  64, 557-562. 
Morrison, W.I., and McKeever, D.J. (2006). Current status of vaccine development 
against Theileria parasites. Parasitology 133, S169-187. 
Morzaria, S.P., Dolan, T.T., Norval, R.A., Bishop, R.P., and Spooner, P.R. (1995). 
Generation and characterization of cloned Theileria parva parasites. Parasitology 111 
( Pt 1), 39-49. 
Morzaria, S., and Williamson, S. (1999). Live Vaccines for Theileria parva: 
Deployment in Eastern, Central and Southern Africa. Proceedings of an FAO, OAU–
IBAR and ILRI Workshop held 12 March 1997 at ILRI, Nairobi, Kenya In –, S. 
Morzaria, and S. Williamson, eds. (ILRI (International Livestock Research Institute) 
Nairobi, Kenya). 
Mugisha, A., McLeod, A., Percy, R., and Kyewalabye, E. (2005). Strategies, 
effectiveness and rationale of vector-borne disease control in the pastoralist system of 
south-western Uganda. Tropical animal health and production 37, 479-489. 
Muleya, W., Namangala, B., Simuunza, M., Nakao, R., Inoue, N., Kimura, T., Ito, K., 
Sugimoto, C., and Sawa, H. (2012). Population genetic analysis and sub-structuring of 
Theileria parva in the northern and eastern parts of Zambia. Parasites & vectors 5, 
255. 
Muraguri, G.R., Kiara, H.K., and McHardy, N. (1999). Treatment of East Coast fever: 





Musisi, F.L., Quiroga, J.C., Kanhai, G.K., Kamwendo, S.P., Mzoma, F.J., and 
Njuguna, L.M. (1996). Theileria parva (Kasoba): isolation and challenge of cattle 
recovered from infection with other Theileria parva stocks. Revue d'elevage et de 
medecine veterinaire des pays tropicaux 49, 42-45. 
Musisi, F.L., and Dolan, T.T. ( 1999 ). Ticks and Tick-borne Disease Control in 
Eastern, Central and Southern Africa, 1991-1994. Proceedings of a Joint OAU, FAO 
and ILRAD Workshop held in Lilongwe, Malawi, 25-28 April 1994.  (ILRI ,Nairobi, 
Kenya), p. 150. 
Musoke, A., Morzaria, S., Nkonge, C., Jones, E., and Nene, V. (1992). A recombinant 
sporozoite surface antigen of Theileria parva induces protection in cattle. Proceedings 
of the National Academy of Sciences of the United States of America 89, 514-518. 
Musoke, A., Rowlands, J., Nene, V., Nyanjui, J., Katende, J., Spooner, P., Mwaura, 
S., Odongo, D., Nkonge, C., Mbogo, S., et al. (2005). Subunit vaccine based on the 
p67 major surface protein of Theileria parva sporozoites reduces severity of infection 
derived from field tick challenge. Vaccine 23, 3084-3095. 
Mutugi, J.J., Young, A.S., Maritim, A.C., Linyonyi, A., Mbogo, S.K., and Leitch, 
B.L. (1988a). Immunization of cattle using varying infective doses of Theileria parva 
lawrencei sporozoites derived from an African buffalo (Syncerus caffer) and treatment 
with buparvaquone. Parasitology 96 ( Pt 2), 391-402. 
Mutugi, J.J., Young, A.S., Maritim, A.C., Ndungu, S.G., Stagg, D.A., Grootenhuis, 
J.G., and Leitch, B.L. (1988b). Immunization of cattle against theileriosis using 
varying doses of Theileria parva lawrencei and T. parva parva sporozoites and 
oxytetracycline treatments. International journal for parasitology 18, 453-461. 
Mutugi, J.J., Ndungu, S.G., Lllnyonyi , A., Maritim, A.C., Mining, S.K., Ngumi, P.N. 
, Kariuki , D.P., Leitch, B.L. ,D'souza, D., Maloo, S. and  Lohr, K.F. (1991). 
Responses to a vaccine trial for East Coast fever in two cattle herds at the Kenyan 
coast. Preventive Veterinary Medicine 21, 215-235. 
Nambota, A., Samui, K., Sugimoto, C., Kakuta, T., and Onuma, M. (1994). 
Theileriosis in Zambia: etiology, epidemiology and control measures. Japanese 
journal of veterinary research 42, 1-18. 
 XLIX
Ndungu, S.G., Brown, C.G., and Dolan, T.T. (2005). In vivo comparison of 
susceptibility between Bos indicus and Bos taurus cattle types to Theileria parva 
infection. The Onderstepoort journal of veterinary research 72, 13-22. 
Ngumi, P.N., Young, A.S., Lampard, D., Mining, S.K., Ndungu, S.G., Lesan, A.C., 
Williamson, S.M., Linyonyi, A., and Kariuki, D.P. (1992). Further evaluation of the 
use of buparvaquone in the infection and treatment method of immunizing cattle 
against Theileria parva derived from African buffalo (Syncerus caffer). Veterinary 
parasitology 43, 15-24. 
Ngumi, P.N., Lesan, A.C., Williamson, S.M., Awich, J.R., Morzaria, S.P., Dolan, 
T.T., Shaw, M.K., and Young, A.S. (1994a). Isolation and preliminary 
characterisation of a previously unidentified Theileria parasite of cattle in Kenya. 
Research in veterinary science 57, 1-9. 
Ngumi, P.N., Lesan, A.C., Williamson, S.M., Awich, J.R., Morzaria, S.P., Dolan, 
T.T., Shaw, M.K., and Young, A.S. (1994b). Isolation and Preliminary 
Characterization of a Previously Unidentified Theileria Parasite of Cattle in Kenya. 
Research in veterinary science 57, 1-9. 
Niklas, N., Proll, J., Danzer, M., Stabentheiner, S., Hofer, K., and Gabriel, C. (2013). 
Routine performance and errors of 454 HLA exon sequencing in diagnostics. BMC 
bioinformatics 14, 176. 
Norval, R.A., Lawrence, J.A., Young, A.S., Perry, B.D., Dolan, T.T., and Scott, J. 
(1991a). Theileria parva: influence of vector, parasite and host relationships on the 
epidemiology of theileriosis in southern Africa. Parasitology 102 Pt 3, 347-356. 
Norval, R.A.I., Perry, B.D., and Young, A.S. (1992). The epidemiology of theileriosis 
in Africa (London: academic press limited). 
Ochanda, H., Young, A.S., Mutugi, J.J., Mumo, J., and Omwoyo, P.L. (1988). The 
effect of temperature on the rate of transmission of Theileria parva parva infection to 






Odongo, D.O., Oura, C.A., Spooner, P.R., Kiara, H., Mburu, D., Hanotte, O.H., and 
Bishop, R.P. (2006). Linkage disequilibrium between alleles at highly polymorphic 
mini- and micro-satellite loci of Theileria parva isolated from cattle in three regions 
of Kenya. International journal for parasitology 36, 937-946. 
Odongo, D.O., Sunter, J.D., Kiara, H.K., Skilton, R.A., and Bishop, R.P. (2010). A 
nested PCR assay exhibits enhanced sensitivity for detection of Theileria parva 
infections in bovine blood samples from carrier animals. Parasitology research 106, 
357-365. 
OIE (2008). OIE Terrestrial Manual 2008. pp. 789-804. 
Oura, C.A.L., Odonga, D.O., Lubega, G.W., Spooner, P.R., Tait, A., and Bishop, R.P. 
(2003). A panel of microsatellite and minisatellite markers for the characterisation of 
field isolates of Theileria parva. International journal for parasitology 33, 1641-1653. 
Oura, C.A., Bishop, R.P., Wampande, E.M., Lubega, G.W., and Tait, A. (2004a). 
Application of a reverse line blot assay to the study of haemoparasites in cattle in 
Uganda. International journal for parasitology 34, 603-613. 
Oura, C.A., Bishop, R., Wampanda, E.M., Lubega, G.W., and Tait, A. (2004b). The 
persistence of component Theileria parva stocks in cattle immunized with the 
'Muguga cocktail' live vaccine against East Coast fever in Uganda. Parasitology 129, 
27-42. 
Oura, C.A., Asiimwe, B.B., Weir, W., Lubega, G.W., and Tait, A. (2005). Population 
genetic analysis and sub-structuring of Theileria parva in Uganda. Molecular and 
biochemical parasitology 140, 229-239. 
Oura, C.A., Bishop, R., Asiimwe, B.B., Spooner, P., Lubega, G.W., and Tait, A. 
(2007). Theileria parva live vaccination: parasite transmission, persistence and 
heterologous challenge in the field. Parasitology 134, 1205-1213. 
Oura, C.A., Tait, A., Asiimwe, B., Lubega, G.W., and Weir, W. (2011a). 
Haemoparasite prevalence and Theileria parva strain diversity in Cape buffalo 
(Syncerus caffer) in Uganda. Veterinary parasitology 175, 212-219. 
LI
Oura, C.A., Tait, A., Asiimwe, B., Lubega, G.W., and Weir, W. (2011b). Theileria 
parva genetic diversity and haemoparasite prevalence in cattle and wildlife in and 
around Lake Mburo National Park in Uganda. Parasitology research 108, 1365-1374. 
Paling, R.W., Grootenhuis, J.G., and Young, A.S. (1981). Isolation of Theileria 
mutans from Kenyan buffalo, and transmission by Amblyomma gemma. Veterinary 
parasitology 8, 31-37. 
Pascucci, I., Capobianco Dondona, A., Camma, C., Marcacci, M., Di Domenico, M., 
Lelli, R., Scacchia, M., Jago, M., Khaiseb, S., Hager, A.L., et al. (2011). Survey of 
ixodid ticks and two tick-borne pathogens in African buffaloes, Syncerus caffer, from 
the Caprivi Strip, Namibia. Journal of zoo and wildlife medicine  42, 634-640. 
Patel, E.H., Lubembe, D.M., Gachanja, J., Mwaura, S., Spooner, P., and Toye, P. 
(2011). Molecular characterization of live Theileria parva sporozoite vaccine 
stabilates reveals extensive genotypic diversity. Veterinary parasitology 179, 62-68. 
Peakall, R., and Smouse, P.E. (2012). GenAlEx 6.5: genetic analysis in Excel. 
Population genetic software for teaching and research--an update. Bioinformatics 28, 
2537-2539. 
Pelle, R., Graham, S.P., Njahira, M.N., Osaso, J., Saya, R.M., Odongo, D.O., Toye, 
P.G., Spooner, P.R., Musoke, A.J., Mwangi, D.M., et al. (2011). Two Theileria parva 
CD8 T cell antigen genes are more variable in buffalo than cattle parasites, but differ 
in pattern of sequence diversity. PloS one 6, e19015. 
Perry, B.D., and Young, A.S. (1993). The Naming Game - the Changing Fortunes of 
East-Coast Fever and Theileria-Parva. Veterinary Record 133, 613-616. 
Pienaar, R., Potgieter, F.T., Latif, A.A., Thekisoe, O.M.M., and Mans, B.J. (2011). 
Mixed Theileria infections in free-ranging buffalo herds: implications for diagnosing 
Theileria parva infections in Cape buffalo (Syncerus caffer). Parasitology 138, 884-
895. 
Potgieter, F.T., Stoltsz, W.H., Blouin, E.F., and Roos, J.A. (1988). Corridor disease in 
South Africa: a review of the current status. Journal of the South African Veterinary 





Quince, C., Lanzen, A., Curtis, T.P., Davenport, R.J., Hall, N., Head, I.M., Read, L.F., 
and Sloan, W.T. (2009). Accurate determination of microbial diversity from 454 
pyrosequencing data. Nature methods 6, 639-641. 
Quince, C., Lanzen, A., Davenport, R.J., and Turnbaugh, P.J. (2011). Removing noise 
from pyrosequenced amplicons. BMC bioinformatics 12, 38. 
Radley, D.E., Brown, C.G.D., Burridge, M.J., Cunningham, M.P., Kirimi, I.M., 
Purnell, R.E., and Young, A.S. (1975a). East coast fever: 1. Chemoprophylactic 
immunization of cattle against Theileria parva (Muguga) and five theilerial strains. 
Veterinary parasitology 1, 35-41. 
Radley, D.E., Brown, C.G.D., Cunningham, M.P., Kimber, C.D., Musisi, F.L., Payne, 
R.C., Purnell, R.E., Stagg, S.M., and Young, A.S. (1975b). East coast fever: 3. 
Chemoprophylactic immunization of cattle using oxytetracycline and a combination 
of theilerial strains. Veterinary parasitology 1, 51-60.  
Radley, D.E., Young, A.S., Brown, C.G.D., Burridge, M.J., Cunningham, M.P., 
Musisi, F.L., and Purnell, R.E. (1975c). East coast fever: 2. Cross-immunity trials 
with a Kenya strain of Theileria lawrencei. Veterinary parasitology 1, 43-50. 
Radley, D.E. (1976). Chemoprophylactic immunisation against east coast fever. In 
Tick-borne disease and their vectors, J.K.H. Wilde, ed. (University of Edinburgh, 
centre for tropical veterinary medicine), pp. 324-329. 
Radley, D.E., Young, A.S., Grootenhuis, J.G., Cunningham, M.P., Dolan, T.T., and 
Morzaria, S.P. (1979). Further studies on the immunization of cattle against Theileria 
lawrencei by infection and chemoprophylaxis. Veterinary parasitology 5, 117-128. 
Schloss, P.D., Westcott, S.L., Ryabin, T., Hall, J.R., Hartmann, M., Hollister, E.B., 
Lesniewski, R.A., Oakley, B.B., Parks, D.H., Robinson, C.J., et al. (2009). 
Introducing mothur: open-source, platform-independent, community-supported 
software for describing and comparing microbial communities. Applied and 
environmental microbiology 75, 7537-7541. 
Schloss, P.D., Gevers, D., and Westcott, S.L. (2011). Reducing the effects of PCR 
amplification and sequencing artifacts on 16S rRNA-based studies. PloS one 6, 
e27310. 
 LIII
Schloss, P.D., and Westcott, S.L. (2011). Assessing and improving methods used in 
operational taxonomic unit-based approaches for 16S rRNA gene sequence analysis. 
Applied and environmental microbiology 77, 3219-3226. 
Shaw, M.K., Tilney, L.G., and Musoke, A.J. (1991). The entry of Theileria parva 
sporozoites into bovine lymphocytes: evidence for MHC class I involvement. The 
Journal of cell biology 113, 87-101.  
Shaw, M.K., and Tilney, L.G. (1992). How individual cells develop from a 
syncytium: merogony in Theileria parva (Apicomplexa). Journal of cell science 101 ( 
Pt 1), 109-123. 
Shaw, M.K., and Tilney, L.G. (1995). The entry of Theileria parva merozoites into 
bovine erythrocytes occurs by a process similar to sporozoite invasion of 
lymphocytes. Parasitology 111 ( Pt 4), 455-461. 
Shaw, M.K. (2003). Cell invasion by Theileria sporozoites. Trends in parasitology 19, 
2-6. 
Sibeko, K.P., Oosthuizen, M.C., Collins, N.E., Geysen, D., Rambritch, N.E., Latif, 
A.A., Groeneveld, H.T., Potgieter, F.T., and Coetzer, J.A. (2008). Development and 
evaluation of a real-time polymerase chain reaction test for the detection of Theileria 
parva infections in Cape buffalo (Syncerus caffer) and cattle. Veterinary parasitology 
155, 37-48. 
Sibeko, K.P., Geysen, D., Oosthuizen, M.C., Matthee, C.A., Troskie, M., Potgieter, 
F.T., Coetzer, J.A., and Collins, N.E. (2010). Four p67 alleles identified in South 
African Theileria parva field samples. Veterinary parasitology 167, 244-254 
Sibeko, K.P., Collins, N.E., Oosthuizen, M.C., Troskie, M., Potgieter, F.T., Coetzer, 
J.A., and Geysen, D. (2011). Analyses of genes encoding Theileria parva p104 and 
polymorphic immunodominant molecule (PIM) reveal evidence of the presence of 
cattle-type alleles in the South African T. parva population. Veterinary parasitology 
181, 120-130. 
Siefert, H.S.H. (1996). Tropical animal health (Kuwer academic publisher). 
Skilton, R.A., Bishop, R.P., Katende, J.M., Mwaura, S., and Morzaria, S.P. (2002). 





which differ in their ability to induce a carrier state: analysis using a novel blood spot 
PCR assay. Parasitology 124, 265-276. 
Skums, P., Dimitrova, Z., Campo, D.S., Vaughan, G., Rossi, L., Forbi, J.C., 
Yokosawa, J., Zelikovsky, A., and Khudyakov, Y. (2012). Efficient error correction 
for next-generation sequencing of viral amplicons. BMC bioinformatics 13( 
Suppementl 10), S6. 
Snodgrass, D.R., Trees, A.J., Bowyer, W.A., Bergman, J.R., Daft, J., and Wall, A.E. 
(1972). East Coast Fever: field challenge of cattle immunised against Theileria parva 
(Muguga). Tropical animal health and production 4, 142-151. 
Speybroeck, N., Marcotty, T., Aerts, M., Dolan, T., Williams, B., Lauer, J., 
Molenberghs, G., Burzykowski, T., Mulumba, M., and Berkvens, K. (2008). Titrating 
Theileria parva: Single stocks against combinations of stocks. Experimental 
parasitology 118, 522-530. 
Spooner, R.L., Innes, E.A., Glass, E.J., Millar, P., and Brown, C.G. (1988). Bovine 
mononuclear cell lines transformed by Theileria parva or Theileria annulata express 
different subpopulation markers. Parasite immunology 10, 619-629. 
Steinaa, L., Saya, R., Awino, E., and Toye, P. (2012). Cytotoxic T lymphocytes from 
cattle immunized against Theileria parva exhibit pronounced cross-reactivity among 
different strain-specific epitopes of the Tp1 antigen. Veterinary immunology and 
immunopathology 145, 571-581. 
Sutherland, I.A., Shiels, B.R., Jackson, L., Brown, D.J., Brown, C.G., and Preston, 
P.M. (1996). Theileria annulata: altered gene expression and clonal selection during 
continuous in vitro culture. Experimental parasitology 83, 125-133. 
Tait, A., and Oura, C. (2004). Reverse line blotting: a new technique for the sensitive 
detection of tick borne pathogens. Archives de l'Institut Pasteur de Tunis 81, 47-50. 
Tamura, K., Nei, M., and Kumar, S. (2004). Prospects for inferring very large 
phylogenies by using the neighbor-joining method. Proceedings of the National 
Academy of Sciences of the United States of America 101, 11030-11035. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011). 
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, 
 LV
Evolutionary Distance, and Maximum Parsimony Methods. Molecular biology and 
evolution 28, 2731-2739. 
Taracha, E.L., Goddeeris, B.M., Morzaria, S.P., and Morrison, W.I. (1995a). Parasite 
strain specificity of precursor cytotoxic T cells in individual animals correlates with 
cross-protection in cattle challenged with Theileria parva. Infection and immunology 
63, 1258-1262. 
Taracha, E.L., Goddeeris, B.M., Teale, A.J., Kemp, S.J., and Morrison, W.I. (1995b). 
Parasite strain specificity of bovine cytotoxic T cell responses to Theileria parva is 
determined primarily by immunodominance. Journal of immunology 155, 4854-4860. 
Taracha, E.L., Awino, E., and McKeever, D.J. (1997). Distinct CD4+ T cell helper 
requirements in Theileria parva immune and naive bovine CTL precursors. Journal of 
immunology 159, 4539-4545 
Taylor, L.H., Matthews, L., Shaw, D.J., and Haydon, D.T. (2005). Competitive 
suppression in mixed-clone parasite cultures. Biology letters 1, 108-111. 
Thompson, B.E., Latif, A.A., Oosthuizen, M.C., Troskie, M., and Penzhorn, B.L. 
(2008). Occurrence of Theileria parva infection in cattle on a farm in the Ladysmith 
district, KwaZulu-Natal, South Africa. Journal of the South African Veterinary 
Association 79, 31-35. 
Tindih, H.S., Geysen, D., Goddeeris, B.M., Awino, E., Dobbelaere, D.A., and 
Naessens, J. (2012). A Theileria parva isolate of low virulence infects a 
subpopulation of lymphocytes. Infection and immunity  80, 1267-1273. 
Toye, P., Gobright, E., Nyanjui, J., Nene, V., and Bishop, R. (1995). Structure and 
sequence variation of the genes encoding the polymorphic, immunodominant 
molecule (PIM), an antigen of Theileria parva recognized by inhibitory monoclonal 
antibodies. Molecular and biochemical parasitology 73, 165-177. 
Uilenberg, G., Schreuder, B.E., Silayo, R.S., and Mpangala, C. (1976). Studies on 
Theileriidae (Sporozoa) in Tanzania. IV. A field trial on immunization against East 






Uilenberg, G., Silayo, R.S., Mpangala, C., Tondeur, W., Tatchell, R.J., and Sanga, 
H.J. (1977). Studies on Theileriidae (Sporozoa) in Tanzania. X. A large-scale field 
trial on immunization against cattle Theileriosis. Tropenmedizin und Parasitologie 28, 
499-506.  
Uilenberg, G. (1978). Some Recent Research on Theileriidae (Sporozoa) of Cattle. 
Tropical and geographical medicine 30, 156-156. 
Walker, A.R., and McKellar, S.B. (1983). Observations on the separation of theileria 
sporozoites from ticks. International journal for parasitology 13, 313-318. 
Walker, A.R., Bouattour, A., Camicas, J.L., Estrada-Peña, A., Horak, I.G., Latif, 
A.A., Pegram, R.G., and Preston, P.M. (2001). Ticks of Domestic Animals in Africa: 
a Guide to Identification of Species (Edinburgh, U.K.,). 
Wambura, P.N., Gwakisa, P.S., Silayo, R.S., and Rugaimukamu, E.A. (1998). Breed-
associated resistance to tick infestation in Bos indicus and their crosses with Bos 
taurus. Veterinary parasitology 77, 63-70. 
Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009). 
Jalview Version 2--a multiple sequence alignment editor and analysis workbench. 
Bioinformatics 25, 1189-1191. 
Wenink, P.W., Groen, A.F., Roelke-Parker, M.E., and Prins, H.H. (1998). African 
buffalo maintain high genetic diversity in the major histocompatibility complex in 
spite of historically known population bottlenecks. Molecular ecology 7, 1315-1322. 
Yewdell, J.W., and Bennink, J.R. (1999). Immunodominance in major 
histocompatibility complex class I-restricted T lymphocyte responses. . Annual 
Reviews of Immunology 17. 
Yewdell, J.W., Reits, E., and Neefjes, J. (2003). Making sense of mass destruction: 
quantitating MHC class I antigen presentation. Nature reviews. Immunology 3, 952-
961. 
Yewdell, J.W. (2006). Confronting Complexicity: Real-world immunodominance in 
antiviral CD8+ T cell responses. Immunity 25, 533-543. 
York, I.A., Brehm, M.A., Zendzian, S., Towne, C.F., and Rock, K.L. (2006). 
Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented 
 LVII
peptides in vivo and plays an important role in immunodominance. Proceedings of the 
National Academy of Sciences of the United States of America 103, 9202-9207. 
Young, A.S., Brown, C.G., Burridge, M.J., Cunningham, M.P., Kirimi, I.M., and 
Irvin, A.D. (1973). Observations on the cross-immunity between Theileria lawrencei 
(Serengeti) and Theileria parva (Muguga) in cattle. International journal for 
parasitology 3, 723-728. 
Young, A.S., Brown, C.G., Burridge, M.J., Cunningham, M.P., Payne, R.C., and 
Purnell, R.E. (1977a). Establishment of an experimental field population of Theileria 
lawrencei-infected ticks maintained by African buffalo (Syncerus caffer). The Journal 
of parasitology 63, 903-907. 
Young, A.S., Brown, C.G.D., Burridge, M.J., Grootenhuis, J.G., Kanhai, G.K., 
Purnell, R.E., and Stagg, D.A. (1978). The incidence of Theilerial parasites in East 
African buffalo (Syncerus caffer). Tropenmedizin und Parasitologie 29, 281-288. 
Young, A.S., Mutugi, J.J., Kariuki, D.P., Lampard, D., Maritim, A.C., Ngumi, P.N., 
Linyonyi, A., Leitch, B.L., Ndungu, S.G., Lesan, A.C., and et al. (1992). 
Immunisation of cattle against theileriosis in Nakuru District of Kenya by infection 
and treatment and the introduction of unconventional tick control. Veterinary 
parasitology 42, 225-240. 
Young, A.S., Ochanda, H., Perry, B.D., Morzaria, S.P., Dolan, T.T., Medley, G.F., 
and Gettinby, G. (1994). The biology of the transmission dynamics of Theileria 
parva, Vol ISVEE 7: Proceedings of the 7th International Symposium on Veterinary 
Epidemiology and Economics, Nairobi, Kenya (published as Vol 18(2) of The Kenya 
Veterinarian) (International Symposia on Veterinary Epidemiology and Economics). 
Young, A.S., and Purnell, R.E. (1973). Transmission of Theileria lawrencei 
(Serengeti) by the ixodid tick, Rhipicephalus appendiculatus. Tropical animal health 
and production 5, 146-152. 
Young, A.S., Radley, D.E., Cunningham, M.P., Musisi, F.L., Payne, R.C., and 
Purnell, R.E. (1977b). Exposure of immunized cattle to prolonged natural challenge of 
Theileria lawrencei derived from african buffalo (Syncerus caffer). Veterinary 





Yusufmia, S.B., Collins, N.E., Nkuna, R., Troskie, M., Van den Bossche, P., and 
Penzhorn, B.L. (2010). Occurrence of Theileria parva and other haemoprotozoa in 
cattle at the edge of Hluhluwe-iMfolozi Park, KwaZulu-Natal, South Africa. Journal 
of the South African Veterinary Association 81, 45-49. 
Zweygarth, E., Koekemoer, O., Josemans, A.I., Rambritch, N., Pienaar, R., Putterill, 
J., Latif, A., and Potgieter, F.T. (2009). Theileria-infected cell line from an African 
buffalo (Syncerus caffer). Parasitology research 105, 579-581. 
